

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : A01H 1/00, C07H 21/04, C07K 14/00, C12N 5/04, 5/10, C12P 19/34, C12Q 1/68</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/30083 (43) International Publication Date: 16 July 1998 (16.07.98)</p>
<p>(21) International Application Number: PCT/US98/00615 (22) International Filing Date: 9 January 1998 (09.01.98) (30) Priority Data: 08/781,734 10 January 1997 (10.01.97) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US). (72) Inventors: SHEN, Kathy; 44228 Country Club Drive, El Macero, CA 95618 (US). MEYERS, Blake; 904 Drake Drive, Davis, CA 95616 (US). MICHELMORE, Richard, W.; 36757 Russel Boulevard, Davis, CA 95616 (US). (74) Agents: EINHORN, Gregory, P. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).</p>		<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>
<p>(54) Title: RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS</p> <p>(57) Abstract</p> <p>The present invention provides RG nucleic acids and proteins which confer disease resistance to plants. The nucleic acids can be used to produce transgenic plants resistant to pests. Antibodies to proteins of the invention are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

5

The present application is a continuation-in-part application ("CIP") of U.S. Patent Application Serial No. ("USSN") 08/781,734, filed January 10, 1997. The
10 aforementioned application is explicitly incorporated herein by reference in its entirety and
for all purposes.

This invention was made with Government support under Grant Nos. 92-37300-7547 and 95-37300-1571, awarded by the United States Department of Agriculture.
15 The Government has certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates generally to plant molecular biology. In particular, it relates to nucleic acids and methods for conferring pest resistance in plants.
20 particularly lettuce.

BACKGROUND OF THE INVENTION

Recently, several resistance genes have been cloned by several groups from several plants. Many of these genes are sequence related. The derived amino acid
25 sequences of the most common class, *RPS2*, *RPM1* (bacterial resistances in *Arabidopsis* (Mindrinos *et al.* *Cell* 78:1089-1099 (1994)); Bent *et al.* *Science* 265:1856-1860 (1994); Grant *et al.*, *Science* 269:843-846 (1995)), *L6* (fungal resistance in flax; Lawrence, *et al.*, *The Plant Cell* 7:1195-1206 (1995)), and *N*, (virus resistance in tobacco; Whitham, *et al.*, *Cell* 78:1101-1115 (1994); and U.S. Patent No. 5,571,706), all contain leucine-rich
30 repeats (LRR) and nucleotide binding sites (NBS).

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

LRR domains can mediate protein-protein interactions and are found in a variety of proteins involved in signal transduction, cell adhesion and various other functions. LRRs are leucine rich regions often comprising 20-30 amino acid repeats where leucine and other aliphatic residues occur periodically. LRRs can function extracellularly or intracellularly.

Since the onset of civilization, plant diseases have had catastrophic effects on crops and the well-being of the human population. Plant diseases continue to effect enormous human and economic costs. An increasing human population and decreasing amounts of arable land make all approaches to preventing and treating plant pathogen destruction critical. The ability to control and enhance a plant's protective responses against pathogens would be of enormous benefit. Tissue-specific and temporal control of mechanisms responsible for plant cell death would also be of great practical and economic value. The present invention fulfills these and other needs.

What is needed in the art are plant disease resistance genes and means to create transgenic disease resistance plants, particularly in lettuce. Further, what is needed in the art is a means to DNA fingerprint cultivars and germplasm with respect to their disease resistance haplotypes for use in plant breeding programs. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid constructs. These constructs comprise an RG (resistance gene) polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and an RG4 polypeptide. RG1, RG2, RG3, RG4, and the like, represent individual "RG families." Each "RG family," as defined herein, is a group of polypeptide sequences that have at least 60% amino acid sequence identity. Individual members of an RG family, *i.e.*, individual species of the genus, typically map to the same genomic locus. The invention provides for constructs comprising nucleotides encoding the RG families of the

invention, which can include sequences encoding a leucine rich region (LRR), and/or a nucleotide binding site (NBS), or both.

The invention provides for an isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide. In alternative embodiments, the nucleic acid construct comprises an RG polynucleotide which encodes an RG polypeptide comprising an leucine rich region (LRR), or, an RG polypeptide comprising a nucleotide binding site (NBS). The nucleic acid construct can comprise a polynucleotide which is a full length gene. In another embodiment, the nucleic acid construct encodes a fusion protein.

In one embodiment, the nucleic acid construct comprises a sequence encoding an RG1 polypeptide. The RG1 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 and SEQ ID NO:137 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

In another embodiment, the nucleic acid construct comprises a sequence encoding an RG2 polypeptide. The RG2 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In other embodiments, the nucleic acid construct comprises a RG3 sequence (SEQ ID NO:68) encoding an RG3 polypeptide (SEQ ID NO:138) (RG3). In other embodiments, the nucleic acid construct comprises an RG4 sequence (SEQ ID NO:69) encoding an RG4 polypeptide (SEQ ID NO:139) (RG4).

5 In other embodiments, the nucleic acid construct comprises a RG5 sequence (SEQ ID NO:134) encoding an RG5 polypeptide (SEQ ID NO:135). The RG5 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

The invention also provides for a nucleic acid construct which comprises an RG7 sequence encoding an RG7 polypeptide. The RG7 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

10 In further embodiments, the nucleic acid construct can further comprise a promoter operably linked to the RG polynucleotide. In alternative embodiments, the promoter can be a plant promoter; a disease resistance promoter; a lettuce promoter; a constitutive promoter; an inducible promoter; or, a tissue-specific promoter. The nucleic acid construct can comprise a promoter sequence from an RG gene linked to a heterologous polynucleotide.

The invention also provides for a transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide. The expression cassette can comprise a plant promoter or a viral promoter; the plant promoter can be a heterologous promoter. In one embodiment, the transgenic plant is lettuce. In alternative embodiments, the transgenic plant comprises an expression cassette which includes an RG polynucleotide selected from the group consisting of SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J); SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104

(RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W); SEQ ID NO:68 (RG3); SEQ ID NO:69 (RG4); SEQ ID NO:134 (RG5); or SEQ ID NO:136 (RG7).

The invention provide for a transgenic plant comprising an expression cassette comprising an RG polynucleotide which can encode an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W); an RG4 polypeptide as set forth by SEQ ID NO:72; an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135; or, an RG7 polypeptide.

The invention also provides for a method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence. In this method, the plant can be a lettuce plant; and, the RG polynucleotide can encode an RG polypeptide selected from the group consisting of an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID

NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:72; SEQ ID NO:74; SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W). In this method, the promoter can be a plant disease resistance promoter, a tissue-specific promoter, a constitutive promoter, or an inducible promoter.

The invention also provides for a method of detecting RG resistance genes in a nucleic acid sample, the method comprising: contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and, wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample. In this method, the RG polynucleotide can be an RG1 polynucleotide, an RG2 polynucleotide, an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide. In this method, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide, and, the RG resistance gene can be amplified by the polymerase chain reaction. In one embodiment, the RG polynucleotide is labeled.

The invention further provides for an RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification, the figures and claims.

All publications, patents and patent applications cited herein are hereby expressly incorporated by reference for all purposes.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to families of RG genes, particularly from *Lactuca sativa*. Nucleic acid sequences of the present invention can be used to confer resistance in plants to a variety of pests including viruses, fungi, nematodes, insects, and bacteria. Sequences from within the RG genes can be used to fingerprint cultivars or germplasm for the presence of desired resistance genes. Promoters of RG genes can be used to drive heterologous gene expression under conditions in which RG genes are expressed. Further, the present invention provides RG proteins and antibodies specifically reactive to RG proteins. Antibodies to RG proteins can be used to detect the type and amount of RG protein expressed in a plant sample.

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*, *Triticum*, and, *Sorghum*. In particularly preferred embodiments, species from the family *Compositae* and in particular the genus *Lactuca* are employed such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

The nucleic acids of the present invention can be used in marker-aided selection. Marker-aided selection does not require the complete sequence of the gene or precise knowledge of which sequence confers which specificity. Instead, partial sequences can be used as hybridization probes or as the basis for oligonucleotide primers to amplify nucleic acid, e.g., by PCR. Partial sequences can be used in other methods, such as to

follow the segregation of chromosome segments containing resistance genes in plants.

Because the RG marker is the gene itself, there can be negligible recombination between the marker and the resistance phenotype. Thus, RG polynucleotides of the present invention provide an optimal means to DNA fingerprint cultivars and wild germplasm with respect to their disease resistance haplotypes. This can be used to indicate which germplasm accessions and cultivars carry the same resistance genes. At present, selection of plants (e.g., lettuce) for resistance to some diseases is slow and difficult. But linked markers allow indirect selection for such resistance genes. Moreover, RG markers also allow resistance genes to be identified and combined in a manner that would not otherwise be possible. Numerous accessions have been identified that provide resistance to all isolates of downy mildew (*Bremia lactucae*). However, without molecular markers it is impossible to combine such resistances from different sources. The nucleic acid sequences of the invention provide for a fast and convenient means to identify and combine resistances from different sources. The RG markers of the invention can also be used to identify recombinants that have new combinations of resistance genes in *cis* on the same chromosome.

In addition, RG markers may allow the identification of the Mendelian factors determining traits, such as field resistance to downy mildew. Once such markers have been identified, they will greatly increase the ease with which field resistance can be transferred between lines and combined with other resistances.

In another application, primers to RG sequences can be also designed to amplify sequences that are conserved in multiple RG family members. This gives genetic information on multiple RG family members. Alternatively, one or more primers can be made to sequences unique to a single resistance gene genus or a single RG specie. This allows an analysis of individual family groups (an RG genus) or an individual family member (a specie). Primers made to individual RGs at the edge of each cluster can be used to select for recombinants within the cluster. This minimizes the amount of linkage drag during introgression. Classical and molecular genetics has shown that pest resistance genes tend to be clustered in the genome. Pest resistance loci comprise arrays of genes and exhibit a variety of complex haplotypes rather than being simple alternate allelic forms. Pest resistance is conferred by families, or genuses, of related RG sequences, individual members, or species, of which have evolved to have a different specificity.

Oligonucleotide primers can be designed that amplify members from multiple haplotypes, or genuses, or amplify only members of one genus, or only amplify an individual specie. This will provide codominant information and allow heterozygotes to be distinguished from homozygotes.

5 Further, comparison of RG sequences will allow a determination of which sequences are critical for resistance and will ultimately lead to engineering resistance genes with new specificities. Resistance gene sequences were not previously available for lettuce. Marker-aided selection will greatly increase the precision and speed of breeding for disease resistance. Transgenic approaches will allow pyramiding of resistance genes
10 into a single Mendelian unit, transfer between sexually-incompatible species, substitute for conventional backcrossing procedures, and allow expression of other genes in parallel with resistance genes.

The RG polynucleotides also have utility in the construction of disease resistant transgenic plants. This avoids lengthy and sometimes difficult backcrossing
15 programs currently necessary for introgression of resistance. It is also possible to transfer resistance polynucleotides between sexually-incompatible species, thereby greatly increasing the germplasm pool that can be used as a source of resistance genes. Cloning of multiple RG sequences in a single cassette will allow pyramiding of genes for resistance against multiple isolates of a single pathogen such as downy mildew or against multiple
20 pathogens. Once introduced, such a cassette can be manipulated by classical breeding methods as a single Mendelian unit.

Transgenic plants of the present invention can also be constructed using an RG promoter. The promoter sequences from RG sequences of the invention can be used with RG genes or heterologous genes. Thus, RG promoters can be used to express a
25 variety of genes in the same temporal and spatial patterns and at similar levels to resistance genes.

Nucleic acids of the Invention and Their Preparation

RG Polynucleotide Families

30 The present invention provides isolated nucleic acid constructs which comprise an RG polynucleotide. In alternative embodiments, the RG polynucleotide is at least 18 nucleotides in length, typically at least 20, 25, or 30 nucleotides in length, more

typically at least 100 nucleotides in length, generally at least 200 nucleotides in length, preferably at least 300 nucleotides in length, more preferably at least 400 nucleotides in length, and most preferably at least 500 nucleotides in length.

In particularly preferred embodiments, the RG polynucleotide encodes a RG protein which confers resistance to plant pests. This RG protein can be longer, equivalent, or shorter than the RG protein encoded by an RG gene. In various embodiments, an RG polynucleotide can hybridize under stringent conditions to members of an RG family (an RG genus); *e.g.*, it can hybridize to a member of the RG1 RG family, such as an RG1 polynucleotide selected from the group consisting of: SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J).

In other embodiments, the polynucleotide can also hybridize under stringent conditions to a member of the RG2 family; such as an RG2 polynucleotide selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In alternative embodiments, each RG2 gene can also include an AC15 sequence which hybridizes under stringent conditions to a polynucleotide selected from the group consisting of: SEQ ID NO:56 (AC15-2A); SEQ ID NO:57 (AC15-2B); SEQ ID NO:58 (AC15-2C); SEQ ID NO:59 (AC15-2D); SEQ ID NO:60 (AC15-2E); SEQ ID NO:61 (AC15-2G); SEQ ID NO:62 (AC15-2H); SEQ ID NO:63 (AC15-2I); SEQ ID

NO:64 (AC15-2J); SEQ ID NO:65 (AC15-2L); SEQ ID NO:66 (AC15-2N); SEQ ID NO:67 (AC15-2O).

In other embodiments, an RG polynucleotide can hybridize under stringent conditions to an RG3 (SEQ ID NO:68), an RG4 (SEQ ID NO:69), and RG5 (SEQ ID NO:135), and an RG7 (SEQ ID NO:137), RG family member.

The present invention further provides nucleic acid constructs which comprise an RG polynucleotide which encodes RG polypeptides from various RG families; such as an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and RG4 polypeptide, and RG5 polypeptide, and an RG7 polypeptide.

Exemplary RG1 polypeptides have the sequences shown in SEQ ID NO:2 (RG1A), SEQ ID NO:4 (RG1B), SEQ ID NO:6 (RG1C), SEQ ID NO:8 (RG1D), SEQ ID NO:10 (RG1E), SEQ ID NO:12 (RG1F), SEQ ID NO:14 (RG1G), SEQ ID NO:16 (RG1H), SEQ ID NO:20 (RG1I). Exemplary RG2 polypeptides have the sequences shown in SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

An exemplary RG3 polypeptide has the sequence shown in SEQ ID NO:138. An exemplary RG4 polypeptide has the sequence shown in SEQ ID NO:139. RG polynucleotides will have at least 60% identity, more typically at least 65% identity, generally at least 70% identity, and preferably at least 75% identity, more preferably at least 80% identity, and most preferably at least 85%, 90%, or 95% identity at the deduced amino acid level. The regions where substantial identity is assessed can be inclusive or exclusive of the nucleotide binding site or the leucine rich region.

Vectors and Transcriptional Control Elements

The invention, providing methods and reagents for making novel species and genres of RG nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic plants and animals, using constitutive and inducible transcriptional and translational *cis*- (e.g., promoters and enhancers) and *trans*-acting control elements.

The expression of natural, recombinant or synthetic plant disease resistance polypeptide-encoding or other (i.e., antisense, ribozyme) nucleic acids can be achieved by operably linking the coding region a promoter (that can be plant-specific or not, constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an *in vitro* reaction system or a suitable host cell or organism. Synthetic procedures may also be used. Typical expression systems contain, in addition to coding or antisense sequence, transcription and translation terminators, polyadenylation sequences, transcription and translation initiation sequences, and promoters useful for transcribing DNA into RNA. The expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette *in vivo*, e.g., plants, eukaryotes, or prokaryotes, or a combination thereof, (e.g., shuttle vectors) and selection markers for the selected expression system, e.g., plant, prokaryotic or eukaryotic systems. To ensure proper polypeptide expression under varying conditions, a polyadenylation region at the 3'-end of the coding region can be included (see Li (1997) *Plant Physiol.* 115:321-325, for a review of the polyadenylation of RNA in plants). The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA (e.g., using *Agrobacterium tumefaciens* T-DNA replacement vectors, see e.g., Thykjaer (1997) *Plant Mol Biol.* 35:523-530; using a plasmid containing a gene of interest flanked by *Agrobacterium* T-DNA border repeat sequences; Hansen (1997) "T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes," *Proc. Natl. Acad. Sci. USA* 94:11726-11730.

To identify the promoters, the 5' portions of the clones described here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further

upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G (see, *e.g.*, Messing, in *Genetic Engineering in Plants*, pp. 221-227, Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the RG coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from viral genes, such as T-DNA.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, for example, episomal expression systems (*e.g.*, cauliflower mosaic virus (CaMV) viral RNA is generated in the nucleus by transcription of an episomal minichromosome containing supercoiled DNA, Covey (1990) *Proc. Natl. Acad. Sci. USA* 87:1633-1637). Alternatively, coding sequences can be inserted into the host cell genome becoming an integral part of the host chromosomal DNA.

Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode biocide resistance, such as antibiotic resistance, particularly resistance to chloramphenicol, kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997. Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*. See also, Mengiste (1997) "High-efficiency transformation of *Arabidopsis thaliana* with a selectable marker gene regulated by the T-DNA 1' promoter," *Plant J.* 12:945-948, showing that the 1' promoter is an attractive alternative to the cauliflower mosaic virus (CaMV) 35S promoter for the generation of T-DNA insertion lines, the 1' promoter may be especially beneficial for the secondary transformation of transgenic strains containing the 35S promoter to exclude homology-mediated gene silencing.

The endogenous promoters from the RG genes of the present invention can be used to direct expression of the genes. These promoters can also be used to direct expression of heterologous structural genes. The promoters can be used, for example, in recombinant expression cassettes to drive expression of genes conferring resistance to any number of pathogens or pests, including fungi, bacteria, and the like.

Constitutive Promoters

In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired gene in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include those from viruses which infect plants, such as the cauliflower mosaic virus (CaMV) 35S transcription initiation region; the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*; the promoter of the tobacco mosaic virus; and, other transcription initiation regions from various plant genes known to those of skill. See also Holtorf (1995) "Comparison of different constitutive and inducible promoters for the overexpression of transgenes in *Arabidopsis thaliana*," *Plant Mol. Biol.* 29:637-646.

Inducible Promoters

Alternatively, a plant promoter may direct expression of the plant disease resistance nucleic acid of the invention under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include pathogenic attack, anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters. For example, the invention incorporates the drought-inducible promoter of maize (Busk (1997) *supra*); the cold, drought, and high salt inducible promoter from potato (Kirch (1997) *Plant Mol. Biol.* 33:897-909).

Embodiments of the invention also incorporate use of plant promoters which are inducible upon injury or infection to express the invention's plant disease resistance (RG) polypeptides. Various embodiments include use of, e.g., the promoter for a tobacco (*Nicotiana tabacum*) sesquiterpene cyclase gene (EAS4 promoter), which is expressed in wounded leaves, roots, and stem tissues, and upon infection with microbial pathogens (Yin

(1997) *Plant Physiol.* 115(2):437-451); the ORF13 promoter from *Agrobacterium rhizogenes* 8196, which is wound inducible in a limited area adjacent to the wound site (Hansen (1997) *Mol. Gen. Genet.* 254:337-343); the Shpx6b gene promoter, which is a plant peroxidase gene promoter induced by microbial pathogens (demonstrated using a fungal pathogen, see Curtis (1997) *Mol. Plant Microbe Interact.* 10:326-338); the wound-inducible gene promoter *wun1*, derived from potato (Siebertz (1989) *Plant Cell* 1:961-968); the wound-inducible *Agrobacterium pmas* gene (mannopine synthesis gene) promoter (Guevara-Garcia (1993) *Plant J.* 4:495-505).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the nucleic acids of the invention. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (*Glycine max* L.) (Liu (1997) *Plant Physiol.* 115:397-407); the auxin-responsive Arabidopsis GST6 promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) *Plant J.* 10: 955-966); the auxin-inducible *parC* promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) *Mol. Plant Microbe Interact.* 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) *Science* 274:1900-1902).

Plant promoters which are inducible upon exposure to chemicals reagents which can be applied to the plant, such as herbicides or antibiotics, are also used to express the nucleic acids of the invention. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) *Plant Cell Physiol.* 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. Coding sequence can be under the control of, *e.g.*, a tetracycline-inducible promoter, *e.g.*, as described with transgenic tobacco plants containing the *Avena sativa* L. (oat) arginine decarboxylase gene (Masgrau (1997) *Plant J.* 11:465-473); or, a salicylic acid-responsive element (Stange (1997) *Plant J.* 11:1315-1324. Using chemically- (*e.g.*, hormone- or pesticide-) induced promoters, harvesting of fruits and plant parts would be greatly facilitated. A chemical which can be applied to the transgenic plant in the field and induce expression of a polypeptide of the invention throughout all or most of the plant would make an environmentally safe defoliant or herbicide. Thus, the invention also provides for transgenic plants containing an inducible gene encoding for the RG

polypeptides of the invention whose host range is limited to target plant species, such as weeds or crops before, during or after harvesting.

Abcission promoters are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. In some embodiments, when a plant disease resistant polypeptide-encoding nucleic acid is under the control of such a promoter, rapid cell death, induced by expression of the invention's polypeptide, can accelerate and/or accentuate abscission, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like. Induction of rapid cell death at this time would accelerate separation of the fruit from the plant, greatly augmenting harvesting procedures. See, *e.g.*, Kalaitzis (1997) *Plant Physiol.* 113:1303-1308, discussing tomato leaf and flower abscission; Payton (1996) *Plant Mol. Biol.* 31:1227-1231, discussing ethylene receptor expression regulation during fruit ripening, flower senescence and abscission; Koehler (1996) *Plant Mol. Biol.* 31:595-606, discussing the gene promoter for a bean abscission cellulase; Kalaitzis (1995) *Plant Mol. Biol.* 28: 647-656, discussing cloning of a tomato polygalacturonase expressed in abscission; del Campillo (1996) *Plant Physiol.* 111:813-820, discussing pedicel breakstrength and cellulase gene expression during tomato flower abscission.

Tissue-Specific Promoters

Tissue specific promoters are transcriptional control elements that are only active in particular cells or tissues. Plant promoters which are active only in specific tissues or at specific times during plant development are used to express the nucleic acids of the invention. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, ovules, pollen, pistils, or flowers. Such promoters are referred to as "tissue specific". The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

For example, a seed-specific promoter directs expression in seed tissues. Such promoters may be, for example, ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed coat-specific, or some combination thereof. A leaf-specific promoter has been identified in maize, Busk (1997) *Plant J.* 11:1285-1295. The ORF13 promoter from *Agrobacterium rhizogenes* exhibits high activity in roots (Hansen (1997) *supra*). A maize pollen-specific promoter has been identified in maize (Guerrero (1990)

Mol. Gen. Genet. 224:161-168). A tomato promoter active during fruit ripening, senescence and abscission of leaves and, to a lesser extent, of flowers can be used (Blume (1997) *Plant J.* 12:731-746). A pistil specific promoter has been identified in the potato (*Solanum tuberosum* L.) SK2 gene, encoding a pistil-specific basic endochitinase (Ficker (1997) *Plant Mol. Biol.* 35:425-431). The Blec4 gene from pea (*Pisum sativum* cv. *Alaska*) is active in epidermal tissue of vegetative and floral shoot apices of transgenic alfalfa, making it a useful tool to target the expression of foreign genes to the epidermal layer of actively growing shoots. The activity of the Blec4 promoter in the epidermis of the shoot apex makes it particularly suitable for genetically engineering defense against insects and diseases that attack the growing shoot apex (Mandaci (1997) *Plant Mol Biol.* 34:961-965).

The invention also provides for use of tissue-specific plant promoters include a promoter from the ovule-specific *BEL1* gene described in Reiser (1995) *Cell* 83:735-742, GenBank No. U39944. Suitable seed specific promoters are derived from the following genes: *MAC1* from maize, Sheridan (1996) *Genetics* 142:1009-1020; *Cat3* from maize, GenBank No. L05934, Abler (1993) *Plant Mol. Biol.* 22:10131-1038; the gene encoding oleosin 18kD from maize, GenBank No. J05212, Lee (1994) *Plant Mol. Biol.* 26:1981-1987; vivparous-1 from *Arabidopsis*, Genbank No. U93215; the gene encoding oleosin from *Arabidopsis*, Genbank No. Z17657; *Atmyc1* from *Arabidopsis*, Urao (1996) *Plant Mol. Biol.* 32:571-576; the 2s seed storage protein gene family from *Arabidopsis*, Conceicao (1994) *Plant* 5:493-505; the gene encoding oleosin 20kD from *Brassica napus*, GenBank No. M63985; *napA* from *Brassica napus*, GenBank No. J02798, Josefsson (1987) *JBL* 26:12196-1301; the napin gene family from *Brassica napus*, Sjodahl (1995) *Planta* 197:264-271; the gene encoding the 2S storage protein from *Brassica napus*, Dasgupta (1993) *Gene* 133:301-302; the genes encoding oleosin a, Genbank No. U09118, and, oleosin B, Genbank No. U09119, from soybean; and, the gene encoding low molecular weight sulphur rich protein from soybean, Choi (1995) *Mol Gen, Genet.* 246:266-268. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins.

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as

used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

The invention also provides for use of tissue-specific promoters derived from viruses which can include, *e.g.*, the tobamovirus subgenomic promoter (Kumagai (1995) *Proc. Natl. Acad. Sci. USA* 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdager (1996) *Plant Mol. Biol.* 31:1129-1139).

In some embodiments, the nucleic acid construct will comprise a promoter functional in a specific plant cell, such as in a species of *Lactuca*, operably linked to an RG polynucleotide. Promoters useful in these embodiments include RG promoters. In additional embodiments, the nucleic acid construct will comprise a RG promoter operably linked to a heterologous polynucleotide. The heterologous polynucleotide is chosen to provide a plant with a desired phenotype. For example, the heterologous polynucleotide can be a structural gene which encodes a polypeptide which imparts a desired resistance phenotype. Alternatively, the heterologous polynucleotide may be a regulatory gene which might play a role in transcriptional and/or translational control to suppress, enhance, or otherwise modify the transcription and/or expression of an endogenous gene within the plant. The heterologous polynucleotide of the nucleic acid construct of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics.

Modifying and Inhibiting RG Gene Expression

The invention also provides for RG nucleic acid sequences which are complementary to the RG polypeptide-encoding sequences of the invention; *i.e.*, antisense RG nucleic acids. Antisense technology can be conveniently used to modify gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, *e.g.*,

Sheehy (1988) *Proc. Nat. Acad. Sci. USA* 85:8805-8809; Hiatt et al., U.S. Patent No. 4,801,340.

Antisense sequences are capable of inhibiting the transport, splicing or transcription of RG-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA. The transcription or function of targeted nucleic acid can be inhibited, *e.g.*, by hybridization and/or cleavage. One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind RG gene or message, in either case preventing or inhibiting the production or function of RG. The association can be through sequence specific hybridization. Such inhibitory nucleic acid sequences can, for example, be used to completely inhibit a plant disease resistance response. Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of RG message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes. The oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the complementary nucleic acid. One may screen a pool of many different such oligonucleotides for those with the desired activity.

Antisense Oligonucleotides

The invention provides for with antisense oligonucleotides capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such RG oligonucleotides using the novel reagents of the invention. In some situations, naturally occurring nucleic acids used as antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; Antisense Therapeutics, ed. Agrawal (Humana Press, Totowa, N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate,

phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described herein.

Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense RG sequences of the invention (for general background information, see, *e.g.*, Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

Inhibitory Ribozymes

The invention provides for with ribozymes capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing ribozymes and selecting the RG-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such RG ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence, or, preventing transport of the message from the nucleus to the cytoplasm. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of any plant gene. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described, *e.g.*, in Haseioff (1988) *Nature* 334:585-591.

In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid

molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single
5 ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio
10 of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead
15 motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16;
20 the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate
25 binding site which imparts an RNA cleaving activity to the molecule.

Sense Supression

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method
30 to modulate expression of endogenous genes see, Napoli et al., *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

Cloning of RG Polypeptides

Synthesis and/or cloning of RG polynucleotides and isolated nucleic acid constructs of the present invention are provided by methods well known to those of ordinary skill in the art. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of RG genes may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as roots and a cDNA library which contains the RG gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which RG genes or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned RG gene such as the genes disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species.

Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%.

Alternatively, the RG nucleic acids of the invention can be amplified from nucleic acid samples using a variety of amplification techniques, such as polymerase chain reaction (PCR) technology, to amplify the sequences of the RG and related genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.

Oligonucleotides can be used to identify and detect additional RG families and RG family species using a variety of hybridization techniques and conditions. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis)), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560; Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117); transcription amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); and, self-sustained sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA*, 87:1874); Q Beta replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316, Sambrook, and Ausubel, as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202; Arnheim (1990) *C&EN* 36-47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt, *Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995) *Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are described in Wallace, U.S. Pat. No. 5,426,039.

The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium as described earlier.

In some preferred embodiments, members of this class of pest resistance genes can be identified by their ability to be amplified by PCR primers based on the sequences disclosed here. Appropriate primers and probes for identifying RG sequences

from plant tissues are generated from comparisons of the sequences provided herein. See, e.g., Table 1. For a general overview of PCR see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

5 Briefly, the first step of each cycle of the PCR involves the separation of the nucleic acid duplex formed by the primer extension. Once the strands are separated, the next step in PCR involves hybridizing the separated strands with primers that flank the target sequence. The primers are then extended to form complementary copies of the target strands. For successful PCR amplification, the primers are designed so that the
10 position at which each primer hybridizes along a duplex sequence is such that an extension product synthesized from one primer, when separated from the template (complement), serves as a template for the extension of the other primer. The cycle of denaturation, hybridization, and extension is repeated as many times as necessary to obtain the desired amount of amplified nucleic acid.

15 In the preferred embodiment of the PCR process, strand separation is achieved by heating the reaction to a sufficiently high temperature for an sufficient time to cause the denaturation of the duplex but not to cause an irreversible denaturation of the polymerase (see U.S. Patent No. 4,965,188). Template-dependent extension of primers in PCR is catalyzed by a polymerizing agent in the presence of adequate amounts of four
20 deoxyribonucleotide triphosphates (typically dATP, dGTP, dCTP, and dTTP) in a reaction medium comprised of the appropriate salts, metal cations, and pH buffering system. Suitable polymerizing agents are enzymes known to catalyze template-dependent DNA synthesis.

 Polynucleotides may also be synthesized by well-known techniques as
25 described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer
30 sequence.

RG Proteins

The present invention further provides isolated RG proteins encoded by the RG polynucleotides disclosed herein. One of skill will recognize that the nucleic acid encoding a functional RG protein need not have a sequence identical to the exemplified genes disclosed here. For example, because of codon degeneracy a large number of nucleic acid sequences can encode the same polypeptide. In addition, the polypeptides encoded by the RG genes, like other proteins, have different domains which perform different functions. Thus, the RG gene sequences need not be full length, so long as the desired functional domain of the protein is expressed.

The resistance proteins are at least 25 amino acid residues in length. Typically, the RG proteins are at least 50 amino acid residues, generally at least 100, preferably at least 150, more preferably at least 200 amino acids in length. In particularly preferred embodiments, the RG proteins are of sufficient length to provide resistance to pests when expressed in the desired plants. Generally then, the RG proteins will be the length encoded by an RG gene of the present invention. However, those of ordinary skill will appreciate that minor deletions, substitutions, or additions to an RG protein will typically yield a protein with pest resistance characteristics similar or identical to that of the full length sequence. Thus, full-length RG proteins modified by 1, 2, 3, 4, or 5 deletions, substitutions, or additions, generally provide an effective degree of pest resistance relative to the full-length protein.

The RG proteins which provide pest resistance will typically comprise at least one of an LRR or an NBS. Preferably, both are present. LRR and/or NBS regions present in the RG proteins of the present invention can be provided by RG genes of the present invention. In some embodiments, the LRR and/or NBS regions are obtained from other pest resistance genes. See, e.g., Yu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11751-11756 (1996); Bent *et al.*, *Science*, 265: 1856-1860 (1994).

Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. Modification can also include swapping domains from the proteins of the invention with related domains from other pest resistance genes.

Pests that can be targeted by RG genes and proteins of the present invention include such bacterial pests as *Erwinia carotovora* and *Pseudomonas marginalis*. Fungal pests which can be targeted by the present invention include *Bremia lactucae*, *Marssonina panattoniana*, *Rhizoctonia solani*, *Olpidium brassicae*, root aphid, *Sclerotinia sclerotiorum* and *S. minor*, and *Botrytis cinerea* which causes gray mold. RG genes also provide resistance to viral diseases such as lettuce and turnip mosaic viruses.

Fusion Proteins

RG polypeptides can also be expressed as recombinant proteins with one or more additional polypeptide domains linked thereto to facilitate protein detection, purification, or other applications. Such detection and purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and plant disease resistant polypeptide may be useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding a plant disease resistant polypeptide of the invention and nucleic acid sequence encoding six histidine residues followed by thioredoxin and an enterokinase cleavage site (*e.g.*, see Williams (1995) *Biochemistry* 34:1787-1797). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described, see *e.g.*, Kroll (1993) *DNA Cell. Biol.*, 12:441-53.

Antibodies Reactive to RG Polypeptides and Immunological Assays

The present invention also provides antibodies which specifically react with RG proteins of the present invention under immunologically reactive conditions. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. "Immunologically reactive conditions" includes reference to conditions which allow an antibody, generated to a particular epitope of an antigen, to bind to that

epitope to a detectably greater degree than the antibody binds to substantially all other epitopes, generally at least two times above background binding, preferably at least five times above background. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols.

"Antibody" includes reference to an immunoglobulin molecule obtained by *in vitro* or *in vivo* generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')₂, Fab, Fv, rIgG, and, inverted IgG). See, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL). An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.* (1989) *Science* 246:1275-1281; and Ward, *et al.* (1989) *Nature* 341:544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14:309-314.

Many methods of making antibodies are known to persons of skill. A number of immunogens are used to produce antibodies specifically reactive to an isolated RG protein of the present invention under immunologically reactive conditions. An isolated recombinant, synthetic, or native RG protein of the present invention is the preferred immunogens (antigen) for the production of monoclonal or polyclonal antibodies.

The RG protein is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the RG protein. Methods of producing monoclonal or polyclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY.

Frequently, the RG proteins and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide

variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The antibodies of the present invention can be used to screen plants for the expression of RG proteins of the present invention. The antibodies of this invention are also used for affinity chromatography in isolating RG protein.

The present invention further provides RG polypeptides that specifically bind, under immunologically reactive conditions, to an antibody generated against a defined immunogen, such as an immunogen consisting of the RG polypeptides of the present invention. Immunogens will generally be at least 10 contiguous amino acids from an RG polypeptide of the present invention. Optionally, immunogens can be from regions exclusive of the NBS and/or LRR regions of the RG polypeptides. Nucleic acids which encode such cross-reactive RG polypeptides are also provided by the present invention. The RG polypeptides can be isolated from any number plants as discussed earlier. Preferred are species from the family *Compositae* and in particular the genus *Lactuca* such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

"Specifically binds" includes reference to the preferential association of a ligand, in whole or part, with a particular target molecule (i.e., "binding partner" or "binding moiety") relative to compositions lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a ligand and a non-target molecule. Nevertheless, specific binding, may be distinguished as mediated through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the ligand and the target molecule than between the ligand and non-target molecule. Specific binding by an antibody to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. The affinity constant of the antibody binding site for its cognate monovalent antigen is at least 10^7 , usually at least 10^8 , preferably at least 10^9 , more preferably at least 10^{10} , and most preferably at least 10^{11} liters/mole. A variety of immunoassay formats are appropriate for selecting antibodies specifically reactive with a particular protein. For

example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically reactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific reactivity. The antibody may be polyclonal but preferably is monoclonal. Generally, antibodies cross-reactive to such proteins as RPS2, RPM1 (bacterial resistances in *Arabidopsis*, L6 (fungal resistance in flax, PRF (resistance to *Pseudomonas syringae* in tomato), and *N*, (virus resistance in tobacco), are removed by immunoabsorption.

Immunoassays in the competitive binding format are typically used for cross-reactivity determinations. For example, an immunogenic RG polypeptide is immobilized to a solid support. Polypeptides added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above polypeptides to compete with the binding of the antisera to the immobilized RG polypeptide is compared to the immunogenic RG polypeptide. The percent cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with such proteins as RPS2, RPM1, L6, PRF, and *N*, are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with these non-RG resistance proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay to compare a second "target" polypeptide to the immunogenic polypeptide. In order to make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorption is detectable. The fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Production of transgenic plants of the invention

Isolated nucleic acid constructs prepared as described herein can be introduced into plants according techniques known in the art. In some embodiments, the introduced nucleic acid is used to provide RG gene expression and therefore pest resistance in desired plants. In some embodiments, RG promoters are used to drive expression of desired heterologous genes in plants. Finally, in some embodiments, the constructs can be used to suppress expression of a target endogenous gene, including RG genes.

To use isolated RG sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

A DNA sequence coding for the desired RG polypeptide, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant. An expression cassette will typically comprise the RG polynucleotide operably linked to transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the RG gene in the intended tissues of the transformed plant.

Such DNA constructs may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment and microinjection of plant cell protoplasts or embryogenic callus, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Transformation techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.* 3:2717-2722 (1984).

Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

Agrobacterium tumefaciens-mediated transformation techniques are well described in the scientific literature. See, for example Horsch *et al. Science* 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983). Although *Agrobacterium* is useful primarily in dicots, certain monocots can be transformed by *Agrobacterium*. For instance, *Agrobacterium* transformation of rice is described by Hiei *et al. Plant J.* 6:271-282 (1994). A particularly preferred means of transforming lettuce is described in Michelmore *et al., Plant Cell Reports*, 6:439-442 (1987).

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired RG-controlled phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the RG nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, Macmillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al. Ann. Rev. of Plant Phys.* 38:467-486 (1987).

The methods of the present invention are particularly useful for incorporating the RG polynucleotides into transformed plants in ways and under circumstances which are not found naturally. In particular, the RG polypeptides may be expressed at times or in quantities which are not characteristic of natural plants.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

Detection of RG Resistance Genes

The present invention further provides methods for detecting RG resistance genes in a nucleic acid sample suspected of comprising an RG resistance gene. The means by which the RG resistance gene is detected is not a critical aspect of the invention. For example, RG resistance genes can be detected by the presence of amplicons using RG resistance gene specific primers. Additionally, RG resistance genes can be detected by assaying for specific hybridization of an RG polynucleotide to an RG resistance gene. In some embodiments, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

In a typical detection method, the nucleic acid sample is contacted with an RG polynucleotide to form a hybridization complex. The hybridization complex may be detected directly (e.g., in Southern or northern blots), or indirectly (e.g., by subsequent primer extension during PCR amplification). The RG polynucleotide hybridizes under stringent conditions to an RG polynucleotide of the invention. Formation of the hybridization complex is directly or indirectly used to indicate the presence of the RG resistance gene in the nucleic acid sample.

Detection of the hybridization complex can be achieved using any number of well known methods. For example, the nucleic acid sample, or a portion thereof, may be assayed by hybridization formats including but not limited to, solution phase, solid phase, mixed phase, or *in situ* hybridization assays. Briefly, in solution (or liquid) phase hybridizations, both the target nucleic acid and the probe or primer are free to interact in the reaction mixture. In solid phase hybridization assays, probes or primers are typically linked to a solid support where they are available for hybridization with target nucleic in solution. In mixed phase, nucleic acid intermediates in solution hybridize to target nucleic acids in solution as well as to a nucleic acid linked to a solid support. In *in situ* hybridization, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the various hybridization assay formats: Singer *et al.*, *Biotechniques* 4(3):230-250 (1986); Haase *et al.*, *Methods in Virology*, Vol. VII, pp. 189-226 (1984); Wilkinson, "The theory and practice of *in situ* hybridization" In: *In situ Hybridization*, Ed. D.G. Wilkinson. IRL Press, Oxford University Press, Oxford; and *Nucleic Acid Hybridization: A Practical Approach*, Ed. Hames, B.D. and Higgins, S.J., IRL Press (1987).

The effect of the modification of RG gene expression can be measured by detection of increases or decreases in mRNA levels using, for instance, Northern blots. In addition, the phenotypic effects of gene expression can be detected by measuring nematode, fungal, bacterial, viral, or other pest resistance in plants. Suitable assays for determining pest resistance are well known. Micheltore and Crute, *Trans. Br. mycol. Soc.*, 79(3): 542-546 (1982).

The means by which hybridization complexes are detected is not a critical aspect of the present invention and can be accomplished by any number of methods currently known or later developed. RG polynucleotides can be labeled by any one of several methods typically used to detect the presence of hybridized nucleic acids. One common method of detection is the use of autoradiography using probes labeled with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P , or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half lives of the selected isotopes. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation. Labeling the RG polynucleotide is readily achieved such as by the use of labeled PCR primers.

The choice of label dictates the manner in which the label is bound to the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by using DNA synthesizers, by nick translation with DNA polymerase I, by tailing radioactive DNA bases to the 3' end of probes with terminal deoxynucleotidyl transferase, by treating single-stranded M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive deoxynucleotides, dNTP, by transcribing from RNA templates using reverse transcriptase in the presence of radioactive deoxynucleotides, dNTP, or by transcribing RNA from vectors containing specific RNA viral promoters (e.g., SP6 promoter) using the corresponding RNA polymerase (e.g., SP6 RNA polymerase) in the presence of radioactive ribonucleotides rNTP.

The probes can be labeled using radioactive nucleotides in which the isotope resides as a part of the nucleotide molecule, or in which the radioactive component is attached to the nucleotide via a terminal hydroxyl group that has been esterified to a radioactive component such as inorganic acids, *e.g.*, ³²P phosphate or ¹⁴C organic acids, or esterified to provide a linking group to the label. Base analogs having nucleophilic linking groups, such as primary amino groups, can also be linked to a label.

Non-radioactive probes are often labeled by indirect means. For example, a ligand molecule is covalently bound to the probe. The ligand then binds to an anti-ligand molecule which is either inherently detectable or covalently bound to a detectable signal system, such as an enzyme, a fluorophore, or a chemiluminescent compound. Enzymes of interest as labels will primarily be hydrolases, such as phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescers include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol.

Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

Probes can also be labeled by direct conjugation with a label. For example, cloned DNA probes have been coupled directly to horseradish peroxidase or alkaline phosphatase, (Renz. M., and Kurz, K. (1984) A Colorimetric Method for DNA Hybridization. *Nucl. Acids Res.* 12: 3435-3444) and synthetic oligonucleotides have been coupled directly with alkaline phosphatase (Jablonski, E., *et al.* (1986) Preparation of Oligodeoxynucleotide-Alkaline Phosphatase Conjugates and Their Use as Hybridization Probes. *Nuc. Acids. Res.* 14: 6115-6128; and Li P., *et al.* (1987) Enzyme-linked Synthetic Oligonucleotide probes: Non-Radioactive Detection of Enterotoxigenic *Escherichia Coli* in Faeca Specimens. *Nucl. Acids Res.* 15:5275-5287).

Definitions

Units, prefixes, and symbols can be denoted in their SI accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation, respectively. The

headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

5 As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

10 As used herein, "pest" includes, but is not limited to, viruses, fungi, nematodes, insects, and bacteria.

 As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.

 As used herein, "RG gene," alternatively referred to as "RLG gene," is a gene encoding resistance to plant pests, such as viruses, fungi, nematodes, insects, and bacteria, and which hybridizes under stringent conditions and/or has at least 60% sequence identity at the deduced amino acid level to the exemplified sequences provided herein. RG genes encode "RG polypeptides," alternatively referred to as "RLG polypeptides," which can comprise LRR motifs and/or NBS motifs. The RG polypeptides encoded by RG genes have at least 55% or 60% sequence identity, typically at least 65% sequence identity, preferably at least 70% sequence identity, often at least 75% sequence identity, more preferably at least 80% sequence identity, and most preferably at least 90% sequence identity at the deduced amino acid level relative to the exemplary RG sequences provided herein. The term "RG family" or "RG family genus" or "genus" includes reference to a group of RG polypeptide sequence species that have at least 60% amino acid sequence identity, and, the nucleic acids encoding these polypeptides. The individual species of a genus, i.e., the members of a family, typically are genetically mapped to the same locus.

 As used herein, "RG polynucleotide" includes reference to a contiguous sequence from an RG gene of at least 18, 20, 25, 30, 40, or 50 nucleotides in length, up to

at least about 100 or at least about 200 nucleotides in length. In some embodiments, the polynucleotide is preferably at least 100 nucleotides in length, more preferably at least 200 nucleotides in length, most preferably at least 500 nucleotides in length. Thus, RG polynucleotide may be a RG gene or a subsequence thereof.

5 As used herein, "isolated," when referring to a molecule or composition, such as, for example, an RG polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (*e.g.*, RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, an RG polypeptide or nucleic acid is considered isolated
10 when it has been isolated from any other component with which it is naturally associated, *e.g.*, cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-
15 PAGE) or high performance liquid chromatography (HPLC).

 The term "nucleic acid" or "nucleic acid molecule" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or
20 improved binding properties, for the purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester,
25 sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see Oligonucleotides and Analogues, a Practical Approach, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; Antisense
30 Research and Applications (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO

97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "exogenous nucleic acid" refers to a nucleic acid that has been isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is found in nature. The term encompasses both nucleic acids originally obtained from a different organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed. invention.

The term "recombinant," when used with reference to a cell, or to the nucleic acid, protein or vector refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new moiety or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise expressed at a different level, typically, under-expressed or not expressed at all. The term "recombinant means" encompasses all means of expressing, *i.e.*, transcription or translation of, an isolated and/or cloned nucleic acid *in vitro* or *in vivo*. For example, the term "recombinant means" encompasses techniques where a recombinant nucleic acid, such as a cDNA encoding a protein, is inserted into an expression vector, the vector is introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from different sources into one vector for expression of a fusion protein, constitutive expression of a protein, or inducible expression of a protein, such as the plant disease resistant, or RG. polypeptides of the invention.

The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe, and can be readily determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and annealing conditions, see, *e.g.*, Sambrook and Ausubel.

The terms "stringent hybridization," "stringent conditions," or "specific hybridization conditions" refers to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as an RG nucleic acid in an expression vector of the invention but not to a non-RG sequence. Stringent conditions are sequence-dependent. Thus, in one set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of RG nucleic acids of the invention. In another set of stringent conditions (less stringent) an oligonucleotide probe will hybridize to all species of the invention's genus but not to non-RG nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5⁰C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30⁰C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60⁰C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45⁰C for 15 minutes (see Sambrook for a description of SSC buffer). An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40⁰C for 15 minutes. a signal to noise ratio of 2x (or higher) than that observed for an unrelated

probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative
5 substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in, *e.g.*, Sambrook, Tijssen (1993) *supra*.

As used herein "operably linked" includes reference to a functional linkage
10 between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

15 In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained herein, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and
20 translated to produce a functional RG polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "RG polynucleotide sequence". In addition, the term specifically includes those full length sequences substantially identical (determined as described herein) with an RG gene sequence which
25 encode proteins that retain the function of the RG protein. Thus, in the case of RG genes disclosed here, the term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring resistance to nematodes, bacteria, viruses, fungi, insects or other pests on a transgenic plant comprising the sequence.

30 Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence, as described below. The term

"complementary to" is used herein to mean that the complementary sequence is identical to all or a specified contiguous portion of a reference polynucleotide sequence.

The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences or the polypeptides of the invention, when optimally aligned, as with, for example, the programs PILEUP, BLAST, GAP, FASTA or BESTFIT (see discussion, *supra*). "Percentage amino acid/nucleic acid sequence identity" refers to a comparison of the sequences of two polypeptides/nucleic acids which, when optimally aligned, have approximately the designated percentage of the same amino acids/nucleic acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two RG nucleic acids or polypeptides which, when optimally aligned, have 60% identity. For example, in one embodiment, nucleic acids encoding RG polypeptides of the invention comprise a sequence with at least 50% nucleic acid sequence identity to SEQ ID NO:1. In other embodiments, the RG polypeptides of the invention are encoded by nucleic acids comprising a sequence with at least 50% sequence identity to SEQ ID NO:1, or, are encoded by nucleic acids comprising SEQ ID NO:1, or, have at least 60% amino acid sequence identity to the polypeptide of SEQ ID NO:2.

"Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 55% or 60% sequence identity, generally at least 65%, preferably at least 70%, often at least 75%, more preferably at least 80% and most preferably at least 90%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding

identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 55% or 60%, preferably at least 70%, more preferably at least 80%, and most preferably at least 95%. Polypeptides having "sequence similarity" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under appropriate conditions. Appropriate conditions can be high or low stringency and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C to about 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50°C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Nucleic acids of the invention can be identified from a cDNA or genomic library prepared according to standard procedures and the nucleic acids disclosed here used as a probe. Thus, for example, stringent hybridization conditions will typically include at least one low stringency wash using 0.3 molar salt (*e.g.*, 2X SSC) at 65°C. The washes

are preferably followed by one or more subsequent washes using 0.03 molar salt (e.g., 0.2X SSC) at 50°C, usually 60°C, or mosre usually 65°C. Nucleic acid probes used to identify the nucleic acids are preferably at least 100 nucleotides in length.

As used herein, "nucleotide binding site" or "nucleotide binding domain" ("NBS") includes reference to highly conserved nucleotide-, *i.e.*, ATP/GTP-, binding domains, typically included in the "kinase domain" of kinase polypeptides, such as a kinase-1a, kinase 2, or a kinase 3a motif, as described herein. For example, the tobacco N and Arabidopsis RPS2 genes, among several recently cloned disease-resistance genes, share highly conserved NBS sequence. Kinase NBS subdomains further consist of three subdomain motifs: the P-loop, kinase-2, and kinase-3a subdomains (Yu (1996) *Proc. Acad. Sci. USA* 93:11751-11756). As discussed in detail herein, examples include the *Arabidopsis* RPP5 gene (Parker (1997) *supra*), the *A. thaliana* RPS2 gene (Mindrinos (1997) *supra*), and the flax L6 rust resistance gene (Lawrence (1995) *supra*) which all encode proteins containing an NBS; and Mindrinos (1994) *Cell* 78:1089-1099; and Shen (1993) *FEBS* 335:380-385. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can identify members having NBS domains, including any of the genus of NBS-containing plant disease resistant polypeptides of the invention.

As used herein, "leucine rich region" ("LRR") includes reference to a region that has a leucine content of at least 20% leucine or isoleucine, or 30% of the aliphatic residues: leucine, isoleucine, methionine, valine, and phenylalanine, and arranged with approximate repeated periodicity. The length of the repeat may vary in length but is generally about 20 to 30 amino acids. An LRR-containing polypeptide typically will have the canonical 24 amino acid leucine-rich repeat (LRR) sequence, which is present in different proteins that mediates molecular recognition and/or interaction processes; as described in Bent (1994) *Science* 265:1856-1860; Parker (1997) *Plant Cell* 9:879-894; Hong (1997) *Plant Physiol.* 113:1203-1212; Schmitz (1997) *Nucleic Acids Res.* 25:756-763; Hipkind (1996) *Mol. Plant Microbe Interact.* 9:819-825; Tornero (1996) *Plant J.* 10:315-330; Dixon (1996) *Cell* 84:451-459; Jones (1994) *Science* 266:789-793; Lawrence (1995) *Plant Cell* 7:1195-1206; Song (1995) *Science* 270:1804-1806; as discussed in further detail *supra*. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can

identify polypeptides having LRR domains, including any member of the genus of LRR-containing RG polypeptides of the invention.

The term "promoter" refers to a region or sequence determinants located upstream or downstream from the start of transcription and which are involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A
5 "plant promoter" is a promoter capable of initiating and/or regulating transcription in plant cells; see also discussion on plant promoters, *supra*.

The term "constitutive promoter" refers to a promoter that initiates and helps control transcription in all tissues. Promoters that drive expression continuously under physiological conditions are referred to herein as "constitutive" promoters and are
10 active under most environmental conditions and states of development or cell differentiation; see also detailed discussion, *supra*.

The term "inducible promoter" refers to a promoter which directs transcription under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by
15 inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters; see also detailed discussion, *supra*.

The term "abscission-induced promoter" or "abscission promoter" refers to a class of promoters which are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. When the plant disease resistant polypeptide-encoding nucleic acid is under the control of an abscission promoter, rapid cell death, induced by expression of the invention's polypeptide, accelerates and/or accentuates abscission of the plant part,
20 increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like; see also detailed discussion, *supra*.

The term "tissue-specific promoter" refers to a class of transcriptional control elements that are only active in particular cells or tissues. Examples of plant promoters under developmental control include promoters that initiate transcription only
30 (or primarily only) in certain tissues, such as roots, leaves, fruit, ovules, seeds, pollen, pistils, or flowers; see also detailed discussion, *supra*.

As used herein "recombinant" includes reference to a cell, or nucleic acid, or vector, that has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

As used herein, a "recombinant expression cassette" or "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter.

As used herein, "transgenic plant" includes reference to a plant modified by introduction of a heterologous polynucleotide. Generally, the heterologous polynucleotide is an RG structural or regulatory gene or subsequences thereof.

As used herein, "hybridization complex" includes reference to a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acids with each other.

As used herein, "amplified" includes reference to an increase in the molarity of a specified sequence. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning methods, host cells, and *in vitro* amplification methodologies are well-known to persons of skill.

As used herein, "nucleic acid sample" includes reference to a specimen suspected of comprising RG resistance genes. Such specimens are generally derived, directly or indirectly, from lettuce tissue.

The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described *supra*.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

5

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1

10 Example 1 describes the use of PCR to amplify RG genes from lettuce.

Multiple primers with low degeneracy, particularly at the 3' end, were designed based on the sequences of two known resistance genes from tobacco and flax.

DNA Templates

15 Lettuce genomic DNA was extracted from cultivar Diana and a mutant line derived from cultivar Diana using a standard CTAB protocol. To generate cDNA templates, RNA was isolated from cultivar Diana and the mutant following standard procedures; first strand cDNA was synthesized using Superscript reverse transcriptase from 1 Φ g total RNA as specified by the manufacturer (Life Technologies). BAC (bacterial artificial chromosome) clones from the *Dm3* region were isolated from a BAC library of 20 over 53,000 clones using marker AC15 that was known to be closely linked to *Dm3*. Bacterial plasmids containing clones of *L6* and *RPS2* were used as positive controls.

PCR with degenerate oligonucleotide primers

25 Oligonucleotide primers were designed based on conserved motifs in the nucleotide binding sites (NBS) of *L6*, *RPS2*, and *N*. Eight primers were made corresponding to the GVGKTT motif in the sense direction; each had 64-fold degeneracy. Six primers were made to the GLPLAL motif in the anti-sense direction; with either 16 or 256-fold degeneracy (Table 1).

30 Oligonucleotides included 14-mer adaptors of (CUA)₄ at the 5' end of the sense primers and (CAU)₄ at the 5' end of the antisense primers to allow rapid cloning of the PCR products into pAMP1 (Life Technologies).

PCR amplification was performed in 50 Φ l reaction volume with 1 Φ M of each of a pair of sense and antisense primers. The templates were denatured by heating to 94EC for 2 min. This was followed by 35 cycles of 30 sec at 94EC, 1 min at 50EC, 2 min at 72EC, with a single final extension of 5 min at 72EC. 25 ng of genomic DNA or cDNA was used. BAC clones as templates required less. The final dNTP concentration was 0.2 mM; $MgCl_2$ was 1.5 mM.

Forty-eight combinations of sense and antisense primers were tested on a panel of nine templates consisting of two genomic DNA samples, two cDNA preparations, three BAC clones and plasmids containing *L6* and *RPS2* as positive controls.

Amplification from *L6* and *RPS2* resulted in fragments of 516 and 513 respectively. Seven combinations of primers resulted in fragments of approximately this size with multiple templates (Table 2). Primers that gave RLG products were: PLOOPAA, PLOOPAG, PLOOPGA, PLOOPGG, PLOOPAC, GLPL3, GLPL4.

(Intentionally left blank)

Table 1

DEGENERATE PRIMER SEQUENCES for NBS PCR

Sense primers based on GVGKTT amino acid sequence from L6, N and rps2 PLOOP motif:

PLOOPAG 5' GGN GTN GGN AAA ACG AC 3'

PLOOPAA 5' GGN GTN GGN AAA ACA AC 3'

PLOOPAT 5' GGN GTN GGN AAA ACT AC 3'

PLOOPAC 5' GGN GTN GGN AAA ACC AC 3'

PLOOPGG 5' GGN GTN GGN AAG ACG AC 3'

PLOOPGA 5' GGN GTN GGN AAG ACA AC 3'

PLOOPGT 5' GGN GTN GGN AAG ACT AC 3'

PLOOPGC 5' GGN GTN GGN AAG ACC AC 3'

Antisense primers based on GLPLAL amino acid sequence:

GLPL1 5' AGN GCN AGN GGN AGG CC 3' .

GLPL2 5' AGN GCN AGN GGN AGA CC 3' ;

GLPL3 5' AGN GCN AGN GGN AGT CC 3' '

GLPL4 5' AGN GCN AGN GGN AGC CC 3'

GLPL5 5' AAN GCC AAN GGC AAA CC 3' .

GLPL6 5' AAN GCC AAN GGC AAT CC 3'

TABLE 2. Characteristics of RLGs isolated from lettuce.

	Template	Primers	Number ^a	Size ^b (bp)	Copy number ^c	Dm linkage
5	RLG1	genomic DNA	PLOOPGA+GLPL6	6/6	522	DM4,
		cDNA	PLOOPGA+GLPL6	1/5		DM13
		genomic DNA	PLOOPAA+GLPL6	5/5		
		cDNA	PLOOPAA+GLPL6	1/1		
	RLG2	BACH8	PLOOPGG+GLPL3	3/3	510	DM1, Dm3
	RLG3	genomic DNA	PLOOPGA+GLPL4	3/6	461	Dm5 Dm8
10	RLG4	genomic DNA	PLOOPGA+GLPL4	1/6	524	

^a Number of RLG sequences out of total number of clones sequenced.

^b Size of fragment amplified from the nucleotide binding domain.

^c Estimated copy number from genomic Southern blot analysis and numbers of clones in the BAC library.

Example 2

Example 2 describes the genetic analysis used to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes.

Bulked segregant analysis was performed to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes. DNA from individuals were pooled for each susceptible and resistant bulk. Amplified products were then mapped by RFLP analysis from our intraspecific mapping population. Resistances from four clusters of resistance genes as well as over six hundred markers have now been mapped on this population. Linkage analysis was done using JIONMAP or MAPMAKER mapping programs. Due to a suppression of recombination in the *Dm3* region, sequences were mapped relative to *Dm3* using a panel of deletion mutants that provided greater genetic resolution than the mapping population (Anderson *et al.* 1996). All blots were washed twice at 63EC in 2x SSC/1% SDS for 20 min, followed by one wash at 63EC in 1x SSC/0.1% SDS for 10 or 30 min.

Most of the RLG sequences were analyzed by bulked segregant analysis (BSA) using pools of resistant and susceptible individuals for each of the four clusters of resistance genes. In genomic Southern analyses, all the RLGs revealed numerous fragments of varying intensity. The numbers of bands was highly dependent of the stringency of hybridization. BSA demonstrated that RLG1 was linked to the *Dm4*, 7 and *Dm13* clusters. Segregation analysis confirmed this linkage.

RLG2 was derived from BAC H8 that was known to be from the *Dm3* region. BSA with RLG2 demonstrated that the polymorphic bands that distinguished the parents of our mapping population mapped to the *Dm1*, *Dm3* cluster. Several bands absolutely cosegregated with *Dm1* or *Dm3*. To provide finer genetic resolution, RLG2 was also mapped using a panel of *Dm3* deletion mutants. A number of fragments were missing in largest deletion mutant demonstrating that several RLG2 family members are physically located very close to *Dm3*. No fragment was missing in all deletion mutants; however, this is not unexpected as there is extensive duplication within the region.

Example 3

Example 3 describes the screening of a bacterial artificial chromosome library.

Over 53,000 BAC clones containing lettuce genomic DNA were screened with two of the amplified products. High density filters each containing 1536 clones were hybridized to ³²P labelled probes. Filters were washed at 65EC with 40 mM Na₂PO₄/0.1 % SDS for 5 min followed by 20 min in the same solution.

To isolate additional RLG sequences we screened our genomic BAC library. Clones were identified that hybridized to RLG1 and RLG2. Nearly all the clones that hybridized to RLG2 also hybridized to marker AC15 that had already been shown by deletion mutant analysis to be clustered around *Dm3*. This provided further evidence for clustering of RLG2 sequences.

Using primers conserved within each family, part of the NBS was amplified from each unique BAC clone and sequenced. This revealed that members within each family varied from 64% identical at the deduced amino acid level. The most divergent members only weakly cross-hybridized to each other. Currently, RLG sequences are

considered to be part of the same family of sequences if they are at least 55% identical at the deduced amino acid level and map to the same region of the chromosome.

Example 4:

5 Example 4 describes the cloning, identification, sequencing and characterization of RG polynucleotide sequences; including use of RG sequences from plasmid and PCR products.

Doubled stranded plasmid DNA clones and PCR products were sequenced using an ABI377 automated sequencer and fluorescently labelled di-deoxy terminators. Sequences were assembled using Sequencher (Genecodes), DNASTar (DNASTar) and Genetics Computer Group (GCG, Madison, WI) software. Database searches were performed using BLASTX and FASTA (GCG) algorithms.

Sequences flanking the NBS region for RLG2 and for some of RLG1 were obtained by a series of IPCR and the products sequenced directly. IPCR worked less well for RLG1. Therefore RLG1 was subcloned from a BAC clone into pBSK (Stratagene) and the double stranded plasmid sequenced by long range sequencing.

Initially, a total of 30 clones were sequenced. Three of these seven primer combinations yielded sequences that comprised continuous open reading frames with sequence identity to the NBS of known resistance genes. Seven out of 10 clones amplified from genomic DNA with the primer pair PLOOPGA/GLP6 were 522 bp long; they were identical to each other and named RLG1. All six clones amplified from genomic DNA or cDNA using the primers PLOOPAA/GLP6 were similar/the same as RLG1. All three clones sequenced from BAC clone H8 were 510 bp long, identical to each other but different from RLG1 and were therefore designated RLG2. The 11 clones sequenced from four other primer combinations had no similarity to any NBS motifs and therefore were not studied further. Therefore, sequencing resulted in the identification of clones containing NBS motifs representing four RLG sequences.

Comparison of the deduced amino acid sequences of RLG1 and RLG2 to those of known resistance genes revealed that RLG1 and RLG2 are as similar to each other as they are to resistance genes from other species and that this is the same level of identity shown between the known resistance genes (Table 3). The percent identity (upper quadrant) and percent identity (lower quadrant) were determined using the MEGALIGN

routine of the DNASTAR package. Identity refers to the proportion of identical amino acids; identity refers to the proportion of identical and similar amino acids and takes into account substitutions of amino acids with similar chemical characteristics. RG1 and RG2 are as similar to each other and to cloned resistance genes as cloned resistance genes from a variety of species are to each other. L6, resistance to *Melampsora lini* in flax (Lawrence *et al.*, 1995). N, resistance to tobacco mosaic virus in tobacco (Whitham *et al.*, 1994). PRF, required for resistance to *Pseudomonas syringae* in tomato. RPS2, resistance to *Pseudomonas syringae* in *Arabidopsis thaliana* (Bent *et al.*, 1994; Mindrinos *et al.*, 1994). RPM1, resistance to *Pseudomonas syringae* pv. *maculicola* in *A. thaliana* (Grant *et al.*, 1995). The initial RG1 and RG2, sequences were amplified from lettuce using degenerate primers.

Table 3

IDENTITIES OF

RESISTANCE GENE HOMOLOGUES

		RG1	RG2	RG3	RG4	N gene	RPS2
Lettuce	RG1	***	22.7	15.0	29.2	25.4	23.8
Lettuce	RG2		***	32.2	21.6	22.7	33.0
Lettuce	RG3			***	17.2	15.0	32.8
Lettuce	RG4				***	44.3	22.7
Tobacco	N gene					***	21.6
<i>Arabidopsis</i>	RPS2						***

The regions homologous to the primers are included in this analysis as the genomic sequences for RLG1 and RLG2 were determined by IPCR. Interestingly, the genomic sequences for RLG1 exactly matched that of the primers used.

To obtain further evidence that we had amplified resistance genes, we amplified the regions flanking the NBSs of RLG1a and RLG2a by IPCR of BAC clones. These products were then directly sequenced without cloning to minimize the introduction of PCR artifacts. Sequence analysis of the 5' regions failed to detect any homology to known resistance genes. However, the sequence of the 3' region contained leucine-rich

repeats (LRRs). When this sequence was used to search GENBANK using BLASTX, it detected identity to the *Arabidopsis* resistance gene, *RPS2*. This region does not contain as regular LRRs as in some resistance genes; however, the repeat structure seems to be consistent with that of the flax resistance gene, *L6*. Therefore, the presence of an LRR region is further evidence that the sequences we amplified using degenerate oligonucleotide primers are probably resistance genes.

The sequences of the IPCR products also provided the genomic sequences of the regions complementary to the sequences of the degenerate oligonucleotide primers.

The genomic sequences for RLG1 were identical to one of the primers in the mixture.

The RLG sequences are resistance genes as supported by three criteria: the presence of multiple sequence motifs characteristic of resistance genes, genetic cosegregation with known resistance genes, and their existence as clustered multi-gene families. The presence of LRR regions in a similar position relative to the NBS as in cloned resistance genes provides stronger evidence than relying solely sequence similarity between NBS regions.

The clustering of RLG sequences at the same position as the known clusters of resistance genes make them strong candidates for encoding resistance genes. The hybridization patterns and genetic distribution of the RLG sequences are similar to that of cloned resistance genes in other species. Most of these hybridize to small multigene families and preliminary genetic evidence indicates that they are clustered in the genome. Therefore, the degenerate primers that we designed from other resistance genes seemed to have been specific enough to amplify resistance genes rather than P-loop containing proteins in general.

(intentionally left blank)

SEQ ID NO: 1

RLG1A
(Strand)

```
1 ATCGTAACCGTTCGTACGAG ANCGCTGTCCTCCTTCATC TTTTGTCAATATGTCATATTC TCATNATMTGCCACATNT
81 AATTTTGTGGTTATTTTAAA TTAATTTTATTCACATAGT CATTTTATGAGTTTTCATAT TTTATTGAGTTTCACATAAT
161 ATTTAAATGTAATAACAATA AATGCATATTTATTTTCTT TAAATAAACGCATATAATAT ATAGATTAAAAATCATATAAT
241 ACATAGGTTAAATCCTATA ATACATATGTTTCATCCCCAG TTTATTATATATGTCATCC TTAATTTATTTATTTATTTAT
321 TTATTAGAGTAGATGATCTT TGTGATATTAATAATTAAT TTTGTCAAAATTTAAATTA TTAATAATCCCAATTTGA
401 ATAAAAATTAATAAATGGN CCCACCATAGTCCATCACT TTTTCAGCTCATCAATATCG TGAGTATCTCCTCTCGTTTC
481 CACCCTAATCAATATTTCCA GCGAATGACAGACTCCTACG CCGTTTCTGAATTTGCGTTC CGACACTGTTTCATTGAAGGA
561 GATAATAATCAATGGAGC TGCTCCAATGTTTCATGCTG ATGAAAGGTGAAATGTATGT GAAGANAATGTCAGCGATCN
641 ATCTCCATCCGGAACCCACC ACATTATCAGTGTACCACCA AACCCTCAAACGGYGGAA GTAGRRAKACWRAAAGTCA
721 TGAAGAATAGATTATTTTGG TCCTCATGGGCTGACTGAGG AGCGGGTTTAGTTCATCATT TTTCTTTGANCAAGAATTA
801 TCGGTCCATCGAATTTTAC ATCGACAAAGAAGTTTCACT TCGCAATGTTTGTGTAACA ATTTTAATCTTTTATCTT
881 TCGTGAAGACTCCTCAATT GCAACTTGCAACTTGCAACT TTTGGGCCACAAAATTTGTG GTGGCGTTAATTTAATCCA
961 CATATTCACGTAAACAATA ATTCAAATCGATCTCTGTTT CTCTTATCATATTAACGAT TGTGATAATGAAATCATTC
1041 CGCTTCATCCATTTTCATCCA CATCTATACTATATCTCTG GAAAGCTGGCATYTGAAGC CTCTGAAGAAGATGTTTCGCT
1121 CCTTCTTGACAGTGGTGT TTTGAGCTGGCATYTGAAGC TTTGAGCTGGCATYTGAAGC CTCTGAAGAAGATGTTTCGCT
1201 CTTAAGAAATGAAGGAGAC ATTAGACCAAAATCCAAGATC TGCTTAACGATGCTTCCAG GAGGATGAAGAACTAATCC
1281 CGTTAAAGATGCGTGAATG ATCTCCAACATTTGGCTTAT GACATAGACGACCTACTTGA CAAGTTGTGTCACAAGTTTC
1361 TTCANCGTGAATGACCGAG GAGGCTGGAGCCTCTCCAG CCHCCAGGTTACAAGAACTG GTAGAGGCAAAAATATCT
1441 TCACAAAGTAATAGGATGCA TGCCAAAGTATAGATATTTG AGGTATGAGGCGCTTTTGGT AGATGAAAGCGGTACTGTG
1521 TGGTTTAAAGTGTGATAACAT ATGAAAGCAAAAATTTGAA GGGGATAAAGATGAATCAG GGAGTCAAAACTTCAGCATC
1601 GACGTGAAGACTCCTCAATT AAATGCTGGAGAAGCTGTT TAGCTAGACTTTTGTATGAT GAAAAGAAAGTGAAGGATCA
1681 GTGCCATAGTTGGTATGGG TGGAGTTGGTAAACAACCTC AGTGTTCCTCAATATAAGCAG AGTTATTTATCAATCTGTGA
1761 CTTCGAACTCAGGCTTGGG TTTGTGTTTCTGATGAGTTC AGAAGCTCTTAAAGAGAAAC TTAGGAACCAAGCTATTTCT
1841 CTGGGAAAGAAAGGAGTGT GTCTGAAAGCTATGGTGAAT GGGAGAAATTAGTGGGCCCA TTCCTTGGGGGCTCTCTGG
1921 ATAGTTTGTGATGATGTTG CTTCGAAAGGAGCAATTCCTC AGAAGCTGGGCTTTTCTCA TCAAGACCTCTCTGGAGGCT
2001 AAGTGAATATCATGACAA CTCTTGTGTTGCTCAACAGC ATTTGGTGTACCAACTTTG ATTCCATCCCAACTCAAGG
2081 TATCAACAGATGATGCTTTG GAAGAAATGTGATGGCTTAC CTCTAGCTTAAAGAACACTT GGAAGGTTTATTAAGGCAAA
2161 CCACATGGAGGAGTTTGT AGGAGCTGTGGATAGTGAG ATATGGAGGTTAGGAAAGAG CGATGAGATGTTTCCGGCTC
2241 AACAGACGAGGAACATGGA CTTTCTGCGCTTTTGAAGCT RTTGTGTCATATGCTCCT TGTTCCTCAAGGACTATGAG
2321 TTAGACTAAGCTACATGAT TCTATGTTGGATGGCAGAGT GGTTTTGGCACCACCACT AYAACAAGTCAAGCAACG
2401 TTTGACAAAGGAGTTGAT AAGAGTTRTGTCAAGRTCR TTTTTCACATGCTCCTAA TRRCAAACTSTGTTGTGTA
2481 KTTGGGTCTTGAATATTTT TGGCTACATTTGTTCTGCG RAAGCACCAACATATGTCAT TGTATGTGAGRATTACATA
2561 TGCATGACCTAATGAATGAT TTGGCTACATTTGTTCTGCG TCTGTGGGGTGGTAGAAGA TTGGAAGATGTTTACTTAT
2641 TTTAGGATGSAATCTTTGGA RAAGCACCAACATATGTCAT TGTATGTGAGRATTACATA TTRRTCTTAYAATAASYRAG
2721 ATTTAGAGGAGCTAAAAAT TGAGAACATTTTTCAGATG GTTAAGGGTCTTRAKTTTGA ATCAACACTTTACCGGAATA
2801 CAAACAGGCTCTGAATGAC WTACTTCARGATTTACCATT TTAATCTATCAGRAACTTWA KTTGCCCAARACCTTCTCAA
2881 GTACCAAAATTCGTTGGTAG TATGAASCACTTGGCGTATC GGCTGTGAMTATTTAGTTAA TARGGATTTGGTARTTGAAA
2961 TKTCTGCAATCTTTATAAT TACARACCTGATTTGTCTCT TTAATCTATCAGRAACTTWA AAYCTCCATGGGAAATTTG
3041 ASCTTAAAAATTTGCASCAT TTTGACATGAGGGTACTCC ACGTTAAGCGAACTTGTCTC AAAAAAGGTTWAATGARITA
3121 ARTCECAAACTCTCTTVMG TAACATTTGGCATAGCAATAA ATGGGAACACTTGAAGAAAG AATTCCTCAATGAAGTATGC
3201 TATTGGCGGCTGGGAAAAA TGGAAAAATGCMGTGGATGC TAGGGGTATAGAGTTTCCA AATTGGGTGTTGTTNCACTA
3281 NAAACTCGRVTGGGGGTGA TRAATTTAATGTTTTCGGAA AGANTGTTTTACGTAGTTTC ATCAATCACCAGTGGGAAA
3361 CTCATAATGGTACTCTANAA GTGTTTCATGGTGTATGAAAA GTATGATAGGGTTCCTTGGG GCGGTAGAAGAAATAAGCAT
3441 GGGTTTCTGAAACTAGAGAT TACTGATGAGATGTTGAGAG GATATTTGTTGGGAATCAGAA TATGAATTTAAGAAGTTTG
3521 TAGATGATATTTTCAGGGCY TGGTGAAGTTTGGGGAGAAA TTGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
3601 CCAATCTTGTAAATGAATAA TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
3681 ATTTAGGTGAATGTGAAAAA TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
3761 ACATCTTTTAGGAGGTTGAA TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
3841 TATGCAATGTTGATTCAA TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
3921 ATTGCAAGAGCTTTCCGAA TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
4001 GAATCAATGATATACGTAA TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
4081 TATATCAAACTGTCGAGTR TGGTGAAGTTTGGGGAGAAA TGGTGAAGTTTGGGGAGAAA TTAATAGTGGGAGCAGCTTA
4161 GACAGCGAATTTGTTACGAA CCGTTACGATTCGACTGGCC GTCTTTTT
```

SEQ ID NO: 2

RLG1B

[Strand]

```
1 AACCGTTGCT ACGAGAATCG CTGTCTCTCT CTTCCTGTAA TATAATGATA AGAAAAATA TGATTAAAGG
71 TTTAAATCCA AAATCCATTA TTCCACCGGT GATATGATGC ACTAGCTGTA GTATGCAAAA ACAGTATTAT
141 AAATGCTAAC CAAAACAGCA GCTAAGAAAC AATATAAATA ATGGTTTGAA TCGTCTTTC TCCGTACAQT
211 CATTTCTTCC AAATCCCTAT CATTCATACA TACAAGTGCT CCCATATTAG GTTTTCACTA TAAGCAATGG
281 CTGAAATCCT TGGTTCGTGG TTCTTTGCGG TGTCTTTTGA AAAGCTTGCT TCTGAAGCCT TGAAGAGGGT
351 TGCTTGCTCC AAAGTAATTG ACAAGGAGCT CGAGAAATTG AATAGCTCAT GAATCAATAT AAAAGCTCTG
421 CTCAATGATG CTTCTCAGAA GGAAATAAGT AAGGAAGCTG TTAAAGAATG GTTGAATGCT CTTCAACATT
491 TGCTTACGCA CATAGATGAT CTACTTGGGG ATTTGGCAAC CAAAGCTATC CATCGTAAGT TCTCTGAGGA
561 ATACGGGGCC ACCATCAACA AGGTACGAAA GTTAATTCCA TCTTGTTTCT CTAGTTTGTG AAGTACTAAG
631 ATGCGCAACA AGATACATAA TATTACCAGC AAGTTACAAG AACTATTAGA AGAGAGAAAT AATCTTGGAT
701 TATGTGAAT TGGTGAAAGC CGAAAACCTC GAAATAGAAA ATCAGAGACC TCCTTGTCTAG ATCCATCTAG
771 TATGTGTGGA CGCACAGATG ATAAGGAAGC GTTGTCTCTC AAGCTATATG AACCATGTGA TAGAAACTTT
841 AGCATCTTGC CNATAGTTGG TATGGGTGGG TTAGATAAGA CCACCTTAGG TAGACTTTTG TATGATNAAA
911 TGCAAGTGAA GGATCACTTC GAACTCAAGG CGTGGGTTTG TGTTCCTGAT GAGTTTGATA TCTTCGGTAT
981 AAGCAAAACC ATTTTCGAAT CGATAGAGGG GGGAAACCAA GAGTTTAAGG ATTTAAATCT GCTTCAGGTG
1051 GCTTTAAAGG AGAAAATCTC AAAGAAACGA TTCTTGTGTG TTCTTGATGA TGTATGGAGC GAGAGCTATA
1121 CTGATTGGGA AATTCTAGAA CGTCCATTTC TAGCAGGAGC ACCAGGAAGT AAAGTAATCA TCACAACCCG
1191 CAAGTTGTCT TTGCTAAACC AATTGGGTCA TGATCAACCA TACCAATTGT CTGATTTGTC ACATGACAA
1261 GCTCTATCTC TATTTGTGCA ACACGCATTT GGTGTAATAA GCTTTGATTC ACATCCGATA CTTAAACCAC
1331 ATGGTGAAAG TATTGTTGAA AAATGTGATG GTTTGCCATT GGCTTTGATT GCACITGGGA GGTATTGAG
1401 GACAAAAGA GATGAGGAAG AATGGAAGGA ACTATTGAAT AGTGAGATAT GGAGTTTAGG AAAGAGAGAT
1471 GAGATTATTC CGGTCTTAG ACTAAGCTAT AATGATCTTT CTGCTCTTTT GAAGCAGTTG TTTGCATATT
1541 GCTCCTTGTT CCCCAGAGAC TATGTGTTCA ACAAGGAGAA GTTGATTTTA TTATGGATGG CAGAAGGGTT
1611 TTTGCACAAAT GAAAATACAA ACAAGTCAAT GGAACGCTTA GNTCTTGAAT ATTTTGACGA CTTGTGTGCA
1681 AGGTCAATTT TTCAACATGC ACTCGATGAC AAATCGTGTG TTGTGGTGCA CGACCTCATG AATGACTTGG
1751 CCACATCTGT TGCTGGAGAT TATTTTTTAA GATTAGACAT TGAAATGAAA AAGGAAGCTT TGGAAAAATA
1821 CCGACATATG TCATTGTTT GTGAGAGTTA CATGGTTTAC AAAAGGTTCTG AACCATTTAA AGGAGCTAAA
1891 AAATTGAGAA CTTTCTTAGC AATGCCCTGT GGGATGATAA AAAGTTGGAC AACATTTTAC TTATCAAATA
1961 AGGTCTTGA TGACTTACTT CACGAATTAC CATGTGTGAG AGTTCTAAGT TTGAGTTATC TTAGCATCAA
2031 GGAGGTACCT GAAATAATAG GCAATTTGAA ACACTTGGCG TATCTTAATT TATCACACAC GAGTATCACA
2101 CATTTACCAG AAAATGTCTG CAATCTTTAC AACTTACAAA CATTGATCCT TTGTGGCTGT TGTTTTATAA
2171 CCAAGTTTCC CAACTTCTC TTAAAGCTTA GAAATTTACG GCATTTGGAC ATTAGCGATA CTCCCGGTTT
2241 GAAGAGATG TCCTCGGGGA TTGGTGAATT GAAGAACCTA CACACVCTCT CCAAGCTCAT TATTTGAGGT
2311 GAAAATAGAC TAAACGAGCT TAAGAACTTA CAAAATCTCC ATG
```

RLG1b - Diana
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTCCTGAT GAGTTTGATA TCTTCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAABAG
211 AGAAGATCTC AAAGAAAAGa TTTCTTCTTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATINTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGGAGG
491 TATTGTTGAA AAATGTGATG GATTGCCATT GGCATTGTG ACATGATGAT GATG
```

SEQ ID 137

SEQ ID NO: 3

RLG1C
[Strand]

```
1   TCCCGTGCAA CGTATATCAT TCAGAAGNGC CCAAAGACCA NAGATNTGTT TAANGNTGNT TMTCAGAAGG
71  AAGTAATTGA TGAAGCTGTN AAAAGATGGC TGATTGATNT CCAACAATTG GCTTAGGACA CTGANGACNA
141 ACTTGATGAT NTCGCAACAG AAGCTATTCA TCGTGAGTTG ATCCGTGAAA CTGGAGCTTC CICCAGCATG
211 GTAAGAAAGC TAATCCCAAG TTGTTGCACA AGTTTCTCAC AAAGTAATAG GATGCATGCC AGGTTAGATG
281 ATATTGCCGC TAAGTNACAA GAACTGGTAG AGGCGAAAAA TAATCTTGGT TTAAGTGTGA TAACATACGA
351 AAAACCCAAA ATTGAAAGAG ATGAGGCGTN TTTGGTAGAT GCAAGTGGTA TCATTGGACG TGAAGATGAT
421 AAGAAAAAAT TGCTTCAGAA GCTGTTGGGG GATACTTATG AATCAAGTAG TCAAAACTTC AACATCGTGC
491 CCATAGTTGG TATGGGTGGG GTAGGTAAAA CAACTCTAGC TAGACTTTTG TATGATGAAA AAAAAGTGAA
561 GGATCACTTC GAACTCAGGG TTTGGGTTTG TGTTCTGAT GAGTTCAGTG TTCCCAATAT AAGCAGAGTT
631 ATCTATCAAT CTGTGACTGG TGA AAACAAA GAATTTGCAG ATTTAAATCT GCTTCAAGAA GCCCTTAAAG
701 AGAAACTTCA GAACAAACTA TTCTTAATAG TTTTAGATGA TGTATGGTCT GAAAGCTATG GTGATTGGGA
771 GAAATTAGTG GGGCCATTTC ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTACTCG GAAGGAGCAA
841 TTACTCAAAC AGCTGGGTTT TTCTCATGAA GACCTCTGCG ATAGTATAGA CTCCCTGCAA CGTCTATCAC
911 AAGAAGATGC TTTGTCTTTG TTTCTCAAC ACGCATTTGG TGTACCTAAC TTTGATTAC ATCCAACACT
981 AAGGCCATAT GGGGAACAGT TTGTGAAAAA ATGTGGGGGA TTGCCTTTGG CCTTGT
```

SEQ ID NO:4

RLG1D

[Strand]

```
1  CHTACCCATTC TAGGAGATCG CTGTCCCTCC TCGATCTGCT TAACGATGCT TCCCAGAAGG AAGTNACTAA
71  TGAAGCCGTT AAAAGATGGC TGAATGATCT CCAACATTTC GCTTATGACA TANACGACCT ACTTGATGAT
141 CTTCGCAACAS AAAGCTATTG CTCSTGAGTT GACCGANGAA GGTGGAGCCT CCACCACTAT GGTAGAAAAA
211 CTAATCCCAA GTTGTTCAC AAGTTTCTCA CAAAGTTATA GGATGCATGC CAAGTTAGAT GATATTGCCA
281 CCAGGTACA AGAACTGGTA GAGGCAAAAA ATAATCTTGG TTAAAGTGTG ATAACATATG AAAAGCCCCA
351 AATTGAAAGG TATGAGGCAT CTTTGGTAGA CGAAAGTGGT ATTTTGGAC GTTNAGATGA TNAGAAAAAA
421 TTGATGGAGA AGCTGTTGGA GGATAAAGAT GAATCCGGAG TCNAACTTC AGCATCCTGC CCATAATTGG
491 TATGGGTGGA GTTGGCNAAA CAACTCTAGC TAGACTCTTG TTTGATGAAA AGACAGTGAA GGATCACTTC
561 GAACCTAGGG CTTGGGTTTG TGTTCCTGAT GAATTCAGTA TTCTCAACAT AAGCAAAGTT ATCTATCAAT
631 CTGTGACCGG GGAAAGAGAA GAGTTTGAAG ACTTAAATCT GCTTCAAGAA GCTCTTAGAG GGAAACTACA
701 AAACAAACTA TTTCTAATAG TTTTGGATGA TGTATGGTCG GAAAGCTATG GTGATTGGGA GAAATTAGTG
771 GGCCCATTTT ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTIONG GAAGGAGCAA TTACTCAAAC
841 AGTTCGGTTT TTCTCATCAA GACCCCTCTG GTTGTATAGA CTCCCTGCAA CGTCTATCAC AAGATGATGC
911 TTTGTCTTTG TTTGCTCAAC ACGCAITTTG TGWCCA
```

RLG1E
[Strand]

```
1  TCTAGCTAGA CTTTGTGATG ACGAGATGCA AGAGAAGGAT CACTTCGAAC TCAAGGCGTG GGTTTGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAAGAAT
141 TTAAGGACTT AAATCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTCAAAG AAACGATTTC TACTTGTTC
211 TGATGATGTT TGGAGTGAAA GCTATGCGGA TTGGGAAATT CTGGAACGCC CATTTCCTGC AGGGGCAGCC
281 GGAAGTAAA TTATCATGAC GACCCGGAAG CAGTCATTGC TAACCAAAC CGGTTACAAG CAACCTTACA
351 ACCTTTCCGT TTTGTCACAT GACAGTGCTC TCTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CGATTCCAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCT
```

SEQ ID NO:5

RLGIF
[Strand]

```
1   ATTTTCNGCT  CNAACAAAN  AAAAGCAATG  GCTGAAATCT  TTCTTTCNGC  ATTCTAGACC  AGTATTCTTT
71  GAAAAGNTGG  CTTCTGAAGC  CTTGAAGAAG  ATCGCTCGCT  TCCATCGGAT  TGATTCTGAG  CTCAAGAAAC
141 TGAAGAGGTC  ATTAATCCAG  ATCAGATCTG  TGCTTAATGA  TGCTTCTGAG  AAGGAAATAA  GTGATGAAQC
211 TGTTAAGAA  TGGCTGAATG  GTCTCCAACA  TTGTCTTAC  GACATAGACG  ACCTACTTGA  TGATTGGCA
281 ACGAAACTA  TGCATCGTGA  GTTGACCCAC  GGATCTGGAG  CCTCCACCAG  CTTGTAAGAA  AGATAATCCC
351 AACTTGTTC  ACAGATTCT  CACTAAGTAG  TAAGATGCGT  AACAAAGTTAG  ATAATATTAC  CATCAAGTTA
421 CAAGAACTGG  TAGAGGAAAA  AGATAATCTT  GGCTTAAGTG  TGAAGGTGA  AAGCCCAAAA  CATACCAACA
491 GAAGATTACA  GACCTCTTTG  GTAGATGCAT  CTAGCATTAT  TGGTCGTGAA  GGTGATAAGG  ATGCATTGCT
561 CCATAAGCTG  CTGGAGGATG  AACCAGTGA  TAGAAACTTT  AGCATCGTGC  CAATAGTTGG  TATGGGTGGT
631 GTGGGTAAGA  CGACTCTAGC  TAGACTTTTG  TATGACGAGA  TGCAAGAGAA  GGATCACTTC  GAACTCAAGG
701 CGTGGGTTTG  TGTTCCTGAT  GAGTTTGATA  TCTTCAATAT  AAGCAAAGTT  ATCTTCCAAT  CGATAGGTGG
771 TGGARACCA  GAATTTAAGG  ACTTAAATCT  CCTTCAAGTA  GCTGTAAAAG  AGAAGATTTC  AAAGAAACGA
841 TTTCTTNTTG  TTCTGGATGA  TGTTTGGAGT  GAAAGCTATA  CAGAATGGGA  AATTCTAGCA  CGTCCATTTC
911 TTGCAGGGGC  ACCAGGAAGT  AAGATTATCA  TGACGACCCG  GAAGTTGTGG  TTGCTAACCA  AACTCGGTTA
981 CAATCAACCT  TACAACCTTT  CSGTTTGTG  ACATGATAAT  GCTTGTCTTT  TATTCTGTCA  GCAYGCATTG
1051 GGTGAAGATA  ACTTCGATTC  ACATCCAACA  CTTAAACCAC  ASGGTGAAAG  TATTGTTGAA  AAATGTGACG
1121 GTTTACCATT  GGCTTTTATT  GCACCTGGGA  GRTTGTGTAR  GACAAAAACA  GATGAGGAAG  AATGGAARGA
1191 AGTGTGAAT  AGTGAAATAT  GGGGGTCAGG  AAAGGGAGAT  GAGATTGTTT  CGGCTCTTAA  ACTAAGCTAC
1261 AATGATCTCT  CTGCTCTTTT  GAAGAAGTTG  TTGCATACT  GCTCCTTGTT  CCCAAAAGAC  TATGTTGTCG
1331 ATAAGGAGGA  GTTGATTTTG  TTGTGGATGG  CAGAAGGGTT  TTTGCACCAA  TCAACCACAA  GCAAGTCBAT
1401 GGAACGCTTG  GGHCATGAAG  GTTTTGATGA  ATTGTGTGCA  AGATCATTTT  TTCAACATGC  CCTGTATGCC
1471 AAATCGATGT  TTGTGATGCA  TGACCTGATG  AATGACTTGG  CHACATCTGT  TGCTGGAGAT  TTTTTCACAA
1541 GGATGGACAT  TGAGATGAAG  AARGAATTTA  GGAAGGAAGC  TTTGSAAAAG  YAYCGCCATA  TGTCAATTGT
1611 TTGTGAKGAT  TACATGGTKK  ACAAAGGTT  CRAGCCATTS  ACAAGGAGCT  AG
```

SEQ ID NO: 6

RLG1G
[Strand]

```
1  GTGAAGGATC ACTTCGAACT CAGGGCTTGG GTTTGTGTTT CTGATGAATT TAATATCCTC AATATAAGCA
71  AAGTAATTTA TCAATCTGTA ACCGGGGAAA AAAAGGAGTT TGAAGACTTA AATCTGCTTC AAGAAGCTCT
141 TAAAGAAAAA CTTTGGAATC AGTTATTTCT AATAGTTCTG GATGATGTGT GGTCTGAAAG CTATCGTGAT
211 TGGGAGAAAT TAGTGGGCCC ATTTTITTCG GGGTCTCCTG GAAGTATGAT TATCATGACA ACTCGGAAGG
281 AGCAATTGCC AAGAAAGCTG GGTITTCCTC ATCAAGACCC TTGCAAGGT CTATCACATG ACGATGCTTT
351 GTCITTGITT GCTCAACACG CATTGGTGT ACCA
```

SEQ ID NO: 7

RLG1H
[Strand]

```
1  TCTAGCTAGA CTTTGTATG AGGAAATGCA AGGGAAGGAT CACTTGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATCTT CAATATAAGC AAAATTATCT TACAATCGAT AGGTGGTGGA AACCAAGAAT
141 TTACGGACTT AAACCTGCTT CAAGTAGCTT TAAAAGAGAA GATCTCAAAG AAAAGATTTC TTCTTGTTCT
211 TGATGATGTT TGGAGTGAAG GCTATACCGA TTGGGAAATT CTAGAACGCC CATTTCCTTC AGGGGCACCT
281 GGAAGTAAGA TTATTATCAC CACCCGGAAG CTGTCATTGT TAAACAAACT CGGTTACAAT CAACCTTACA
351 ACCTTTCGGT TTGTCACAT GAGAATGCTT TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CAATTCACAT CCAACACTTA AACCACATGG CGAAGGTATT GTTGAAAAAT GTGAT
```

SEQ ID NO: 8

RLG1
[Strand]

```
1   TCTAGCTAGA CTTGTGTATG ATGAGATGCA AGAGAAGGAT CACTTTGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAAATCGAT AGGAGGTGGA AACCAGAAT
141 TTAAGGACTT AAACCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTTAAAG AACGATTTC TTCTGTTCCT
211 TGACGACGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT NTGGAACGCC CATTTCTTGC AGGGGCAGCC
281 GGAAGTAAAA TTATCATGAC AACCAGAAAG CAGTCATTGC TAACCAACT CGGTACAAG CACCTTACA
351 ACCTTTCGGT TTTGTACAT GACAGTGCTC TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGGTAACTT
421 CGATTACAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCTGGATT GCCATTGGCA
491 TTGTCGACA
```

SEQ ID NO. 9

RLGLJ
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTCCTGAT GAGTTTGATA TCCTCAATAT AAGCAAAATT
141 ATCTTACAAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATcTC AAAGAAAAGa TTTCCTCTTG TTCTTGATGA TGTTTGAGT GAAAGCTATA CCGATIGGGA
281 AATTINTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGGAGG
491 TATTGTGGAA AAATGTGATG GATTGCCATT GGCATGTGTC ACATGATGAT GATG
```

SEQ ID NO:10

RLGIA aa.

IVTVRTR?LSLLHLLSYVIFS?I?PH?ILWLF.INFYSTCHFMSFSILLSFT.YLNVITINAYLFFFK.THIIYR
LKSynt.VKLI.YICSSPVLYVSSLIYLLFIY.SR.SL.Y.KFNLFKI.NY..SHNLNKIKKNGPTISPSLFQJINIV
SILLRFHPNQYFQRMtdSYGVSEFAFRHCSLKEIINQMELLQCSLLMKGELYVK?MSAI?LHPEPTTLsv
YHQTTONGGSR?T?KS.RIDYFCPHGLTEERV.FIIFL?KNYRSIEFLHRQRSFTSQCFVKQFJFLSFR.NS
SIATCNLQLLGPQICGGR.FNPHIHCKQ.FKSISVHPIHQHLLIEIIHASSISSTSILYSLLLSY.TMAEIVLS
AFLTVVFEKLA?EALKKIVRSKRIESELKKLKETLDQIQDLLNDASQKEVTNEAVKRWLNDLQHLAYDID
DILLDD?ATEAV?RELTEGGASSSMVRKLIPSCCTSFSQSNRMHAKLDDIATRLQELVEAKNNLGLSVI
TYEKPkieryEASLVDESGTVGREDDKKKLEKLLGDKDESGSQNFSIVPIVGMGGVGKTTLARILLYDEK
KVKDHFELRAWVCVSEFSVPNISRVYQSVTGEKKEFDLNLQELKEKLRNQLFLVDDVWSESY
GDWEKLVGPFLAGSPGSRIMTTRKEQLLRKLGFSHQDPLEGLSQDDALSFAQHAFGVNFDShPTLR
PHGELFVKKCDGLPLALRTLGRLLRKTDEEQWKELLDSEIWRLGKSDEIVPALRLSYNDLSA?LKLFA
YCSLFPKDYEFdKEELLLWMAEGFLHQPT?NKSQRLGLEYP?ELLSRSFFQHAPN?KSLFVMHDLMDND
LATFVAGEFFSRLDIEMKKEFRM?SLEKHRHMSFVCE?YIGYK?FEPFRGAKNLRtFLALSVGVVEDWK
MFYLSNKVLND?LQDLPLLRVL?LI?L?I?VP??VGSM?HLRYLNLS?T?ITHLPE??CNLYNLQTLIV
SGC?YLV?LPKTFS?LKNL?HFDMR?TP?LKNMPL?IGELK?LQTLF?NIGIAITELKNL?NLHGK?CIGG
LGKMENAVGCTLSELVSKKV?..??NW??G..I.CFPKWEHLKKKSSMK.CLIMVL?KKP?IMSIGGIEFPN
WVGSLRVSETRDVFMVYEK?CFT.FHQSPSGK.MIFSG?TDEMWRGMIG?LGAVEEISIHSCNEIRYLWE
SEAEASKVLMNLKKLDLGECEENLVSLGEKKEDNHNINSGSSLTSFRRLNWRCNSLEHCRCPDSMENLY
MHMCDS?TSVSFPTGGGQIKSLTITDCKLSEELGGRERTRVLINSKMQMLESVDIRNWPNLKSISEL
SCFIHLNRLYISNCPS?ESFPDHELPNLTSLTDRRRRGQRFSYERLRFDWPSF

SEQ ID NO:11

RLGIB a.a.

NRSYENRCPLLPVI...EKI.LKV.IQNPLFHR.YDALAVVCKNSIINANQNSS.ETI.IMV.IVLSPTYTHFFQIPII
HTYKCSHIRFSLAMAEILGSAFFAVFFEKLASEALKRVACSKVIDKELEKLNSS.INIKALLNDASQKEIS
KEAVKEWLNALQHLPYDIDDLGDLATKAIHRKFSEYGATINKVRKLIPSCFSSLSSTKMRNKIHNTS
KLQELLEERNNLGLCEIGESRKLNRKSETS?LDPSSIVGRTDDKEALLKLYEPCDRNFSILPIVGMGGL
DKTTLGRLLYD?MQVKDHFELKAWVCVSDEFDIFGISKTIFESIEGGNQEFKDLNLLQVALKEKISKKRFL
VLDDVWSESYTDWEILERPFLAGAPGSKVIITTRKLSLLNQLGHDQPYQLSDLSHDNALSIFCQHAFG
VNSFDSHPILKPHGEGIVEKCDGLPLALIALGRLLRTKRDEEEWKELLNSEIWRLGKRDEIIP?LRLSYND
LSASLKQLFAYCSLFPKDYVFNKEKLILLWMAEGFLHNENTNKSMERL?LEYFDDLLSRFFQHALDDKS
LFVVHDLMLNDLATS VAGDYFLRLDIEMKKEALEKYRHMSFVCESYMVYKRFEPFKGAKKLRTFLAMPV
GMIKSWTTTFYLSNKVLDLHLLHELP LLRVLSLSYSIKEVPEIIGNLKHLRYLNLSTHSITHLPENVCNLYN
LQTLILCGCCFITKFPNNFLKLRNLRLHLDISDTPGLKKMSSGIGELKNLHTLSKLIIGGENRLNELKNLQNL
H

SEQ ID NO:12

RLG 1c aa.

SRAT?IIQK?PKT?D?F????QKEVIDEAVKRWLID?QQLAYDT?D?LDD?ATEAIHRELIRETGAS?S
MVRKLIPSCCTSFSSQSNRMHARLDDIAAK?QELVEAKNNLGLSVITYEKP KIERDEA?LVDASGIIGRED
DKKKLLQKLLGDTYESSQNFNIVPIVGMGGVGKTTLARLLYDEKKVKDHFELRVWVCVSDEFSPNIS
RVIYQSVTGENKEFADLNLLQEALKEKLQNKLFLLVLDVWSESYGDWEKLVGPFFHAGTSGSRIIMTTR
KEQLLKQLGFSHEDPLHSIDSLQRLSQEDALSLFSQHAFGVNFD SHPTLRPYGEQFVKKCGGLPLAL

SEQ ID NO:13

RLGID

?T?LRDRCPSSICLTMLPRRK?LMKPLKDG.MISNIWLMT?TTYLMILQ?KAI??ELT?EGGASTSMVRK
LIPSCCTSFSQSYRMHAKLDDIATRLQELVEAKNNLGLSVITYEKP KIERYEASLVDES GIFGR?DD?KK
LMEKLLEDKDESGVKLQHLP IIGMGGVG?TTLARLLFDEKTVKDH FELRAWVCVSDEF SILNISKVIYQS
VTGEKKEFEDLNLLQEALRGKLQNKLFJVLDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTRKEQLLK
QLGFSHQDPLRCIDSLQRLSQDDALSLFAQHAFG?

SEQ ID NO: 14

RLGIE

LARLLYDEM QE K D H F E L K A W V C V S D E F D I F N I S K I I F Q S I G G G N Q E F K D L N L L Q V A V K E K I S K K R F L L V L D
D V W S E S Y A D W E I L E R P F L A G A A G S K I I M T T R K Q S L L T K L G Y K Q P Y N L S V L S H D S A L S L F C Q H A L G E D N F
D S H P T L K P H G E G I V E K C A

SEQ ID NO: 15

RLGIF

FSA?NK?KQWLKSFF?HSRPVFFEK?ASEALKKIARFHRIDSELKKLKRSUQIRSVLNDASEKEISDEA
VKEWLNGLQHLSYDIDDLDDLATETMHRELTDDLEPPPACCKDNPTCCTDFSLSSKMRNKLDNITIKL
QELVEEKDNLGLSVKGESPKHTNRRLQTSVLDASSIIGREGDKDALLHKLLEDEPSDRNFSIVPIVGMGG
VGKTTLARLLYDEMKEKDHFEKAWVCVSDEFDIFNISKVIFQSIGGG?QEFKDLNLLQVAVKEKISKKR
FL?VLDDVWSESYTEWEILARPFLAGAPGSKIIMTTRKLSLLTKLGYNQPYNLSVLSHDNALSLFCQHA
LGEDNFDSHPTLKP?GESIVEKCDGLPLALIALGRLL?TKTDEEEWKEVLNSEIWGSGKGDEIVPALKLS
YNDLSASLKKLFAYCSLFPKDYVFDKEELJLLWMAEGFLHQSTTSKSMERLGHEGFDELLSRFFQHAPD
AKSMFVMHDLMLNDLATS VAGDFFSRMDIEMKKEFRKEAL?K?RHMS?VC?DYMV?KRF?P?TRS.

SEQ ID NO: 16

RLG1 G

VKDHFE LRAWVCVSDEFN ILNISKVIYQSVTGEKKEFEDLNLLQEALKEKLWNQLFLIVLDDVWSESYR
DWEKLVGPFFSGSPGSMIIMTTRKEQLPRKLGFPHQDPLOGLSHDDALS LFAQHAFGVP

SEQ ID NO: 17

RLG 1 H

LARLLYEEMQKDHFKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLQVALKEKISKKRFLVLD
DVWSESYTDWEILERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSIFCQHALGEDNFN
SHPTLKPHGEGIVEKCD

SEQ ID NO: 18

RLGI I

LARLVYDEMQEKFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKILKKRFLVLD
DVWSESYADWEI?ERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEGNF
DSHPTLKPHGEGIVEKCAGLPLALST

SEQ ID NO: 19

RLG 15

EFGVGKTTLARLLYEEMQGKDFELKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLRVALKEKISK
KRFLVLDDVWSESYTDWEI?ERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSIFCQH
ALGEDNFNSHPTLKPHG?GIVEKCDGLPLALS

SEQ ID NO: 20

SEQ ID NO: 21
RLG 2A

```
1   TTNACACCAT AAATCTCNA CCTGNGGGGA CAAAAACCTA AAAATGGTCC ATAATGCNCA AATCAGNAAG
71  GTTGANAAAG CTCTAAGTTT TTNACCTCCA NCTGATGCNC NMTCCTCNTA AAGTTCANAT CCAAGCTTGC
141 CCTCCAACCTC TANCNCTTC AATGGCACCT CCTTCTCTTC AAAAGCACAC AAGAACACTT TCAAGCTCAA
211 CCACACTCAC ACAAGCTCTA GAACNAGGGT TAGGGGCACAT TTAGGGTTTT GCTCTCTGGA AATGGTGTCT
281 AAAAGTGAGG CCATAATGTT CCTTATATAA GGCTCACTCC CACAATTAGG CTTTCAATCT GAACGTANTA
351 CGCCCACTGT ACACATATGGT ACGCCCAACG TACTCGGTAG TCTCCGCGTC AANAATACAC TCATGAGTAC
421 GCGCAACGTA CTTTCCCTTA CGCCCAAGCT ACTCAAAAGC CAAACATCTT TTTCAAGGAC TAAATTTTGAC
491 AACTTGAAGGA AAGAAAAGGA TCAAGANAT ATACTTGAAT TCCGGGATGT TACAATGAAG TTGANACCTT
561 GGCTAAAAAA TTAAATTGGT TGTGGAAGCC GTTGGCTGAG CAAGCAACAA GGGTAAAAAT CGTAATCTAC
631 AAATGGTGTT ATTTTCTATT TCTTCTTATT ATTTTACTTG ATTTACGGGT AGTTTTTTTT TCTTACAAAA
701 AATATTAAAG TTGATAAAGT ATAGCCACTA AAATTGACTT TTTCCAAAAC ATAATGTCAA ATGGTGCSTA
771 TATGTATCAT GTTGATTAN ATAATGAATA TGATGATNCT GTTCTATTTA ANCCGAAAAA ATTATCTAAT
841 GATTTTATAT TGGAAAACAA AGTTGTGATT TTTNGCATAA TATAATCAA TCCNCTTTTG TNGGGAGGT
911 CGATAAATGT GGTAAATTTA NAACAAGTGT TTNACNTTG AAGGGTNGG AAAGGTTGAA AAAAGTTAA
981 ATGATAAAAT GTTTACACAA ATGTTGTATC CGACTGAATA TNAATGTTAA GGATNATTGT ATTAATTTGT
1051 TGATATATAG TAAGCATAAA TATTTAGAAT TGTGACTTAA ATTTATAAGT TATNCNACT GGATTGAAAC
1121 ATTTTGTGATA TANATTAGGA ATGAAATGA GCAACCCATA CATACTTATC TTTGGTAGTT TGGTTATTAT
1191 ATTTTATTA NAATATAGAA NCATCCCTTT ATTTTAAACC CATATGTGG ACGGACTTGA ATAAATGGGA
1261 AAAATGTACC TTGCTATTTA GCACAAAAAA ATTATAAAAA TGTACATTGC TATTTAGCAC AAACAAAAAA
1331 AAAAAACTTA TCCTTTTTCG ATTAGGTCAC AAAGAAATAT AAAATGGGAA ATGTGTGTCT ATTTAATGCA
1401 CTAAGAGAAA CTATTTTGCC TTTATTAAC CGGGTAAACC AATAGAAAAA TGGAGTACA TTGTCATTTA
1471 GCATGAAAAA AAATAACTTT CCATTTTGTG CATCCGGTCA CAATAATAGA AAAATGAAAG TACGTTGCTA
1541 TTTAGCGAAA CTAATCTCCT TTTTCTTTT TGGCATCGTA TCATAAAATA TAGACTAAAA TACGTTAGTT
1611 TTACTTTTTT AATACATTGA AATGTCTAAT CCACATGTTA TTCTATAAAA AGGGAAATGT AATTTACTTA
1681 TCTTTTGAAT CTTTGGCTTC TTTTATGATC CCAAAACATC CCTCTATCCA TCTATTCCAA CTAATAATAT
1751 GAAACTATA TTCCTTCCAT TGTAGGGATG TTATAAATTT TGTAAATGTT TTTATGCAAA AAAGTGTITT
1821 TTGTTAACTA GATTAAACGAG ATTCATTTTT CAGCATTTTA GGAGAAGTTC ATCCATCTTT TGGATATGAA
1891 GTGCAAGCCA AGTTCTTTAA CATGGAATAT GAGGTCCCTA TATGCTCAAA AAATAGCAAA TGAGAAATTT
1961 TTTAAATTTG ATCCCATATA AAGAAATTT GTTAATGGTT GTTTAATAT TGGTCAATGT GTCCACCGGA
2031 TGAGCATTAAT ACTAGTTTAT AAGGGGTAAA GGTGGGTTTG GTGGGCCCAT TTATCTTTAT TATTTCTAAA
2101 AGTCAGAAAT AAGTAAAAAA AATTATAAGA TAAATACCAT AAGGATAAAA AATCATTTTA TTTGGACCAA
2171 AGACCAAGT TGTAAAGGG CTGTTTGT TTMTGTGAA GAGCTGTGCA ACCACTTTTG TCTCGCGCCG
2241 ACAGACAACG TGCAGACATA TGCCCTCGCA GAGTGTTTGT TTTTGAAG TGGCAGACC AAAAAACGT
2311 CTGCGCGAGG TCATCTGGC GCATATATGT CTACCTGTCT TCAAAGGTCT TCAGACCTCA TTTTAACCAA
2381 AAAAAAAGG GACCACCGGT TTTTTTTTT TTTTNTTCT TTCTCTGTA GCTGAAATG CATTTTAAAT
2451 CTTTATGACA TGAATTAAG TTTGAAAAAT TAATTTATTT CAACAGCTGT AGACGTTAAA AACAAACAGT
2521 CTTCTTGTG CAGACTGTG ACATTTGGTC CACCTCTTCT ACCGCAGAGA CTTCGAGATG TGGTCCGAG
2591 ACTGCAGACA TTTTGGCTTC AAATAAACAA ACATCACCTA ATTTGACTAC ACCACACGGA CCTCCAATGT
2661 AACAAAAAA AGGTTGAAC AAAGTTGCC ATTTCTCCAT ATCCAGGGGC CATTTATGTA AGAGTTATCT
2731 AAATTTTAGT TCGGTAGATC AGTTCTCACA TTTTAAACGG GTAAAGTGTA TG/TGTACG CGCGCACCTG
2801 AAAGGTTTGA ANGTRAACCT CAACTGAAN CAANAATCGA TATGAAGTAT CAAGTTAGAG GTTCAATTGS
2871 TGAAGGAATC AGCTGGAGGT TGGGGAATCG AGCTTCCACT ATTAAGGTAA AATCCATAAC CCTAAATGTT
2941 GGTACGCTCA TATATCAAAT TCGGTGTTTT GTTGAATGAA AAAAGCATGC TCAAAAAACC AGTGTAAAGG
3011 ACGGTATATG ACATATTTAT AGTTACTGAT AACAAATAT GATAATTTTG GGTTTACGTA AGTTAGGATT
3081 CGTACTTCAA CCAATGTAA TAGTTTTTGT GAGTCTATCT ATGTATTTTG GGAATCACAT TAGCAACGG
3151 ATTGTACTAG TAATTGAAA AAGTCTTTTA AATAATTTT CTGTTTATA TTTATGAATA GTTTTAGCGA
3221 CATCTAATAT TAAATAGAAT GTATCTGATA TTGAATTAAT GTCCTTAATG TGAACATAGA CCTTTTCCAT
3291 TTACTAATGC CTAATTATTA GTTCTAATC AATAAATTT AATTTCTGTT TTATGCTTCT AAGACAATA
3361 AAATCCATTA TTTACCTTTA AATATTACA AAAATGACCA TAAATAAATA AAAAATTAGG ATACCAAAAC
3431 CCCCCGCCAT GCCCAATGTC TAAATATCT TGATGCTTTT GCTTTTCCCT CTTTCTCTTG TTAGTCTATT
3501 ATTTCTGAGA GTTTGAGAGA GTTTTATACA AGAAATTTT AAGAAGAAAG CAAAGGTCCA GGTATTCTCT
3571 TTTCTEATTT ATGTATTAA TTAACAGCAT TTTTACACG ATCCATGGTT TTTTGTGTAT GTTTTTCAAA
3641 TTGAAACTAG ATTGGGACTT TTGCCCTTGA TGATTCATAA GATATTGCAT GAGGTTGAGA TTGTGTAAGA
3711 AAAGTGTGTA ATAGAAAGAG CAAGTGAATC CAGATATAGT ATTTGGTAATA TATGATGATG AGATAGAGAT
3781 ATGTTAAAC TGGCTAGAAA ATTGTTTTAA TTTGAAATTT AGGTTGTGTA ATTTGAAAGA TACCAAGCTA
3851 ATAACTEATTT AGTTATGCTA AATAGTTATA AAGAACAACA AACTCGTAGT TTTTPTTCA TGATTTTCAA
3921 CTTCTCTGTA CCAAACTAAA TTATAACAAA ATTTGAATATC ATTTCTCTGA ATCAATTTTA ACTTTTGTTA
3991 TTATCATCAT GTCTAAATTT GCCACAAGTT TATTTTCATA GTCATATTGG ATATGAAAG GACTATTTTT
4061 ACCAATTACA TCTTTACTTT ATGGCCAAAG CTAATACAA CCGACTAAAC TAAAGGATTC TAGGATGCAT
```


SEQ ID NO: 2/
RLG 2A cont.

```
4131 ATAGTTTGCT CCCCATTAT AGATTCTAT CTAATTGTC TATTGTAATA ATTTAGGTGC CACCACAAGT
4201 AAATTCTCTGA AATGGATGTC GTTAATGCCA TTCTTAAACC AGTTGTCGAG ACTCTCATGG TACCCGTTAA
4271 GAAACACATA GGGTACCTCA TTCTCTGCAG GCAATATATG AGGGAATATG GTATCAAAAT GAGGGGATTG
4341 AATGCTACAA GACTTGGTGT CGAAGAGCAC GTGAACCGGA ACATAAGCAA CCAGCTTGAG GTTCCAGCCC
4411 AAGTCAAGGG TTGTTTGA GAAGTAGGAA AGATCAATGC AAAAGTGGAA AATTCCCTA GCGATGTTGG
4481 CAGTTGTTTC AATCTTAAGG TTAGACACGG GGTCCGAAAG AGAGCCTCCA AGATAATTGA GGACATCGAC
4551 AGTGTCTATG GAGAACACTC TATCATCATT TGGAAATGATC ATTCCATTCC TTTAGGAAGA ATTTGATTCCA
4621 CGAAAGCATC CACTCAATA CCATCAACCG ATCATCATGA TGAGTTCCAG TCAAGAGAGC AAATTTTCAC
4691 AGAAGCACTA AACGCACTCG ATCTTAACCA CAAATCCAC ATGATAGCCT TATGGGGAAT GGGCGGAGTG
4761 GGAAGACGA CAATGATGCA TCGGCTCAAA AAGGTTGTGA AAGAAAAGAA AATGTTTAA TTTATATTG
4831 AGGCGGTTGT AGGGGAAAA ACAGACCCCA TTGCTATTCA ATCAGCTGTA GCAGATTACC TAGGTATAGA
4901 GCTCAATGAA AAAACTAAAC CAGCAAGAAC TGAGAAGCTT CGGAAATGGT TTGTGGACAA TTCTGGTGGT
4971 AAGAAGATCC TAGTCATACT CGACGATGTA TGGCAGTTTG TGGATCTGAA TGATATTGGT TTAAGTCCCT
5041 TACCAATCA AGGTGTCGAC TTCAAGGTGT TGTGACATC ACGAGACAAA GATGTTTGCA CTGAGATGGG
5111 AGCTGAAGTT AATTCAACTT TTAATGTGAA AATGTTAATA GAAACAGAAG CACAAAGTTT ATTCCACCAA
5181 TTTATAGAAA TTTCCGATGA TGTGATCCT GAGCTCCATA ATATAGGAGT GAATATTGTA AGGAAGTGTG
5251 GGGGTCTACC CATTGCCATA AAAACCATGG CGTGTACTCT TAGAGGAAAA AGCAAGGATG CATGGAAGAA
5321 TGCACCTTCTT CGTTTAGAGC ACTATGACAT TGAAAATATT GTTAATGGAG TTTTAAAT GAGTTACGAC
5391 AATCTCCAAG ATGAGGAGAC TAAATCCACC TTTTGTCTTT GTGGAATGTA TCCCGAARAC TTTGATATTG
5461 TTACCCGAGGA GTTGGTGAGG TATGGATGGG GGTGGAATTT ATTTAAAAAA NIGTATACTA TAGGAGAAGC
5531 AAGAACCCAG CTCACACAT GCATTGAGCG GCTCATTCAT ACAATTTGT TGATGGAAGT TGATGATGTT
5601 AGGTCAATGA AGATGATCAT TCTTGTCTGT TGGATATGTA TTCTAAAGTC GAGCATGCTT
5671 CCATTGTCAA CCATAGTAAT ACATAGAGT GGCATGCAGA TAATATGCAC GACTCTTGTA AAAGACTTTC
5741 ATTAACATGC AAGGGTATGT CTAAGTTTCC TACAGACCTG AAGTTTCCAA ACCTCTCCAT TTTGAAACTT
5811 ATGCATGAAG ATATATCATT GAGGTTTCCC AAAAATCTTT ATGAAGAAAT GGAGAAGCTT GAGGTTATAT
5881 CCTATGATAA AATGAAATAT CCATTGCTTC CCTCATCACC TCAATGTTC GTCACCTTC CGGTGTTTCA
5951 TCTACATAAA TGCTCGTTAG TGATGTTTGA CTGCTCTGT ATTGGAATTC TGTCGAATCT AGAAGTGCTT
6021 AGCTTTGCTG ATTCGCCAT TGACCGGTTG CCTTCCACAA TCGGAAAGTT GAAGAAGCTA AGGCTACTGG
6091 ATTTGACGAA TTGTATGTT GTTCGTATAG ATAATGTTGT CTAAAAAA TTGGTCAAA TGGAGGAGCT
6161 CTATATGACA GTGGTTGATC GAGGTCGAAA GCGGATTAGC CTCACAGATG ATAAGTCAA GGAGATGGCA
6231 GAGCGTTCAA AAGATATTTA TGCATAGAA CTGTAGTTCT TTGAAAACGA TGCTCAACCA AAGAATATGT
6301 CATTTGAGAA GCTACACGA TTCCAGATCT CAGTGGGCG CTATTTATAT GGAGATTCCA TAAAGAGTAG
6371 GCACCTCGAT GAAAACACAT TGAAGTTGTT TCTTGAAGAA GGTGAATTTAT TGGAGCTCG AATGAACGAG
6441 TTGTTTAAAG AAAACAGAGG GTTATGTTTA AGTGTGGGAG ATATGAATGA TCTTGAAGAT ATTGAGGTTA
6511 AGTCACTCTC ACAACTTCTT CAATCTTCTT CGTTCAACAA TTTAAGAGTC CTGTGCTGTT CAAAGTGTGC
6581 AGAGTTGAAA CACTTCTTCA CACTTGGTGT TGCAAACACT TTAAAAAGC TTGAGCATCT TGAAGTTTAC
6651 AAATGTGATA ATATGGAAGA ACTCATAGT AGCAGGGGTA GTGAAGAAGA GACGATTACA TTCCCCAAGC
6721 TGAAGTTTAT ATCTTTGTTT GGGCTACCAA AGCTATCGGG TTTGTGCGAT AATGTCAAAA TAATTGAGCT
6791 ACCACAATCT ATGGAGTTGG AACTTGACGA CATTTCCAGG TTCAACAGCA TATATCCCAT GAAAAAGTTT
6861 GAAACATTTA GTTTGTTGAA GGAAGAGGTA AATATAAAT TTTAATGCTA ATACATTACA AAGGATCTTT
6931 TCAAGTAAAT CTTTCAAAAT ATATTGTAAT TTGATTGTAT GGGGTATTAT TGTGGATGG GACTATTAAAT
7001 AAATGATTAT CTGTCAGGTT CTGATTCCTA AGTTAGAGAA ACTGCATGTT AGTAGTATGT GGAATCTGAA
7071 GGAGATATGG CCTTCCGAAT TTAATATGAG TGAGGAAGTT AAGTTACAGAG AGATTAAAGT GAGTAAGTGT
7141 GATAAGCTTG TGAATTTGTT TCCGCACAAG CCCATATCTC TGCTGCATCA TCTTGAAGAG CTTAAAGTCA
7211 AGAATTTGGG TTCCATTGAA TCGTTATTCA ACATCCATTT GGATTGTTT GGTGCAACTG GAGATGAATA
7281 CACAACAGT GGTGTAAGAA TTATTAAAGT GATCAGTTGT GATAAGCTTG TGAATCTCTT TCCACACAAT
7351 CCCATGTCTA TACTGCATCA TCTTGAAGAG CTTGAAGTGG AGAATTGTTG TTCCATTGAA TCGTTATTCA
7421 ACATTGACTT GGATTGTGCT GGTGCAATTG GCGAAGAAGA CAACAGCATC AGCTTAAAGAA ACATCAAAGT
7491 GGAGAATTTA GGAAGCTAA GANAGGTGTG GAGGATAAAA GGTGGAGATA ACTCTCGTCC CCTTGTTCAT
7561 GGCTTTCAAT CTGTTGAAAG CATAAGGTTT ACNAAATGTT AGAAGTTTAG AAATGTATT ACACCTACCA
7631 CCACAAATTT TAATCTGGGG GCACTTTTGG AGATTTCAAT AGATGACTGC GAGAGAAAACA GGGGAAATGA
7701 CGAATCGGAA GAGAGTAGCC ATGAGCAAGA GCAGGTAAAG ATTTCAATTT CACTGTCTTA ATTAATGATT
7771 AAGCTCTGCG TTTTGAATA AAAAAGGAC AAACCATTTT ATGACTTAAT GTAGCAATAC AAGTCATGTA
7841 TAAGAGTGAC CAACTCTTTT TTATTATATA AATGACTACA AAATATTTT TTTCAATTAGA GATCATGTAT
7911 AAATGTGACT AATTTTTCAT CACCTAATTT TAGTTGATAA ATCTTTATAA ATGTCACTAG TTACTTTTCA
7981 GTAAATAAAC AAATTTAATA AATTATCAAC AAAAAGCATC AACTAAAAAA ATCCCAACAC CCGTAATTAAT
8051 TTAATAATAA AGGATTTAAC ATCTAATACG AACAAATTTT TTTCTAAACA TGATTGGAC CAAATATCAC
8121 CAGCAACTCA AGTTTGAAT CGATTCAAGT TAAACTTGA CCAGCATAAT TAGATAGATG AGAGTTGAAG
8191 CTAAGTGCC TATATAAGTT CGTTTCATCT TTTTCTTGA TCTTGATAGC AAGTTGAATG ATTTTCTTCT
```

RLG 2A cont.

8261 TCAAAATGGA TAAAAATCTA CATTATAAAG AGACTAGCTT GAAAAAAAT GGTCTAGGTG GGTCTTGGGT
8331 TCTGCTAGAT GAAGATGGAA GGGGAGAGTA TGATTTCAAA GACACAACAC ATCCTTCATT TTATTTATTT
8401 ATTATATTAT TTATTTTITG ATATCTTGCT CATATTTGTT ACAGATATGT GAGGTCTATT AATCTTTTAA
8471 AATATATAAA AAAATAAATA ACATAAATGA GAAAAATTAA TAAAGAATAA ATTAATAAGG GCACAATAGT
8541 CTTTTTAGGT AAGACAAGGA CCAAAACAGC AACAAAAATA AACAGTAGGG ACCATCCGAT TTAACAAAAA
8611 TAATTAGGGA CCAAAACAT AAATTCCTCC AAACCATAGG GACCATTCT GTAAATTTACT CTTACTTTTC
8681 GTTTTGTTC TATTTGGGTA ACTATTTTIT TTGTACACAT CTAGGTAACG AACTTGTGTA AGTGTTCCTA
8751 TTTAGGATGT GACCTACTAC AACCGATCAT AATAGTCATA TGTGAACACT TCCAACAAC TTATTACTTA
8821 GGTGTGTACA AAAAAACAAT AGTTACCATG ATGTGAACAT ACTGAAAAAT TAATTACCTT AGCAAGTTAT
8891 TTTCCCATTT AGGTTGTATG GAAACAGTTC CGTGAGACCG TGACTTGGAT GGTAGATAAA TTTAGTAAAC
8961 TTAACCTTTC AATTAACCTA CCTTTTCTT ATTTAACTCA TTTCAACCTA AATTCTGATT CTGTGTGAA
9031 AGTAAGTTGC ATCTTTATTT TTGTATTATC TTGTTCATA GGATCCTTAG CATCTTTTAA TAATTTATTT
9101 GAAGGTGAAA GATCCAACTA TTTTAACTCT GTTGGCATTT TCCATCATTT GCAACTGTTT CTGTGAAAAA
9171 AAATACCTAA AATCAAAATA ACCATTTTCA AATCCAAAT TATAAGAGAG AATTGTAAAT GGACATGGAA
9241 TCATAAATCA TTAACACAGT TCAGTAAACA AGTTGCTAAT TACATTTCTT GCTGTGCAGA TTGAAATCTT
9311 ATCAGAGAAA GAGACATTAC AAGAAGCCAC TGACAGTATT TCTAATGTTG TATTCCTATC CTGTCTCATG
9381 CACTCTTTTC ATAACCTCCA GAAACTTATA TTGAACAGAG TTAAAGGAGT GGAGGTGGTG TTGAGATAG
9451 AGAGTGAGAG TCCAACAAGT AGAGAATTGG TAACAACCTA CCATAACCAA CAACAACCTA TTACTTTCC
9521 CAACCTCCAG GAATTGATTC TATGGAATAT GGACAACATG AGTCATGTGT GGAAGTGCAG CAACTGGAAT
9591 AAATCTTCA CTCTTCCAAA ACAACAATCA GAATCCCCAT TCCACAACCT CACAACCTA AAAATTATGT
9661 ATTGCAAAAG CATTAAGTAC TTGTTTTCCG CTCTCATGGC AGAATCTCTT TCCAACCTAA AGCATATCAA
9731 GATAAGAGAG TGTGATGGTA TTGGAGAAGT TGTTTCAAAC AGAGATGATG AGGATGAAGA AATGACTACA
9801 TTTACATCTA CCCACACAAC CACCACTTTG TTCCCTAGTC TTGATTCTCT CACTCTAAGT TTCTGGAGA
9871 ATCTGAAGTG TATTGGTGGG GGTGGTGCCA AGGATGAAGG GAGCAATGAA ATATCTTTCA ATAATACCAC
9941 TGCAACTACT GCTGTCTTTG ATCAATTTGA GGTATGCTTT GTACATATTC AATTATTAT TTAATTTCTT
10011 TTTTATTTTG CAATATTCTA TAAATAATAC ATTTTATACC CACTATACTA AGATAATAAT TACCTAGAGG
10081 GATGGATGCT ATGACACAGC TGCTACACTT CAGAACTCT AGTAAGGGCA GTTATGGAAG TTCAATAAAA
10151 TGATAATGGC ATCTTTTGAT GGGTAATATA GGCAATTTAA GTTTTATTTT TGTAAAGCA GTATTTAGCA
10221 AGTACTGGCC AGTAGGAGAG GAGAATATCA CCTTTTGTA AAATCTGGTC ATTGTACCCA GAATTTAGTT
10291 AAATGTACA TTTTAGATAT CAGGGGTCAT CAGGTGACAG ATATTGTAGA ATAGAACAAT ATATAATATC
10361 ACCCAAACT ATTTTCTTA AGGTTATCT GTTAAATATG TGCTTTCTTG TTTTCATNGA ATINGCATTC
10431 GTATATTTTA GGTGTAAAG TGATTTTNTC TTCAATAAAT CCGGAAATTA ATTAACAAAA AAAAAACAAA
10501 AGTACATTTT TGATGTGGAG AGCACTGGTA TCACTTAGTA TATAAAAAGC TTGATTTTGA ATTAACCTTC
10571 TTATACAAAA GTTGTGTATA TAGTTTAAAT AGTTTACAT CATTTTCCA TGTGGTGTG CAGTTGTCTG
10641 AAGCAGGTGG TGTTCCTGG AGCTTATGCC AATACGCTAG AGAGATGAGA ATAGAATTCT GCAATGCATT
10711 GTCAAGTGTA ATTCATGTT ATGCAGCAGG ACAAATGCAA AAGCTGAAGG AGAGGACAGC GATTCTCGTA
10781 CGAACGGTTA CGATTGACT GGCCTGCTT TTACA

SEQ ID NO: 21

RLGIA a.a.

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVNRNISNQLEVPQV
RGWFEEVGKINAKVENFPSDVGSCFNKVRHGVGKRASKIIEDIDSVMREHSIIWNDHSIPLGRIDSTK
ASTSIPSTDHHDEFQSREQTTFTEALNALDPNHKSHMIALWGMGGVGKTTMMHRLKVVKEKKMFNFII
EAVVGEKTDPIAIQSAVADYLGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLS
PLPNQGVDFKVLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIGVNIVRK
CGGLPIAIKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNLQDEETKSTFLLCGMYPE?FD
ILTEELVRYGWGLKLFKK?YTIGEARTRLNTCIERLIHTNLLMEVDDVRCIKMHDLVRAFVLDMYSKVEH
ASIVNHSNTLEWHADNMHDSCKRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFPKNFYEEEMKLE
VISYDKMKYP LLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGKLLKLR
LLDLTNCYGVRIIDNGVLKLVKLEELYMTVDRGRKAISLTDDNCKEMAERSKDIYALEFFENDAQPK
NMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLKELLEARMNELFKKTEVLCLSVGDMNDLEDIE
VKSSSQLLQSSSFNNLRVLVWSKCAELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEEETITFP
KLKFLSLCGLPKLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLLKEEVLPKLEKLHVSSM
WNLKEIWPCFEFNMSEEVKFREIKVSNCDKLVNLFPHKPISLHHLEELKVKNCGSIESLFNIHLDCVGAT
GDEYNNSGVRIIKVISCDKLVNLFPHNPMSILHHLEEELEVENCGSIESLFNIDLDCAGAIGQEDNSISLRNI
KVENLGKLR?VWRIKGGDNSRPLVHGFQSVESIRVTKC?KFRNVFTPTTTNFNLGALLEISIDDCGENR
GNDESEESSHEQEIEILSEKETLQEATDSISNVVFPSCLMHSFHNLOKLILNRVKGVEVVFEIESESPTS
RELVTTTHHNQQQPIILPNLQELILWNMDNMSSHVWKCSNWNKFFTLPKQQSESPFHNLTITIKIMYCKSIKY
LFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTTLFPSLDSLTLSFLENLKCIGGG
GAKDEGSNEISFNNTTATTAVLDQFEVCFVHIQLFI.

SEQ ID NO:22

RLG 2B

SEQ ID NO: 23

1 AGTTTTTTTTT TTCCCAATA TCCATTATA TGGGATTAT TTCTGAAATA ATTTTATCAA AACGCAGGAA
71 ACAATGTAGA ATAATACTGG TATAATTAAT TATATAAAGT TATTAGGCTG AAATCTTGAG GCTACTATAA
141 TTTAATTATC ATAATTGAA AATCATCAAA TTGTATTCCA TGTATATTTA TGTATACAGA TAATTAATAA
211 TATGTGAGCC ACACAAATCC ACATCATCAG ACACCCACC TTATGTGCGG CTACCTCACC ACTTGCATGA
281 TCCCGACATC TTCCCAACCC CACCGACGAC TTGGGGTCTC CTTAATATAT CAATTATTTT CTGTAAGTAT
351 TTATTGTGTT AAATGTGTAA TGTCAITTTA CCTTTTTTCT AATATATACA GAAACATAAA TTTTAAATGA
421 AATTCAACTG CGTTTCATTC TTGCATTAAA AAAAAAGACT GTACTGTGTT CAATATTTTA CTTATAACCT
491 GATTAAATTA TTAAGCGTA ATTGCATAAT TTGCATTAGG TTGTAATTTT GTGTTTATA GGGAGGGTGA
561 GGGTCACCGG GAATCAAAGC ACTTATGTAA AAGCAGGGGA AATACAAAAA ATTTACTCGA AACAAATTTT
631 ATTCAATTTA AGTGAGATAA TAAATGTCTG ATTAGATTAT GAGAACTAGG AGATTAAAGT GATATATCCC
701 ATTTAAAAAG AATTGCATTA TTAATTTTGG ATCTCTTGAT GATGACAAAA TTAACCTCGT ACAGGTATATA
771 TATCATATAC AAAATGAGTG GCTATGCTTT CGCTTTCCAA AAAGCAATTA TAGTTATACT ACACCTACAA
841 ATTTTAAAG GGGTTAAACA TATCAAAATA CTTGATAAGT AATTATATAA ATATGCATTT AACCCCTCAA
911 AGAAAAATGCT ACTAAGCTTG GACCATCTCA GAATTACAAAT CATACCCCTC CCCTCAAAAA AGATTCTGAT
981 ATATCATGTC ATTTGGCATT CATTTCTTTT TCACAATTCA TAGTTCTATT CTCAAAAAAT TCGAGTTCTC
1051 GTATTGTGTA GGAAGATCAG AAGAGACTGT TCACACAGGT ACTCTCTTTT ATTTATIGAT TCACATTCAT
1121 ATATGTTATT GTTTCTTTCG TTAATGGTTT CGTCAGTCTA ACTGCGCTTG CTGATTAAAA TTTCTTCACT
1191 TTCTTCCACG GATTTTTTAA ATATTAGTTT ATAAGGGTAT ATGCTAAAT GAACTATGCC CATTCACCTT
1261 TTTTCTAAAG TAAACCTAGA TACTTAGGTT ATAAGGGTAT ATGCTAAAT GAACTATGCC CATTCACCTT
1331 TGCCCTTTCT TTTACTTTT AGTTTTTAGA ATCCAAAGTT TCATATGTAT CTCGATGTGT GAGAAGAATA
1401 GGCATTAGAA AGGTAAAGGA CGTACATAAA ATTGATTAAT TAGTGAATGT TCTTTGATAT CATTAATTTT
1471 ACTCTCATAA AAAGCATATA GATCAACAC AAATTGCTAC TTGTTAGTGT AACAACTTCG ACTTAATAAT
1541 GTTAATAATC AAGATTCTCT TGATTTCAC TATTTTCTAA CCGAACAAGC TCCTAAAAA CTCATATTGC
1611 TTGAGTCTG AGTGGTTTAT ATTTGGGGTT TTACATTTAA TTTTGTGTC ATGAATGTGA AAATAGACTG
1681 CTTATTGATA CTTTGTGTTT CATTGAGTTG ATTTTCATTA TTACTACCTT ACAAATTGCT CAGTGATAGA
1751 TTTCCATTAA TTTGCTAATT CGGTGCTTC TAAATATGTA GGAGCTACTA AAAGCAAAAA TATCGAGCAA
1821 TGTCGGACCC AACGGGGATT GCTGGTGCCA TTATTAACCC AATTGCTCAG ACGGCTTGG TTCCCGTTAC
1891 GGACCAATGA GGTCTACATGA TTTCCCTGAG AAAATATGTG AGGGTCTATG AGATGAAAA GACAGAGTTG
1961 AATACCTCAA GAATCAGTGT AGAGGAACAC ATTAGCCGGA ACACAAGAAA TCATCTTCAG TTCCATCTCA
2031 AACTAAAGAA TGTTTGGACC AAGTAGAAGG GATCAGAGCA AATGTGAAA ACTTTCOGAT TGATGTCATC
2101 ACTTGTGTA GTCTCAGGAT CAGGCACAAG CTTGGACAGA AAGCMTTCAA GATAACTGAG CAGATTGAAA
2171 GTCTAACGAG ACAACTCTCC CTGATCAGTT GGACTGATGA TCCAGTTCTT CTAGGAAGAG TTGGTTCCAT
2241 GAATGCTATC ACCTCTGCAT CATTAAAGTA TGATTTCCCA TCAAGAGAGA AAACCTTTAC ACAAGCACTA
2311 ATAGCACTCG AACCCAACCA AAAATTCCAC ATGGTAGCCT TGTGTGGGAT GGGTGGAGTG GGGAGACTA
2381 GAATGATGCA AAGGCTGAAG AAGGCTGTTG AAGAAAAGAA ATTGTTAAT TATATTGTTG GGGCAGTTAT
2451 AKGGGAAGAG ACGGACCCCT TTGCCATTCA AGAAGCTATA GCAGATTACC TCGGTATACA ACTCAATGAA
2521 AAAACATAGC CAGCAAGAGC TGATAAGCTT CGTGAATGGT TCAAAAAGAA TTCAGATGGA GGTAAAGACTA
2591 AGTTCTTCAT AGTACTTGAC GATGTTTGGC AATTAGTTGA TCTTGAAGAT ATTGGGTTAA GTCCCTTTCC
2661 AAATCAAGGT GTCCACTTCA AGGTCTTGTT GACATCAGCA GACTCACAAG TTTGCACTAT GATGGGGTT
2731 GAAGCTAATT CAATTATTAA CGTGGGCTTT CTAACCTGAAG CAGAAGCTCA AAGTCTGTTT CAACAATTTG
2801 TAGAACTTTC TGAGCCCGAG CTCCAGAAGA TAGGAGAGGA TATCGTAAGG AAGTGTGCG GTCTACCTAT
2871 TGCCATAAAA ACCATGGCAT GTWCTCTTAG AAATAAAGAA AAGGATGCAT GGAAGGATGC ACTTTCGCC
2941 ATAGAGCACT ATGACATTCA CAATGTGCG CCCAAAGTCT TTGAAACGAG CTACCACAAT CTCCAAGAA
3011 AGGAGACTAA ATCCACTTTT TTAATGTGTG GTTTGTTTCC CGAAGACTTC GATATTCTTA CTGAGGAGTT
3081 GATGAGGTAT GGTGGGGCT TGAAGCTATT TGATAGAGTT TATACGATTA GAGAAGCAAG AACCCAGGCTC
3151 AACACCTGCA TTGAGCGACT GGTGCAGACA AATTGTGTTA TTGAAAGTGA TGATGTTGGG TGTGTCAGA
3221 TGCAATGATCT GGTCCGTGCT TTGTGTTTGG GTATGTTTTC TGAAGTGGAG CATGCTTCTA TTGTCAACCA
3291 TGGTAATATG CTTGGGTGGC CTGATGAAAA TGATATGATC GTGCACCTTT GCAAAAGAAAT TTCATTAA
3361 TGCAAGGGTA TGATTGAGAT TCCAGTAGAC CTCAGTTTC CTAAGTTTC GATTTTGAAG CTTATGCAATG
3431 GAGATAAGTC GCTAAGGTTT CCTCAAGACT TTTATGAAGG AATGGAAGG CTCATGTTA TATCATACGA
3501 TAAAAAGAAG TACCCATTGC TTCCCTTGGC ACCTCGATGC TCCACCAACA TTCCGGTGCT TCATCTCACT
3571 GAATGTTTAT TAAAGATGTT TGATTGCTCT TCTATCGGAA ATCTATCGAA TCTGGAAGTG CTGAGCTTTG
3641 CAAATTTCTA CATTTGAATG TTACCTTCCA CAGTCAGAAA TTTAAAGAG CTAAGGTTAC TTGATCTGAG
3711 ATTTTGTGAT GGTCTCCGTA TAGAACAGGG TGCTCTGAAA AGTTTGTGCA AACTTGAAGA ATTTTATATT
3781 GGAGATGCTAT CTGGGTTTAT AGATGATAAC TGCAATGAGA TGGCAGAGCG TTCTTACAAC CTTCTGCAAT
3851 TAGAACTTCC GTTCTTTAAT AACAAAGCTG AAGTGAAAAA TATGTCATTT GAGAATCTTG AACGATTCAA
3921 GATCTCAGTG GGATGCTCTT TTGATGAAAA TATCAATATG AGTAGCCACT CATACGAAAA CATGTTGCAA
3991 TTGGTGACCA ACAAGGTGA TGTATTAGAC TCTAAACTTA ATGGGTTATT TTTGAAAAA GAGGTGCTTT
4061 TTTTAAAGTGT GCATGGCATG AATGATCTTG AAGATGTGTA GGTGAAGTCG ACACATCCTA CTCAGTCTTC

RLG 2B cont.

SEQ ID NO: 23

```
4131 TTCATTCTGC AATTAAAAAG TTCTTATTAT TTCAAAGTGT GTAGAGTTGA GATACCTTTT CAAACTCAAT
4201 CTGCAAAACA CTTTGTCAAG ACTTGAGCAT CTAGAAGTTT GTGAATGTGA GAATATGGAA GAACTCATAC
4271 ATACTGGAAT TGGGGTGTGT GGAGAAGAGA CAATTACTTT CCCTAAGCTG AAGTTTTTAT CTTTGAGTCA
4341 ACTACCGAAG TTATCAAGTT TGTGCCATAA TGCAACATA ATTGGGCTAC CACATCTCGT AGACTTGATA
4411 CTTAAGGGCA TTCCAGGTTT CACAGTCATT TATCCGCAGA ACAAGTTGCG AACATCTAGT TTGTTGAAGG
4481 AAGGGGTAGA TATATGTTCT TTATGTTAAT ACAATTAAAA TAATATTTTC AACCAAATTT TCATAATATA
4551 TCTGTAATTT GATTGTATGA TGTGTTATTG TTTATATGTG GCTATTAAGG GATGATTATT TTGCGAGTTG
4621 TGATTCTTAA GTTGGAGACA CTTCAAATTG ATGACATGGA GAACCTAGAA GAAATATGGC CTTGTGAAGT
4691 TAGTGGAGGT GAGAAAGTTA AGTTGAGAGC GATTAAAGTG AGTAGCTGTG ATAAGCTTGT GAATCTATTT
4761 CCGCGCAATC CCATGCTCTT GTTGATCAT CTTGAAGAGC TTACAGTCTG GAATTGCGGT TCCATTGAGT
4831 CGTTATTCAA CATTGACTTG GATTGTGTG GTGCAATTGG AGAAGAAGAC AACCAAGAGCC TCTTAAGAAG
4901 CATCAACGTT GAGAATTTAG GGAAGCTAAG AGAGGTGTGG AGGATAAAAG GTGCAGATAA CTTGATCTC
4971 ATCAACGGTT TTCAAGCTGT TGAAGCATA AAGATTGAAA AATGTAAGAG GTTTAGAAAT ATATTCACAC
5041 CTATCACCGC CAATTTTTAT CTGGAGGCAC TTTTGGAGAT TCAGATAGAA GGTTCGGGAG GAAATCAGCA
5111 ATCAGAAGAG CAGGTAACGC TTTCAATTTT ACTTTCTTAA TTAATTAAGG ACTAAGCTCC TGTTTTTTGA
5181 ATAATAAAGA GGTGGGATGA CTAAACTTGG GCATCACAAT TGCAACAAAA TGTACAAAC CATGAAACGT
5251 TCAAAACATT TCTTGAATTA AGGTTTCAAT ACAAGTCATT TAAAAATATG GCTTAAATTT TTTTATATT
5321 TATGTATCAA CATGATTTT CATTAGAGAT CATTATTATA ATAGTAAGTT TAAAGCAATT TAAATCAGAA
5391 CTAATTCTAA CTTTAGCTAA TAAATCGTTA TAAATGTAAA TAATTACTTT TTAGTGAAAT AAGCAACGGA
5461 TTTAATAAGT TAACAACCTA AATGTCATTT CCTAACAAAA AAAACTTTTG TTCAGAAAAA CCGCAATTCA
5531 AGATACTAA AATAAAAAATA TTTGACATTC ACTAAGAGCA TTTTTTTTTT TAAATATGAT TGCAAAATGA
5601 TAAAACTTAA ATTTATACAG AAAATTCTTT TATATATGTT ATACAAAAAT TACAAATGTA AATTGGATAT
5671 GTTAATTAAC GGTTTATAAT TCTGGTATCA CAAAGGGATA TATAATAAAA TATTATTTTC TGTAGTCATT
5741 TGTAAATGTA CTAGTTTATA ACCCGTGGGA ACCATGAGTT CTAAAATTAG TTAACCTTTC ATAATAAAAA
5811 TTTATAATTA TTATTATT TAAATAAATT ATTAATTAAG AGATATATCA AAAATTAAAA GTTATTATAA
5881 CTTCAAATTT AACATATAAT TAGAAAAATAT ATGATCATAA CTTCTGCAC CTCTTTGTAT AAATGCAGAG
5951 AAGCTATTAG TATATTTCTA ATCAAGTCCA AACCTAATGA AGCCTATATA ATTTTGTGAA AACTCAATTA
6021 GCATTAAGTT TTAAGAGTCA CCAAAATCAA AGAATAATCC AATGCTTTCA TTACCACATG GGAGAAAAATA
6091 TTTTCTTAGT TTAATGAAA TGAACACAAA CATTCAAATC AATTGTTGCT TATTAAACCA AAGACCCATT
6161 ACTTAGCCAA GAGTTTAACA AAAAAAATTT ACATTCAATG ATCATTATT CAGGGAATTC CTCAAAATAA
6231 ATGAAGGGAG TTTTATAGA AAATATAATC ATAGATATTC AACATAACTT CAGGGAATTC CTCAAAATAA
6301 CCAAGTTATT CAAGAAATTA CATCCAAATC AACCAAGAG AAGTTTAGCC TAGCATGGCT AAACCTCAAG
6371 AACCTAAATA AGGATTAGAA GTACCAAAACA TGTAGTAAGA ATCAGAGTAA AAGATGATGT TGTCTTGAT
6441 GTTCTTCTAA GTTCTTCAAG TCTCCAGTTG CTCTTAATAA TGCAAGGAG AGCCATTAAA TTCGTATGTA
6511 TTGATCCCTT CAAAAGCTGC ACCAACCTCC CTTAAATAAC ACTCAAAGCA AAAATGACAA AATGCCCTGA
6581 AGGACCCCTT GTGGGTGCGT TGCGCGGGTG GAGCTGCATA CGAAAGGTCT TTGCTCTTTG TGAGGGTGAT
6651 GTTGTGCGGG ATAGCTTGTG GCATGCTTCC GCGGGTTTCA CGCACATGTG CACAGGTGAT GCATGGTGTG
6721 TGCGTCTTTG AGTTTGTAGC CTCGGATGCT TAGTCCACTT GGCCCAATTC GAGTCCAATC AGCTTATAAC
6791 CCATTTTCTT TCAAGTTATC TTCAAGTTAA GCCCAATTTG GCTTCTCCAA ATCATCCATA ACTTCACAGA
6861 ATCGCCCGTT CATCTTAATC CCGGATGCAC AATTATTCTC CCGTCTTCAT TTTAAGCAAG ATACACCTT
6931 CTTCAATGCT CATCCATCAA TAGTACACTT CATGTATCAT CTCTACTAGT TATTTAGTCC ACAAACTCTT
7001 GTTGTCTTCC AAATTTAATT ATCTCAATTA GTTCCCGTT CCGTACTTT CTTAAAAATT TGGAAATTAAG
7071 CTCAGAGAAA TATTAAGTAC CCGAAATGGT CATAAAATTA ACAAAGGGA AAATGCATGA AGATTAACTA
7141 AATGATGAAC GAAATATGCT AAAATAGACT ATAAATGAA GTAAATAAAA TGAATTTATC GCACTCCGAC
7211 CACCCCTTATG GCTTGTAGTC CACCCACCTT TCATTCTTTG TACCAATATG GGATGGAAAC ATCATTAATT
7281 AAGCCAAAAA GCTAACATAT AAGGGTTTAG TGACAAAGGT AAGTACTAAA GATGAAAAATA ATCCATTTT
7351 CTTGTTTTTA CACAACACAC ACATAGGGGC AGACGTAGGA TTTCAAAGTA CAGATTGTTG GTGGCACATA
7421 AGTGTGCTG GTGACATTTT TTTTCTCTT TTACGTGGTG GCACAACAGT AGGAAAAACG AAAAATTCGA
7491 AATTTTTTAT AATTGTCTTT AAAAAAACA GGGGTGTGTG GTGCCACTAT GGACAACAAA GTTGAAGTCC
7561 CCTACGCGCG CACACACACA CACACACATA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA AAGAAAGAAA
7631 GAGAGAGAGA GTTGGGATG TGATACTTCT TTTAGGAAAA TGGAGTTATA TCTTTGATAT TGTATTTTTT
7701 TAAATGTAAT TATNATTTA ATCATTTTAG TTTATAAGTT NTATTTATTN GGNATGAAA AAAAAAGTCT
7771 TTTATACATT GGATTTAACA TAAAAATCCA ACAATATTAA TCAAAAAGAC CAAACATGTG GACATTTATG
7841 TATATAATTA ATTCACAATA GTCTTTAGGA ATAGTATTAT ATATATAATT AATTCTCAAT GGTCTTAGGA
7911 ATAGTAAGTT CITATATTTC AAACCTTTTG CACAATTCTT TGCTTACTTT GACACTTTTC CTTCTTAAGT
7981 TTACATATAT ATATATATTA AAGCGCAAGG GTCTAGGAAA TATAATATTT TCTATTATTC TACGTTTTGC
8051 CACAAAAGTT TGAAACATTT GCCACTTTT GTCCCTCTCT AACCTTTTCA ATGTTTTGCG ACAAAAGTTC
8121 CAAAACCTTG CCACCTTGAT CATTCCTCAA CTTTTCACCG CATTAGTTTG TGGAGTTGGC AGTTTTGGTC
8191 CCTCTAATCT CGATATTCTC TACTGCTAGC CAAAAGGGT TCCAGAGTTT CACACTTTTG GTCCCTGACA
```

RLG2B cont.

8261 GTAACCAAT GTGAGATGTC AAATTTTTCG CACATTAGTT TGTGGAGTTG TCCCTTTTGG TCCCCCACA
8331 TTCCGATATC TACTATACGA TCTTATTTTT CTCAAATAAC AACACGTATA TTTTCATC:CT AATTGGAAAA
8401 AGAGTTTTAA AA:AAATAAC GACTAGG:: G:GC:GAGTT TTTTIT:ACA AGTTTGTATC AAATCATATC
8471 AAAATTTAAG GTGGAACGGT GACCACATTA ACCAGAAATG TAATTTATTC TTTGATTTTG ATAATTTTTA
8541 ATATTTTGTG GTGATCTATG TATTTAAAG TAAACAACAA AGAACATAAT CCAAAACCCCT AAATTGCAAG
8611 TCTCGCCCAA TTTCTCTATC ACTAGTCCCTC ACTTACGATG GCGTTACGTC GCTCTCTCAC TGCTTACAAC
8681 CCTTTGTGTC TACTCATTAC AATAACGAAA AGTTGAATAT CCATATATTT ATTTGGATGT GGAATTGAAC
8751 GAATCTCGTC AAAATTTTGA TTTTGTGAT GGATTTGAGT AGAAGTTTGG GCAGAACGGG AATGATGGTC
8821 TGCAAGTGGT TATAAACTTG ATTCTGAGTT ATTACTATAT ATGTAGCCTC TTTACAACGA CCAAGGTTTC
8891 TTCCAGGTAC CATTTGATCT TTTTAGAAT TAGTTTTCCTG AAACACCCCTG ATTTGGATCA AATATCACCA
8961 ACAACTCTTA AAAACTTGAT TAATCAATTG TTTTCTTCAT CTTGATAACA AGTGGAAATGA TTTTCTACTT
9031 AGATTAACTT GAAAAAAAAG GTCCATGTGC GTCTGGTGGG TCTGGTAAAT GAAGATGGAA GGGAGAGCTG
9101 ACTTTAAAGA CACAAACACG TCACCATATC TCTTATTTTA TTTTAAATTT GCTTTTGGTG TATTTTCTTT
9171 TTTCTTATTT CTTCCTTTCT TGATCTCCAG ATGGTATGTG GTGTGGATAA TTTACACCTA GAGATTGGGA
9241 ACGATGGGAA GGGGTCTGTG ATTTATGGCT GGCCGAGTTT TACTTATTA CTCAATTTCA ACCTAAATTC
9311 TGATCTTGT TTGAAAAATA GTTGCATCTT TATTTTGTG TATCTTGTG GCATAGGATC CTTAGCATCT
9381 TTTAATAATT TATTTGAAGG TGAAAGATCC AACTATTTTT TAGCTGTGG CATTTTCCAT CATTTGCAAC
9451 TGTTCTTGA AAAAAAATA CCTAAAATAA AAATAACCAT TTTCAAATCC AAAATTATAA GAGAGAATTG
9521 TAAATGGACA TGAATCATA AATCATTAAC ACAGTTCAGT AAACAAGTTG CTAATTACAT TCTTGTCTGT
9591 GCAGATTGAA ATTCTATCAG AGAAAGAGAC ATTACAAGAA GCCACTGGCA GTATTTCAAA TCTTGTATTC
9661 CCATCCTGTC TCATGCACTC TTTTCATAAC CTCCGTGTGC TTACATTGGA TAATTATGAA GGAGTGGAGG
9731 TGGTATTTGA GATAGAGAGT GAGAGTCCAA CATGTAGAGA ATTGGTAACA ACTCGCAATA ACCACAACA
9801 GCCTATTATA CTTCCTTACC TCCAGGATTT GTATCTAAGG AATATGGACA ACACGAGTCA TGTGTGGAAG
9871 TGCAGCAACT GGAATAAATT CTTCACCTCT CCAAAACAAC AATCAGAATC CCCATTCCAC AACCTCACAA
9941 CCATAAATAT TCTTAAATGC AAAAGCATT AGTACTTGT TTTCCCTCTC ATGGCAGAAC TTTTTCCTAA
10011 CCTAAAGGAT ATCCGGATAA GTGAGTGTGA TGGTATTAAG GAAGTTGTTT CAAACAGAGA TGATGAGGAT
10081 GAAGAAATGA CTACATTTAC ATCTACCCAC ACAACCACCA CTTTGTTCCT TAGTCTTGAT TCTCTCACTC
10151 TAAGTTTCTT GGAGAATCTG AAGTGTATTG GTGGAAGTGG TGCCAAGGAT GAGGGGAGCA ATGAAATATC
10221 TTTCAATAAT ACCACTGCAA CTACTGCTGT TCTTGATCAA TTTGAAGTAT GCTTTGTACA TATTCCATTA
10291 TTTATTTAAT TTCTTTTIT ATTTGCAATA TTCTATAAAT AATACATTTT ATACCCACTA TACTAAGATA
10361 ATAATTACCT AGAGGGATGG ATGCTATGAC ACAGCTGCTA CACTTCAGAA ACTCTARTAA GGGCAGTTAT
10431 GGAAGTTCAA TAAATGATA ATGGCATCTT TTGATGGGTA ATATAGGCAA TTTAAGTTT ATTTCTGTTA
10501 AAGCAGTATT TAGCAAGTAC TGGCCAGTAG GAGAGGAGAA TATCACCTTT TGTGAAAATC TGGTCATTGT
10571 ACCCAGAATT TAGTTAAATG TAACATTTTA GATATTAGGG GTTATCAGGT GACAGATATT GTAGAATAGA
10641 ACAATATGTA ATATTACCCA AAACATTTTT TTCTAAGGTT GCTCTGTAA ATATGTGCTT TCTTGATTC
10711 ATTGAATTTG CATTCCTATA TTTTAGGTGG TAAAGTGATT GTCTCTCAA TAAATCCCGA AATTTTTTAA
10781 TTTAAAAAAA AAAAAACAAA AGTAAATTTT TGATATGGAG AGCACTGGTA TCATTTAGTA TATAAAAAAC
10851 AGATTTTGA TTAAGTTTCT TATATAAAAG CTGTGTATAT AGTTTAAATTA GTTTTACATC ATTTTCCAT
10921 GTGGTGTGTC AGTTGTCTGA AGCAGGTGGT GTTCTTGTGA GCTTATGCCA ATACGCTAGA GAGATAAAAA
10991 TAGGCAACTG CCATGCATTG TCAAGTGTGA TTCCATGTTA TGCAGCAGTA CAAATGCAGA AAGCTT

SEQ ID NO: 23

RLG2 B a.u.


































MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEEHISRNTRNHLOIP
SQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITEQIESLTRQLSLISWTDDPV?LGRVG
SMNASTSASLSDDFPSREKTFTQALIALEPNQKFHMVALCGMGGVGKTRMMQRLKKA?EEKLNFYIV
GAVI?EKTDPFQIAIEADYLGQILNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGL
SPFPNQGVDFKVLTSRDSQVCTMMGVEANSIINVGLL TEAEASLFFQOFVETSEPELQKIGEDIVKRC
CGLPIAKTMAC?LRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQEEETKSTFLMCGLPEDFDI
PTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQTNLLIESDDVGCVKMHDLVRAFVLGMFSEVEH
ASIVNHGNMPGWPDENMIVHSCKRISLTCKGMIEIPVDLKFPLTILKLMHGDKSLRFPQDFYEGMEKL
HVISYDKMKYPLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSHIEWLPSTVRNLKKL
RLDLRFCDGLRIEQGVKSFVKLEEFYIGDASGFDDNCNEMAERSYNLSALEFAFFNNKAEVKNMSFE
NLERFKISVGCSDENINMSSHYSYENMLQLVTNKGVDLDSKLNGLFLKTEVLFLSVHGMNDLEDVEVKS
THPTQSSSFCNLKVLISKVELRYLFKLNLANLTSRLEHLEVCECENMEELIHTGIGGCGETITFPKLF
LSLSQLPKLSSLCHNVNIIIGLPHLVDLILKGIPGFTVIYPQNKLRSSLLKEGVVIPKLETLOIDDMENLEE
IWPCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHLEELTVENCGSIESLFNIDLDCVGAIGEEDN
KSLLRSINVENLGKLREVWRIKGADNSDLINGFOAVESIKIEKCKRFRNIFTPTANFYLEALLEIQIEGCG
GNHESEEQVTLSSLS

SEQ ID NO: 24

→ 25

[illegible]

[illegible]

RLG2A
RLG2B
RLG2C
RLG2D
RLG2E
RLG2F
RLG2G
RLG2H
RLG2I
RLG2J
RLG2K
RLG2L
RLG2M

[illegible]

[illegible]

[illegible]

SEQ ID NO:

40

GETT-----LKEVVEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 100
 10 20 30 40 50 60 70 80 90 100
 RLG2A protein in GKTTHMRLKVKVKEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-41
 RLG2B protein in GKTTHMRLKVKVKEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-42
 RLG2C protein in NTRX--AKAEVAKKKEEFGYIIEAVIGEISDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-43
 RLG2D protein in EVAK--RK--FGYIIEAVIGEISDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-44
 RLG2E protein in GRND--AKVEEVAKKKEEFGYIIEAVIGEISDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-45
 RLG2F protein in LEUTMQRLLKVKVKEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-46
 RLG2G protein in GRIDD--EELKEVVEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-47
 RLG2H protein in -----KEVVEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-48
 RLG2I protein in CKXS--MKVEVQKKTENIIVGVVIGKTNPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-49
 RLG2J protein in ERGR-----GKKTENIIVGVVIGKTNPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-50
 RLG2K protein in LEUTMQRLLKVKVKEKQKFNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-51
 RLG2L protein in -----FSTVWEVIGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-52
 RLG2H protein in AEE-----AAEKKLKNIVGAIVGKTDPTAIQQAVADYIGIELKSTPRADKIREMFAESQSGKNEFLVLDVWQSVLDIGLSPFNQ 98-53

VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 110
 110 120 130 140 150 160 170 180 190 200
 RLG2A protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 196
 RLG2B protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 195
 RLG2C protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 193
 RLG2D protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 185
 RLG2E protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 193
 RLG2F protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 195
 RLG2G protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 197
 RLG2H protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 189
 RLG2I protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 194
 RLG2J protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 189
 RLG2K protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 195
 RLG2L protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 177
 RLG2H protein in VDFKVLITSRDSHVCTHMGVEANSILNVGLLIEAEQSLFQGVETS--E---PELQKIGEDIVRKCQGLPIAKTHACTLRKRKQDAWDMALSRLEHYD 187

[illegible]

```

410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

```

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2O

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2O

[illegible]

[illegible]

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2Q

[illegible][illegible]

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2O

SEQ ID NO:

AC15-2A	810	820	779
AC15-2B	TAAGTACTTGTTTTCACCTCTCAAGG - 56		777
AC15-2C	TAAGTACTTGTTTTCACCTCTCAAGG - 57		777
AC15-2D	TAGTACTTGTTTTCACCTCTCAAGG - 58		788
AC15-2E	TAGTACTTGTTTTCACCTCTCAAGG - 59		721
AC15-2G	TAAGTACTTGTTTTCACCTCTCAAGG - 60		781
AC15-2H	TAAGTACTTGTTTTCACCTCTCAAGG - 61		738
AC15-2I	TAAGTACTTGTTTTCACCTCTCAAGG - 62		722
AC15-2J	TAAGTACTTGTTTTCACCTCTCAAGG - 63		786
AC15-2K	TAAGTACTTGTTTTCACCTCTCAAGG - 64		699
AC15-2L	TAAGTACTTGTTTTCACCTCTCAAGG - 65		778
AC15-2M	TAAGTACTTGTTTTCACCTCTCAAGG - 66		763
AC15-2N	TAAGTACTTGTTTTCACCTCTCAAGG - 67		

SEQ ID NO:68

RLG3 (real RLG3)

[Strand]

```
1  AATGGCAAAA GAAGTCGGAG CAAGAGCTAA GTTAGAGCAT CTATTGACG TCATTATCAT GGTAGATGTC
71  ACTCAAGCAC CCAACAAGAA CACAATTCAA AGTAGTATTT CAGAACAGTT GGGATTAAAA CTGCAAGAAG
141 AGAGCTTGTG GGTAAAGAGCA GCTAGGGTAA GTGCGAGSTT AAAAAATGCTT ACAAGGGTGC TGGTGATATT
211 AGACGATATA TGGTCAAGGC TTGACATGGA GGAACCTGGG ATTCCCTTTG GATCAGATAG ACAACACCAC
281 GGCTGCAAAA TCTTGTTGAC TTCAAGAAGT ATTAGTGCTT GTAACCAGAT GAGAGCTGAT AGAATCTTTA
351 AAATACGAGA AATGCCACTG AATGAAGCAT GGCTTCTTTT CGAAAGAACA GCTAAAAAAG CTCCGAATCT
421 GCATCAAGTA GCAAGAGATA TCGTGGAGGA GTGTGGTGGG C
```


RLG4
SEQ ID NO: 69

```
1  GAATTCGGTG TTGGTAAGAC AACTCTTGCC TCTTCTGTTT ATGATGAAAT CTCTAGCAAG TTTGATGGTT
71  GCTGCTTTCT AAAAATATCT GCGAGGAATC AAGTAATAAA GACGGTATAG AAAGATTGCA AGAAAAAATC
141 ATTTGTGATG TTTTGAAACA AGAGCAAGTG GCGTAGGGA GAGTTGAAGA AGGAAAGCGC ATGATAAAGG
211 ATAGGTTACA ACATAGAAAG GTATTGATTG TGCTTGATGA TGTCGACAAC GTTGAGCAGC TAGCTAGAAC
281 AGTTGGGCTGG ATCACATGAT TGGTTTGGTG AAGGTAGCCG CATAATATC ACAACTAGAG ATGAACATGT
351 ATTAATTGCA CACAAAGTAG ATGTGATACA CAATATAAGC TTGTTAAACA ACGATGAAGC TATGCATCTC
421 TTCTGCAAGC AAGCACCACG GGGTCACAAA CGTATACAAG ATTATGAGCA ACTTTTAAAA CATGTGGTTT
491 CTTATGCTGG TGGGCTTCCA CTAGCACTGT CGAC
```

SEQ. ID NO: 70
RLG1-E169
[Strand]

```
1  ATCGTAACCG  TTGCTACGAG  ANCGCTGTCC  CTCCTTCATC  TTTTGTGATA  TGTCATATTC  TCATNATTN
71  TGGCAGATG  AATTTTGTGG  TTATTTTAAA  TTAATTTTFA  TTCCACATGT  CATTTTATGA  GTTTTCTAT
141  TTTATTGAST  TTCACATAAT  ATTAAATGT  AATAACAATA  AATGCATATT  TATTTTCTT  TAAATAAACG
211  CATATAATAT  ATAGATTAAA  ATCATATAAT  ACATAGGTTA  AACTCATATA  ATACATATGT  TCATCCOCAG
281  TTTATTTATA  TGCTCATCC  TTAATTTATT  TATTATTAT  TTATTAGAGT  AGATGATCTT  TGTGATATTA
351  AAAATTTAAT  TTGTTCAAAA  TTDAAAATTA  TTAATAATCC  CACAATTIGA  ATAAAAITPA  AAAAAATGNN
421  CCCACCATTA  GTCCATCACT  TTTTCAGCTC  ATCAATATCG  TGAGTATICT  CCTTCGTTTC  CACCCTAATC
491  AATATTTCCA  GCGAATGACA  GACTCCTACG  GCGTTTCTGA  ATTTGCGTTC  CGACACTGTT  CATTGAAGGA
561  GATAATAAAT  CMAATGGAGC  TGCTCCAATG  TTCAATTGCTG  ATGAAAGGTG  AATGTATGT  GAAGANAATG
631  TCAGCGATCN  ATCTCCATCC  GGAACCCACC  ACATTATCAG  TGACCCACA  AACCACTCAA  AACGSGGAA
701  GTAGRRKAC  WRKAAAGTCA  TGAAGAATAG  ATTATTTTGG  TCCTCATGGG  CTGACTGAGG  AGCGGTTTA
771  GTTCATCAAT  TTTCTTTGAN  CAAAGAATTA  TCGTCCATC  GAAITTTTAC  ATCGACAAG  AAGTTTCACT
841  TCGCAATGTT  TTGTTAAACA  AITTTTAAATC  TTTTATCTT  TTGTTTGA  CTCTCAAT  GCAACTTGCA
911  ACTTGCAACT  TTTGGGCCCA  CAAATTTGTG  GTGGGCGTTA  ATTTAATCCA  CATATTCACT  GTAAACAATA
981  ATTCAAATCG  ATCTCTGTT  ATCCAAATCA  TCAACATCTC  TTGATAATTG  AAATCATICA  CGCTTCATCC
1051  ATTTCATCCA  CATCTATACT  ATATTCTCTG  CTCTTATCAT  ATTAAAGAT  GGCTGAAATC  GTTCTTCTG
1121  CTTCTGTAG  AGTCTGTTT  GAAAGCTGG  CATYTGAGC  CTGGAAGAG  ATTGTTCGCT  CCAAAAGAT
1191  TGAATCTGAG  CTTAAGAAAT  TGAAGGAGAC  ATTAGACCAA  ATCCAAGATC  TCGTTAAGGA  TGCTTCCAG
1261  AAGGAAGTAA  CTAATGAAGC  CGTTAAAGA  TGGCTGAATG  ATCTCCAACA  TTTGGCTTAT  GACATAGAGG
1331  ACCTACTTGA  TGAATTTGCA  ACTGAAGCTG  TTCAWCTGTA  GTTGACCGAG  GAGGGTGGAG  CCTCTCCAG
1401  TATGGTAAGA  AAACATAATCC  CAAGTTGTTG  CACAAGTTTC  TCACAAAGTA  ATAGGATGCA  TGCCAAGTTA
1471  GATGATATG  CCACCAAGTT  ACAGAAGCTG  GTAGAGGCAA  AAATAATCT  TGGTTAAGT  GTGATAACAT
1541  ATGAAAAGCC  AAAAATGAA  AGGTATGAGG  CSTCTTTGTT  AGATGAAGC  GGTACTGTCC  GACSTGAAGA
1611  TGATAAGAAA  AAATTCCTGG  AGAAGCTGTT  GGGGGATAAA  GATGAATCAG  GGAGTCAAAA  CTTGAGATC
1681  GTGCCCATG  TTGCTATGGG  TGGAGTTGGT  AAAACAACCT  TAGCTAGACT  TTTGTATGAT  GAAAAGAAAG
1751  TGAAGGATCA  CTTGGAATC  AGGGCTTGGG  TTTGTGTTTC  TGATGAGTTC  AGTGTCCCA  ATATAAGCAG
1821  AGTTATTTAT  CAATCTGTGA  CTGGGGAATA  GAAGGAGTTT  GAAGACTTAA  ATCTGTCTCA  AGAAGCTCTT
1891  AAAGAGAAAC  TTAGGAACCA  GCTATTCTTA  ATAGTTTGTG  ATGATGTGTG  GTCTGAAAGC  TATGGTGATT
1961  GGGGAAAT  AGTGGGCCCA  TTCTTGTGGG  GGTCTCTCTG  AAGTAGAATA  ATCATGACAA  CTGGGAAGGA
2031  GCAATTCCTC  AGAAGCTGG  GCTTTTCTCA  TCAAGACCTT  CTGGAGGTC  TATCACAAGA  TGAATGCTTG
2101  TCTTTGTTG  CTCACACCC  ATTITGGTGA  CCAAACCTTG  ATTCACATCC  AACACTAAGG  CCACATGGAG
2171  AACTGTTTGT  GAAGAAATGT  GATGGCTTAC  CTCTAGCTTT  AAGAACACTT  GGAAGGTTAT  TAAGGACAAA
2241  AACAGACGAG  GAACAAATGA  AGGAGCTGTT  GATAGTGAG  ATATGGAGGT  TAGGAAGAG  CGATGAGATT
2311  GTTCCGGCTC  TTAGACTAAG  CTACAATGAT  CTTTCTGCCW  CTTTGAAGCT  RTTCTTTCGA  TATGTCTCTT
2381  TGTTCCTCAA  GGACTATGAG  TTTGACAAAG  AGGAGTTGAT  TCTATGTGTT  ATGGCAGAAG  GGTMTTTCGA
2451  CCAACCAACT  AYAAACAAGT  CAAAGCAAG  KTTGGGTCCT  GAATATTTTR  AAGAGTTTTR  GTCAAGTCTR
2521  TTTTTCAC  ATGCTCTTAA  TRCAAAATCS  TTGTTTGTGA  TGCAATGACCT  AATGAATGAT  TTGGCTACAT
2591  TTGTTGCTGG  AGAATTTTTT  TCAAGGTTAG  ACATAGAGAT  GAAGAAGGAA  TTTAGGATGS  AATCTTTGGA
2661  RAAGCACCG  CATATGTCAT  TTGATGTGTA  GRATTACATA  GGTACAAAA  RGTTCGAGCC  ATTTAGAGGA
2731  GCTAAAAAT  TTGAAACATT  TTTAGCATTG  TCTGTGGGG  TGGTAGAAGA  TTGGAAGATG  TTTTACTTAT
2801  CAAACAAGGT  CTGAATGAC  WTACTTCARG  ATTACCATT  GTTAGGGTC  CTRAKTTTGA  TTRTCTTAY
2871  AATAASYRAG  GTACCARAAC  TCGTSGGTAG  TATGAASCAC  TTGCGGTATC  TTAATCTATC  WGRAACTTWA
2941  ATCACHCAT  TACCGGAAWA  TRCTTGCAAT  CTTTATAATT  TACARACCTT  GATTGTNCT  GCTCTGAMT
3011  ATTTAGTTAA  KTTGCCCAAR  ACCTTCTCAA  ASCTTAAAAA  TTTGCASCAT  TTTGACATGA  GGGTACTCC
3081  KAAKTTRAAR  AACATGCCCT  TARGGATTGG  TGARTGAAA  ARTCTACAAA  CTCTCTTMM  TAACATTTGC
3151  ATAGCAATTA  CCGAGCTTAA  GAACCTTGCA  AAYCTCCATG  GGAARITTTG  TATTGGGGGG  CTGGGAAAAA
3221  TGGAAAATGC  HTTGGGATGC  ACGTTAAGCG  AACTTGTCTC  A: AAAAAAGT  TWAATGARTT  ANAACTGGR
3291  WTKGGGGCTG  ATRAATTTAA  TGTMTTCCGA  AATGGGAACA  CTGAAAAA  NAAGTCTCTC  AATCAATTGA
3361  ATCCCTCACA  ATGGTAYTCY  AAWAARRRY  YWTAARWAT  TWKAWRRK  GKTTYATRR  TKTMYRAAW
3431  WAGRTKTTT  TATAGGTT  TCAATCAATC  ACCCAAGTGG  GAAATAGAT  GATATTTTCA  GGGCTTACTG
3501  ATGAGATG  GAGAGGTATG  ATAGGTTNVC  TTGGGGCGGT  AGAAGAAATA  AGCATCCATT  CTGTGATTA
3571  AATAAGATAT  YTTGGGAAT  CAGAAGCAGA  GGCAGTAAAG  GTTCTTATGA  ATTTAAAGAA  GTTGGATTTA
3641  GGTGAATG  AAAATTTGGT  GAGTTTAGGG  GAGAAAAAGG  AGGATAATCA  TAATATTAT  AGTGGAGCA
3711  CCTCAACAT  TTTTAGAGG  TTGAATGTAT  GGAGATGTA  CAGCTTGGAG  CATTCGAGGT  GTCCAGATG
3781  CATGGAGAT  TTGTATATGC  ACATGTGTGA  TTCAATNACA  TCCCTCTCT  TCCCAACAGG  AGGAGGACAG
3851  AAGATCAAGT  CACTTACCAT  CACTGATTGC  AAGAAGCTTT  CGGAAGAGGA  GTTGGGAGGA  CGAGAGAGGA
3921  CAAGAGTCT  TATAAATCA  AAAATSCAGA  TGCTTGAATC  AGTAGATATA  CGTAATTTGG  CAAATCTGAA
3991  ATCTATCA  GAATTGAGTT  GCTTCATICA  CCTGAACAGA  TTATATATAT  CAAACTGTCC  GAGTGTGGAG
4061  TCAATTCCT  ACCATGAGTT  GCCAATCTC  ACCTCTCTAA  CAGATCGAAG  GAGAGGACAG  CGATTTCCT
```

RLG1-E169
[Strand]

4131 ACGAACGGTT ACGATTGAC TGGCGTCTT TTT

SEQ ID NO: 70

Further Characterization of RG2 Family Members:

Further sequencing of cloned RG2 polynucleotide sequences, as discussed above, identified additional RG2 species, listed below. Additionally, further sequencing of the 5' sections of RG2 sequences listed above resulted in modified and/or new sequence information, also listed below. The AC15 sequences found in the 3' sections of RG2 family have not changed.

Listed below are: four full length species, RG2A, RG2B, RG2C and RG2S; two near complete, but with a gap in the largest intron, RG2D and RG2J; three nearly complete RG2 gene sequences, RG2K, RG2N, and RG2O. The deduced translation products (polypeptides) encoded by these RG2 species are listed below. The polynucleotide sequences do not contain any gaps (as with some of the polynucleotide sequences), because all of the gaps in the sequences are in introns, *i.e.*, there are no gaps in exon, or coding, sequences.

They include: an RG2A polynucleotide sequence (SEQ ID NO:87) and its deduced polypeptide sequence (SEQ ID NO:88); an RG2B polynucleotide sequence (SEQ ID NO:89) and its deduced polypeptide sequence (SEQ ID NO:90); an RG2C polynucleotide sequence (SEQ ID NO:91) and its deduced polypeptide sequence (SEQ ID NO:92); an RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94), and its deduced polypeptide sequence (SEQ ID NO:95); an RG2E polynucleotide sequence (SEQ ID NO:96) and its deduced polypeptide sequence (SEQ ID NO:97); an RG2F polynucleotide sequence (SEQ ID NO:98) and its deduced polypeptide sequence (SEQ ID NO:99); an RG2G polynucleotide sequence (SEQ ID NO:100) and its deduced polypeptide sequence (SEQ ID NO:101); an RG2H polynucleotide sequence (SEQ ID NO:102) and its deduced polypeptide sequence (SEQ ID NO:103); an RG2I polynucleotide sequence (SEQ ID NO:104) and its deduced polypeptide sequence (SEQ ID NO:105); an RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107), and its deduced polypeptide sequence (SEQ ID NO:108); an RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110), and its deduced polypeptide sequence (SEQ ID NO:111); an RG2L polynucleotide sequence (SEQ ID NO:112) and its deduced polypeptide sequence (SEQ ID NO:113); an RG2M polynucleotide sequence (SEQ ID NO:114) and its deduced polypeptide sequence (SEQ ID NO:115); an RG2N polynucleotide sequence (SEQ ID NO:116) and its deduced polypeptide sequence (SEQ ID NO:117); an RG2O

polynucleotide sequence (SEQ ID NO:118) and its deduced polypeptide sequence (SEQ ID NO:119); an RG2P polynucleotide sequence (SEQ ID NO:120) and its deduced polypeptide sequence (SEQ ID NO:121); an RG2Q polynucleotide sequence (SEQ ID NO:122) and its deduced polypeptide sequence (SEQ ID NO:123); RG2S polynucleotide sequence (SEQ ID NO:124) and its deduced polypeptide sequence (SEQ ID NO:125); an RG2T polynucleotide sequence (SEQ ID NO:126) and its deduced polypeptide sequence (SEQ ID NO:127); an RG2U polynucleotide sequence (SEQ ID NO:128) and its deduced polypeptide sequence (SEQ ID NO:129); and RG2V polynucleotide sequence (SEQ ID NO:130) and its deduced polypeptide sequence (SEQ ID NO:131); and, an RG2W polynucleotide sequence (SEQ ID NO:132) and its deduced polypeptide sequence (SEQ ID NO:133).

Characterization of New RG Family Groups and RG Species:

Further BAC insert characterization and sequencing, as discussed above, identified new RG polynucleotide sequences. The new sequences were characterized as belonging to new RG families; designated RG5 and RG7. These RG polynucleotides sequences, and their predicted translation products (the polypeptides which are encoded by these sequences) are summarized and listed below.

Identified and listed below is an RG5 family member, designated as the RG5 polynucleotide sequence set forth in SEQ ID NO:134, and its deduced polypeptide sequence (SEQ ID NO:135). This sequence contains an NBS region sequence.

Also identified and listed below is an RG7 family member, designated as the RG7 polynucleotide sequence set forth in SEQ ID NO:136. No deduced polypeptide sequence is given for the new RG7 family member as this sequence appears to be a pseudogene.

RG2A polynucleotide sequence (SEQ ID NO:87)

AAAGTTCATATCCAAGCTTGCCCTCCAACTCTAGCTCCTTCAATGGCACC
TCCTTCTCTTCAAAGCACACAAGAACTTTCAAGCTCAACCACACTCA
CACAAAGCTCTAGAACGAGGGTTAGGGCACATTTAGGGTTTTGCTCTCTGG
AAATGGTGTCTAAAAGTGAGGCCATAATGTTCTTATATAAGGCTCACTC
CCACAATTAGGCTTTCAATCTGAACGTANTACGCCCAGTGTAACACTATGG
TACGCCCAACGTACTCGGTAGTCTCCGCGTCAANAATACACTCATGAGTA

CGCGCAACGTACTTTCCCTTACGCCCAGCGTACTCAAAAGCCAAACATTC
TTTTCAAGGACTAATTTTGACAACTTGAGGAAAGAAAAGGATCAAAGANA
TATACTTGAATTCGGGATGTTACAATGAAGTTGANACCTTGGCTAAAAA
ATTA AATTGGTTGTGGAAGCCGTTGGCTGAGCAAGCAACAAGGGTAA AAT
5 TCGTAATCTACAAATGGTGTTATTTTCTATTTCTTCTTATTATTTTACTT
GATTTACGGGTAGTTTTTTTTTCTTACAAAAAATATTAAAGTTGATAAAG
TATAGCCACTAAAATTGACTTTTTTCCAAAACATAATGTCAAATGGTGCGT
ATATGTATCATGTTGTATTANATAATGAATATGATGATNCTGTTCTATTT
AANCCGAAAAAATTATCTAATGATTTTATATTGGAAAACAAAGTTGTGAT
10 TTTTNGCATAATATAATCAAATCCNCTTTTGTNTGGGAGGTGGATAAATG
TGGTAAATTTANAACAAGTGTTTTNACNTTGAAGGGTNTGGAAAGGTTGA
AAAAAGTTAAAATGATAAAATGTTTACACAAATGTTGTATCCGACTGAAT
ATNATGTTTAAGGATNATTGTATTAAATGTTGATATATAGTAAGCATAA
ATATTTAGAATTGTGACTTAAATTTATAAGTTATNCNAACTGGATTGAAA
15 CATTTTTGATATANATTAGGAATGAAAATGAGCAACCCTAACATACTTAT
CTTTGGTAGTTTGGTTATTATATTTTATTANAATATAGAANCATCCCTT
TATTTTAAACCCATATTGTGGACGGACTTGAATAAATGGGAAAAATGTAC
CTTGCTATTTAGCACAAAAAATTATAAAAATGTACATTGCTATTTAGCA
CAAACAAAAA AAAAAA AACTTATCCTTTTTGCATTAGGTCACAAAGAAATA
20 TAA AATGGGAAATGTGTGCTATTTAATGCACTAAAAGAACTATTTTGC
CTTTATTAAACCGGGTAAACCAATAGAAAAATGGAAGTACATTGTCAATT
AGCATGAAAAAATAA CTTTCCATTTTTTGCATCCGGTCACAATAATAG
AAAAATGAAAGTACGTTGCTATTTAGCGAACTAACTTCCTTTTTTCTTT
TTGGCATCGTATCATAAAATATAGACTAAAATACGTTAGTTTTACATTTT
25 TAATACATTGAAATGTCTAATCCACATGTTATTCTATAAAAAGGGAAATG
TAATTTACTTATTCTTTGATTCTTTGGCTTCTTTTAGTACCCAAAACAT
CCCTCTATCCATCTATTCCAATAAATAATGAAAATATATTCTTCCA
TTGTAGGGATGTTATAAATTTTGTAATTGTTTTTATGCAAAAAAGTGTTT
TTTGTTAACTAGATTAACGAGATTCATTTTTCAGCATTTTAGGAGAAGTT
30 CATCCATCTTTTGATATGAAGTGCAAGCCAAGTTCTTTAACATGGAATA
TGAGGTCCCTATATGCTCAAAAAATAGCAAATGAGAAATTTTTAAATTG
GATCCCATATAAAGAAAAATTTGTTAATGGTTGTTTTAATATTGGTCAATG
TGTCCACCGGATGAGCATAATACTAGTTTATAAGGGGTAAAGGTGGGTTT
GGTGGGCCCATTTATCTTTATTATTTCTAAAAGTCAGAATTAAGTAAAAA
35 AAATTATAAGATAAATACCATAAGGATAAAAAATCATTTTATTTGGACCA
AAGACCAAAGTTGTTAAGGGGCTGTTTGTTTTTTTTTGTAAGAGCTGTGC
AACCCTTTTGTCTGCGCCGCACAGACAACGTGCAGACATATGCCCTCGC
AGAGTGTTTGTTTTTTGAAAGTGCGCAGACCAAAAAACGTCTGCGCGAG
GTCATCCTGGCGCATATATGTGTCACTGTCTTCAAAGGTCTTCAGACCTC
40 ATTTTAAACCAAAAAA AAAAAAGACCACGGTTTTTTTTTTTTTTTTNTTC
TTTCTCTGTAGCTGAAAATGCATTTTAAATCTTTATGACATGAAATTAA
GTTTGAAAAATTAATTTATTTCAACAGCTGTAGACGTTAAAAACAAACAG
TCTTCTTGTTGCAGACTGTGGACATTTGGTCCACCTCTTCTACCGCAGAG

ACTTGCAGATGTGGTCCGCAGACTGCAGACATTTTGGCTTCAAATAAACA
AACATCACCTAATTTGACTACACCACACGGACCTCCAATGTAACAAAAAA
AAGGTTGAAACAAAGTTGCCTATTTCTCCATATCCAGGGGCCATTTATGT
AAGAGTTATCTAAATTTTAGTTTCGGTAGATCAGTTCTCACATTTTAACCG
5 GGTAAAGTGTATGTGTGTACGCGCGCACCTGAAAGGTTTGAANGTAACTT
CCAAACTGAANCAANAATCGATATGAAGTATCAAGTTAGAGGTTCAATTG
GTGAAGGAATCAGCTGGAGGTTGGGGAATCGAGCTTCCACTATTAAGGTA
AAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCGTGTTT
TGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGGTATAT
10 GACATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTTTACGT
AAGTTAGGATTCGTA CT TCAACCAAATGTAATAGTTTTTGTGAGTCTATC
TATGTATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAATTCGAA
AAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTTTAGCG
ACATCTAATATTAAATAGAATGTATCTGATATTGAATTAATGTCCTTAAT
15 GTG.AACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTTTCTAAT
CAATAAATTTTAAATTTCTGTTTTATGCTTCTAAGACAATAAAAAATCCATG
ATTTACCTTTAAATATTAACAAAAATGACCATAAATAAAAAAATTAG
GATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGATGCTTT
TGCTTTTCCCTCTTTTCCTTGTTAGTCTATTATTCTGGAGAGTTTGAGAG
20 AGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTATTCTC
TTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTACACGATCCATGGT
TTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGCCCTTG
ATG.ATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAGTGGTG
AATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATGATGAT
25 GAG.ATAGAGATATGTTAAAACTGGCTAGAAAATTGTTTTAATTTGAAATT
TAGGTTGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTTATGCT
AAATAGTTATAAAGAACAACAACTCGTAGTTTTTTTTTTCATGATTTTCA
ACCTCTTCGTACCAAACCTAAATTATAACAAAATTGAATATCATTCTCTGC
AATCAATTTTAACTTTTGTATTATCATCATGTCTAAAATTGCCACAAGT
30 TTATTTTCATAGTCATATTGGATTATGAAAGGACTATTTTACCAATTAC
ATCTTTACTTTATGGCCAAAGCTAATACAATCCGACTAACTAAAGGATT
CTAGGATGCATATAGTTTGCTCCCCGATTATAGATTTCTATCTAATTTGT
CTATTGTACTAATTTAGGTGCCACCACAAGTAAATTCCTGAAATGGATGT
CGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTACCCGTTA
35 AGAAACACATAGGGTACCTCATTTCTGCAGGCAATATATGAGGGAAATG
GGT.ATCAAATGAGGGGATTGAATGCTACAAGACTTGGTGTGCAAGAGCA
CGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAAGTCAGGG
GTTGGTTTGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAATTTCCCT
AGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGGTCGGAAA
40 GAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTGATGAGAGAACACT
CTATCATCATTTTGAATGATCATTCCATTCCTTTAGGAAGAATTGATTCC
ACG.AAAGCATCCACCTCAATACCATCAACCGATCATCATGATGAGTTCCA
GTC.AAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGATCCTAACC

ACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGGGAAGACG
ACAATGATGCATCGGCTCAAAAAGGTTGTGAAAGAAAAGAAAATGTTTAA
TTTTATAATTGAGGCGGTTGTAGGGGAAAAAACAGACCCCATTGCTATTC
AATCAGCTGTAGCAGATTACCTAGGTATAGAGCTCAATGAAAAAACTAAA
5 CCAGCAAGAACTGAGAAGCTTCGGAAATGGTTTGTGGACAATTCTGGTGG
TAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTGGATCTGA
ATGATATTGGTTTAAGTCCTTTACCAAATCAAGGTGTGCACTTCAAGGTG
TTGTTGACATCACGAGACAAAGATGTTTGCCTGAGATGGGAGCTGAAGT
TAATTCAACTTTTAATGTGAAAATGTTAATAGAAACAGAAGCACAAAGTT
10 TATTCCACCAATTTATAGAAATTTCCGGATGATGTTGATCCTGAGCTCCAT
AATATAGGAGTGAATATTGTAAGGAAGTGTGGGGGTCTACCCATTGCCAT
AAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCATGGAAGA
ATGCACTTCTTCGTTTAGAGCACTATGACATTGAAAATATTGTTAATGGA
GTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTAAATCCAC
15 CTTTTTGCTTTGTGGAATGTATCCCGAAGACTTTGATATTCTTACCGAGG
AGTTGGTGAGGTATGGATGGGGGTGAAATTATTTAAAAAAGTGTATACT
ATAGGAGAAGCAAGAACCAGGCTCAACACATGCATTGAGCGGCTCATTCA
TACAAATTTGTTGATGGAAGTTGATGATGTTAGGTGCATCAAGATGCATG
ATCTTGTTCTGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGAGCATGCT
20 TCCATTGTCAACCATAGTAATACACTAGAGTGGCATGCAGATAATATGCA
CGACTCTTGTAAGAACTTTTCAATTAACATGCAAGGGTATGTCTAAGTTTC
CTACAGACCTGAAGTTTCCAAACCTCTCCATTTTGAACTTATGCATGAA
GATATATCATTGAGGTTTCCCAAAAACCTTTATGAAGAAATGGAGAAGCT
TGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCCTCATCAC
25 CTCATGTTCCGTCAACCTTCGCGTGTTCATCTACATAAATGCTCGTTA
GTGATGTTGACTGCTCTTGATTGGAAATCTGTGCAATCTAGAAGTGCT
TAGCTTTGCTGATTCTGCCATTGACCGGTTGCCTTCCACAATCGGAAAGT
TGAAGAAGCTAAGGCTACTGGATTTGACGAATTGTTATGGTGTTTCGTATA
GATAATGGTGTCTTAAAAAATTTGGTCAAACTGGAGGAGCTCTATATGAC
30 AGTGGTTGATCGAGGTCGAAAGGCGATTAGCCTCACAGATGATAACTGCA
AGGAGATGGCAGAGCGTTCAAAAGATATTTATGCATTAGAAGCTGAGTTC
TTTGAAAACGATGCTCAACCAAGAATATGTCATTGAGAAGCTACAACG
ATTCCAGATCTCAGTGGGGCGCTATTTATATGGAGATTCCATAAAGAGTA
GGCACTCGTATGAAAACACATTGAAGTTGGTTCTTGAAAAAGGTGAATTA
35 TTGGAAGCTCGAATGAACGAGTTGTTTAAGAAAACAGAGGTGTTATGTTT
AAGTGTGGGAGATATGAATGATCTTGAAGATATTGAGGTAAAGTCATCCT
CACAACTTCTTCAATCTTCTTCGTTCAACAATTTAAGAGTCCTTGTCGTT
TCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTGTTGCAACAC
TTTAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGATAATATGGAAG
40 AACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTACATCCCCAAG
CTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGGGTTTGTGCGA
TAATGTCAAAATAATTGAGCTACCACAACCTCATGGAGTTGGAAGTTGACG
ACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTTTGAAACATTT

AGTTTGTGAAGGAAGAGGTAATATAAAATTTTAAATGCTAATACATTAC
AAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAATTTGATTGTA
TGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTATCTTGCAGGT
TCTGATTCTTAAGTTAGAGAACTGCATGTTAGTAGTATGTGGAATCTGA
5 AGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGTTAAGTTCAGA
GAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGTTTCCGCACAA
GCCCATATCTCTGCTGCATCATCTTGAAGAGCTTAAAGTCAAGAATTGTG
GTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGTTGGTGCAACT
GGAGATGAATACAACAACAGTGGTGTGAAGAATTATTAAAGTGATCAGTTG
10 TGATAAGCTTGTGAATCTCTTTCCACACAATCCCATGTCTATACTGCATC
ATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGAATCGTTATTC
AACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAGACAACAGCAT
CAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTAAGAGAGGTGT
GGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTTCATGGCTTTCAA
15 TCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAAGTTTAGAAATGTATT
CACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTGGAGATTTCAA
TAGATGACTGCGGAGAAAACAGGGGAAATGACGAATCGGAAGAGAGTAGC
CATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTGTCTTAATTAATGAT
TAAGCTCCTGCTTTTTGAATAAAAAAGGGACAAACCATTTTCATGACTTAA
20 TGTAGCAATACAAGTCATGTATAAGAGTGACCAACTCTTTTTTATTATA
AAATGACTACAAAATATTTTTTTTCATTAGAGATCATGTATAAATGTGAC
TAATTTTTTCATCACCTAACTTTAGTTGATAAATCTTTATAAATGTCACTA
GTTACTTTTCAGTAAAATAACAAATTTAATAAATTATCAACAAAAAGCAT
CAACTAAAAAATCCCACAACCCGTAATAATTTAAAAATAAAAGGATTTAA
25 CATCTAATACGAACAATTTTTTTTCTAAACATGATTTGGACCAAATATCA
CCAGCAACTCAAGTTTGAATCGATTGAGCTTAAACTTGACCAGCATAA
TTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATATAAGTTTCGTTTCATC
TTTTTTCTTGATCTTGATAGCAAGTTGAATGATTTTCTTCTTCAAAATTG
ATAAAAATCTACATTATAAAGAGACTAGCTTGAAAAAAATGGTCTAGGT
30 GGGTCTTGGGTTCTGGTAGATGAAGATGGAAGGGGAGAGTAGATTTCAA
GACACAACACATCCTTCATTTTATTTATTATTATTATTATTTTGTG
ATATCTTGCTCATATTTGTTACAGATATGTGAGGTCTATTAATCTTTTA
AATATATAAAAAAATAAATAACATAAATGAGAAAATTAAATAAAGAATAA
ATTAAATAAGGGCACAATAGTCTTTTTAGGTAAGACAAGGACCAAACACGC
35 AACAAAAATAAACAGTAGGGACCATCCGATTTAAAAAAATAATTAGGGA
CCAAAAACATAAATCCCCCAAACCATAGGGACCATTCATGTAATTTACT
CTTACTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTTTTGTACACAT
CTAGGTAACGAACCTTGTGGAAGTGTTCCCATTTAGGATGTGACCTACTAC
AACCGATCATAATAGTCATATGTGAACACTTCCAACAACCTTTATTACTTA
40 GGTGTGTACAAAAAACAATAGTTACCATGATGTGAACATACTGAAAAAT
TAATTACCTTAGCAAGTTATTTTCCCATTTAGGTTGTATGGAAACAGTTC
CGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCTTC
AATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGATT

CTTGTTTGAAAGTAAGTTGCATCTTTATTTTTGTATTATCTTGTTGCATA
GGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAACTA
TTTTTAATCTGTTGGCATTTCATCATTTGCAACTGTTTCTTGAAAAA
AAATACCTAAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGAG
5 AATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAACA
AGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAA
GAGACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATC
CTGTCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAG
TTAAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGT
10 AGAGAATTGGTAACAACTCACCATAACCAACAACAACCTATTATACTTCC
CAACCTCCAGGAATTGATTCTATGGAATATGGACAACATGAGTCATGTGT
GGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATCA
GAATCCCCATTCCACAACCTCACAACCATAAAAAATTATGTATTGCAAAAG
CATTAAAGTACTTGTTTTCGCCTCTCATGGCAGAACTTCTTTCCAACCTAA
15 AGCATATCAAGATAAGAGAGTGTGATGGTATTGGAGAAGTTGTTTCAAAC
AGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAAC
CACCACCTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCCTGGAGA
ATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAA
ATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGA
20 GGTATGCTTTGTACATATTCAATTATTTATTTAATTTCCCTTTTTTATTTG
CAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAAT
TACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCT
AGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGAT
GGGTAATATAGGCAATTTAAGTTTATTTCTGTAAAGCAGTATTTAGCA
25 AGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTC
ATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGTCAT
CAGGTGACAGATATTGTAGAATAGAACAATATATAATATCACCCAAAAC
ATTTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGTTTTCATNGA
ATTNGCATTCGTATATTTTAGGTGTTAAAGTGATTTTNTCTTCAATAAAT
30 CCCGAAATTAATTAAAAAAAAAAAAAACAAAAGTACATTTTGATGTGGAG
AGCACTGGTATCACTTAGTATATAAAAAGCTTGATTTTGAATTAACCTTC
TTATACAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCA
TGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTCTTGAGCTTATGCC
AATACGCTAGAGAGATGAGAATAGAATTCTGCAATGCATTGTCAAGTGTA
35 ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT
AAGTGATTGCAAAGGGATGAAGGAGGTATTTGAACTCAATTAAGGAGGA
GCAGCAACAAAAACAACAAGAGTGGTGCAGGTGAGGAAGGAATTCCAAGA
GTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATTGGAAATCAG
CTTTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCC
40 TGAGACAGCTCCAAGAGTTAAAGATAACATTTTGCTACGGAATGAAAGTG
ATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGTAAACAACAACAAC
AACACAATAACGAAGGGGGCATCATCATCATCTTCTTCATCTTCTA
AGGAGGTTGTGGTCTTTCCTCGTCTCAAATCCATTGAACTAAATGATGTA

CCAGAGCTGGTAGGATTCTTCTTGGGGAAGAATGAGTTCCGGTTGCCTTC
ATTGGAAGAAGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCAG
CTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACACAGAATTAGGC
AGACATGCTCTTGATCAAGAATCTGGCCTTAACTTTCATCAGGTATATAT
5 ATTTCTTTAATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAG
TAAATTTACTTCAAACACATTACACTGGTTTCAGTCTAAGTTTATGTTG
TTCTAGGAAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGATTT
CAGTGGAAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGG
CTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATTATTATTCTGATTT
10 GCTTGTTTCTTTATCATTTTTTCTTAGCCTCTGGAACAGCTAGAAACCCT
TTT.AATCTTTTGATTTTCAATGACAAAATTTTCCCTGTTACTACATTGA
TTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCT
TTTGATTGTTATTTTCATATCATGTTAGTCACTTGAATCAAGCTTTTCTA
TTTTCAACCAGGGCAAAGGTCAAAGTAACCTACTTTATGAGATCAAAA
15 ACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC
AGC.ACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT
GGCGTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTG
ACACCTTGGGCCCTGTAACCTCAGAAGGGACAACCTGTTCTTTTCATAAC
20 TTG.ATCGAATTATATATGGAATTTAATGATGCTGTTAAAAAGATTATTCC
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTTCATGTGACTT
ATTGTAATTGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG
AGAAATGGAAATAGTGGAATTGGTTTTGATGAATCGTCACAAACAACCTAC
CACTACTCTTGTCAATCTTCCAAACCTCAGAGAAATGAAGTTATGGTATC
25 TAA.ATTGCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG
TTTCCAAACCTAACAAGAGTCGATATATGGGGATGTGATAGGTTAGAACA
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAC
GCATATGGAAGTGCAGTCAGATAGAGGTCGTGATTGTTTCAGGATGCAGAT
GTTTGTGTAGAAGAAGACAAAGAGAAAGAAATCTGATGGCAAGACGAATAA
30 GGAGATACTTGTGTTACCTCGTCTAAAGTCCTTGATATTAAACACCTTC
CAW.GTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTA
TTGGATACYTTGGAAATCTACRAATGCCCAGCAATAACCACCTTCACCAA
GGGAAATTCCRCTACTCCACAGCTAAAAGAAATTGAAACAMATTTTGGCT
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC
35 AAACAACAGGTAAACCAGATCTTTGTTGCTTNNATAATTCTTAAACNACA
TNTGAAAAGCTTCATGCAAGTTTTTTTNGTTATATNGTCAAAAACCGCAA
CCT.ACATTTTCAGCTTTANATTTATGTACTTTATGCAGGATTTCAAACAA
GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT
TCCTAGTNGCCTATTAATTAAGGCCTTTTAGTTCGNGATTTTGGATGT
40 ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA
TATGAAGGACATTAAAGAACATGGATGCTCTGAAGATGTTGGGAACACA

RG2A deduced polypeptide sequence (SEQ ID NO:88)

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVN
RNISNQLEVPAQVRGWFEVVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDI
DSVMREHSIIWNDHSIPLGRIDSTKASTSIPSTDHHDEFQSREQTFTEALNALDPNHK
5 SHMIALWGMGGVGKTTMMHRLKKVVEKKMFNFIEAVVGEKTDPIAIQSAVADY
LGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLSPLNQGV
DFKVLLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIG
VNIVRKCGGLPIAKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNL
QDEETKSTFLLCGMYPEDFDILTEELVRYGWGLKLFKKVYTIGEARTRLNTCIERLI
10 HTNLLMEVDDVRCIKMHDLVRAFLDMYSKVEHASIVNHSNTLEWHADNMHDSC
KRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLIVISYDKMKY
PLLSPSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVL SFADSAIDRLPSTIGKLG
KLRLLDLTNCYGVRIDNGVLKKLVKLEELYMTVVDRGRKAISLTDDNCKEMAERS
KDIYALELEFFENDAQPKNMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKL VLEK
15 GELLEARMNELFKKTEVLCLSVGDMNDLEDIEVKSSSQLQSSSFNNLRVLV VSKC
AELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEETITFPKLKFLSLCGLP
KLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLKKEVLPKLEKLHVSS
MWNLKEIWPCEFNMSSEVKFREIKVSNCDKLVNLFPHKPISLLHHLEELKVKNCGSI
ESLFNIHLDCVGATGDEYNNSGVRIIKVISCDKLVNLFPHNPMSILHHLEEELENC
20 GSIESLFNIDLDCAGAIGQEDNSISLRNIKVENLGKLREVWRIKGGDNSRPLVHGFQS
VESIRVTKCKKFRNVFTPTTTNFNLGALLEISIDDCGENRGNDSEESSHEQEIEILS
EKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVEVVFEIESESPTSREL VTT
HHNQQQPIILPNLQELILWNMDNM SHVWKCSNWNKFFTLPKQQSES PFHNLTTKI
MYCKSIKYLFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTT
25 LFPSLDSLTLFLENLKCIGGGGAKDEGSNEISFNNTTATTA VLDQFELSEAGGVSW
SLCQYAREMRIEFCNALSSVIPCYAAGQMQLQVLT VSDCKGMKEVFETQLRRSSN
KNNKSGAGEEGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLQELKITFC
YGMKVIVKKEEDEYGEQ.TTTTTTITKGASSSSSSSSKEVVVFPRLKSIELNDVPELV
GFFLGKNEFRLPSLEEVTIKYCSKMMVFAAGGSTAPQLKYIHTELGRHALDQESGL
30 NFHQTSFQSLYGD T LGPVTSEGTTC SFHNLIELYMEFNDAVKKIIPSELLQLQKLEK
IHVTYCNWVEEVFETALEAAGRNGNSGIGFDESSQTTTTTLVNL PNLREMKLWYL
NCLRYIWKSNQWTA FEFPNLTRVDIWGCDRLEHVFTSSMVGSL LQLQELRIWNCSQ
IEVVTVQDADVCVEEDKEKESDGKTNKEILVLPRLKSLILKHL PCLKGFSLGKEDFSF
PLD TLEIYKCPAITTFTKGNSTTPQLKEIETHFGFFYAAGEKDINSSIIKIKQQDFKQ
35 DSD.CEVNIK

RG2B polynucleotide sequence (SEQ ID NO:89)

TTTTTTAAGATCAGGGATTCAAATTCAGCCCTAGTGATTACAATTGTGTC
TAAACTTTCCCATACCTTCACATTATTGTAAGTATACTTTCTCAGTTTCT
40 CTCTTGGAAGCTTCCTTGGTATTTTAACTCGTGTTCTAATATTTAACTCT
GATAGTTATTTTGGCCAATCTACTATCTGCATGTCCGGTTATTGAATCCG
AAGGCACTGGAATCTTGGATTCCATTCCGTTGTGTGTTTGGTTGCCAAAT

GAACGGAATTGAATTATGTAAGATTCCCTTCAAAAATCCATGTTTAGGTATA
TCGTTGTTTCTTGGGATGGATGGTAAAGAACGGAATTTCTCCTGTTCAATT
TTTTAATGAAAGACCAAATTGACCTTATAAACCTGTTAAAAAAATTACAT
TCCAGTTTCTTAACAAACTGAAAATGGTAAAGGAGTGTGATTGAATTCC
5 AATCTGTTTCCTGTCCAAAACACGTGACGGAATATTACAATTCCTTCAAA
TTTCATTTTCTTAAATTGTTATTCCCTTTCTTACAAAAACAAGGTAAACG
AAACACCCGCTTACTTAATCATACTCCTACATGATGTAAATGAAAAGGGT
ATAAATGGTATTTTATTACAGGGATGAGTCACCATGGTCATGAAAGAAT
CATTAACCGCCCTTACCCAATTCATGTTTGCCCTAAAATATGATTTAAA
10 GTAATATTGGCTTATGGGATTCAAGTTGACTTTTTTGTGGCGAAGAAATA
ATGAAAATCTTCATTTCTAAAGTGCTTCTACCACTGACATTTTCTAAGA
AAGAACTTGCTAGAAGAAGGTGGGTGTTTGTAGTCTTTTACTCTTTAAAT
GTGAAGACTGTTGAGTTATTATTATTATTTTGCCAACTATGGACAACCTG
TTTAGTTTTTTTTTTTCCCAATATCCATTTATATGCGATTTATTTCTGA
15 AATAATTTTATCAAAACGCAGGAAACAATGTAGAATAATACTGGTATAAT
TAATTATATAAAGTTATTAGGCTGAAATCTTGAGGCTACTATAATTTAAT
TATCATAATTTGAAAATCATCAAATTGTATTCCATGTATATTTATGTTAT
CAGATAATTAATAATATGTGAGCCACACAAATCCACATCATCAGACACCC
CACCTTATTGTCGGCTACCTCACCACTTGCAATGATCCCGACATCTTCCCA
20 ACCCCACCGACGACTTGGGGTCTCCTTAATATATCAATTATTTTCTGTAA
GTATTTATTTGTGTAAATGTGTAATGTCATTTTACCTTTTTTCTAATATA
TACAGAAACATAAATTTTAAATGAAATTCAACTGCGTTTCATTCTTGCAAT
TAA.AAAAAAAGACTGTACTGTTGTCAATATTTTACTTATAACCTGATTAA
TTA.ATTAAGCGTAATTGCATAATTTGCATTAGGTTGTAATTTTGTGTTT
25 TATAGGGAGGGTGAGGGTCACCGGAATCAAAGCACTTATGTAAAAGCAG
GGAAATACAAAAAATTTACTCGAAACAAATTTTATTCAATTTAAGTGAGA
TAATAATGTTCTGATTAGATTATGAGAACTAGGAGATTTAAGTGATATAT
CCC.ATTTAAAAGAAATTGCATTATTAATTTTGGATCTCTTGATGATGACA
AAATTAACCTCGTGACAGGTTATATATCATATACAAAATGAGTGGCTATGC
30 TTTCGCTTTCCAAAAAGCAATTATAGTTATACTACACCTACAAATTTTAA
AAGGGGTAAACATATCAAAATACTTGATAAGTAATTATATAAATATGCA
TTT.AACCCTCTAAAGAAAATGCTACTAAGCTTGGACCATCTCAGAATTAC
AATCATACCCTTCCCCTCAAAAAAGATTTCGTATATATCATGTCATTTGGC
ATTCATTTCTTTTTCACAATTCATAGTTCTATTCTCAAAAAATTCGAGTT
35 CTCGTATTTGTAAGGAAGATCAGAAGAGACTGTTACACAGGTACTCTCT
TTT.ATTTATTGATTCACATTCATATATGTTATTGTTTTCTTGCTTAATGG
TTTCGTCACTTAACTGCGCTTGCTGATTTAAATTTCTTCACTTTCTTCC
ACGGATTTTTTAAATATTAGTTTTGTGAATGAACAATTGGTGAAGGAAAG
AAACATGGGAGTCTTTTCTAAAGTAAACCTAGATACTTAGGTTATAAGGG
40 TATATGCTAAATGAACTATGCCATTACCTTTGCCTTTTCTTTTACTT
TTTAGTTTTTAGAATCCAAGTTTTTCATATGTATCTCGATGTGTGAGAAGA
ATAGGCATTAGAAAGGTAAAGGACGTACATAAAATTGATTAATTAGTGAA
TGTTCTTTGATATCATTATTTTACTCTCATAAAAAGCATATAGATCAAA

CACAAATTGCTACTTGTTAGTGTAACAACTTCGACTTAATAATGTTAATA
ATC.AAGATTCTCTTGATTTCAACTATTTTCTAACCGAACAAGCTCACTAA
AAACTCATATTGCTTTGAGTCTGAGTGGTTTATATTTGGGGTTTTACATT
TAATTTTTTGTGCATGAATGTGAAAATAGACTGCTTATTGATTCTTTGTG
5 TTTCATTGAGTTGATTTTCATTATTACTACCTTACAAATTGCTCAGTGAT
AGATTTCCATTAATTTGCTAATTCGGTTGCTTCTAAATATGTAGGAGCTA
CTAAAGCAAAAATATCGAGCAATGTCGGACCCAACGGGGATTGCTGGTG
CCATTATTAACCCAATTGCTCAGACGGCCTTGGTTCCCGTTACGGACCAT
GTAGGCTACATGATTTCCCTGCAGAAAATATGTGAGGGTCATGCAGATGAA
10 AATGACAGAGTTGAATACCTCAAGAATCAGTGTAGAGGAACACATTAGCC
GGAACACAAGAAATCATCTTCAGATTCCATCTCAAACCTAAGGAATGGTTG
GACCAAGTAGAAGGGATCAGAGCAAATGTGGAACCTTTCCGATTGATGT
CATCACTTGTTGTAGTCTCAGGATCAGGCACAAGCTTGGACAGAAAGCCT
TCAAGATAACTGAGCAGATTGAAAGTCTAACGAGACAACTCTCCCTGATC
15 AGTTGGACTGATGATCCAGTTCCTCTAGGAAGAGTTGGTTCCATGAATGC
ATCCACCTCTGCATCATTAAAGTGATGATTTCCCATCAAGAGAGAAAACCTT
TTACACAAGCACTAAAAGCACTCGAACCCAACCAAAAATTCCACATGGTA
GCCTTGTGTGGGATGGGTGGAGTGGGGAAGACTAGAATGATGCAAAGGCT
GAAGAAGGCTGCTGAAGAAAAGAAATTGTTTAATTATATTGTTGGGGCAG
20 TTATAGGGGAAAAGACGGACCCCTTTGCCATTCAAGAAGCTATAGCAGAT
TACCTCGGTATACAACCTCAATGAAAAAACTAAGCCAGCAAGAGCTGATAA
GCTTCGTGAATGGTTCAAAAAGAATTCAGATGGAGGTAAGACTAAGTTCC
TCATAGTACTTGACGATGTTTGGCAATTAGTTGATCTTGAAGATATTGGG
TTAAGTCCTTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGACATC
25 ACGAGACTCACAAGTTTGCATATGATGGGGGTTGAAGCTAATTCAATTA
TTAACGTGGGCCTTCTAACTGAAGCAGAAGCTCAAAGTCTGTTCCAACAA
TTTGTAGAACTTCTGAGCCCGAGCTCCAGAAGATAGGAGAGGATATCGT
AAGGAAGTGTTGCGGTCTACCTATTGCCATAAAAACCATGGCATGTACTC
TTAGAAATAAAAAGAAAGGATGCATGGAAGGATGCACTTTCGCGCATAGAG
30 CACTATGACATTCACAATGTTGCGCCCAAAGTCTTTGAAACGAGCTACCA
CAATCTCCAAGAAGAGGAGACTAAATCCACTTTTTTAATGTGTGGTTGT
TTCCCGAAGACTTCGATATTCTACTGAGGAGTTGATGAGGTATGGATGG
GGCTTGAAGCTATTTGATAGAGTTTATACGATTAGAGAAGCAAGAACCAG
GCTCAACACCTGCATTGAGCGACTGGTGCAGACAAATTTGTTAATTGAAA
35 GTG.ATGATGTTGGGTGTGTCAAGATGCATGATCTGGTCCGTGCTTTTGT
TTGGGTATGTTTTCTGAAGTCGAGCATGCTTCTATTGTCAACCATGGTAA
TATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCCTCTTGCAAAA
GAATTTTCATTAACATGCAAGGGTATGATTGAGATTCCAGTAGACCTCAAG
TTTCCTAAACTAACGATTTTGAAACTTATGCATGGAGATAAGTCGCTAAG
40 GTTTCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCATGTTATATCAT
ACGATAAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCGATGCTCCACC
AACATTGCGGTGCTTCATCTCACTGAATGTTCAATTAAGATGTTTGATTG
CTCTTCTATCGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCAAATT

CTCACATTGAATGGTTACCTTCCACAGTCAGAAATTTAAAGAAGCTAAGG
TTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAACAGGGTGTCTT
GAAAAGTTTTGTCAAACCTGAAGAATTTTATATTGGAGATGCATCTGGGT
TTATAGATGATAACTGCAATGAGATGGCAGAGCGTCTTACAACCTTTCT
5 GCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATATGTC
ATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGCTCTTTTGATG
AAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCAATTGGTG
ACC.AACAAAGGTGATGTATTAGACTCTAACTTAATGGGTTATTTTTGAA
AACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAGATG
10 TTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAATTTA
AAAGTTCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAAAC
CAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTGAAT
GTG.AGAATATGGAAGAACTCATACATACTGGAATTGGGGGTGTGGAGAA
GAGACAATTACTTTCCCTAAGCTGAAGTTTTTATCTTTGAGTCAACTACC
15 GAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACCACATC
TCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTTATCCG
CAG.AACAAGTTGCGAACATCTAGTTTGTGAAGGAAGGGGTAGATATATG
TTCTTTATGTTAATAACAATTTAAATATATTTTCAACCAAATTTTCATAA
TATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCTATT
20 AAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGACACTTCAA
ATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAGTGG
AGGTGAGAAAGTTAAGTTGAGAGCGATTAAAGTGAGTAGCTGTGATAAGC
TTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTTGAA
GAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACATTGA
25 CTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCTTAA
GAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGGATA
AAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTTGAAAG
CAT.AAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTATCA
CCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGTTGC
30 GGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCAATTTCACTTTC
TTA.ATTAATTAAGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGTGGG
ATG.ACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCATGAA
ACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAAAAA
TATGGCTTAAATTTTTTTTATATTTATGTATCAACATGATTTTTTCATTAG
35 AGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATCAGAACTAATT
CTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAGTG
AAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCCCTAAC
AAAAAAAACCTATTTGGTTCAGAAAAACCGTAATTCAAGATAACTAAAATA
AAAATATTTGACATTCCTAAGAGCATTTTTTTTTCTAAATATGATTGCA
40 AATGAATAAAACTTAAATTTATACAGAAAATCTTTTATATATGTTATAC
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG
GTATCACAAAGGGATATATAATAAAATATTATTTCTGTAGTCATTTGTA
ATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTAA

[illegible]

TNGCCACAATTCTTTGKTTACTTGWGACACTTYCCTCTCTCTAATTATATA
TATATATATATATATATATATATATATATACACACACACACACACACTAG
ATGTGTGCCCCGCGCAAAGCAGTGACGTNNNGGAGAANACTTTCTTAAGCA
TAAATAATTATTATATTTTTTTATTGGGTATTATATAATAAAAAATTACAA
5 CTTTAAATAAAATATTTATGTTTATACTTTATATTTATATTGCTTGTAT
ACTATTAATATAATAAATTAATATTTATGTCTAATTTATGAAATGTAAAT
TAATTTAAATACATGAATTTAATATTTTTAAATTTTCAGTTTGCTTCAA
ATTGAGTTTCTTAATTATTTTTTTTTAATTCANGTATTCAAACCTTTTGGTA
AGTATTAAGAATTATTTATGCATAATTGATTTATACAAAAAATTTGTA
10 ACTTATACATCTTAAATTCAGATATACTAACATGTTTACAATATAT
AT
TAAAGCGCAAAGGTCATAGGAATAGAATATTTTCTATTATTCTACGTTTT
GCCACAAAAGTTTGAACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTT
CAATGTTTTGCGACAAAAGTTCCAAAACCTTTGCCACTTTGATCATTCCCTC
15 AACTTTTCACCGCAATTAGTTTGTGGAGTTGGCAGTTTTGATCCCCCTAA
CTTCGATATTCTCTACTGCTAGCCAAAAAGGGTCCAGAGTTTCACACTT
TTGGTCCCTGACAGTAACCAAATGTGAGATGTCAAATTTTTGCCACATTA
GTTTGTGGAGTTGTCCCTTTTGGTCCCCCACCATTGATATTCTANTATA
CGACCTTATTTTTNTCAAATAACAACACGTATATTTAATTACCAATTATA
20 GAAATAGATATCAAATAAAGTATTTGTAACTGTGTAAGAACGGTGCTA
CTATAGGTAAAAATAAACATTTCAAAGTACGATATCCTAATTGAAAAAAG
AGTTTTAAAAAATAACGACTAGGGGCGAGTTTTTTTTACAAGTTTGTAT
CAAATCATATCAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAAT
GTAATTTATTCTTTGATTTTGATAATTTTTAATATTTTGTGTGATCTAT
25 GTATTTAAAGTAAACAACAAGAACATAATCCAAAACCCTAAATTGCAA
GTCTCGCCCAATTTCTCTATCACTAGTCCCTCACTTACGATGGCGTTACGT
CGCTCTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAA
AAGTTGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGT
CAAATTTTGATTTTGTGATGGATTTGAGTAGAAGTTTGGGCAGAACGG
30 GAATGATGGTCTGCAAGTGTTTATAAATCTGATTCTGAGTTATTACTATA
TATGTAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATC
TTTTTAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACC
AACAACTCTTAAAAACTTGATTAATCAATTGTTTTCTTCATCTTGATAAC
AAGTGGAATGATTTTCTACTTAGATTAACCTGAAAAAAAGGTCCATGTG
35 CGTCTGGTGGATCTGGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAG
ACACAAACACGTCACCATATCTCTTATTTTATTTTAAATTTGCTTTTGGT
GTATTTTCTTTTTTCTTATTTCTTTCTTTGATCTCCAGATGGTATGT
GGTGTGGATAATTTACACCTAGAGATTGGGAACGATGGGAAGGGGTCTGT
GATTTATGGCTGGCCGAGTTTTACTTATTAATCAATTTCAACCTAAAT
40 CTGATTCTTGTGTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGT
TGCATAGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATC
CAACTATTTTTTAGCTGTTGGCATTTTCCATCATTTGCAACTGTTTCTTG
AAAAAAAATACCTAAAATAAAAAATAACCATTTTCAAATCCAAAATTATA

[illegible]

CAGGTATATATATATTTCTTTAATTGGCATCATCTAATTAAGAAAGATAT
CATTCCTGCCAAGTAAATTTACTTCAAACACATTCACTGGTTTCAGTC
TAAGTTTATGTTGTTCTAAGAAGGCCAAAATGGGAAAGCAAGATAGGGAA
AAATAGTGTATTTCAAGTGGAAAGGGTATTTAGGCATTTTCTGTCAAAAG
5 TTGTTATTGCAGGCTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATT
ATT.ATTCTGATTTGCTTGTTTCTTTATCATTTTTTCTTAGCCTCTCGAAC
AGCTAGAAACCCTTTTAATCTTTTGATTTTCAATGACGAAATTTTCCCT
GTTACTCCATTTGATTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCT
CATCTGTTACTTCTTTTGATTGTTATTTTCATATCATGTTGTCCTTTGAA
10 TCAAGCTTTTCCATTTTCAACCAGGGCAAAAGGTCAAAAGTAACCTACTT
TATGAGATCAAAAACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAAT
AGTTACAATTACCATTGTGATTAATAATTATAATATCTTGTATTAATTCA
TAAAAATTGGTACAGCACATATATGACATTTCAAAGGTTTTTGTGTTGACA
TAT.ATATGCCTCTGGCGTTTTCTTTATTGGACTTGCAGACCTCATTCCAA
15 AGTTTATACGGTGACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTG
GTCTTTTCATAACTTTATCGAATTAGATGTGGAAGGTAATCATGATGTTA
AAAAGATTATTCCATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAG
ATT.AATGTAAGGTGGTGTAAGGGGTAGAGGAGGTATTTGAACTGCATT
GGAAGCAGCAGGGAGAAATGGAAATAGTGGAAATTGGTTTTGATGAATCGT
20 CAC.AAACAACCTACCACTACTCTTGTCAATCTTCCAAACCTTAGAGAAATG
AACTTATGGGGTCTAGATTGTCTGAGGTATATATGGAAGAGCAATCAGTG
GACAGCATTTGAGTTTCCAAACCTAACAAGAGTTGATATCTATAAATGTA
AAAGGTTAGAACATGTATTTACTAGTTCCATGGTTGGTAGTCTATCGCAA
CTCCAAGAGCTACATATATCCAAGTGCAGTGAGATGGAGGAGGTGATTGT
25 TAAGGATGCAGATGATTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATG
GGGAGACGAATAAGGAGATACTTGTGTTACCTCGTCTAAACTCCTTGATA
TTA.AGAGAACTTCCATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTT
TTC.ATTCCCATTATTGGATACTTTAAGAATTGAGGAATGCCCAGCAATAA
CCACCTTCACCAAGGGAAATCCGCTACTCCACAGCTAAAAGAAATTGAA
30 ACACATTTTGGCTCGTTTTGTGCTGCAGGGGAAAAAGACATCAACTCTCT
TAT.AAAGATCAAACAACAGGTAAATCAGATCTTTGTTGCTTTAATAATTC
TTAAACTACATTTGAAAAGCTTCATGCAAGTTTTTTTTGTTATATTGTCA
AAAACCGCAACCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGA
GTTCAAACAAGACTCTGATTAATGTGAAGTAAATACTAAAGGTAAATTAT
35 ATTTTCATGTTTCTAGTTGCCTATTAATTAATTGCCTTTTAGTTCATGAT
TTTTGGATGCATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCAT
TGTTTGGTTGAATGTTGACTCTATGTCTTGATGAATATTCAAGGGAAGAA
TTGTTTCATCATATGAAGGACATTAAAGAAGAACATGGATGCTATGAAGAT
GTGGGAAAACAA
40

RG2B deduced polypeptide sequence (SEQ ID NO:90)

MSDPTGIAGAIINPIAQTALVPVTDHVGYMISCRKYVRVMQMKMTELNTSRISVEE
HISRNTRNHLQIPSQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITE
QIESLTRQLSLISWTDDPVPLGRVGS MNASTSASLSDDFPSREKTFTQALKALEPNQK
5 FHMVALCGMGGVGKTRMMQRLKKAEEKKLFNYIVGAVIGEKTDPFAIQEAIADY
LGIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQ
GVDFKVL LTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGE
DIVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQ
EEETKSTFLMCGLPEDFDIPTEELMRYGWGLKLFDRVYTIREARLNTCIERLVQ
10 TNLLIESDDVGCVMHDLVRAFVLGMFSEVEHASIVNHGNMPGWP DENDMIVHSC
KRISLTCKGMIEIPVDLKFPKL TILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKY
PLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSHIEWLPSTVRNLK
KLRLDLRFCDGLRIEQGVLSFVKLEEFYIGDASGFIDDNCNEMAERSYNLSALEF
AFFNKAAEVKNMSFENLERFKISVGCSDENINMSSHSYENMLQLVTNKGDVLD SK
15 LNGLFLKTEVFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFKL
NLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLKFLSLSQLPKLSSLCHN
VNIIGLPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEGVVIPKLET LQIDDMENLEEIW
PCELSGGEKVKLRAIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNIDLD
CVGAIGEEDNKSLRSINVENLGKLREVWRIKGADNSHLINGFQAVESIKIECKRFR
20 NIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSCLMH
SFHNLRVLTLDNYEGVEVVFEIESESPTCRELV TTRNNQQQPIILPYLQDLYLRNMD
NTSHVWKCSNWNKFFTL PKQQSES PFHNLT TINILKCKSIKYLFSPLMAELLSNLKDI
RISECDGIKEVVS NRDD EDEEMTTFTSTHTTTTLPFSLDSLTSFLENLKICGGGGAK
DEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEIVGCYALSSVIPCYAA
25 GQMQL

RG2C polynucleotide sequence (SEQ ID NO:91)

ATAATATTACACAAAGGTAACGTCATTAATTAATTACGATACGAGACAGA
CTTTTTCCTACTCGGACATNAACGGTCTATTCCTAACTTNANNTAATTNAAT
30 GAATTTAGGATGTGCTAATATGCATGTAANATTCGCTACCGTCATCTTTC
AAATGACCATATTTTTATGTATTTATAATGAATCAATGAAAAACCGGATT
TCT.ATTTAAATTCCTTAAACTTCATCTTTTAAGCCAGGGTGAATACAAT
TGCTAGATCCACTGTTAATTTCCATCGAATTATGCCTGATCAATTGTTGG
CTGCCTACGATGCAGGTGCTACCACAAGAATATGGCCATGGAACTGCTA
35 ATGAAATTATAAAACAAGTTGTTCCAGTTCTCATGGTTCCTATTAACGAT
TACCTACGCTACCTCGTTTCTGCAGAAAGTACATCAGTGACATGGATTT
GAAAATGAAGGAATTAAGAAGCAAAAGACAATGTTGAAGAGCACAAAGA
ATCATAACATTAGTAATCGTCTTGAGGTTCAGCAGCTCAAGTCCAGAGC
TGGTTGGAAGATGTAGAAAAGATCAATGCAAAAGTGGAAGTGTTCCTAA
40 AGATGTCGGCTGTTGCTTCAATCTAAAGATTAGGTACAGGGCCGGAAGGG
ATGCCTTCAATATAATTGAGGAGATCGACAGTGT CATGAGACGACACTCT
CTG.ATCACTTGGACCGATCATCCCATTCTTTGGGAAGAGTTGATTCCGT

GATGGCATCCACCTCTACGCTTTCAACTGAACACAATGACTTCCAGTCAA
GAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACTTGAGGCCAACACATG
ATAGCCTTATGTGGAATGGGGGGAGTGGGGAAGACCCACATGATGCAAAG
GCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTTGGTTATATCATCGAGG
5 CGGTTATAGGGGAAATATCGGACCCCATTGCTATTCAGCAAGTTGTAGCA
GATTACCTATGCATAGAAGTGAAGAAAGCGATAAGAAAACAAGAGCTGA
GAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGATGGAGGTAACACTAAGT
TCCTCATAATATTGGATGATGTCTGGCAGTCCGTTGATCTAGAAGATATT
GGTTTAAGCCCTTCTCCCAATCAAGGTGTCGACTTCAAGGTCTTGTTGAC
10 TTCACGAGACGAACATGTTTGCTCAGTGATGGGGGTTGAAGCTAATTCAA
TTATTAACGTGGGACTTCTAATTGAAGCAGAAGCACAAAGATTGTTCCAG
CAATTTGTAGAACTTCTGAGCCCCGAGCTCCACAAGATAGGAGAAGATAT
TGTTAGGAGGTGTTGCGGTCTACCCATTGCCATCAAACCATGGCGTGTA
CTCTAAGAAATAAAAGAAAGGATGCATGGAAGGATGCACTTTCTCGTTTA
15 CAACACCATGACATTGGTAATGTTGCTACTGCAGTTTTTAGAACCAGCTA
TGAGAATCTCCCGGACAAGGAGACAAAATCTGTTTTTTTGATGTGTGGTT
TGTTTCCCGAAGACTTCAATATTCCTACCGAGGAGTTGATGAGGTATGGA
TGGGGCTTAAAGTTATTTGATAGAGTTTATACAATTATAGAAGCAAGAAA
CAGGCTCAACACCTGCATTGACCGACTGGTGCAGACAAATTTACTAATTG
20 GAAGTGATAATGGTGTACATGTCAAGATGCATGATCTGGTCCGTGCTTTT
GTTTTGGGTATGTATTCTGAAGTCGAGCAAGCTTCAATTGTCAACCATGG
TAATATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCA
AAAGAATTTCAATTAACATGCAAGGGTATGATTGAGTTTCCAGTAGACCTC
AAGTTTCCTAAACTAACGATTTTGAACTTATGCATGGAGATAAATCGCT
25 AAAGTTTCCTCAAGAATTTTATGAAGGAATGGAAAAGCTCCGGGTTATAT
CATACCATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCAATGCTCC
ACCAACATTCCGGGTGCTTCATCTCACGGAATGTTCAATTAAGATGTTTGA
TTGCTCGTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCTA
ATTCTTGCAATTGAGTGGTTACCTTCCACGGTCAGAAATTTAAAAAAGCTA
30 AGGTTACTTGATTTGAGATTGTGTTATGGTCTCCGTATAGAACAGGGTGT
CTTGAAAAGTTTGGTCAAACCTGAAGAATTTTATATTGGAAATGCATATG
GGTTTATAGATGATAACTGCAAGGAGATGGCAGAGCGTTCTTACAACCTT
TCTGCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATAT
GTC.ATTTGAGAATCTTGAACGATTTAAGATCTCAGTGGGATGCTCTTTTG
35 ATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCGATTG
GTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGGTTATTTTT
GAAAACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAG
ATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAAT
TTAAAAGTCCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAA
40 ACTCAATGTTGCAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTA
AATGCAAGAATATGGAAGAACTCATACATACTGGGATTGGGGGTTGTGGA
GAAGAGACAATTACTTTCCCAAGCTGAAGTTTTATCTTTGAGTCAACT
ACCGAAGTTATCAGGTTTGTGCCATAATGTCAACATAATTGGGCTACCAC

ATCTCGTAGACTTGAACTTAAGGGCATTCCAGGTTTCACAGTCATTTAT
CCGCAGAACAAGTTGCGAACATCTAGTTTGTGAAGGAAGAGGTAGATAT
ATGTTCTTTATGTTAATACAATTTAAACAATATTTTCAACCAAATTTTCA
TAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCT
5 ATTAAGGGATGATAATTTTGCAGGTTGTGATTCCTAAGTTGGAGACACTT
CAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAG
TGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGATA
AGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTT
GAAGAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACAT
10 TGACTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCT
TAAGAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGG
ATAAAAGGTGCAGATAACTCTCATCTCATCAATGGTTTTCAAGCTGTTGA
AAGCATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTA
TCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGT
15 TGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTC AATTTCACT
TTCTTAATTAATTANGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGT
GGGATGACTAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCAT
GAAACGCTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAA
AAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTTCACT
20 AGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACTAA
TTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAG
TGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCTTA
ACAAAAAAACTATTTGGTTCAGAAAACTGTAATTCAAGATAACTAAAA
TAAAAATATTTGACATTCACTAAGAGCATTTTTTTCTAAATATGATTGCA
25 AATGAATAAACTTAAATTTATACAGAAAAGATTTTTATATATGTTATAC
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG
GTATCACAAGGGATATATAATAAAATATTATTTTTCTGTAGTCATTTAT
AATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTA
AACTTTCATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATTATT
30 AATTAAGAGATATATCAAAAAATTTAAAGTTATTATAACTTCAAATTTAAC
ATATAATTAAAAAATATATGATCATAACTTTCCGCAACTCTTCTTTTGTA
TTAAATGACCAGAGAAGCTCTTAGTATATTTTCTAAATCAAAGTCACAA
AACTAATGAAGCATATAATTTGTGAAAATCAATTAGCATTAGGTTTTAA
GAGTCACCAAATTC AAAGAGTAATCCAATGCTTTCATTACCACTATGGAG
35 AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTAATT
GTTGCTTATTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAACCAAAA
AAAATTACATTCATGTATCATTATTAATGACTAGATATATATGAATATGA
AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCATG
GAATTCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACC
40 AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAAGGA
TTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTT
CTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCA
AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCACCA

ACCTCCCTTAAATAAACTCAAAGCAAAAATGACAAAATTGCCCTGAAG
GACCCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATATGAAAGGTCTTT
GGTCTTTGTGAGGGTGATGTTGTGCGGGTTAGCTTGTCGCATGCTTCCGC
GCGGTTGCGGCACATGTGCACAGGTGATGCATGGTGTGTACGTTCTTGAC
5 TTTTGAGCCTCCGATGCTTAGTCCACTTGGCCCAATTCGAGTCCAATCAA
CTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTTGCC
TTCTCCAAATCATCCATAACTTCACAGAATCGCCCGTTCATCTTAATCCC
GAATGAACAATTATTCTCCCGTCTTCATTTTAAGCAAGATACCACCTTCT
TCATGCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTA
10 TTTAGTCCACAGTCCCTTGTTGTCCTCCAAATTTAATTATCTCATTTAGTT
CCCGTTCGCTAGTTTCCTTAAAATTTGCAATTAAGCTCACAGAAATATT
AAGTACCCGAAATGGTCATAAAATAACAGAAAGGAAAATATGCATGAAGA
TAACTAAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTA
AATAAAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAGTCCA
15 CCCACCCTTCATTCCCTTGTAACCAATATGGGATGGAAACATCATTAAATTA
GCCAAAAAACTAACATATAAGGGGTGAGTGACAAAGGTAAGTACTAAAGA
TGAAAAAAATCCATTTTTCTTGTATATACACAACACACACATAGGGGCAG
ACGTAGGATTTTCATAGTACAGATTGTTGGTGGCACATAAGTGTTGCTAGT
GACATTTTTTTTTCTTTTACGTAGTGGCACAACAGTARAAAAAACRAAA
20 AATTCGAAATTTTTTACAATGTGCCTAAAAAAAACAGTGGTTGTTGGTGC
CACTATGGACACCAAAGTTGAACTGCCCTGCGCGCGCACACACACACAC
ACATAAAGTTTG
GGATGTGATACTTCTTTTGGGAAAATGGAGTTATATCTTTGATATTGTAT
TTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAAGTTTATT
25 TATTTKGATATGAAAAAAAAGTCTTTTATACATTGGATTTAACATAAAA
ATCCAACAATATTAATCAAAAAGACCAAACATGTGGACAATTATGTATAT
AATTAATTCACAATAGTCTTTAGGAATAGNATTATATATATAATTAATTC
TCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACNTTTGCCACAN
TTCTTTGNTTACTTNGACACTTTYCTCTMWNNANWMWWTWATATATATAT
30 ATATATATATATAHAHAHAHAVACACACACACTAGATGTGTGCCMGCGCA
AAGCAGTGACGTNNNGAGAANACTTTCTTAAGCATAAATAATTATTATA
TTTTTTATTGGGTATTATATAATAAAAAATTACAACTTTAAATAAAATA
TTTATGTTTATACTTTATATTTATATTGCTTGTATACTATTAATATAATA
AATTAATATTTATGTCTAATTTATGAAATGTAAATTAATTTAAATACATG
35 AATTTAATATTTTTAAAATTTTCAGTTTGCTTCAAATTGAGTTTCTTAAT
TATTGACCAAACATGTGGACAATTATGTATATAATTAATTCACAATAGTC
TTTAGGAATAGTATTATATATATAATTAATTCTCAATGGTCTTAGGAATA
GTAAGTTCTTATATTTCAAACCTTTTGCCACAATTCTTTGCTTACTTTGAC
ACTTTTCCTTCCTAACTTTACATATATATATATATTAAGCGCAAAGGTC
40 ATAGGAATATAATATTTTCTATTATTCTACGTTTTGCCACAAAAGTTGA
ACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTTCAATGTTTTGCGACA
AAAGTTCCAAAACCTTTGCCACTTTGATCATTCCTCAACTTTTCACCGCAT
TAGTTTGTGGAGTTGGCAGTTTTGGTCCCTCTAACTTCGATATTCTCTAC

TGCTAGCCAAAAAGGGTTCAGAGTTTCACACTTTTGGTCCCTGACAGTA
ACCAAATGTGAGATGTCAAATTTTTGCCACATTAGTTTGTGGAGTTGTCC
CTTTTGGTCCCCCACATTCGATATTCTACTATACGATCTTATTTTTCTC
AAATAACAACACGTATATTTAATTACTAATGATAGAAATAGATATCAAAT
5 AAAGTATTTGTAACTGTGTAGAGTTTTTTTTTACAAGTTTGTATCAAA
TCATATCAAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAATGTAA
TTTATTCTTTGATTTTGATAATTTTAAATTTTTGTTGTGATCTATGTAT
TAAAAAGTAAACAACAAGAACATAATCCAAAACCCTAAATTGCAAGTCT
CGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGTCGCT
10 CTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAAAAGT
TGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGTCAAA
TTTTTGATTTAGTTGATGGATTTGAGTAGAAGTTTGGGCAGAACGGGAAT
GATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATATATG
TAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATCTTTT
15 TAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACCAACA
ACTCTTAAAACTTGATTAATCAATTGTTTACTTCATCTTGATAACAAGT
GGAATGATTTTCTACTTGAAAAAAAAGGTCCATGTGCGTCTGGTGGATCT
GGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAGACACAAACACGTCA
CCATATCTTTATTTTATTTTAAATTTTCTTTTTTCCTATTTCTTTCTTT
20 CTTGATCTCCAGATGGTATGTGGTGTGGATAATTTACACATAGAGATTGG
GAACGACTGTGATTTAGAGAGGACGTGGCTTGGGGTTGAGGATGGTTTAT
GGCTGGCCGAGTTTCATTTATATAAAACAAACAATATATAAAACAAGGGG
TAAATGGCCATCTTATATGTATTTAACCGTCCTCTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTGTAAATTTAAGAAGGGGTATACCAGTGTCAAGC
25 CTCTTATTCCCAACCAGTCAAATAGGGACTTAGGTTGTTTGGAAACAGTT
CCGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCCTT
CAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGAT
TCTTGTTTGAATAAGTTGCATCTTTATTTTGTATTATCTTGTTGCAT
AGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAAC
30 ATTTTAAATCTGTTGACGTTTCCATCATTTGCAACTGTTTCTTGAAAAA
AAAATACCTAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGA
GAATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAAC
AAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAA
AGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTTGATTCCCAT
35 CCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGGATAAT
TATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAG
TAGAGAATTGGTAACAACCTCACAATAACCAACAACAGCCTATTATACTTC
CCTACCTCCAGGAATTGTATCTAAGGAATATGGACAACACGAGTCATGTG
TGG.AAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATC
40 AGAATCACCATTCCACAACCTCACAACCATAGAAATGAGATGGTGTGATG
GCTTTAGGTACTTGTTTTCGCCTCTCATGGCAGAACTTCTTTCCAACCTA
AAGAAAGTCAAGATACTTGGGTGTGATGGTATTAAAGAAGTTGTTTCAAA
CAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACAAAA

CCACCAACTTGTTCCCTCATCTTGATTCTCTCACTCTAAACCAACTGAAG
AATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGA
AATATCTTTCAATAATACCACTGCAACGACTGCTGTTCTTGATCAATTTG
AGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCCCTTTTTTATTT
5 GCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAA
TTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTC
TAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGA
TGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTTAGC
AAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGT
10 CATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGGTTA
TCAGGTGACAGATATTGTAGAATAGAACAAATATGTAATATTACCCAAAAC
TATTTTTTCTAAGGTTGCTCTGTAAATATGTGCTTTCTTGATTTTCATTG
AATTTGCATTCCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAA
TCCCGAAATTAATTAACAAAAAACAAGTAAATTTTTGATATGGA
15 GAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTT
TCTTATATAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTC
CATGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTTGGAGCTTATG
CCAATACGCTAGAGAGATAAAAAATAGGCAACTGCCATGCATTGTCAAGTG
TGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGA
20 GTAATGGCTTGCAATGGGATGAAGGAGGTATTTGAACTCAATTAGGGAC
GAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTCCAA
GAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTAAGTATT
GGAATTTGTGGGGGTTTGGAACATATATTACATTCTCTGCACTTGAAAG
CCTGAGACAGCTCCAAGAGTTAACGATTAAAGGGTGTACAGAATGAAAG
25 TGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACA
ACAACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTAAGAAGGTGGT
GGTCTTTCCTTGCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGG
TAGGATTCTTCTTGGGGATGAATGAGTTCGGGTTGCCCTTCATTAGATAAA
CTTATCATCGAGAAATGCCCAAAAATGATGGTGTTCACAGCTGGTGGGTC
30 CACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTC
TTGATCAAGAATCTGGCCTTAACCTTTCATCAGGTACATATATATTCCTTT
AATTGGCATCATCTAATTAAGAAAGATATCATTCCTGCCAAGTAAATTTA
CTTCAAACACATTACACTAGTTTTCAGTCCAAGTTTATGTTGTTCTAGGA
AGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGAGTATTTCAGTGGAA
35 AGGGTATTTTAGGTATTTTCTGTCAAAAATTGTTATTGCAGGCTTTTTAG
TACCTGGAAGAGCATGATTATTCTCGATTTGCTTGTTTCTTTATCATTTT
TCTTAGCCTAGCATGATTTTCAATGAAATCTTCCCTGTTACTCCATTTG
ATTGTTGTTCTTCATGGTTCTAAGTGAGTTAGTGGCTCATCTGTTACTTC
TTTTGATTGTTATTTTCATAGCATGTTGTCACTTGAATCAAGCTTTTCCA
40 TTTTCAACAAGGACAAAAGGTCAAACTAACCTACTTTATGAGATCAAAA
ATAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATACTTACAATTACC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT

GGCGTTTTCTTTATTGGACATGCAGACTTCATTCCAAAGTTTATACGGTG
ACACCTTGGGCCCTGCTACTTCAGAAGGGACAACTTGGTCTTTTCATAAC
TTTATCGAATTAGATGTGAAATCTAATCATGATGTTAAAAAGATTATTCC
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGTAAAGATTAATGTAATGT
5 GGTGTAAGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG
AGAAATGGAAATAGTGGAAATTGGTTTTGATGAATCGTCACAAACAACTAC
CACTACTCTTGTCAATCTTCCAAACCTTGGAGAAATGAAGTTACGGGGTC
TCGATTGTCTGAGGTATATGGAAGAGCAATCAGTGGACAGCATTGAG
TTTCCAAACCTAACAAGAGTTGAAATTTATGAATGTAATTCATTAGAACA
10 TGTATTTACTAGTTCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG
AGATTGGTTTGTGCAACCATATGGAGGTCGTGCATGTTTCAGGATGCAGAT
GTTTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAA
GGAGATACTTGTGTTACCTCATCTAAAGTCATTGAAATTACTACTTCTTC
AAAGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATT
15 TTGGATACTTTGGAAATCTACGAATGCCAGCAATAACCACCTTCACCAA
GGGAAATTCCGCTACTCCACAGCTAAAAGAAATGGAAACAAATTTTGGCT
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC
AAACAACAGGTAAACCAGATCTTTGTTGCTTTAATAATTCTTAAACTACA
TTTGAAGAGCTTCATGCAAGTTTTTTTTGTTATATTGTCAAAAACCGCAA
20 CCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGATTTCAAACAA
GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT
TCCTAGTTGCCTATTAATTAAGGCCTTTTAGTTCGTGATTTTGGATGT
ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA
25 TATGAAGGACATTAAAGAACATGGTGCTAT

RG2C deduced polypeptide sequence (SEQ ID NO:92)

MAMETANEIKQVVPVLMVPINDYLRYLVSCKRYISDMDLKMKEAKDNVEEH
KNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGDAFNI
30 IEEIDSVMRRHSLITWTDHPIPLGRVDSVMASSTLSTEHNDFQSREVRFSEALKALE
ANHMIALCGMGGVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQVVDY
LCIELKESDKKTRAELRQGFKAKSDGGNTKFLIILDDVWQSVLEDIGLSPSPNQG
VDFKVLTSRDEHVCVSMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIGEDI
VRRCCGLPIAIKTMACTLRNKRKDAWKDALSRHQHDIGNVATAVFRTSYENLPD
35 KETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTHIARNRLNNTCIDRLVQT
NLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMPGWPDENDMIVHSC
KRISLTCKGMIEFPVDLKFPLTILKLMHGDKSLKFPQEFYEGMEKLRVISYHKMKY
PLLPLAPQCSTNIRVLHLTECSLKMFDSCIGNLSNLEVLSFANSIEWLPSTVRNLK
KLRLDLRLCYGLRIEQGVLSLVKLEEFYIGNAYGFIDDNCKEMAERSYNLSALEF
40 AFFNKAIEVKNMSFENLERFKISVGCSTGDNINMSSHSYENMLRLVTNKGVDLDSK
LNLFLKTEVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFLK
NVANTLSRLEHLEVCKCKNMEELIHTGIGGCGETITFPKLKFLSLSQLPKLSGLCH

NVNIIGLPHLVDLKLKGIPGFTVIYPQNKLRTSSLLKEEVVIPKLETQIDDMENLEEI.
WPCELSGGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELTVENC GSIESLFNID
LDCVGAIGEEDNKSLLRSINVENLGKLEVVWRIKGADNSHLINGFQAVESIKIEKCK
RFRNIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSC
5 LMHSFHNLRVLTLDNYEGVEVVFEIESESPTSRELVTTHNNQQQPILPYLQELYLR
NMDNTSHVWKC SNWNKFFTL PKQQSES PFHNLTTIEMRWCHGF RYLF SPLMAELL
SNLKKVKILGCDGIKEVVS NRDD EDEEMTTFSTHKT TNL FPHLDSLTLNQLKNLK
CIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIKIGNCHAL
SSVIPCYAAGQMOKLQVLRVMACNGMKEVFETQLGTSSNKNNEKSGCEE GIPRVN
10 NNVTMLPNLKILSIGNCGGLEHIFTSALES LRQLQELTIKGCYRMKVIVKKEEDEY G
EQQTTTTTTKGASSSSSSSKKVVFPC LKSI VLVNLP ELVGFFLG MNEFRLPSLDKLI
EKCPKMMVFTAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGD TLGPAT
SEGTTWSFHNFIELDVKS NHDVKKIIPSELLQLQKLVKINVMWCKRVEEVFETALE
AAGRNGNSGIGFDESSQTTTTLVNLPNLGEMKLRGLDCLRYWKS NQWTA FEFPN
15 LTRVEIYECNSLEHVFTSSMVGSLLQLQELEIGLCNHMEVVHVQDADVSVEEDKEK
ESDGKMNKEILVLP HLKSLKLLLLQSLKGFS LGKEDFSFPLD TLEIYEC PAITTF TK
GNS.ATPQLKEMETNFGFFYAAGEKDINSSI KIKQQDFKQDSD.

RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94)

20 ACGACCACTATAGGGCGAATTGGGCCCCGACGTCGCATGCTCCCGGCCGCC
ATGGCCGCGGGATGTAAAACGACGGCCAGTCAATCGTAACCGTTCGTAC
GAGAATCGCTGTCCTCTCCTTCAACCATTAAATGTATATGAGCTAAATTG
AAACATCTACTATCATGTTTAAATTTATAAACTTTTTCCTTTAGATTAC
TTGTCTGGATGTGTTTAATAAAAACCCAATTTCCCATATGCGTAGAGATCA
25 TAG.ATGTAAC TATTGTTAATCAATTTTGCCTGCCAAGTTTAATAATTAT
ACTTGGATATTAACAAAAC TTTATCTAACGACCAAGGTAATATTA AAAAT
AGGTTATTATTTCTCATGCTAATTA AAAAGATGGGTTGCAAAAGTGAGACC
ATGAAAACATTAACACGTTGATATTTTCAACTTTTATTCTTT CATATTCA
CCATATTTTTTACTTTCTGATTGATTAATCATCTTTCAATCACAGGCTCC
30 TTGGCAAAAAGTCAGATCTATTAACAAATACTTCCATGTGGTTGCAAATT
ACAAGGATTTCAACATAATTACCAAAACATAGCATTATCATAAGATCGAA
TAATAATCAAATCTTCTATAATATTACACAAAGGTAACGTCATTAATTA
ATTACGATACGAGACAGACTTTTTCACTCGTGACATCAACGGTCTATTCT
AACTTTACTTAATTAATGAATCTAGGATGTGCTCATATGCATGTAATAT
35 TTGCTACCGTCATCTTTCAAATGACCATATTTTTATGTATTTATAATGAA
TCAATGAAAAACCGGATTTCTATTTAAAATTCTTAAACTTTCATCTTTTA
AGCCAGGGTGAATACAATTGTAGATCCACTGTTAATTTCCATCGATTATG
CGTGATCAATTGTTGGCTGCATACGATGCAGGTGCTACCACAAGAATATG
GCCATGGAACTGCTAATGAAATTATAAAACAAGTTGTTCCAGTTCTCAT
40 GGTTCCCTATTAACGATTACCTACGCTACGTCGTTTCCTGCAGAAAGTACA
TCAGTGACATGGATTTGAAAATGAAGGAATTA AAAAGAAGCAAAAGACAAT
GTTGAAGAGCACAAGAATCATAACATTAGTAATCGTCTTGAGGTTCCAGC

AGCTCAAGTCCAGAGCTGGTTGGAAGATGTAGAAAAGATCAATGCAAAAG
TGGAAACTGTTCTTAAAGATGTCGGCTGTTGCTTCAATCTAAAGATTAGG
TACAGGGCCGGAAGGGATGCCTTCAATATAATTGAGGAGATCGACAGTGT
CATGAGACGACACTCTCTGATCACTTGGACCGATCATCCCATTCTTTGG
5 GAAGAGTTGATTCCGTGATGGCATCCACCTCTACGCTTCAACTGAACAC
AATGACTTCCAGTCAAGAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACT
TGAGGCCAACCACATGATAGCATTATGTGGAATGGGGAGAGTGGGGAAGA
CCCACATGATGCAAAGGCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTT
GGTTATATCATCGAGGCAGTTATAGGGGAAATATCGGACCCCATTGCTAT
10 TCAGCAAGTTGTAGCAGATTACCTATGCATAGAGCTGAAAGAAAGCGATA
AGAAAACAAGAGCTGAGAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGAT
GGAGGTAACACTAAGTTCCTCATAATATTGGATGATGTCTGGCAGTCCGT
TGATCTAGAAGATATTGGTTTAAGCCCTTCTCCCAATCAAGGTGTGCACT
TCAAGGTCTTGTTGACTTCACGAGACGAACATGTTTGCTCAGTGATGGGG
15 GTTGAAGCTAATTCAATTATTAACGTGGGACTTCTAATTGAAGCAGAAGC
ACAAGATTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCACA
AGATAGGAGAAGATATTGTTAGGAGGTGTTGCGGTCTACCCATTGCCATC
AAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGGAAGGA
TGCACCTTCTCGTTTACAACACCATGACATTGGTAATGTTGCTACTGCAG
20 TTTTGTAGAACCAGCTATGAGAATCTCCCGGACAAGGAGACAAAATCTGTT
TTTTTGATGTGTGGTTTGTTCCTCGAAGACTTCAATATTCCTACCGAGGA
GTTGATGAGGTATGGATGGGGCTTAAAGTTATTTGATAGAGTTTATACAA
TTATAGAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
GCAAATTTACTAATTGGAAGTGATAATGGTGTACACGTCAAGATGCATGA
25 TCTGGTCCGTGCTTTTGTTCCTGAGTATGTATTCTGAAGTCGAGCAAGCTT
CAATTGTCAACCATGGTAATATGCCTGGGTGGCCTGATGAAAATGATATG
ATCGTGCCTCTTGCAAAAGAATTTTCAATTAACATGCAAGGGTATGATTGA
GATTCCAGTAGACCTCAAGTTTCCTAAACTAACGATTTTGAACTTATGC
ATGGAGATAAGTCTCTAAAGTTTCCTCAAGAATTTTATGAAGGAATGGAA
30 AAGCTCCAGGTTATATCATACGATAAAAATGAAGTACCCATTGCTTCCTTT
GGCACCTCAATGCTCCACCAACATTCCGGTGCTTCATCTCACTGAATGTT
CATTAAAGATGTTTGATTGCTCTTCTATCGGAAATCTATCGAATCTGGAA
GTGCTGAGCTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAG
AAATTTAAAGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCC
35 GTATAGAACAGGGTGTCTTGAAAAGTTTGGTCAAACCTGAAGAATTTTAT
ATTGGAAATGCATATGGGTTTATAGATGATAACTGCAAGGACATGGCAGA
GCGTTCTTACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGG
CTGAAGTGAAGAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCA
GTGGGGTGCTCTTTTGATGGAAATATCAGTATGAGTAGCCACTCATACGA
40 AAACATGTTGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAAC
TTAATGGGTTATTTTGAAGACAGAGGTGCTTTTTTAAAGTGTGCATGGC
ATGAATGATCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTC
CTCTTCATTCTGCAATTTAAAGTCCGTATTATTCAAAGTGTGTAGAGT

TGAGATACCTTTTCAAACCTCCATGTTGCAAACACTTTGTCAAGCCTTGAG
CATCTAGAAGTTTGTGGATGCGAAAATATGGAAGAACTCATACATACTGG
GATTGGGGGTTGTGGAGAAGAGACAATTACTTTCCCAAGCTGAAGTCTT
TATCTTTGAGTCAACTACCGAAGTTATCAGGTTTGTGCCATAATGTCAAC
5 ATAATTGGGCTACCACATCTCGTAGACTTGAACTTAAGGGCATTCCAGG
TTTCACAGTCATTTATCCGCAGAACAAAGTTGCGAACATCTAGTTTGTGTA
AGGAAGAGGTAGATATATGTTCTTTATGTTAATAACAATTTAAATAATATT
TTCAACCAAAATTTTATAATATATCTGTAATTTGATTGTATGATGTGTTA
TTGTTTATATGTGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCC
10 TAAGTTGGAGACACTTCAAATTGATGGCATGGAGAACTTAGAAGAAATAT
GGCCTTGTGAGCTTAGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAA
GTGAGTAGCTGTGATAAGCTTGTGAATCTATTTCCGCACAATCCCATGTC
TCTGTTGCATCATCTTGAAGAGCTTAAAGTCAAAAATTGTCGTTCCATTG
AGTCGTTATTCAACATCGACTTGGATTGTGTGTCAGTGCAATTGGAGAAGAA
15 GACAACAAGAGCATCTTAAGAAGAATCAAAGTGAAGAATTTAGGGAAGCT
AAGAGAGGTGTGGAGGATAAAAGGTGCAGATAACTCTCGTCCCCTCATCC
ATGGCTTTCCAGCTGTTGAAAGCATAAGTATCTGGGGATGTAAGCGGTTT
AGAAATATATTCACACCTATCACCGCCAATTTTGATCTGGTGGCACTTTT
GGAGATTACATAGGAAATTACAGAGAAAATCATGAATCGGAAGAGCAGG
20 TAACGCTTTCAATTTCACTTTCTTACTTAATTAAGGACTAAGCTCTTGTT
TTTTGAATAATAAAGAGGTGGGATGACTAACTTGGGCATCACAATTGTA
ACAAAATGTTACAAACCATGAACGTACAAACCATTTCTTGAATTAAGGTT
TCAATACAAGTCATTTACAAATATGGCTTAAGTTTTTTTATATTTATGTA
TCAACATTATTTTTTATTAGAGGTCATTATTATAATAGTAAGTTTAAAGC
25 AATTTAAATTAGCACTAATTTTTTCATCATCTAACTTTAGCTAATAAATCG
TTATAAATGTCAATAGCTAAAATAAAAATATTTGACATTCACTGAGAGCA
ATTTTTTCTAAACATGATTGCAAATGATTAAAACTTAAATTTAAACTAAA
AAGATTTTTATATATGTTATACAAAATTTACAAATTGAAATTGGATATGT
TAATTAACAGTTTATAATTATTGTATTACAAAGCGATATATAATAAATA
30 TATTTTTCTGTAGTCATGTATAATTGTATATGTAAATGATTTTTTAAGA
TGGTAGAAGTGGAACCTAGTCAATCTCACTTAACTCATTGTCACACCAGT
TTTATATCCGTTTCTCTCTCTCTCTCTTGCCTCCATCTTTTTTCAAC
TCATAACACATAAAAATAACATATTTTCCAACACATTTAAGTCACTACCA
CATCATTATTTTTAATTTAATTAAATTAGAAAATATAAAATTAATAAAAA
35 CATAACATTTTTTTATTAAGGCACTAATAACAAATAAAAAGATACACGG
TAAATAAAAAAACGATAATTAGAAAAAAACATAATAAAAAAAGACAACA
TTAAAAATAWAAAGCGACAATAAAATTAATAATGATCAAGAAAATTCT
AAAACCTCCACCATATTTTTCTGCAATTTGTCATTTATGTTCAAACACCA
TTCGCAGAATCCCTCCTATCAAGTGATCATGTTGATTGAGAAAAAACTGT
40 ATGTCTCTCATGTATCTCCAAGTCCAACAAGTTAGCTTTCATTTCTTC
ATTTTCTCATGTAAGACGCAAATTTTCATCCCGATATTGTTTTCTATCTT
CCACCTCTACTTTATTACAGTGTGGATGAAGGAGAGGACAGCGATTCTC
GTACGAACGGTTACGATTGCGACTGGCCGTCGTTTTACAATCCCGCGGCCA

TGGCGGCCGGGAGCATGCGACGTCGGGCCCATTTCGCCCTATAGTGGTCGT
AATACA (SEQ ID NO:93)

Sequence gap

5 TGAGCCTCCGATGCTTAGTCCACTTGGCACAGTTCAAGTCCAATCAACTT
ATAACCCATTTTTCTTCAAGTTGTCTTCAAGTTAAGCCCAATTTGCCTTC
TCCAAATCATCCATAACTTCATGGAATCGCCCCCTTCATCTTAATCCCGAA
TGCACAATTATTCTCCCATCTTCATTTTAAGCAAGAGGCCACCTTCTTCA
TGCTTCATCCATCAATAGTCTGTTGGAATAGTGTCTAAGGCTGCAACTAT
10 ATTAGACAAGTATTTGACCCGTTGTGCATGGTCCTTTTGGGTTGCCTTC
ACCATAGCAACTTGATAGGATGATTTATTAAGAGAGAGTAAATATTATTA
ATATATTATGAGAATAATATAATGAATAATATATTTGTTATTTGATTAAT
ATAAGTCATAGAATTAATTAGAATTAATTTGGTGACTTAAAGAGATTAAT
TAAATAAAGGGGTATAAACTGTCAATTGTTTGATAGTTAAGCTTTAGACT
GTAATCCATTTGGATATGGTATGGACGAATCCTAAGGGATTTAGGATAG
15 CTAAAATCGTCCATATGAGTTATCTAAGAAGGATTTGGATAGCCTTAAGA
GAAGATTATCTGATAGGGACTTATCTGTAATCCTTAAGGAGTCTACAAGT
ATAAATAGACCCTATGGCTGATGGAATTCGACACATCTCCTAAAGTAAGA
GAGCCTTGGCCGAATTCCTCCCCCTCACCTCTCTCCTAAATCATTCTTCTT
GCTATTGGTGTTTGTAAAGCCATTAGAGGAGTGACATTTGTGACTCTAGAA
20 TCTCCAAGACCTCAAGATCAACAAGGAATTCAAAGGTATGATTCTAGATC
TGTTTCAATGTTGTTATTTGTCCTAATTAGTCATTAGAAGACTTGGATTTC
AAAGCATGTTTATTAGAAAGCCTAGATCYGAGCAATAGGGTTTTGCATGC
GCACATAGGAAAGTTCTTATGGCTAAAACCCATCATAGTCCACTTCATGT
ATCATCTCTACTAGTTATTTAGTCCATAATCCTTGTTGTCCTCCAAGTTT
25 AATTACCTCCCTTAGTTCCCTGTTCTGCTAGTTTCCTTAAAATTTGCTATT
AAGATCACAGAACTAGAGAGTACCCAAAATGGTTATAAAATAACAAAAAG
GAA-AATATGCATGAAGATTAATAAATTATAAATGTAATATGCTAAAATA
AACTATAAAAAAAAAGTAAATAAAATGAAACTATCACACTCCGACCACCC
TTATAGGCTTGTACTGCACCCACCTTCATTCCTTGTAACCAATATGGGAT
30 GGAACATTATTCATTAAGCCAAAAAATAACATTTAAGGGGTGAGTGAC
AAAGGTAAGTACTAAAGACAACAATAATCCATTTTTCTTGTAACATACACA
ACACACACATAGGGGCGGACGTAGGATTTGTAGTATGTGTTGTGGGTGAC
ACATTTTTTCTTTTACGTAGTGACACAATAGTAGAGAAAACGAGAAATTC
CAATTTTTTACATTGTGTTTCGAAAAAATATACAGGGGTTGCTGGTGCTAC
35 TCTGGGCACCAAAGTGGAACCGCCCCTGCACACACACACATAGAGGGA
GAGAGAGAGGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGATT
TGGGATGTGATACTTCTTTTGGGAAAATGGAGCAATATCTTTAATATTGT
ATTTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAACTTTTA
GTTTTTTTTTATTTAATCTGTATATTTAATCATTTTCAGTTTATAAGTTT
40 ATTTATTTTGGTATACCAGAAAAAAAGTCTTTTATGTGTTGGATTAAAC
ATAAAAATCTAACAATATTAATCAAAAAGACCAAACATGTGGACAATTAT
GTATATAATTAATTCTCAATGGTCTTAGTGTAACGATATAAATTTCAAAA
CAATTTTTTCACATTAAAAAAAAACACTTTCAGTCATAATTGTTATAAATTA

TCATTGTATCACAAAATCAGTTCATAACATCACATCCCAAGATCAATAAA
GTGTAAATACTCCTCATGTGTGTAATAATCAAGCCGACGCCTTCCCGCGA
TTCTCACTGGTACCTGAAACACGTAACATAACAACACTGTAAGCATAAAATGC
TTAGTGAGTTCCCCAAAATACCACATACCACATATATGCCTTTCCAGGCC
5 ATA.ACTCTGTAGGATCTTCCGACCCAAGTGTCTCAGGGGACTTCCGTCCC
GAATCCCGGTAGACCTTCCGGTCCTACCCGTATTGACCTTCCGGTCCGTA
TCATACATAACATAACATAACACATACATATCACATAACAACATATAGCAC
ATACATCTCATAACATAAAAGACCTTCCGGTCACATAAAGGTACCCTTCC
AGGTACAGTATAGTGAGAACTCACCTCGTATGATGTCTAATACCTCAC
10 GTGCTCGATATCCCTGAATCTCGAAACAATGACCTAGCCCCGCCTACTCA
CAT.AAAGTAATTATTTCAAATCATTAAACGGCTCTCAAGGCTAGACTACAT
CCCTTTCTATAAATCCACAGAAGGGTAAAAGACCATTTTACCCCTCCTTG
ACCCAAAAGTCCAAATGTTGATCAAAACCCCAAAAGTCAACGAAAGACAA
TGGTCAACTTTGACCCTACTCGTGGAGTGCACAAAGGTGACTCGGCAAGT
15 ACATGCGGGTCCTCTGAATCCTTTAGTCTCTCTTGGCTCGTCGAGTCTT
TCTTCCACCCGACGAGTTACACCTGTCATGAATCGCGGGGCAACCCCGAC
TCG.ACTTGTGCGAGTCCGCTCATGGACTCAACGAGTTCATTCCATGCTCAC
ACTCAAATGACCTCCTGAGGTCAGATCTGTTCCCTCTAATCCATAGATCTG
ACCTTCCCAAGCTCAATAAACACGTAAAGGTTCGAACTTGATACTCATGC
20 AACGTCCAAATGATTCTACTTGATGATTTAGCCCCAAATACAACATCCTA
AGTCCATACGACCTTATTTTTCTCAAATAACAACACATATATTTAATTAC
CAATGACAGTAATAGATATCATATAAAGTATTTGTAACACTTTGTAAGAA
CCTTGCTACTATAGGTAAAAAGAAACATTTCAAAGTACATGCCCTAATTA
GAAAAAAAGTTATAAAAAAATAATGACTAGGGGCGTGTTTTTTTACTAG
25 TTTGTATCAAATTATATCAAAATTTAAGGTGGAAAAGAATGACGACCACA
TTA.ACCAGAAATGTAATTATTTTTTTTATTTGGTAATTTTTAATATTTGTT
GTG.ATCTATGTATTTAAAAGTAAATATCAAACAAGAACATAATCCAAACC
CTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGA
TGGCGTTACGTCGCTCTCTCACTTCCTACAACCCATTGTTGCTACTAATT
30 A.CACTAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGAAATTGA
ACG.AATCTCGTCAAATTTTTTATTTTGTGATGGATTTGAGTGGAAGTTT
AGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACATGGGTGAAGA
TAA.AATGGAGTTGTCGCCGTTGTATTATAGATCTCTTAGGGGTTTGATTC
TGAGTTATTACTGTATACGTAGCCTCTTTACAACGACCATTCTTCCAAGT
35 ACCATTTGATCTTTTTAGAAATCCAGTTGTCTGAAACACCCTGATTTGGAT
CAAATATCACCACAACTCTTAAGAACTGGACTAATTAATTGTTTTCTTG
ATCTTGATAACAAGAGGAAACACGTCACCATATCTTTTATTTTAAATTTG
CTTTTGGTGTATTTTCTTTCTTCCCATTTCTTTCTTGATCTGTTCCAGAT
GGTATTTGGTGTGGATAATTTACACCTGGAGATTGTGAACGATGGGAAGG
40 GGTATGTGATTTACAGAGGATGTGGCTTGTGGTTGAGGATGGTTTATGGC
TGGCCGAGTCTAATTTATATTTATATAAACAATAAATATATAAAACAAG
GGTAAAATATGTATTTAAGCGTCCTCTTTTAAATGGTGACAATTTTACAG
TTT.ACTCTCTTTGTTTTTTAATTGTGATGCCCACGATCGAACTCATTCAT

CCCCCCCCCTTTTTTTTTTAAAAATAAAAAATTAAGAAGGGGTACCACCAT
ATACCCGTGTCAGCTTCTTATTCCCAAGCAGTCAAATAGGGACTTAGGTT
GTATGGAAACAGTTCCGTGACTTGGATGGCAGATAAAATTTAGTAACTTA
ACCCTTCAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAAGCTAAAT
5 TCTGATTCTTGTTTGAAAATAAGTTGCATCTTTATTTTGCATATTATCT
TGTTGCATAGGATCCTTAGCATCTTTTAATAGTTTATTTGAAGCTGAAAG
ATCCAACCTAGTTTTGATCTGTTGGCATTTCATCATTTGCAACTGTTTC
TTGAAAAAAAATACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTA
TAAGAGAGAATTGTTAATGGACGTGGAATCATAAATCATTAACACAGTTC
10 AGTACACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTAT
CAGAGAAAGAGACATTACAAGAAGTCACTGATACTAATATTTCTAATGAT
GTTGTATTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAA
ACTTAAATTGAAAAATTATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGA
GTGAGAGTCCAACATGTAGAGAATTGGTAACAACCTCACAATAACCAACAA
15 CAGCCTATTATACTTCCCAACCTCCAGGAATTGTATCTAAGGAATATGGA
CAACACGAGTCATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTC
TTCCAAAACAACAATCAGAATCACCATTCCACAACCTCACAACCATAGAA
ATGAGATGGTGTGTCATGGCTTTAGGTACTTGTTCGCTCTCATGGCAGA
ACTTCTTTCCAACCTAAAGAAAGTCAAGATACTTGGGTGTGATGGTATTG
20 AAGAAGTTGTTTCAAACAGAGATGATGAGGATGAAGAAATGACTACATTT
ACATCTACCCACACAACCACCAACTTGTTCCCTCATCTTGATTCTCTCAC
TCTAAAATACATGCACTGTCTGAAGTGTATTGGTGGAGGTGGTGCCAAGG
ATGAGGGGAGCAATGAAATATCTTTCAATAATACCACTACAACCTACCGAT
CAATTTAAGGTATGTTTGTACATATTTAATTATATATTTAATTTCCCTGT
25 TAATTTCCCTTTTCTTTGCAATATTCTATGCGAACTCAAGAATGGGATTG
GAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCTTTTATTTGTT
ATTTATCATTTTCATATCAAGTACCTATAACATTTCTTTTTTATTTTTCT
AATTAGAAGAGGTCCACATGTCTAATTAGGTTTTCCATTCTATGTGTAAC
CTCTATTCTCTCTGTAATCAAGCATCTTAGATTATTTATCCATTTTCATA
30 ATTGTTGTTTATTTTTACAGTTTTTTTTTTTTATTTAATTTTAATAATTTAA
TTTTAATTTATTTATTTTTTTTTTTTTGGTAATTGCAACCTGTCATATAT
TCAAGTCTTAATGTAACATAATAATACATTTTATACCCACTATACTAAGA
TAATAATTACCTAAAGGGATGGATGCCATGACACTGCTACACTTCAGNAA
CTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAAATGATAATGGCATCTTT
35 TGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTT
AGCTAGTAGTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTCAAAATCT
GGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGG
TCATCAGGTGACAGATATTGTAGAATAGAACAAATATGTAATATTACCCAA
AACTATTTTTCTAAGGTTGCTCTGTAAATATGTGCTTTCTTGATTTCA
40 TTGAATTTGCATTCGTATATTTTAGGTGGTAAACTGATTGTCTCTTCAAT
AAATCCTGAAATTAATTAACAAAAAACAACAAAGTACATTTTGTATTT
GGAGAGCACTGGTATCATTTAGTATAGAAAAAACTAGATTTTGAATTAY
CTTCTTATATAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTT

TTCTATGTGTTGTTGCAGTTGTCTGAAGCAGGTGGTGTGTTGTTGGAGCTT
ATGCCAATACTCTAGAGAGATAGAGATATATAGGTGTGATGCACTGTCAA
GTGTAATTCATGTTACGCAGCAGGACAAATGCAAAAGCTGCAAGTGCTG
ACAGTCAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAACTCAATTAGG
5 GACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTC
CAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTGGAA
ATCTACGGTTGTGGGGGTTTGGAACATATATTACATTCTCTGCACTTGA
AAGCCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTACTACTCTTGTC
AATCTTCCAAACCTCAAAGAAATGAGGTTGGAGTGGCTAAGTAATCTGAG
10 GTATATATGGAAGAGCAATCAGTGGACAGCATTTGAGTTTCCAAACCTAA
CAAGAGTTGAAATTTGTGAATGTAATTCATTAGAACATGTATTTACTAGT
TCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTACATATATTTAACTG
CAGTCTGATGGAGGAGGTAATTGTTAAGGATGCAGATGTTTCTGTAGAAG
AAGACAAAGAGAAAAGAATCTGATGGCAAGACGAATAAGGAGATACTTGTG
15 TTACCTCATCTAAAGTCCTTGAATTACAACCTTCTTCGAAGTCTTAAGGG
GTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCCATTATTGGATACTTTAG
AAATCAAAAGATGCCCAACAATAACCACCTTCACCAAAGGAAATTCGCT
ACTCCACAACATAAAAGAAATACAAACAAATTTTGGCTTCTTTTATGCTGC
AGGGGAAAAAGACATCAACTCTCTTATAAAGATCAAACAACAGGTAAATC
20 AGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTGAAAAGCTTCATG
CAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTACATTCAGCTTTAT
ATTTATGTACTTTATGCAGGATTTCAAACAAGACTCAGATTAATGTGAAG
TGAATATTAAAGGTAAATTATATTTTCATGTTCCTAGTTGCCTATTAATT
AATGGCCTTTTAGTTCATGATTTTTTGGATGTATTCTTCATGATGATGTGA
25 ATCTTCTAATACCCCATTCATTGTTTGGTTGAATGTTGACTCTATGTCAG
GATGAATATTCAAGGGAAGAATTGTTTCATCAWATGAAGGACATTAAAGAA
CATGGATGCTATGAAGATGTTGGGAAAACATATGTATCAAGTGGCAARCT
GCTTAATGATCTAAGTTTGTGTTGGTTGANGATGTTGATTTTAATATTCAA
ATTCATTGGTTATATGGGCTTATCAATAGTGTTAATGGGATAATGAGTGA
30 CTTAACCTAAATTATGTTGTTGGTAAATGTTGGACAAGTATGGAAAATTA
GGAATGACTTGTGAAAAAAAATAAAAAAAAAA (SEQ ID NO:94)

RG2D deduced polypeptide sequence (SEQ ID NO:95)

MAMETANEIKQVVPVLMVPINDYLRYVVSCRKYISDMDLKMKEAKDNVEE
35 HKNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGDAF
NIIIEIDSVMRHSLITWTDHPIPLGRVDSVMASTSTLSTEHNDFQSREVRFSEALKA
LEANHMIALCGMGRVVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQVVA
DYLIELKESDKKTRAELRQGFKAASDGGNTKFLIILDDVWQSVLEDIGLSPSPN
QGVDFKVLITSRDEHVCSVMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIG
40 EDIVRRCCGLPIAKTMACTLRNKRKDAWKDALSRQHHDIGNVATAVFRTSYENL
PKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKLFDRVYTHIERNRLNTCIERLV
QANLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMPGWPDENMIVH

SCKRISLTCKGMIEIPVDLKF PKLTILKLMHGD KSLKFPQEFYEGMEKLQVISYDKM .
KYPLLPLAPQCSTNIRVLHLTECSLKMFD CSSIGNLSNLEVLSFANSRIEWLPSTVRN
LKKLRLLDLRFCDGLRIEQGVLSLVKLEEFYIGNAYGFIDDNCKDMAERSYNLSA
LEFAFFNNKAEVKNMSFENLERFKISVGC SFDGNISMSSHSYENMLQLVTNKG DVL
5 DSKLNGFLFKTEVLF LSVHGMNDLEDVEVKSTHPTQSSSFCNLKVRIISKCVELRYL
FKLHVANTLSSLEHLEVCGCENMEELIHTGIGGCGEETITFPKLKSLSLSQLPKLSGL
CHNVNIIGLPHLVDLKLKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDGMENL
EEIWPCELSGGEKVKLREIKVSSCDKL VNLFPHPNMSLLHHLEELKVKNCRSIESLF
NIDLDCVSAIGEEDNKSILRRIKVKNL GKLREVWRIKGADNSRPLIHGFPAVESISIW
10 GCKRFRNIFT PITANFDLVALLEIHIGNYRENHESEEQIEILSEKETLQEVTD TNISND
VVLFPSCLMHSFHNLHKLKLENYEGVEV VFEIESESPTCRELVTTHNNQQQPILPN
LQELYL RNM DNTSHVWKCSNWNKFFTL PKQQSESPFHNLT TIEMRWCHGFRYLFS
PLMAELLSNLKKVKILGCDGIEEVVSNR DDEDEEMTFTSTHTTTNLFP HLDSTLTK
YMHCLKCIGGGGAKDEGSNEISFNNT TTTTDDQFKLSEAGGVCWSLCQYSREIEIYRC
15 DALSSVIPCYAAGQMQLQVLT VSSCNGLKEVFETQLGTSSNKNNEKSGCEE GIPR
VNNNVIMLPNLKILEIYGCGGLEHIFTFSALESRLQLQELTIKGY YTLVNLPNLKEM
RLEWLSNLRYTWKSNQWTA FEFPNLTRVEICECNSLEHVFTSSMVG SLLQLQELHIF
NCSLMEEVIVKDADV SVEEDKEKESDGKTNKEILVPLHLSLKLQLL RSLKGFSLGK
EDFSFPLLD TLEIKRCPTITFTTKGNSATPQLKEIQTNFGFFYA AGEKDINSLIKIKQQ
20 DFKQDSD.CEVNIK

RG2E polynucleotide sequence (SEQ ID NO:96)

TGGGAAGACACAATGATGCAAAGGTTGAAGAAGGTTGCTAAAGAAAATAGAAT
GTTCAATTATATGGTTGAGGCAGTTATAGGGGAAAAGACAGACCCACTTGCTAT
25 TCAACAAGCTGTAGCGGATTACCTTTGTATAGAGTTAAAAGAAAGCACTAAACC
AGCAAGAGCTGATAAGCTTCGTGAATGGTTTAAGGCCAACTCTGGAGAAGGTA
AGAATAAGTTCCTTGTAATATTTGATGATGTTTGGCAGTCCGTTGATCTGGAAG
ACATTGGTTTAAAGTCATTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGA
CTTCACGAGACGAACATGTTTTGCACAGTAATGGGGGTTGAAGCTAATTCAATTC
30 TTAATGTGGGACTTCTAGTAGAAGCAGAAGCACAAAGTTTGTTCAGCAATTTG
TAGAAACTTTTGAGCCCGAGCTCCATAAGATAGGAGAAGATATCGTAAGGAAG
TGTTGTGGTTTACCTATTGCCATTAAAACCATGGCATGTACTCTAAGAAATAAA
AGAAAGGATGCATGGAAGGATGCACTTTTGCATTTAGAGTACCATGACATTAGC
AGTGTTGCGCCCAAAGTCTTTGAAACGAGCTACCATAATCTCCACAACAAGGAG
35 ACTAAATCTGTGTTTTTGATGTGTGGTTTTTTTCTGAAGACTTCAATATTCCAA
TCGAGGAGTTGATGAGGTATGGATGGGGCTTAAAGATATTTGATAGAGTTTATA
CTATTAGACAAGCAAGAATCAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
ACAAATTTGTTAATAGAAAGTGATGATGGTGTGCACGTCAAGATGCATGATCTG
GTCCGTGCTTTCTGTTTTGGTTATGTTTTCTGAAGTTGAACATGCTTCAATTATCA
40 ACCATGGTAATATGCTTGGATGGCCTGAAAATTATATGACCAACTCTTGCAAAA
CAATTTTCATTAACATGCAAGAGTATGTCTGAATTTCCGGGAGATCTCAAGTTTC
CAAACCTAACGATTTTGAAACTCATGCATGGAGATAAGTTGCTAAGATATCCTC

AAGACTTTTATGAAGGAATGGAAAAGCTCTGGGTTATATCATATGATGAAATGA
AGTATCCATTGCTTCCCTCGTTACCTCAATGCTCCATCAACCTTCGAGTGCTTCA
CCTCCATCGATGCTCATTAAATGATGTTTGATTGCTCTTGTATTGGAAATATGTTG
AATCTGGAAGTGCTTAGCTTTGTAAATCTGGCATTGAATGGTTACCTTCCACA
5 ATAGGAAATTTAAAGAAGCTAAGGTTACTTGATCTGAGAGATTGTTATGGTCTT
CGTATAGAAAAAGGTGTCTTGAAAAATTTGGTGAAAATTGGAGGAATTTATATT
GGTAGAGCAGATATTTTATAGAT

RG2E deduced polypeptide sequence (SEQ ID NO:97)

10 WEDTMMQRLKKVAKENRMFNYMVEAVIGEKTDLAIQQA VADYLCIELKESTKP
ARADKLREWFKANS GEGKNKFLVIFDDVWQSV DLEDIGLSHFNPQGVDFKVLLTS
RDEHVCTVMGVEANSILNVGLLVEAEAQSLFQQFVETFEPELHKIGEDIVRKCGL
PIAKTMACTLRNKRKDAWKDALLHLEYHDISSVAPKVFETSYHNLHNKETKSVFL
MCGFFPEDFNIPIEELMRYGWGLKIFDRVYTIRQARIRLNTCIERLVQTNLLIESDDG
15 VHVKMHDLVRAFVLVMFSEVEHASIINHGNMLGWPENYMTNSCKTISLTCKSMSE
FPGDLKFPNLTILKLMHGDKLLRYPQDFYEGMEKLWVISYDEMKYPLLPSLPQCSI
NLRVLHLHRCSLMMFDCSCIGNMLNLEVL SFVKSGIEWLPSTIGNLKKLRLLDLRD
CYGLRIEKGVLKNLVKIGGIYIGRADIL.

RG2F polynucleotide sequence (SEQ ID NO:98)

CTGTGGAAGACACAATGATGCAAAGGCTGAAAAAGGTTGTGCATGAAAAGAAA
ATGTTTAACTTTATTGTTGAAGCAGTTATAGGGGAAAAGACAGACCCCGTTGCC
ATTCAGGATGCTATAGCAGATTACCTAGGTGTAGAGCTCAATGAAAAATCTAAG
CAAGCAAGAGCTGATAAGCTCCGTCAAGGATTCAAGGACAAATCAGATGGAGG
25 CAAAAATAAGTTCTTTGTAATACTTGACGATGTTTGGCAGTCTGTTGATCTGGA
AGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGCGTCGACTTCAAGGTCTTGTT
GACATCACGAGACAGACATGTTTGCACAGTGATGGGGGTGAAGCCAAATTAA
TTCTAAACGTGGGACTTCTAATTGAAGCTGAAGCACAAAGTTTGTTCACCAAT
TTGTTGTCACTTCTGAGCCCGAGCTCCATAAGATAGGAGAAGATATTGTAAAGA
30 AGTGTTCGGTCTGCCAATTGCCATCAAAACCATGGCATGTACTCTACGACATA
AAAGAAAGGATGCATGGAAGGATGCACTTTCACGTTTAGAGCACCATGACATT
CAAAGTGTTGTGCCTAAAGTATTTGAAACGAGCTACAACAATCTCAAAGACAA
GGAGACTAAATCCGTATTTTTGATGTGTGGTTTGTTCCTGAAGACTTGGATAT
ACCTATCGAGGAGTTGATGAGGTATGGATGGGGCTTAAGATTATTTGATAGAGT
35 TAATACTATTACACAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGG
TGCACACAAATTTGTTAATTGAAAGTGTTGATGGTGTGCATGTCAAGATGCATG
ATCTGGTTCGTGCTTTTGT TTTGGGAATGTTTTCTGAAGTGAGCATGCTTCAAT
TGTC AACCATGGTAATATGCCCAGGTGGACTGAAAATGATATGACTGACTCTTG
CAAACAAATTCATTAACATGCAAGAGTATGTTGGAGTTTCCTGGAGACCTCAA
40 GTTTCCAAACCTAAAGATTTTGAAACTTATGCATGGAGGTAAGTCACTAAGGTA
TCCTCAAGACTTTTATCAAGGAATGGAAAAGCTGGAGGTTATATCATACGATGA
AATGAAGTATCCATTGCTTCCCTCGTTGCCTCAATGTTCCACCATCCTTCGAGTG

CTTCATCTCCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTCAATCGGTAATC.
TTTTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAGCATTGAATTGTTACCTTC
CGTAATTGGAAATTTGAAGAAGTTGCGGCTGCTAGATTTGACAACTGTTATGG
TGTTTCGTATAGAAAAGGATGTCTTGAAAAATTTGGTGAAACTTGAAGAGCTTTA
5 TATTAGGAATGGTCTACCAGTTTACAGAGGAT

RG2F deduced polypeptide sequence (SEQ ID NO:99)

VEDTMMQRLKKVVHEKKMFNFIVEAVIGEKTDPVAIQDAIADYLGVELNEKSKQA
RADKLRQGFKDKSDGGKNKFFVILDDVWQSVLDLEDIGLSPFPNQGVDFKVLLTSRD
10 RHVCTVMGVEAKLILNVGLLIEAEAQSLFHQFVVTSEPELHKIGEDIVKKCFGLPIAI
KTMACTLRHKRKDAWKDALSRLEHHDIQSVVPKVFETSYNNLKDKETKSVFLMCG
LFPEDLDIPIEELMRYGWGLRFLDRVNTTQARNRLNTCIERLVHTNLLIESVDGVH
VKMHDLVRAFLGMFSEVEHASIVNHGNMPEWTENDMTDSCQISLTCKSMLEFP
GDLKFPNLKILKLMHGGKSLRYPQDFYQGMKLEVISYDEMKYPLLPSLPQCSTILR
15 VLHLHECSLRMFDCSSIGNLFNMEVLSFANSSIPELLSVIGNLKKLRLLDLTNCYGV
RIEKDVLKNLVKLEELYIRNGLPVYRG

RG2G polynucleotide sequence (SEQ ID NO:100)

GAAGACACGATGATGAAGAACTGAAGGAGGTCGTGGGACAAAAGAAATCATT
20 AATATTATTATTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCAATTCAG
CAAGCTGTAGCAGATTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGC
AAGAGCTGATAAGCTTCGTAAACGGTTTGAAGCCGATGGAGGAAAGAATAAGT
TCCTTGTAATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTT
AAGTCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAGA
25 TTCACATGTTTGCACCTCTGATGGGAGCTGAAGCAAATTCAATTCTTAATATAAA
AGTTTTTAAAGATGTAGAAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGC
GGGTGATGATGACCTGGATCCTGCTTCAATGGGATAGCAGATAGTATTGCAAG
TAGATGTCAAGGTTTGGCCATTGCCATCAAAACCATTGCCTTAAGTCTTAAAGG
TAGAAGCAAGTCTGCATGGGACGTTGCACTTTCTCGTCTGGAGAATCATAAGAT
30 TGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATTAGCTACGACAATCTCCA
AGATGAGGTTACTAAATCTATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTT
GATATTCTACTGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATA
GAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCG
GCTTAGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGTGTCAAGAT
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAACACGC
TTCAATTGTCAACCATGGTAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCAT
CTACTCTTGTA AAAAGAATTTTCATTAACATGCAAGGGTATGTCTCAGTTTCCCAA
AGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTATGCATGGAGATAAGTC
ACTGAGCTTTCTGAAAACCTTTATGGAAAGATGGAAAAGGTTCAAGTAATATC
40 ATATGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACCAA
CGTTTCGAGTGCTTCATCTTCATTACTGTTTCATTAAGGATGTTTGATTGCTCTTCA
ATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTGAA

TGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACA
AATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTTGGTCAAACCTT
GAAGAGCTTTATATGGGTGTTAATCGTCCGTATGGACAGGCCGTTAGCTTGACA
GATGAAAA

5

RG2G deduced polypeptide sequence (SEQ ID NO:101)

RHDDEELKEVVGQKKSFNIIQVVIGEKTNPPIAQQAVADYLSIELKENTKEARADKL
RKRFEADGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTL
MGAEANSILNIKVLKDVEGQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGLPIAI
10 KTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCAL
FPEDFDIPEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVK
MHDVVRDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSQFPKDL
KFPNLSILKLMHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNVRVLH
LHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRID
15 NGVLKNLVKLEELYMGVNRPYQAVSLTDE

RG2H polynucleotide sequence (SEQ ID NO:102)

TGAAGGAGGTTGTGGAACGAAAGAAAATGTTTCAGTATTATTGTTCAAGTG
GTCATAGGAGAGAAGACAAACCCTATTGCTATTTCAGCAAGCTGTAGCAGA
20 TTACCTCTCTATAGAGCTGAAAGAAAACTAAAGAAGCAAGAGCTGATA
AGCTTCGTAAATGGTTTCGAGGCCGATGGAGGAAAGAATAAGTTCCTTGTA
ATACTTGACGATGTATGGCAGTTTGTTCGATCTTGAAGATATTGGTTTAAG
TCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAG
ATTCACATGTTTTGCACTCTGATGGGAGCCGAAGCCAATTCAATTCTCAAT
25 ATAAAAGTTTTAACAGCTGTAGAAAGGACAAAGTTTGTTCGCCAGTTTGC
TAAAATGCGGGTGATGATGACCTGGATCCTGCTTTCAATAGGATAGCAG
ATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATTGCCATCAAAACCATT
GCCTTAAGTCTTAAAGGTAGAAAGCAAGCCTGCGTGGGACCATGCGCTTTC
TCGTTTGGAGAACCATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTT
30 TTAAAATTAGCTATGACAATCTCCAAGATGAGATTACTAAATCTATTTTT
TTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTACTGAGGAGTT
GATGAGGTATGGATGGGGCTTGAAATTATTTATAGAAGCAAAAACCTATAA
GAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTTAGGGAGACA
AATTTGTTATTTGGAAGCGATGACATTGGATGCGTCAAGATGCACGATGT
35 GGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAGCACGCTTCAA
TTGTCAACCATGGTAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCATC
TACTCTTGTAAGAATTTTCATTAACATGCAAGGGTATGTCTGAGTTTCC
CAAAGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTATGCATGGAG
ATAAGTCGCTGAGCTTTCCTGAAAACCTTTATGGAAAGATGGAAAAGGTT
40 CAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCCCTCATCACT
TGAATGCTCCACTAACGTTTCGAGTGCTTCATCTCCATTATTGTTTATTAA
GGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTC

AGCTTTGCTAATTCTAACATTGAATGGTTACCATCTACAATTGGAAATTT
GAAGAAGCTAAGGCTACTAGATTTGACAAATTGTAAAGGTCTTCGTATAG
ATAATGGTGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTTTATATGGGT
GTTAATCATCCGTATGGAC

5

RG2H deduced polypeptide sequence (SEQ ID NO:103)

KEVVERKKMFSIIVQVVIGEKTNP IAIQQA VADYLSIELKENTKEARADKLRKWFEA
DGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTLMGAEAN
SILNIKVLTAVEGQSLFRQFAKNAGDDDLDPAFNRIADSIASRCQGLPIAIKTIALSLK
10 GRSKPAWDHALSRLENHKIGSEEVVREVFKISYDNLQDEITKSIFLLCALFPEDFDIP
TEELMRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVVR
DFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLSI
LKL.MHGDKSLSFPENFYGKMEKVQVISYDKLMYPLLPSLECSTNVRVLHLHYCSL
RMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRIDNGVLKN
15 LVKLEELYMGVNHPYG

RG2I polynucleotide sequence (SEQ ID NO:104)

AAG.AAGAGCTGAAGGAGGTTGTGGAACAAAAGAAAACGTTCAATATTATT
GTTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCTATTCAAGCAAGC
20 TGTAGCAGATTCCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAA
GAGCTGATAAGCTTCGTAAATGGTTCGAGGCTGATGGAGGAAAGAATAAG
TTCCTCGTNATACTTGACGATGTATGGCNGTTTGTGATCTTGAAGATAT
TGGTTTAAGTCCTCATCCAAATAAAGGTGTCANCTTCAAGGTCTTGTGGA
CGTCAAGAGATTACATGTTTGCACCTCTGATGGGAGCTGAAGCCAATTCA
25 ATTCTCAATATAAAAGTTTTAAAGATGTAGAAGGAAAAAGTTTGTTCG
CCAGTTTGCTAAAAATGCGGGTGATGATGACCTGGATCCTGCTTTCATTG
GGATAGCAGATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATGCCATC
AAAACCATTGCCTTAAGTCTTAAAGGTAGAAGCAAGTCTGCATGGGACGT
TGC.ACTTTCTCGTCTGGAGAATCATAAGATTGGTAGTGAAGAAGTTGTGC
30 GTG.AAGTTTTTAAATTAGCTATGACAATCTCCAAGATGAGGTTACTAAA
TCT.ATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTAC
TGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATAGAAGCAA
AACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTT
AGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGCGTCAAGAT
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAGC
ACGCTTCAATTGTCAACCATGGTAATGTGTCAGAGTGGCTAGAGGAAAAT
CATAGCATCTACTCTTGTAAGAATTTTCAATTAACATGCAAGGGTATGTC
TGAGTTTCCCAAAGACCTCAAATTTCCAAACCTTCAATTTTGAACTTA
TGC.ATGGAGATAAGTCGCTGAGCTTTCTGAAAACCTTTATGGAAAGATG
40 GAAAAGGTTCAAGTAATATCATATGATAAATTGATGTATCCATTGCTTCC
CTC.ATCACTTGAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCAATTAAGGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATG

GAAGTGCTCAGCTTTGCTAATTCTGGCATTGAATGGTTACCATCTACAAT
TGGAAATTTGAAGAAGCTAAGGCTACTGGATCTGACAGATTGTGGAGGTC
TTCATATAGATAATGGCGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTT
TATATGGGTGCTAATCGTCTGTTTGGAAAGTGCCAT

5

RG2I deduced polypeptide sequence (SEQ ID NO:105)

EELKEVVEQKKT FNIVQV VIGEKTNP IAIQQA VADSL SIELKENTKEARADKLRKWF
EADGGKNKFLVILDDVW?FVDLEDIGLSPHPNKGV?FKVLLTSRDSHVCTLMGAEA
NSIL_NIKVLKDVEGKSLFRQFAKNAGDDDLDPAFIGIADSIASRCQGLPIAKTIALSL
10 KGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCALFPEDFDI
PTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVV
RDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYCKRISLTCKGMSEFPKDLKFPNLS
ILKLMHGDKSLSFPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNLRVLHLHECSL
RMFDCSSIGNLLNMEVLSFANSIGIEWLPSTIGNLKKLRLLDLTDCGGLHIDNGVLKN
15 LVKLEELYMGANRLFGKCH

RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107)

ATGTCCGACCCAACAGGGATTGTTGGTGCCATTATTAACCCAATTGCTCA
AACGGCCTTGGTTCCCCTTACAGACCATGTAGGCTACATGATTTCTCTGCA
20 GAAAATATGTGAGGGACATGCAAATGAAAATGACAGAGTTAAATACCTCA
AGAATCAGTGCAGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCA
GATTCCATCTCAAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAG
CGAATGTTGCAAACCTTTCCAATTGATGTCATCAGTTGTTGTAGTCTCAGG
ATCAGGCACAAGCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATCGA
25 AAGTCTAACGAGACAAAATTCGCTGATTATCTGGACTGATGAACCTGTTC
CCCTGGGAAGAGTTGGTTCCATGATTGCATCCACCTCTGCAGCATCAAGT
GATCATCATGATGTCTTCCCTTCAAGAGAGCAAATTTTTAGGAAAGCACT
AGAAGCACTTGAACCCGTCCAAAAATCCACATAATAGCCTTATGGGGGA
TGGGCGGAGTGGGGAAGACCACGATGATGAAGAAGCTGAAAGAGGTCGTG
30 GAACAAAAGAAAACGTGCAATATTATTGTTCAAGTGGTCATAGGAGAGAA
GACAAACCCTATTGCTATCCAGCAAGCTGTAGCAGATTACCTCTCTATAG
AGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTAAACGG
TTCGAAGCCGATGGAGGAAAGAATAAGTTCCTTGTAACTTGACGATGT
ATGGCAGTTTTTCGATCTTGAAGATATTGGTTTAAGTCCTCTGCCAAATA
35 AAGGTGTCAACTTCAAGGTCTTGTGACGTCAAGAGATTCACATGTTTGC
ACTCTGATGGGAGCTGAAGCCAATTCTATTCTCAATATAAAAGTTTTAAA
AGATGTAGAAAGGAAAAAGTTTGTTCGCCAGTTTGCTAAAAATGCGGGTG
ATGATGACCTGGATCCTGCTTTCATTGGGATAGCAGATAGTATTGCAAGT
AGATGTCAAGGTTTGCCCATTCATCAAAACCATTGCCTTAAGTCTTAA
40 AGGTAGAAGCAAGTCTGCATGGGACGTCGCACTTTCTCGTCTGGAGAATC
ATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATAGCTAT
GACAATCTCCAAGATGAGGTTACTAAATCTATTTTTTTACTCTGTGCTTT

ATTTCTGAAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGT
GGGGCTTGAAATTATTTATAGAAGCAAAAACATAAGAGAAGCAAGAAAC
AGGCTCAACAACTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGG
AAGTCATGACTTTGGGTGCGTCAAGATGCACGATGTGGTGCGTGATTTTG
5 TTTTGCATATGTTTTCAGAAGTCAAGCATGCTTCAATTGTCAACCATGGT
AACATGTCAGAGTGGCCAGAGAAAAATGATACCAGCAACTCTTGTA AAAAG
AATTTCAATTAACATGCAAGGGTATGTCTAAGTTTCCTAAAGACATCAACT
ATCCAAACCTTTTGATTTTGAACTTATGCATGGAGATAAGTCGCTGTGC
TTTCCTGAAAACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATA
10 TGATAAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTA
ACGTTGAGTGTCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGC
TCTTCAATTGGTAATCTTCTCAACATGGAAAGTGCTCAGCTTTGCTAATTC
TAACATTGAATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGC
TACTAGATTTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTA
15 AAAAATTTGGTCAAACCTTGAAGAGCTTTATATGGGTGTTAATCGTCCGTA
TGGACAGGCCGTTAGCTTGACAGATGAAAACCTGCAATGAAATGGTAGAAG
GTTCCAAAAAATCTTGTCACTAGAATATGAGTTGTTTAAATACAATGCT
CAAGTGAAGAATATATCCTTCGAGAATCTTAAACGATTCAAGATCTCAGT
GGGATGTTCTTTACATGGATCTTTTCAGTAAAAGCAGGCACTCATACGAAA
20 ACACGTTGAAGTTGGCCATTGACAAAGGCGAACTATTGGAATCCCGAATG
AACGGGTTGTTTGAGAAAACGGAGGTTCTTTGTTTAAAGTGTGGGGGATAT
GTATCATCTTTTCAGATGTAAAGGTGAAGTCCTCTTCGTTCTACAATTTAA
GAGTCCTTGTCGTTTCAGAGTGTGCAGAGTTGAAACACCTCTTCACACTT
GGTGTTGCAAATACTTTGTCAAAGCTTGAGCATCTTAAAGTCTACAAATG
25 CGATAATATGGAAGAACTCATACATACCGGGGGTAGTGAAGGAGATACAA
TTACATTCCCAAGCTGAAGCTTTTATATTTGCATGGGCTGCCAAACCTA
TTGGGTTTGTGTCTTAATGTCAACGCAATTGAGCTACCAAACTTGTGCA
AATGAAGCTTTACAGCATTCCGGGTTTCACAAGCATTATCCGCGGAACA
AGTTGGAAGCATCTAGTTTGTGAAAGAAGAGGTACATATACATATAGTT
30 TATGTTAATACATTTTAAACAATCTTTCAACTAAAAGTTTCAGAATATA
TCTGTATTTTGATTGTATGATGTGTTAGTGTGTTGGATGTGGCTATTAAAG
GATAATTATTTGGCAGGTTGTGATTCCCTAAGTTGGATATACTTGAAATTC
ATGACATGGAGAATTTAAAGGAAATATGGCCTAGTGAGCTTAGTAGAGGT
GAGAAAGTTAAGTTGAGAAAGATTAAAGTGAGAAATTGTGATAAACTTGT
35 GAATCTATTTCCACACAATCCCATGTCTCTGCTGCATCATCTTGAAGAGC
TTATAGTCGAGAAATGTGGTTCCATTGAAGAGTTGTTCAACATCGACTTG
GATTGTGCCAGTGTAATTGGAGAAGAAGACAACAACAGCAGCTTAAGAAA
CATCAATGTGGAGAATTCAATGAAGCTAAGAGAGGTGTGGAGGATAAAAAG
GTGCAGATAACTCTCGTCCCCTCTTTTCGTGGCTTTCAAGTTGTTGAAAAG
40 ATAATCATTACGAGATGTAAGAGGTTTACAAATGTATTCACACCTATCAC
CACAAATTTTGATCTGGGGGCACTTTTGGAGATTTTCAGTTGATTGTAGAG
GAAATGATGAATCAGACCAAAGTAACCAAGAGCAAGAGCAGGTATGGATT
TCAATTTTACTCTTTTACTTAATTAATGATTAAGCCCCTGCTTTTAAATA

AAAAGGGGACAAACCATTCTTGACTTAATGTTGCAATACAAGTCATGTA
TAAGAGTGATTAACCTTTTTTTTATTATATAAAATAACTACAAAACATGTTT
TTTCATTATAGATCATGTATAAATGTGACTAATTTTTTTTCATCGCCTAAC
TTTTGTTGATAAATCATTAGAAATGTCACCTAATTACTTTTTTAGTATTTAT
5 AAAATAACTACAAAACATGTTTTTTTCATTATAGATCATGTATATATCAAC
TAAAAATATTATTCCTTACACAAAAAAGGTTCAAGAAAGCCTGTA
TTTCGAAATAACTAAAAAGAAATATTTGATATTCACCTAAGAGAAATTTT
TTTCTAAACATGATCGCAAATGATTAAACTTAAATTAAACTAAAAAGA
TTTTTATATATGTTATNCAAAATTAATAATTTGAAATTAAGTTTATAATTC
10 TNGTNTCACAAAGGGATATATATAGTAAATATTATTTTTTTGCGAGTCAT
GCATAGTTGTATTTTTAAATGATTTATTAACGTGGTAGGAGTGGAACCA
CTCAATCTAGTAGACCCACTATCACATGTCACATCAGCTTTACATCTATT
TTTCTTTCTCCTTTTTTTCATCTTTTTTAACTCATAACACNTAAAANTANC
ATATTTTCCAACACACTNAACTCATTGTCACATTATTATTTTTAATTTAA
15 TTAAATTNGAAAATTAATAAATAAANCNTAACATTTTTTAATTAATAA
AATATTAATCCAAATAAAAANTNCACGATAAATTAATAAANGTTTANTTTG
GAAAAAANCC (SEQ ID NO:106)

Sequence gap

20 ATAACCCTTTCAAGGGTCAACTCAAGTCCAAGTTAAAGTCAAGGTCAAAA
CCTTGGTTAAAGTCAACTTTGGTCAAAGTCAACATCTACTTGACTCACCT
CACCGAGTTGGTCCACCAACTTGTCGAGTCCCTTAATCCACAACTTCAA
GAACTTCGATCCTACTCGTCGAGTCTTTCAAGAACTCTTCGAGTTTCCAT
TACACAGAATCGGGACCTTTTGCTCATGACTCGCCGAGTTCATCCTTGAA
CTTGTCGAGTCTAGCTTCATACGAGTTCGAGTGTTTAGTCCTTGACTCGT
25 CGAGTTCTTCCTTGAACCTCGTCGAGTCCATCTTCGTATAGTTGGGACATT
GCCTTGAACCTACCGAGTTCATCATTGAACCTCATCGAGTCCCTTCGATCTT
CAAGTCCATAATCCTGTCCATCTTGTTGAGTCCTCTTCTAGACTCAACCA
GATTCCTCAGAAACAGAAAAGGTTAGGGAACCATTACCTGACTCGCCGAG
TCCCAAGAACGAATCCCCGAGTCCCCCAATGTCCATGACCATAACAATCGA
30 TTTTCGTTGGGCTCATTGCATCCAAAGCATAGATCTAACCTCCTAGGGTC
CATATTACACGTAAAGCTACGAACCTTGACGTCCATGCATGGGGGATTGG
CTCAAATGGCATTAAAATGGGGTTTATCTGATGCATGGGACTCCCATGGC
CATAAAGTTAACACCTTTATGCCATGGGAATCCTCAATGGTTCCATATCT
GAAGTTAACTCTACAATATGTTCTAAACCCGAAGGTGGCTTAGAAATG
35 CCCCCAAATGGCAAGATTCAAGCCTTAAAGGAGATCTAACAAATGATAAG
TCAAGGTTCAAGCTTTTTACCTTGAATAAGCTGGAAATGAAGCAAAATCT
CTGGATCCACTTGCTTCTTCAAGAACCCCAAGCTTCCACTTCTTCCTTC
AAGTTTCAACAACCTTTAAACACTCAAAAATGGCTCAAGAACACTCAAAA
AGCTTTAGGGTTTCGAGTTAGGGCTTTTTGGAAGCGAGAGGGACGATGGG
40 GGCTGAAATGAGGCTAGAAAAAGTGTTTAAATAGGGGGCAAACCCTAAAT
ATTAGGGTTTCATCCAGGCAGCCCTACTCGTCGAGTCGGGCTCCCGACTC
GTCGAGTAGGTCACCTTAAAACCCGCGTCCATAATCCAGTCTACTCGACGA
GTTGGGCCTCCAACCTCGTCGATTCCGAGTGCAAAACGTTCAATTACTTAA

ATTTAAATATGTACCAGGAACCGGGTGTACAGTTGAGACTTTATACCTC
CATAAGATAGATCTAGGTGCACATAGCCTGGATCCACAAGCTCCATGTCA
ACAAGCGACTCTTCAAGAAGTTCATTCTTCCTCCTTAAGCACCAAAAAAC
ACACAAAATCACCATGAAGCTCAAGAAATACTCAAATAGAGGATAGGGTT
5 TCGTTCGTAGGGTTAGAGAGGATGGAGGCTAGAGGAAATGAGGGATAGAG
GCGAGTTAAGGTCTTTAAATAGGGTCCAAGACCCTAAATTAGGGTTTTAA
TCTGGCCAGACGAACGCAGGGTGTCCCAAATGCATATGTGTCCAAATTC
TCGTGTGCGCCATGCGTACCTCCCTTGTACGCCATGTGTACCGGGTTTGG
TCCAAACCCTTCTAACTTCAAATGATCATAACTTGCACCCCTTATCTGTT
10 TTCGATGTTCTTTATATCCACGGAAAGGTAACAAGAAGCCCTATACTTCT
ATAAACTTTATTTAATCTGAAAACCAACCGAAATTAAATCCAAAATTCAT
AAAAGTCCCGAACCAACACATTTACCGATACCCTTGGGCTCCAAAACACA
AATTGAAAACCCGGATCATCCAACTACATCATCCACCTCCAAATGAGCC
CAAACCTCAATTATTCAAGGGTCTAAGCCTGTTAATGCCCACTCCTCGAT
15 TACCACCCCGCAATGGGAAACGATTCAAACAGGGCGTTACATAATTTGT
TGTGGTTTTGTATTTTTTATTTCCGGTGAAGGTGAAAGATCCAACCTATTT
TTAATCTGTTGGCATTTTCCATCATTTGCAACTGTTTCTTGAAAAA
TACCTAAAATCAAATAACCATTTTCAAATCCAAAATTATAAGAGAGAAT
TGTAATGGACATGGAATCTTAAATCATTAAACACAGTTCAGTACACAAGT
20 TGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAAGAG
ACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATCCTG
TCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAGTTA
AAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGA
GAATTGGTAACAACCTCACCATAACCAACAACAGCCTGTTATATTTCCCAA
25 CCTCCAGCATTTGGATCTAAGGGGTATGGACAACATGATTTCGCGTGTGGA
AGTGCAGCAACTGGAATAAATTCCTCACTCTTCCAAAACAACAATCAGAA
TCCCCATTCCACAACCTCACAACCATAAATATTGATTTTTGCAGAAGCAT
TAAGTACTTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGA
AAGTCAATATAAAATGGTGTGTTATGGTATTGAAGAAGTTGTTTCAAACAGA
30 GATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAACCAC
CATCTTGTTCCCTCATCTTGATTCTCTCACTCTAAGTTTCCTGGAGAATC
TGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATA
TCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGAGGT
ATGCTTTGTTTCATATTCAATTATTTATTTAATTTCTTTTTTTATTTGCAA
35 TATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAATTAC
CTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCTAGT
AAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGG
TAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTTAGCAAGT
ACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATT
40 GTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAG
GTGACAGATATTGTAGAATAGAACAAATATATAATATTACCCAAAACCTATT
TTTTCTAAGGTTTTTCTGTAAATATGTGCTTCTTGATTTCATTGAATT
TGCATTCCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCC

GAAATTAATTAAAAAAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGA
GCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTC
TTATATAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCA
TGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTTGGAGCTTATGCC
5 AATACGCTAGAGAGATAAGTATAGAATTCTGCAATGCATTGTCAAGTGTG
ATTCCATGTTATGCAGCAGGACAAAATGCAAAAGCTTCAAGTGCTGACAGT
CAGTTCTTGTAAATGGTCTGAAGGAGGTATTTGAAACTCAATTAAGGAGGA
GCAGCAACAAAAACAACGAGAAGAGTGGTTGTGATGAAGGAAATGGTGGA
ATTCCAAGAGTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATT
10 GGAAATCAGCTTTTGTGGGGGTTTGGAAACATATATTCACATTCTCTGCAC
TTGAAAGCCTGAGACAGCTCGAAGAGTTAACGATAATGAATTGCTGGTCA
ATGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAAC
AACAAACAACAACGAAGGGGACTTCTTCTTCTTCTTCTTCTTCTTCTTCTT
CTTCTTCTTCTTCTTCTTCTCCTCCTTCTTCTTCTAAGAAGGTTGTGGTC
15 TTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGGTAGG
ATTCTTCTTGGGGATGAATGAGTTCGGGTTGCCTTCATTAGATGAACTTA
TCATCGAGAAATGCCCAAAAATGATGGTGTTCACAGCTGGTGGGTCCACA
GCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAAACATACTATTGA
TCAAGAATCTGGCCTTAACCTTTCATCAGGTATATATGTTTCTTTAATTGG
20 CATCATCTAATTAAGAAAGATATCATTCTGCCAAGTAAATTTACTTCAA
ACACATTACACTGGTTTTCAGTCTAAGTTTATGTTGTTCTAGGAAGGCCA
AAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTTCAAGTGGAAGGGTA
TTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTGTAGTACCTG
GAATCGTGTGTGGGAGGAGCATTATTCTGATTGCTTGTTCCTTTAT
25 CATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATCTTTTGAT
TTTAAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTGTTCTTCA
TGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGATTGTTATT
TTCATAGCATGTTAGTCACTTGAATCAAGCTTTTTTCATTTTCAACCAGGG
CAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAAACAGCAACCCATC
30 GGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGATTAATA
ATTATAATATCCTGTATTAATTCATAAAAAATTGGTACAGCACATATATGA
CATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCTGGCGTTTTCTTTA
TTGGACTTGCAGACCTCATTCCAAAGTTTATACGGTGACACCTTGGGCCC
TGCTACTTCAGAAGGGACAACCTTGGTCTTTTCATAACTTGATTGAATTAG
35 ATGTGAAATTTAATAAGGATGTTAAAAAGATTATTCCATCCAGTGAGTTG
CTGCAACTGCAAAAGCTGGAAAAGATAAATATAAACAGTTGTGTTGGGGT
AGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGGAGAAATGGAATA
GTGGAATTGGTTTTGATGAATCGTCACAAACAACCTACCACTACTCTTGTC
AATCTTCCAAACCTTAGAGAAATGAACTTATGGGGTCTAGATTGTCTGAG
40 GTATATATGGAAGAGCAATCAGTGGACAGCATTTGAGTTTCCAAAACATA
CAAGAGTTGAAATTAGTAATTGCAACAGTTTAGAACATGTATTTACTAGT
TCCATGGTTGGTAGTCTATCGCAACTCCAAGAGCTACATATAAGTCAGTG
CAAACTTATGGAGGAGGTGATTGTTAAGGATGCAGATGTTTCTGTAGAAG

AAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAAGGAGATACTTGCG
TTACCTAGTCTAAAGTCCCTGAAATTAGAAAGCTTACCATCTCTTGAGGG
GTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTATTGGATACTTTAA
GAATTGAGGAATGCCCAGCAATAACCACCTTCACCAAGGGAAATTCCGCT
5 ACTCCACAATAAGAGAAATAGAAACAAGATTTGGCTCGGTTTATGCAGG
GGAAGACATCAAATCCTCTATTATAAAGATCAAACAACAGGTAAATCAGA
TCATTGTTGGTTTAATAATTCTTAAACTACATTTGAAAAGTTTCATGTAA
GTTTTTTATTATTGTCAAAAGCCGCAACCTATATTTTCAACTTTATATTT
ATGTACTTTTATGCAGGATTTCAAAAAGCCCAGGACTCTATTTAATGTGA
10 AGTAAATACTAGAAGAGGTAAATTCTATTTACATGTCTCCTGATTGCCTA
TTAATTAATGGCCTTTCAGTTCATGGTTTTTGGATGTATTCTTCATGATG
ACGTGAATGTTTAAATACCCCACTAGTTAATTGTTAGGTTGAATGTTGAT
GACCAAAGGACTATATGTCGGGAAGAATATTCAAGGAAAGAATTGTTTCAT
CATATGAAGGGCATTAAATTAAGAAGAACATGGATGCTATGAAGATGTTG
15 GGAATAATATATGAATCAAATAACAAGCTACTCACTTATCTAAGTTTGTTG
GTTGAGGATGTTGATTTTAATATTTCAAATTCATTGGTATCATTATATGG
GTTTATCAGTAGTGTTAATGGGATAATGAGCAACTTAACCTTAAATTATG
CTGTTGGTAAATGTTGGACTCAAGTATGGAAAATTAGGAATAACTTGTGA
AAAATATATGCAAAAAGTAGGATTGAGATTTTCAATGAAAAAAATTATGAA
20 ACTATACTACTATAGTATATAAATAAATTCAACTTACTGTTGGGTATATT
GGAAGCACATATCATGAAAGTAAGTAGAAGCAGAATTTGTTCCCATCTTC
ATCTACTTATAGTTTCCATTTCTTACTTGTAATAATCTGATTAACTTTA
GAGTATTTTCTATTTTTTACCAACCAAAATTTTCATATAAAGGCCACAAG
T (SEQ ID NO:107)

25

RG2J deduced polypeptide sequence (SEQ ID NO:108)

MSDPTGIVGAIINPIAQTALVPLTDHVGYMISCRKYVRDMQMKMTELNTSRISAEHH
ISRNTRNHLQIPSIKDWLDQVEGIRANVANFPIDVISCCSLRIRHKLQKAFKITEQI
ESLTRQNSLIWTDEPVPLGRVGSMAISTSAASSDHHDVFPSREQIFRKALEALEPVQ
30 KSHIALWGMGGVGKTTMMKKLKEVVEQKKTENIIVQVVIGEKTNPPIAQAVADY
LSIELKENTKEARADKLKRFEADGGKNKFLVILDDVWQFFDLEDIGLSPLPNKGV
NFKVLLTSRDSHVCTLMGAEANSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPFI
GIADSIASRCQGLPIAKTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYD
NLQDEVTKSIFLLCALFPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNNCTERL
35 RETNLLFGSHDFGCVKMHDVVRDFVLHMFSEVKHASIVNHGNMSEWPEKNDTSN
SCKRISLTCKGMSKFPKDINYPNLLILKLMHGDKSLCFPENFYGKMEKVQVISYDKL
MYPLLPSSLECSTNVRVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIG
NLKKLRLLDLTNCKGLRIDNGVLKNLVKLEELYMGVNRYPYQAVSLTDENCNEM
VEGSKKLLALEYELFKYNAQVKNISFENLKRKISVGC SLHGSFSKSRHSYENTLKL
40 AIDKGELLESRMNGLFEKTEVLCLSVGDMYHLSDVKVKSSSFYNLRLVVSECAEL
KHLFTLGVANTLSKLEHLKVYKCDNMEELIHTGGSEGDTITFPKLKLLYLHGLPNL
LGLCLNVNAIELPKLVQMKLYSIPGFTSIYPRNKLEASSLLKEEVVPEELIVEKCGSI
EELFNIDLDCASVIGEEDNSSLRNINVENSMKLEVVWRIKGADNSRPLFRGFQVVE

KIITRCKRFTNVFTPITTNFDLGALLEISVDCRGNDESDQSNQEQEQIEILSEKETLQE
ATDSISNVVFPSCLMHSFHNLOKLILNRVKGVFVFEIESESPTSRELVTTHNQQQP
VIFPNLQHLDLRGMDNMIRVWKCSNWNKFFTLPKQQSESPFHNLTINIDFCRSIKY
LFSPLMAELLSNLKKVNIKWCYGIEEVVSNRDEDEEMTTFTSTHTTTILFPHLDSL
5 TLSFLENLKCIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAR
EISIEFCNALSSVIPCYAAGQMOKLQVLTVSSCNGLKEVFETQLRRSSNKNNEKSGC
DEGNGGIPRVNNNVIMLSGLKILEISFCGGLEHIFTSALESRLQLEELTIMNCWSMK
VIVKKEEDEYGEQQTTTTTTKGTSSSSSSSSSSSSSSSSPSSSKKVVFPCLSIVLVNLP
ELVGFFLGMNEFRLPSLDELIEKCPKMMVFTAGGSTAPQLKYIHTRLGKHTIDQES
10 GLNFHQDIYMPLAFSLDLQTSFQSLYGDTLGPATSEGTTWSFHNLIELDVKFNKD
VKKIIPSELLQLQKLEKININSCVGVVEVFETALEAAGRNGNSGIGFDESSQTTTTTL
VNLPLNREMNLWGLDCLRYIWKSQWTAFEFPLTRVEISNCNSLEHVFTSSMVGS
LSQLQELHISQCKLMEEVIVKDAADVSEEDKEKESDGKMNKEILALPSLKSLESL
PSLEGFSLGKEDFSFPLDLRIEECPAITTFTKGNSATPQLREIETRFSGSVYAGEDIKS
15 SIIKIKQQDFKKAQDSI.CEVNTR

RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110)

TGGGATTCCATATATAAAAACATATATTTTTATAAAGTGGGATTCCATTG
TTTATATAGATTTTTATTCACCAATAGACAATAGATTAAAAAAGATATA
20 AAAACATGTCGGCTTTTGACTAAAAATATAGATTTTTATGAATAGAATAT
TCAATTTGCTTAACTCGTTTAAAAAAAATGAAAAAGATGTCGATATAAAA
TCTCATATGGGCCTTCTTTACCATTCAAATAGTAAAATAGTAAAAGATAC
TTGTTTGGGGCATGAACTGACCATAGTCAAACCCATACAAAATCAAACGA
ATCCACATGGATGATGACGATGGGGTCGCAGTAAATGTGTTTTGGTCCT
25 TTTTTTCGAGAGAACAGAAGCTTCTGCTCTTCATCTTCTTTAGATTTTG
GGGATTTTCTGGTTTCAGGGGTTGTGAGTGGAACTAAATTGAAGCAA
AAAGTATGGTATAATTGGTTGCTAGTGAAATTGATGCTTTCTATTACTAT
CATCTTTAAAATTGTCAAACATTATGTATTAAATTATGAGATCGAAAGT
GGTCTATGGGCCAAAGGTAATACAAGCTTACTCAATGAAATGAATCTAGG
30 ATGCATCATGCATGTATTGGTTAGATTAAAGATTTTCATCAAATTTCTT
TATCAAATTGTTGTATACCATGTTATGTAGGTGCTACCACAAGCCATAAC
ATCGAGCAATGGAGTGTATTACTGGCATCTTTAGCAACCCGTTTGCTCAG
TGTCTCATCGCTCCTGTGAAAGAACACCTTTGCCTTCTGATTTTCTATAC
ACAATATGTAGGGGATATGCTTACTGCAATGACGGAGTTGAATGCTGCAA
35 AAGACATTGTTGAAGAGCGGAAGAATCAAAACGTAGAAAAATGTTTTGAG
GTTCCAAACCATGTCAACCGTTGGTTGGAAGATGTTCAAACAATCAACAG
AAAAGTGGAACGTGTTCTTAACGATAATTGCAATTGGTTCAATCTATGTA
ATAGGTACATGCTCGCAGTGAAAGCCTTGGAGATAACTCAGGAGATCGAT
CATGCCATGAAACAACTCTCTCGGATAGAATGGACTGATGATTCAGTTCC
40 TTTGGGAAGAAATGATTCCACAAAGGCATCCACCTCTACACCATCAAGTG
ATTACAATGACTTCGAGTCAAGAGAACACACTTTTAGGAAAGCACTTGAA
GCACTTGATCCAACACACATCCACATGGTAGCCTTATGGGGGATGGG

TGGAGTTGGGAAGACCACGATGATGAAGAGGCTGAAAAATATTATTAAG
AAAAGAGGACGTTTCATTATATTGTTTTGGTGGTTATAAAGGAAAATATG
GATCTCATTTCATCCAGGATGCTGTAGCAGATTATCTGGATATGAAGCT
AACAGAAAGCAATGAATCAGAAAGAGCCGATAAACTTCGTGAAGGGTTTC
5 AGGCCAAATCAGATGGAGGTAAGAATAGGTTCCCTCATAATACTGGATGAT
GTATGGCAATCTGTTAATATGGAAGATATTGGTTTAAGTCCTTTCCGAA
TCAAGGTGTCGACTTCAAGGTCTTGTTGACCTCGGAAAACAAAGATGTTT
GTGCAAAAATGGGAGTTGAAGCTAATTTAATTTTCGACGTGAAATTCTTA
ACAGAAGAAGAAGCACAAAGTTTGTTTTATCAATTTGTAAAAGTTTCTGA
10 TACCCACCTTGATAAGATTGGAAGCTATTGTAAGAACTGTGGTGGTC
TACCCATTGCCATCAAACCATAGCCAATACTCTTAAAAATAGAAACAAG
GATGTATGGAAGGATGCACTTTCTCGTATAGAGCATCATGACATTGAGAC
AATTGCACATGTTGTTTTTCAAATGAGCTACGACAATCTCCAAAACGAAG
AAGCTCAATCCATTTTTTTGCTTTGTGGATTGTTTCCTGAAGACTTTGAT
15 ATTCCTACTGAGGAATTGGTGAGGTATGGATGGGGATTGAGAGTATTTAA
TGGAGTGTATACTATAGGAGAAGCAAGACACAGGTTGAACGCCTACATCG
AGCTGCTCAAGGATTCTAATTTATTGATTGAAAGTGATGATGTTCACTGC
ATCAAGATGCATGATTTAGTTTCGTGCTTTTGTGGTGGTACGTTTAATAG
ATTCAAGCATTCTTTGATTGTTAACCATGGTAATGGTGGTATGTTAGGGT
20 GGCCTGAAAATGATATGAGTGCCTCATCTTGCAAAAGAATTTCAATTAATA
TGCAAGGGCATGTCCGATTTTCTAGAGACGTAAAGTTTCCAAATCTCTT
GATTTTGAACTTATGCATGCAGATAAGTCTTTGAAGTTTCTCAAGACT
TTTATGGAGAAATGAAGAAGCTTCAGGTTATATCATAACGATCACATGAAG
TATCCCTTGCTTCCAACATCACCTCAATGCTCCACCAACCTTCGTGTGCT
25 TCATCTTCATCAATGCTCATTGATGTTTGATTGCTCTTCTATTGGAAATC
TGTTGAATCTGGAAGTGCTCAGCTTTGCTAATTCTGGTATTGAGTGGTTG
CCTTCCACAATCGGAAATTTGAAGGAGCTAAGGGTACTAGATTGACAAA
TTGTGATGGTCTTCGTATAGATAATGGTGTCTTAAAGAAATTGGTGAAC
TTGAAGAGCTTTATATGAGAGTTGGTGGTCGATATCAAAGGCCATTAGC
30 TTCCTGATGAAAATGCAATGAAATGGCAGAGCGTTCAAAAAATCTTTC
TGCATTAGAATTTGAGTTCTTCAAAAACAATGCTCAACCAAGAATATGT
CATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGTTATTTTAAG
GGAGATTTTCGGTAAGATCTTTCCTCTTTTGAACACGTTGCGGTTGGT
CACCAACAGAACTGAAGTTCTTGAATCTAGGCTTAATGAGTTGTTTGAGA
35 AAACAGATGTTCTTTATTTAAGTGTGGGAGATATGAATGATCTTGAAGAT
GTTGAGGTAAAGTTGGCACATCTTCCTAAATCCTCTTCTTCCACAATTT
AAGAGTCCTTATCATTCTGAGTGTATAGAGTTGAGATACCTTTTCACAC
TTGATGTTGCAACACTTTGTCAAAGCTTGAGCATCTTCAAGTTTACGAA
TGCGATAATATGGAAGAAATCATACATACAGAGGGTAGAGGAGAAGTGAC
40 AATTACATTCCCAAAGCTGAAGTTTTTATCATTGTGTGGGCTACCAAATC
TGTTGGGTTTGTGTGGTAATGTGCACATAATTAATCTACCACAACTCACA
GAGTTGAACTTAATGGCATTCCAGGTTTCACAAGCATATATCCTGAAAA
AGATGTTGAAACATCTAGTTTGTGAATAAAGAGGTAAATGTGTTTTATG

TTAATACAATACAATCTTTTCAATTAACCGTTTCAAAATATATTGTATGA
TTTATTTTTGTTTGGATGGGGTTATTAATGGGTGATTATTTCTCAGGTTG
TAATTCCTAATTTGGAGAACTTGATATTAGTTATATGAAGGATTTGAAA
GAGATATGGCCTTGTGAATTAGGGATGAGTCAGGAAGTTGATGTTTCTAC
5 GTTGAGAGTGATTAAAGTAAGCAGTTGTGATAATCTTGTGAATCTATTCC
CGTGCAATCCTATGCCATTGATACATCACCTTGAAGAGCTTCAAGTGATA
TTTTGTGGTTCCATTGAAGTGTTATTCAACATTGAGTTGGATTCTATTGG
TCAAATTGGAGAAGGCATCAACAATAGCAGCTTGAGAATCATCCAATTGC
AGAACTTAGGGAAGCTAAGTGAGGTGTGGAGGATAAAAGGTGCGGATAAC
10 TCTAGTCTTCTCATCAGTGGCTTTCAAGGTGTTGAAAGCATTATCGTTAA
CAAATGCAAGATGTTTAGAAATGTATTCACACCTACCACCACCAATTTTG
ATCTGGGGGCACTTATGGAGATTCGGATACAAGATTGTGGAGAAAAGAGG
AGAAACAACGAATTGGTAGAGAGTAGCCAAGAGCAAGAGCAGGTATGGCT
TTCAATTTTCACTTTTCTTACTTAATGAAGGATTAAGCTCCTGCTTTTTGAA
15 TAAAAAGTGGATGAATGACTAAATTCGGGAATGCCACCCGGAAAGTTATC
AACCATTAGCTACACCATTTTTTGAACATAATGTTGCAATAAATGCATAA
TATAATTAAAAATGGTCATTGATAAATGTAAACCAACCTTTTTTATTTA
TTAAAATGTCTACAATAAATGATTTTCTTTATTATATATCATTTTATAAC
AATAAGCTTAAAGATGTTTAAATAGCCAATGTCAGTTATAGATCGTAACT
20 AATTTTTTATTAAGTATTTTAGTTAAGATATCACTCATTATTATTTTAA
TAGAAAAAAGACAAGATTGGCTAATCCTCATAAGAATTTGGAAGATTTAA
GCAAAATATAGAGCTTTTCCAAACATAGCCAATAGTTTCTTTTGCAGGTC
CCATCTACGAAATTATCAATAGATTTGCGATTTTTTTTTTGGCACCCGGA
AATTTCCATTAAATTAAGGTTCAAGCCATTTTGTAGTTGGCACCTG
25 CAAAATGGTAGTTTGCACCTGCGGAAATCACCTTTCACCATTTTCGCATCT
ATG.ACTTGTGAAAATGTTAATTTGTGAAATGGTCATGTGCACCTCATGAG
AAATACGAAATGGTCAGTAATATGACTTTTTTATATAAATATGATGGTGG
CATATATTTATAGGAAAATATAGCTGCACGATATTAATTAATAGTGAAAT
TAGTTAACTGTATACGATAAGTATACAAAATTTATATGTATGAAGTATAC
30 TCAATTTAGGACGACTCGGGCAATGAAATCATCATTTAATAGGAGCAATG
AAATCATTTTTCGAAAAATGTTTACAAATGAATAAAATATTAAATTAACT
TAAACATTTTGTAGTAGTTTGAATTTACAACTGAAATTTGTTGTAT
TTATTAACATTTATAAATGTTGTACTATGATTTTTTCTTGTGTTGCAAAT
ATTCCTTAAAAATCCACCTAAAATCAAAATAATTAATCTTTTTCAAGTTG
35 AAAAATGAAAATCGTATGATATAACCGTGTATGGATGTGGAATTATATAT
CAGTTACTAATTACATTTTTTGTGTTGGGATATATGTGCGCAGATTGATATT
GCAATCCCATTCACTCTCACACACTCTTCCAAAACCTCCGTAAACTTGC
TTTGGAAAAGTATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTCCAA
CAAGTAGAGAATTGATAACAATTCACCATAATCAACAACCACTACTTCCC
40 AACCTTGAGTTATTGGATATAAGTTTATGGACAGCATGAGTCATGTATG
GAAGTGCAACTGGAATAAATCTTCATTCTTCAAAAACAACAGTCAGAAT
CCCCATTCTGTAATCTCACAACCATACATATTCAATATTGCCAAAGCATT
AAGTACTTGTGTTTCAACTCTCATGGCAAACTTCTTTCCAACCTAAAGAA

GGTCGAGGTAAGAGAGTGTTCATGGTATTGAAGAAGTTGTTTCGAACAGAG
ATGATGAAGATGAGGAAAAGACTACATTTACATCTACATCTTCTGAAAAA
AGCACTAATTTGTTCCCTCGTCTTGAATCTCTCGCTCTTTATCAACTTCC
AAATCTCAAGTGTATTGGTGGTGGTGGTCTGCCAACAGTGGGAACAATG
5 AAATATCTCTTGATAATCCACTACTACTTCTTTTGTGATCAATCT
AAGGTATGTTTTTTTTTTNGTTNCCCTT (SEQ ID NO:109)

Sequence gap

CCTCCCTAATAACATGTTATGCACACTATACTAACATATTAGACACGT
AAAGGATAAATGCTATGCCTCATATAATACGTTATATTTATAATCTTTAA
10 ACAATCAAATTTATTAAACAAATAACTAAGTGTGAGCAAAGGCAGGTACC
CGACTAAATTGCCCAAACCAGTCTGGTGGTTCGTGGAATGTTGGGCCAG
GTCGTAAAACGTCTACACACCGGTTCTTTAAATCACAGATCCGCTTCTC
ATACTGTGAACCCGGTTTTAATTTTAAAAGAAAATTTCAATTATAAAGTAA
ATGACTTAAACCATTACAAACAACAAAAATTTACCATTACAATGTTGGAC
15 TATCATTATTTGCAACATAAACTGAAAATACACATATTTCTTCTGATA
TCAGCATGAGTGGCTGGTTGGCTAACCCAAAAATCCATGCATTGTAGATG
TGTGTTACAACACATAGTATCAATGAAAGGCATATTTTAGGCTAGAATT
TAACAATCTGTAATAATATCCCTAAAATAATATCATCATCAACCAACT
AATATAAAACCATTGGGTTCGTCAATTTTAGGTACAAAACATAGATTTTTC
20 TAAGCTTGTGTATTTAAACATATGCTTTCTAACTTAATTGATTTTGCA
TTCCAAAATTTTAGGTTGTAAAGTGGTATGTCATTTGTTGTCTTTTCAAC
ATTAAATTGTACAAAACCAAACTACATAATTGATGTAGATATCATAACA
ATTGTGTTATTTAGTATATAAACTAAATTTGAATTGAATTTCTTATA
CAAAAGTTGTGTCTATGTATACATGTTTATGTAGGTAATAGACAATTAGT
25 CTCTGTTAAGTATATGGAGTTTAATTTTAGACTAATTTTCATGTGTTG
CAGTTTTATCAGGCAGGTGGCGTTTTTTGGACGTTATGCCAATACTCCAG
AGAGATAAATATAAGGGAGTGTTATGCATTGTCAAGTGTAATTCCATGTT
ATGCAGCAGGACAGATGCAAAATGTTCAAGTGCTGAATATATACAGGTGC
AACTCAATGAAGGAGTTATTTGAACTCAAGGGATGAACAACAACATGG
30 TGACAGTGGTTGTGATGAAGGAAATGGTTGTATACCAGCAATTCCAAGAC
TAAATAACGTTATTATGCTACCCAATCTAAAGATATTGAAGATTGAAGAT
TGTGGTCATCTGGAACATGTATTACATTCTCTGCACTTGGAAGCCTGAG
ACAGCTCGAAGAGTTAACGATAGAGAAATGCAAGGCAATGAAAGTGATAG
TGAAGGAAGAAGATGAATATGGAGAGCAAACAACAAGGCATCTTCGAAG
35 GAGGTTGTGGTCTTTCCTCGTCTCAAGTCCATTGAACTGGAAAATCTACA
AGAGCTCATGGGTTTCTACTTAGGGAAGAATGAGATTCAGTGGCCTTCAT
TGGATAAGGTTATGATCAAGAATTGCCCGAGAAATGATGGTGTGTTGCACCT
GGTGAGTCCACAGTTCCTCAAGCGCAAGTATATAAATACAAGCTTTGGCAT
ATATGGGATGGAGGAGGTACTTGAACTCAAGGGATGAACAACAATAATG
40 ATGACAATTGTTGTGATGATGGAAATGGTGGAAATCCAAGACTAAATAAC
GTTATTATGTTTCAAATATAAAGATATTGCAAATCAGCAATTGTGGCAG
TTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGATGCAGCTCA
AAGAGTTAACAATAGCGGATTGCAAGGCAATGAAAGTGATTGTGAAGGAG

GAATATGATGTAGAGCAAACAAGGGTATTGAAGGCTGTGGTATTTTCTTG
TCTAAAGTCCATTACACTATGCCATCTACCAGAGTTGGTGGGTTTCTTCT
TGGGGAAGAATGAGTTCTGGTGGCCTTCATTGGATAAGGTTACCATCATT
GATTGCCCACAAATGATGGGGTTCACACCTGGTGGGTCAACAACTTCCCA
5 CCTCAAGTACATACACTCAAGCTTAGGCAAACATACTCTTGAATGTGGCC
TTAATTTCAAGTCACAACTACTGCATATCATCAGGTATAATTATTATTCT
TTNACACCATCTAATTATGGAATCATGACGCTAATTACAGTATTAAACAC
(SEQ ID NO:110)

10 **RG2K deduced polypeptide sequence (SEQ ID NO:111)**

MECITGIFSNPFAQCLIAPVKEHLCLLIFYTQYVGDMLTAMTELNAKDIVEERK
NQNVKEKCFEVPNHVNRWLEDVQTINRKVERVLNDNCNWFNLCNRYMLAVKAL
EITQEIDHAMKQLSRIEWTDDSVPLGRNDSTKASTSTPSSDYNDFESREHTFRKAL
EALGSNHTSHMVALWGMGGVGKTTMMKRLKNIIEKRTFHYIVLVVIKENMDL
15 ISIQDAVADYLDMLKTESNESERADKLREGFQAKSDGGKNRFLIILDDVWQSVN
MEDIGLSPFPNQGVDFKVLLTSENKDVCAKMGVEANLIFDVKFLTEEEAQSIFY
QFVKVSDTHLDKIGKAIVRNCGGPLIAIKTIANLTKNRNKDVWKDALSRIEHHD
IETIAHVVFQMSYDNLQNEEAQSIFLLCGLFPEDFDIPTTEELVRYGWGLRVFNGV
YTIGEARHRLNAYIELLKDSNLLIESDDVHCIMHDLVRAFVLDTFNRFKHSLIV
20 NHGNGGMLGWPENDMSASSCKRISLICKGMSDFPRDVKFPNLLILKLMHADKS
LKFPQDFYGEKMLQVISYDHMKYPLLPTSPQCSTNLRVLHLHQCSLMFDCSSI
GNLLNLEVLFSFANGIEWLPSTIGNLKELRVLDLTNCDGLRIDNGVLKKLVKLEELY
MRVGGRYQKAISFTDENCNEMAERSKNLSALEFEFFKNNAPKNMSFENLERFKIS
VGCYFKGDFGKIFHSFENTLRLVTNRTEVLESRLNELFEKTDVLYLSVGDMNDLED
25 VEVKLAHLPKSSSFHNLRLVLIIECEIERYLFTLDVANTLSKLEHLQVYECNMEIEI
HTEGRGEVTITFPKLKFLSLCGLPNLLGLCGNVHIINLPQLTELKLNIGIPGFTSIYPEK
DVETSSLLNKEVVIPNLEKLDISYMKDLKEIWPCELGMSQEVVDVSTLRVIKVSSCDN
LVNLFPCNPMPLIHHLEELQVIFCGSIEVLFNIELDSIGQIGEGINSSLRHQLQNLGK
LSEVWRIKGADNSSLLISGFQGVESIIVNKCKMFRNVFTPTTTNFDLGALMEIRIQDC
30 GEKRRNNELVESSQEQEQ

RG2L polynucleotide sequence (SEQ ID NO:112)

GGAAGACACAATGATGCAAAGACTGAAGAAGGTTGCCAAAGAAAATAGAA
TGTTTCAGTTACATGGTCGAGGCAGTTATAGGGGAAAAGACAGACCCAATT
35 GCTATTCAACAAGCTGTAGCCGATTACCTTCGTATACAGTTCAAAGAAAG
CACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCCACT
CTGNAGACGGTAAGAATAAGTTCCTCGTAATATTTGATGACGTCTGGCAG
TCCGTTGATCTGGAAGATATTGGNTTAAGTCCTTTTCCAAATCAAGGTGT
CGACTTCAAGGTCTTGTTGACTTCACGAGACGAACACGTTTGACAATGA
40 TGGGGGTTGAAGCTAATTCAGTTATTAATGTGGGACTTCTAACTGAAGTA
GAAGCACAAAGTCTGTTCCAGCAATTTGTAGAACTTTTGAGCCCGAGCT
CTGTAAGATAGGAGAAGTTATCGTAAGAAAGTGTGCGGTCTACCTATTG

CCATCAAACCATGGCGTGTA CTCTAAGAAATAAAAGAAAGGATGCATGG
AAGGATGCACTTTCACGTATAGAGCACTATGACATTCGTAGTGTTGCGCC
TAAAGTCTTTGAAACAAGCTATCACAATCTCCAAGACAGGGAGACTAAAT
CCGTGTTTTTGTATGTGTGGTTTGTTCCTGAAGACTTCAATATTCCTACC
5 GAGGAGTTGATGAGGTATGGATGGGGCTTAAAGCTATTTGACAGAGTTTA
TACAATTAGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTTG
TGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATG
CATGATCTGGTGCCTGCTTTTGTTCCTGAAGTTCGAGCA
TGCTTCAATTGTCAACCATGGTAATATGCATGGGTGGACTAAAAATGATA
10 TGAACGACTCTTGCAAAACAGTTTCTTTAACATGCGAGAGTGTTCTGAG
TTTCCAGGAGACCTCAAGTTTCCAAACCTAAAGCTTTTGAACTTATGCA
TGGAGATAAGATGCTAAGGTTTTCTCAAGACTTTTATGAAGGAATGGAAA
AGCTCCAGGTAATATCATACCATAAAATGAAGTATCCATTGCTTCCCTCG
TCACCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTTCATCGGTGTTT
15 ATTACGGATGCTTGATTGCTCTTGATCGGAAATTTGACGAATCTGGAAG
TGTTGAGCTTCGCTAATTCTGGCATTGAACGGATACCTTCAGCAATCGGA
AATTTGAAGAAGCTTAGGCAACTTGATCTGAGAGGTCGTTATGGTCTTTG
TATAGAACAGGGTGTCTTGAAAAATTTGGTCGAACTTGAAGAACTTTATA
TTGGAAATGCATCTGCGTTTAGAGATTATAACTGCAATGAGATGGCAG
20

RG2L deduced polypeptide sequence (SEQ ID NO:113)

EDTMMQRLKKVAKENRMFSYMVEAVIGEKTDPPIAQQAVADYLRIQFKESTKPAR
ADKLREWFKAHS?DGKNKFLVIFDDVWQSVLDLEDIGLSPFPNQGVDFKVLLTSRDE
HVCTMMMGVEANSVINVGLL TEVEAQSLFQQFVETFEPELCKIGEIVVRKCCGLPIAI
25 KTMACTLRNKRKDAWKDALSRIEHYDIRSVAPKVFETSYHNLQDRETKSVFLMCG
LFPEDFNIPTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQTNLLIESDDVGC
VKMHDLVRAFVLGMYSEVEHASIVNHGNMHGWTKNMNDSCKT VSLTCEVSVEF
PGDLKFPNLKLLKLMHGDKMLRFSQDFYEGMEKLQVISYHKMKYPLLSPSPQCST
NLRVLHLHRCSLRMLDCSCIGNLTNLEVLSFANS GIERIPSAIGNLKKLRQLDLRGR
30 YGLCIEQGV LKNLVELEELYIGNASAFRDYCNEMA

RG2M polynucleotide sequence (SEQ ID NO:114)

GGGGAAGACACAATAGATGCAAAGGCTGAAGAAGTTGCCAAAGAAAAGAG
AATGTTTCAGTTATATCATTGAGGCGGTTATAGGGGAAAAGACAGACCCCA
35 TTTCCATT CAGGAAGCTATATCATATTACCTTGGTGTAGAGCTCAATGCA
AATACTAAGTCAGTAAGAGCTGATATGCTTCGTCAAGGGTTCAAGGCCAA
ATCTGATGTAGGTAAGGATAAATTCTTAATAATACTCGACGATGTATGGC
AGTCTGTTGATTGGAAGATATTGGATTAAGTCCATTTCCAAATCAAGGT
GTTAACTTCAAGGTCCTGTAAACATCACGAGACCGACATATTTGCACTGT
40 GATGGGGGTTGAAGGTCATTCGATTTTAAATGTGGGACTTCTCACAGAAG
CAGAATCAAAAAGATTGTTCTGGCAGTTTGTAGAAGGTTCTGATCCTGAG
CTCCATAAGATAGGAGAAGATATTGTAAGTAAGTGTTGTGGTCTACCCAT

TGCCATTAAAACCATGGCATGTACACTTAGAGATAAAAGTACGGATGCAT
GGAAGGATGCACTGTCTCGTTTAGAGCATCATGACATTGAAAATGTTGCC
TCTAAAGTTTTTAGAGCGAGCTATGACCATCTCCAAGACGAGGAGACTAA
ATCCACTTTTTTCTATGTGGATTGTTTCCAGAAGATTCCAATATTCCTA
5 TGGAGGAGTTGGTGAGGTATGGGTGGGGATTGAAATTATTTAAAAAAGTG
TATACCATAAGAGAAGCAAGAACTAGGCTCAACACTTGCAATTGAGCGGCT
CATCTATACCAATTTGTTGATAAAAGTTGATGATGTTTCAGTGCATCAAGA
TGCATGATCTCATCCGTTCTTTTGTGTTTGGATATGTTTTCTAAAGTTGAG
CATGCTTCGATTGTCAACCATGGTAATACGCTAGAGTGGCCTGCAGATNA
10 TNTGCACGACTCTTGTAAGGGCTTTCATTAACATGCAAGGGTANATGTG
AGTTTTGTGGAGACCTNAANTTTCCAACCCTAATGATTTTAAACTTATG
CATGGAGATAAATCGCTAAGGTTT

RG2M deduced polypeptide sequence (SEQ ID NO:115)

15 GEDTIDAKAEVAKERMFYSYIEAVIGEKTDPISIQEASYYLGVELNANTKSVRAD
MLRQGFKAQSDVGKDKFLIILDDVWQSVLEDIGLSPFPNQGVNFKVLLTSRDRHI
CTVMGVEGHSIFNVGLLTEAESKRLFWQFVEGSDPELHKIGEDIVSKCCGLPIAKT
MACTLRDKSTDAWKDALSRLEHHDNIENVASKVFRASYDHLQDEETKSTFFLCGLFP
EDSNIPMEELVRYGWGLKLFKKVYTIREARLNTCIERLIYTNLLIKVDDVQCIKM
20 HDLIRSFVLDMFSKVEHASIVNHGNTLEWPA?HDSCKGLSLTCKG?CEFCGDL?F
PTLMILKLMHGDKSLRF

RG2N polynucleotide sequence (SEQ ID NO:116)

AGGTAAAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCG
25 TGTTTTGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGG
TATATGACATATTTATAGTTACTGATAACAAATTATGATAATTTGGGTT
TACRTAAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGT
CTATCTATGATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAAT
TCG.AAAAGTCTTTTAAATAATTTTTCTGTTTATAATTTATGAATAGTTT
30 TAGCGACATCTAATATTAATAAGAATGTATCTGATATTGAATTAATGTCC
TTAATGTGAACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTT
CTAATCAATAAATTTTAATTTCTGTTTTATGCTTCTAAGACAATAAAAAAT
CCATGATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAA
ATTAGGATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGAT
35 GCTTTTGCTTTTCCCTCTTTTCCTTGTTAGTCTATTATTCTGGAGAGTTT
GAGAGAGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTA
TTCTCTTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTTACACGATCC
ATGGTTTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGC
CCTTGATGATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAG
40 TGGTGAATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATG
ATGATGAGATAGAGATATGTTAAACTGGCTAGAAAATTGTTTTAATTTG
AAATTTAGGTKGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTT

ATGCTAAWTAGTTATAAAGAACAACAACTCTTAGTTTTTTTTTCATGA
TTTTCAACCTCTTTGTACCAAATAAATTATAGCAAAATTGAATATCATT
CTCTGCAATCAATCTTAACCTTTTGTATTATCATCATGTCTAAAATTGCC
ACAAGTTTATTTTCAAAGTCATATTGGATTATGAAAGGACTATTTTACC
5 AATTACATCTTTACTTTATGGGCCAAAGCTAATACAATCCGACTAAACTA
AAGGAATATGGGATGCATATAGTTTGCTTCCCGATTATAGATTTCTATCT
AATTTGTCTATTGTACTAATTTAGGTGCCACCACAAGTAAATTTGTTAAA
TGGATATCGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTA
CCCGTTAAGAAACACATAGGGTACCTCATTTCTGCAGGCAATATATGAG
10 GGAAATGGGTATCAAAATGAGGGGATTGAATGCTACTAGACTTGGTGTCTG
AAGAGCATGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAA
GGCAGGGGTTGGTATGAAGAAGTAGGAAAGATCAATGCAAAAGTGAAAAA
TTTTCTAGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGG
TCGGAAAGAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTCTATGAGA
15 GAACACTCTATCATCATCTGGAATGATCATTCCATTCTTCTAGGAAGAAT
TGATTCCACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATG
AGTTCCAGTCAAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGAT
CCTAACCACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGG
GAAGACGACAATGATGCATCGGCTGAAAAAGGTTGTGAAAGAAAAAGAAA
20 TGTTTAATTTTATTGTTGAGGCGGTTGTAGGGGAAAAAACAGACCCCAT
GCTATTCAATCAGCTGTGGCAGATTACCTAGGTATAGAGCTCAATGAAAA
AACTAAACCAGCAAGAAGCTGAGAAGCTTCGTAAATGGTTTGTGGACAATT
CTGCTGGTAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGT
GATCTGAATGATATTGGTTTAAAGTCCTTTACCAAATCAAGGTGTGCACTT
25 CAAGGTGTTGTTGACATCACGAGACAAAGATGTTTGCACTGAGATGGGAG
CTGAAGTTAATTCAACTTTTAAATGTGAAAATGTTAATAGAAACAGAAGCA
CAAAGTTTATTCCACCAATTTGTAGAAATTTCCGATGATGTTGATCGTGA
GCTCCATAATATAGGAGTGAATATTGTAAGGAAGTGTGGCGGTCTACCCA
TTGTCATCAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCA
30 TGAAGAATGCACTTCTTCGTTTAGTGAACACTACAACATTGAAAATATAGT
GAATGGAGTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTA
AATCCACCTTTTGTCTTTGTGGAATGTTTCCCGAAGACTTTAATATTCT
ACCGAGGAGTTGGTGAGGTATGGATGGGGGTTGAAATTATTTAAAAAGT
GTATACTATAGGAGAAGCAAGAATCAGGCTCAACACATGCATTGAGCGGC
35 TCATTCATACAAATTTGTTGATTGAAGTTGATGATGTTAGGTGCATCAAG
ATGCATGATCTTGTCCGTGCTTTTGTGTTGGATATGTATTCTAAAGTCGA
GCATGCTTCCATTGTCAACCATGGTAATACACTAGAGTGGCATGTGGATA
ATATGCACAACTCTTGTAAGAACTTTTCAATTAACATGCAAGGGTATGTCT
AAGTTTCTACAGACCTCAAGTTTCCAAACCTCTCGATTTGAACTTAT
40 GCATGAAGATATATCATTGAGGTTTCCCAAAACTTTTATGAAGAAATGG
AGAAGCTTGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCC
TCATCACCGCAATGCTCCGTCAACCTTTGCGTGTTTCATCTCCATAAATG
CTCGTTAGTGATGTTTGACTGCTCTTGTATTGGAAATCTGTCTGAATCTAG

AAGTGCTTAGCTTTGCTGATTCTGCCATTGACCTGTTGCCTTCCACAATC
GGAATTTTGAAGAAGCTAAGGCTACTGGATTGACAAATTGTTATGGTCT
TTGTATAGCTAATGGTGTCTTTAAAAAATTGGTCAAACCTGAAGAGCTCT
ATATGACAGTGGTTAATGGAGGAGTTCGAAAGGCGATCAGCCTCACTGAG
5 GATAACTGCAATGAGATGGCAGAACGTTCAAAAGACCTTTCTGCATTAGA
ACTTGAGTTCTTTGAAAACAATGCTCAGCCAAAGAATATGTCATTTGAGA
AGCTACAACGATTCCAGATCTCAGTGGGGTGCTATTTATATGGAGCTTCC
ATAAAGAGCAGGCACTCGTATGAAAACACATTGAAGTTGGTTATTGACAA
AGGTGAATTATTTGAATCTTGAATGAACGGCCTGTTTAAGAAAACAGAGG
10 TGTTATGTTTAAGTGTGGGAGATATGAATGATCTTGAAGATRTTGAGGTT
AAGTCATCCTCACAACYTCTTCAATCTTCTTCGTTCAACAATTTAAGAGT
CCTTGTCGTTTCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTG
TTGCAAACACTTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGAT
AATATGGAAGAACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTAC
15 ATCCCCCAAGCTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGG
GTTTGTGCGATAATGTCAAAATAATTGAGCTACCACAACCTCATGGAGTTG
GAACTTGACGACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTT
TGAAACATTTAGTTTGTGAAGGAAGAGGTAATATAAATTTTTAATGCT
AATACATTACAAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAA
20 TTTGATTGTATGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTA
TCTTGCAAGTTCTGATTCTTAAGTTAGAGAACTGCATGTTAGTAGTATG
TGGAATCTGAAGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGT
TAAGTTCAAGAGAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGT
TTCCGCACAAGCCCATATCTCTGCTGCGTCATCTTGAAGAGCTTAAAGTC
25 AAGAATTGTGGTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGC
TGGTGCAACTGGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAG
TGATCAGTTGTGATAAGCTTGTGAATCTCTTTCCACACAATCCCATGTCT
ATACTGCATCATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGA
ATCGTTATTCAACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAG
30 ACAACAGAAGCAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTA
AGAGAGGTGTGGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTCA
TGGCTTTCAATCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAGGTTTA
GAAATGTATTACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTG
GAGATTTCAATAGATGACTGCGGAGAAAACAGGGAAAATGACGAATCGGA
35 AGAGAGTAGCCATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTTTCKT
ACTTAATTAATGATTAAGCTCCTGCTTTTTRAATAAAAAAGGGACAAACC
ATTTTCATGACTTAATGTAGCAATACAAGTCATGTATAAGAGTGACCAACT
CTTTTTTATTTATAAAATGACTACAAAATATTTTTTTTCATTAGAGATCA
TGTATAAATGTGACTAATTTTTCATCACCTAACTTTAGTTGATAAATCTT
40 TATAAATGTCACTAGTTACTTTTCAGTAAAATAACAAATTTAATAAATTA
TCAACAAAAAGCATCAACTAAAAAATCCCACAACCCGTAATAATTTAAA
ATAAAAAGGATTTAACATCTAATACGAACAATTTTTTTTCTAAACATGATT
TGGACCAAATATCACCAGCAACTCAAGTTTGAATCGATTCAGCTTAAAA

CTTGACCARCATAATTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATAT
AAGTTCGTTTCATCTTTTTTCTTGATCTTGATAGCAAGTTGAATSATTTT
CTTCTTCAAAATTGATAAAAAATCTACATTATAAAGAGACTAGCTTGAAAA
AAAATGGTCTAGGTGGGTCTTGGGTCTGGTAGATGAAGATGGAAGGGAGA
5 GTAGATTTCAAAGACACAAACACATCTTCATTTTATTTATTTATTTATTA
TTATTATTTTTTGATATCTTGCTCATATTTGTTACAGATATGTGAGGTCT
ATTAATCTTTTTAAATATATAAAAAATAAATACATAAATGAGAAAAATTA
ATAAAGAATAAATTAATAAGGGCACAATAGTCTTTTTTGGTAAGACAAGG
ACCAAAAGCGCAACAAAAGTAAACAGTAGGGACCATCCGATTTAAAAAAT
10 TAATTAGGGACCAAAAACATAAATTCCCCCAAACCATAGGGACCATTCTGT
GTAATTTACTCTTGCTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTT
TTGTACATATCTAGGTAACGAACTTGTTGAAAGTGTTACATCTACGATG
TGACCTACTACAACCGATCATAATGGTCATATATGAACACTTCCAACAAG
TTTGTTATCTAGGTGTGTACAAAAAACGATAGTTACCATGATGTGAACA
15 TACCAAAAAATTAATTACCTTAGCAAGTTATTTTCCCATTTAGGTTGTAT
GGAAACAGTTCCGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAA
CTTAACCCTTCAATTAACCTACCTTTTTCTTATTAACTCAATTTCAAGCT
AAATTCTGATTCTTGTTTGAAAGTAAGTTGCATCTTTATGTTTGTATTAT
CTTGTTGCATAGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAA
20 AGATCCAACATATTTTAATCTGTTGGCATTTCATCATTTGCAACTGTT
TCTTGAAAAAAA::TACCTAAAATCAAATAACCATTTTCATATCCAAAA
TTATAAGAGAGAATTGTTAACGGACATGGAATCATAAATCATTAAACACAG
TTCAGTACACAGGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTC
TATCAGAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATATT
25 GTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAAACTTAA
CTTGAACAGAGTTGAAGGAGTGGAGGTGGTGTGAGATAGAGAGTGAGA
GTCCAACAAGTAGAGAATTGGTAACAACCTACCATAACCAACAACAACCT
ATTATACTTCCCAACCTCCAGGAATTGATTCTATGGAATATGGACAACAT
GAGTCATGTGTGGAAGTGCGGCAACTGGAATAAATTCTTCACTCTTCCAA
30 AAGAACAATCAGAATCCCCATTCCACAACCTCAGTAACATACATATTTAT
GAATGCAAAAGCATTAAGTACTTGTTTCACCTCTCATGGCAGAACTTCT
TTCCAACCTAAAGCATATCGAGATAAGAGAGTGTGATGGTATTGAAGAAG
TTGTTTCAAAAAGAGATGGTGAGGATGAAGACATGACTACATCTAC:::
:::GCACACAACCACCACTTTTTCCCTCATCTTGATTCTCTCACTCTAAA
35 GCAACTGAAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGG
GGAGCAATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTT
GATCAATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCC
TTGTTAATTTCTTTTTTCTTTGCAATATTCTATGAAAAAATCACCAAA
TCACAAATAAGAGATTTAAACTTTTATTTACACCCATGCGGACTCAAGA
40 ATGGGATTTGGAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCA
TTT.ATTTGTTATTTATCATTTTCATATCATTTACTGATAACATTTCTTTT
TTACTTTTCTAATTAGAAAAGGTCCACATGTCTAATTAGGTTTTCCATTC
TATGTGAATCCTCTATTCTGTCTGTAATCAAGCATCTTAGATTATTTATC

CATTTTCATAATTGTGTTTATATTGACAGTTTTTTTCTTTTATAGTTGT
AATTGCAACCTGTCATATWTTMWWKCKWWATKYWMWWARTAATACATTT
TATACCCWCTATACTAAGATA

5 **RG2N deduced polypeptide sequence (SEQ ID NO:117)**

LGKTTMMHRLKKVVKEKKMFNFIVEAVVGEKTDPIAIQSAVADYLGIELNEKTKPA
RTEKLRKWFVDNSAGKKILVILDDVWQFVDLNDIGLSPLNQGVDFKVLLTSRDKD
VCTEMGAENVSTFNVKMLIETEAQSLFHQFVEISDDVDRELHNIGVNIVRKCGGLPI
VIKTMACTLRGKSKDAWKNAALLRLVNYNIENIVNGVFKMSYDNLQDEETKSTFLL
10 CGMFPEDFNIPTEELVRYGWGLKLFKKVYTIGEARIRLNTCIERLIHTNLLIEVDDVR
CIKMHDLVRAFVLDMYSKVEHASIVNHGNTLEWHVDNMHNSCKRSLTCKGMSK
FPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKYPLLPSSPQCSVNL
CVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDLLPSTIGILKKLRLDLTNCYGL
CIANGVFKKLVKLEELYMTVVNGGVRKAISL

15

RG2O polynucleotide sequence (SEQ ID NO:118)

TTGTAAAACGACGGCCAGTCGAATCGTAACCGTTCGTACGAGAATCGCTG
TCCTCTCCTTCATTTGAATCATGATATTTGAATATCGATACTTTTGACTG
TAGCTTTTGGGTCGATTTTTTAGCAAGATACATAACTGGCCAAACCCATT
20 GGCTATTTTAGCCCAAATATGAAATGGACTGGATTGTTTTTTCCTTTC
TAACACGCACACATCTGGCGATCAGTATCACTCCATTATGAAGACCTAGT
CAAATTCATTAACGTTCAAGTCGTTCTTCAAAGTTTCAAAGTTCCAATT
CCAATTCCCTCTTTTTTTTTCTTTCCTCGATTCTGATTGGAATCCGAT
TCTGCGACGAAGGAGAGCTTGGTCAGAGGGCTGTGATTCTTGAGTCTTGA
25 CCTCCGAATCTAGCTGGATTATTTTCGACACACCAGACCACGTATCAGGT
TGCTCATCCCGAAATACTGCTTTGCAAAGTGTGTATCATCGCCTAGGAA
ATTAAAGTTTCTTTTTTGGCTCTGTTACTGAATCAGTAGCTTTGCAACTTG
CTCATTATAAGCTGATCCATATTTTACATATCTTTTGAAGAATAATAGGT
ACTGACTTTACCTTTCTGATGAGAGCGATTTAAGAGATACCTCTGTAAAA
30 TCCATTTTTGTGAAGGGATCTGGGTAGTTTTTAAAGGATTTGCTACAAC
AGTATCCCAACAAACGATCTATTTCCCATTTNACTCATCCGCTCAAGATCT
ATCCACCTTTATATATGTTAATTGGGAGTCTTCCATGGTGCAATGAATCT
AGGATGCATTTAGAAGCCCAATCCATTACAAGTTTTATCCAATTTTCATG
TGACAAGTTGTTGGTTACTATGTAGGTACTTCCACAATTAAGAATTTCCA
35 GCAATGGATGTTGTTAATGCCATTCTTAAACCAGTTGCCGAGACACTTAT
GGAACCTGTTAAGAAACATCTAGGCTACATCATTTCAGCACAAAACATG
TGAGGGATATGAGTAACAAAATGAGGGAGTTGAACGCTGCAAGACATGCT
GAAGAAGACCACTTGGACAGGAACATAAGAACTCGTCTTGAGATTTCAAA
TCAAGTTAGGAGTTGGTTAGAAGAAGTAGAAAAGATCGATGCAAAAGTAA
40 AAGCCCTTCCTAGTGATGTCACCGCTTGTTGCAGTCTCAAGATCAAACAT
GAAGTCGGAAGGGAAGCCTTGAAGCTAATTGTGGAGATTGAAAGTGCCAC
AAGACAACACTCTTTGATCACCTGGACTGATCATCCCATTCCTCTGGGAA

AAGTTGATTCCATGAAGGCATCGATGTCCACAGCATCAACCGATTACAAT
GACTTTCAGTCAAGAGAAAAAACTTTTACTCAAGCATTGAAAGCACTTGA
ACCAAACAACGCTTCCCACATGATAGCGTTATGTGGGATGGGTGGAGTGG
GGAAGACCACAATGATGCAAAGACTAAAAAAAGTTGCTAAACAAAATAGA
5 ATGTTTCAGTTATATGGTTGAGGCAGTTATAGGGGAAAAGACGGACCCAAT
TGCTATTCAACAAGCTGTAGCGGATTACCTTCGTATAGAGTTAAAAAGAA
GCACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCAAC
TCTGGAGAAGGTAAGAATAAATTCCTTGTAATACTTGATGACGTCTGGCA
GTCTGTTGATCTAGAAGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGTG
10 TCGACTTCAAGGTCTTATTGACTTCACGAGACGAACATGTTTGCACAGTA
ATGGGAGTTGGATCTAATTCAATTCTTAATGTGGGACTTCTAATAGAAGC
AGAAGCACAAAGTTTGTTCACAATTTGTAGAACTTCTGAGCCCGAGC
TCCATAAGATAGGAGAAGATATTGTAAGGAAGTGTGCGGTCTACCTATT
GCCATCAAAACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCTTG
15 GAAGGATGCACTTTCGCGTATAGAGCACTATGACCTTCGCAATGTTGCGC
CTAAAGTCTTTGAAACGAGCTACCACAATCTCCATGACAAAGAGACTAAA
TCAGTGTTTTTGATGTGTGGTTTGTTCGGAAGACTTCAATATTCCTAC
TGAGGAGTTGATGAGGTATGGATGGGGATTAAAGATATTTGATAGAGTCT
ATACATTTATAGAAGCAAGAAACAGGATCAACACCTGCATTGAGCGACTG
20 GTGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGAT
GCATGATCTGGTCCGTGCTTTTGTTTTAGGTATGTATTCTGAAGTAGAGC
ATGCTTCAGTTGTCAACCATGGTAATATACCTGGATGGACTGAAAATGAT
CCGACTGACTCTTGTAAGCAATTCATTAAACATGCGAGAGTATGTCTGG
AAACATTCCAGGAGACTTCAAGTTTCCAAACCTAACGATTTTGAACTTA
25 TGCATGGAGATAAGTCGCTAAGATTTCCACAAGACTTTTATGAAGGAATG
GAAAAGCTCCAGGTTATATCATACGATAAAATGAAGTATCCAATGCTTCC
CTTGTCTCCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCAATTAAGATGTTTGATTGCTCTTGTATTGGAAATATGGCGAATGTG
GAAGTGTTGAGCTTTGCTAATTCTGGCATTGAAATGTTACCTTCCACTAT
30 CGGAAATTTAAAGAAGCTAAGGTTACTTGATTTAACAGATTGTCATGGTC
TTCATATAACACACGGTGTCTTTAACAATTTGGTCAAACCTGAAGAGTTG
TATATGGGATTTTCTGATCGACCTGATCAAACCTCGTGGTAATATTAGCAT
GACAGATGTCAGCTACAATGAATTAGCAGAACGTTCAAAAGGCCTTTCTG
CATTAGAGTTCCAGTTCTTTGAAAACAATGCCCAACCAAATAATATGTCG
35 TTTGGGAAACTTAAACGATTCAAGATCTCAATGGGATGCACTTTATATGG
AGGATCAGATTACTTTAAGAAAACGTATGCTGTCCAAAACACATTGAAGT
TGGTTACTAACAAAGGTGAACCTATTGGACTCTAGAATGAACGAGTTGTTT
GTTGAAACAGAAATGCTTTGTTTAAAGTGTTGATGATATGAATGATCTTGG
TGATGTTTGTGTGAAGTCCTCACGTTCTCCTCAACCTTCTGTGTTCAAAA
40 TTCTAAGAGTCTTTGTCTGTTTCCAAGTGTTGAGTTGAGATACCTTTTC
ACAATTGGTGTAGCCAAGGATTTGTCAAATCTTGAGCATCTTGAAGTTGA
TTCATGTAATAATATGGAACAACTCATATGTATTGAGAATGCTGGAAAAG
AGACAATTACATTCCTAAAGCTGAAGATTTTATCTTTGAGTGGGCTACCA

AAGCTTTTCGGGTTTGTGCCAAAATGTCAACAACTTGAGCTACCACAACT
CATAGAGTTGAAACTTAAGGGCATTCCAGGGTTCACATGCATTTATCCGC
AAAACAAGTTGGAACATCTAGTTTGTGAAGGAAGAGGTAGATATATGT
5 TATATCTATATGTCTATAATTTGATTATATGATGTATTAGTGTGGATG
TGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGA
CACTTCAAATTGATGAGATGGAGAATTTAAAGGAAATATGGCATTATAAA
GTTAGTAATGGTGAGAGAGTTAAGTTGAGAAAGATTGAAGTGAGTAACTG
TGATAAGCTTGTGAATCTATTTCCACACAACCCCATGTCTCTGCTGCATC
10 ATCTTGAAGAGCTTGAAGTCAAGAAATGTGGTTCCATTGAATCGTTATTC
AACATCGACTTGGATTGTGTTGATGCCATAGGAGAAGAAGACAACATGAG
GAGCTTAAGAAACATTAAAGTGAAGAATTCATGGAAGTTAAGAGAAGTGT
GGTGTATAAAAGGTGAAAATAACTCTTGCCCCCTTGTTTCTGGCTTTCAA
GCTGTTGAAAGCATAAGCATTGAAAGTTGTAAGAGGTTTAGAAATGTATT
15 CACACCTACCACCACCAATTTTAATATGGGGGCACTTTGGAGATATCAA
TAGATGACTGTGGAGAATACATGGAAAATGAAAATCGGAAAAGAGTAGC
CAAGAGCAAGAGCAGGTATGGATTTCATTTCACTTTCTTACTTACTTAA
GGATTAAGCTTCTGTTTTTTGAATAAAAAAGGGACATCTTCTAATAATG
CACATCTTAAATTA AAAAGTATTTAATTGTTGCATAGCAGCGTATAACAT
20 CTTCTAATAATTTATCTGAAGGTGAAAGATCCAATACTTCTAATTTGTT
AAC.AATTTCAATCATTGTGCAATGTTCTTAAAAAATTAATTACCTGAAA
TCAAAACAATCTTCTTCAAATCCAAAATTATGAGACAGAATTGAGAAGGG
ATGTGAAATTATAAACCATTAAACAATTCCATGCTCACGTTACTAATTA
CATTTCTTGTTGGGATATATATGTACAGACTGATATTTTGTGAGAGGAAG
25 TGA.AATTACAAGAAGTCACTGATACTATTTCTAATGTTGTATTACATCG
TGTCTCATACACTCTTTTATAACAACCTCCGTAAACTCAACTTGGAGAA
GTATGGAGGAGTTGAGGTTGTGTTTGAGATAGAGAGTTCAACAAGTAGAG
AATTGGTAACAACATACCATAAACAACAACAACAACAACCTATATTT
CCC.AACCTTGAGGAATTATATCTATATTATATGGACAACATGAGTCATGT
30 ATGGAAGTGCAACAACTGGAATAAATTTTACAACAATCAGAATCCCCAT
TCC.ACAACCTCACAACCATAACATGTCCGATTGCAAAAGCATTAAAGTAC
TTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGAGAATCAA
TATTGACGAGTGTGATGGTATTGAAGAAATTGTTTCAAAAAGAGATGATG
TGG.ATGAAGAA

35

RG2O deduced polypeptide sequence (SEQ ID NO:119)

MDVVNAILKPVAETLMEPVKKHLGYIISSTKHVRDMSNKMRELNAARHAEEDHLD
RNIRTRLEISNQVRSWLEEVKIDAKVKALPSDVTACCSLKIKHEVGREALKLIVEIE
SATRQHS�ITWTDHPIPLGKVDSMKASMSTASTDYNDFQSREKFTTQALKALEPNN
40 ASHMIALCGMGGVGKTTMMQRLKKVAKQNRMFSYMVEAVIGEKTDPJAIQQA
VADYLRIELKESTKPARADKLREWFKANSGEKKNKFLVILDDVWQSVLDLEDIGLSPFP
NQGVDFKVLTSRDEHVCTVMGVGSNSILNVGLLIEAEAQSLFQQFVETSEPELHKI

GEDIVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDLRNVAPKVFETSYHN
LHDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKIFDRVYTFIEARNRINTCIERL
VQTNLLIESDDVGCVKMHDLVRAFVLGMYSEVEHASVVNHGNIPGWTENDPTDSC
KAISLTCEMSGNIPGDFKFPNLTILKLMHGDKSLRFPQDFYEGMEKLQVISYDKMK
5 YPMLPLSPQCSTNLRVLHLHECSLKMFDSCIGNMANVEVLSFANSIEMIPLSTIGN
LKKLRLLDLTDCHGLHITHGVFNNLVKLEELYMGFSDRPDQTRGNISMTDVSUNE
LAERSKGLSALEFQFFENNAQPNMNSFGKLKRFKISMGTLYGGSDYFKKTYAVQ
NTLKLVTNKGELLSRMNELFVETEMLCLSVDDMNDLGDVCVKSSRSPQSPVFKIL
RVFVVSKCVELRYLFTIGVAKDLSNLEHLEVDSCNNMEQLICIENAGKETITFLKIKI
10 LSLSGLPKLSGLCQNVNKLLELPQLIELKLKIPGFTCIYPQNKLETSSLLKEEVVIPKL
ETLQIDEMENLKEIWHYKVSNGERVKLRKIEVSNCCKLVNLFPHNPMSELLHLEEL
EVKKCGSIESLFNIDLCVDAIGEEDNMRSRNLKIKVKNWKLREVWCIGENNSCPL
VSGFQAVESISIESCKRFRNVFTPTTTFNFMGALLEISIDDCGEYMEKSEKSSSEQ
EQTDLSEEVKLQEVTDITISNVVFTSLIHSFYNNLRKLNLEKYGGVEVVFEIESSTS
15 RELVTTHYHKQQQQQPIFPNLEELYLYMDNM SHVWKCNNWNKFLQQSESPFHN
LTTIHMSDCKSIKYLFSPLMAELLSNLKRINIDECGI

RG2P polynucleotide sequence (SEQ ID NO:120)

CCCATTGCTATTTCAGGAAGCAGTAGCAGATTACCTCNGTATAGAGCTCAA
20 AGAAAAAACTAAATCNGCAAGAGCTGATATGCTTCGTAAAATGTTAGTTG
CCAAGTCCGATGGTGGTAAAAATAAGTTCCTAGTAATACTTGACGATGTA
TGGCAGTTTGTGATTTAGAAGATATCGGTTTAAGTCCTTTGCCAAATCA
AGGTGTTAACTTCAAGGTCTTGCTAACATCACGGGATGTAGATGTTTGCA
CTATGATGGGAGTCGAAGCCAATTCAATTCTCAACATGAAAATCTTACTA
25 GATGAAGAAGCACAAAGTTTGTTCATGGAGTTTGTACAAATTTGAGTGA
TGTTGATCCCAAGCTTCATAAGATAGGAGAAGATATTGTAAGAAAGTGTT
GTGGTTTGCCTATTGCCATCAAAACCATGGCCCTTACTCTTAGAAATAAA
AGCAAGGATGCATGGAGTGATGCACTTTCTCGTTTAGAGCATCATGACCT
TCACAATTTTGTGAATGAAGTTTTTGAATTAGCTACGACTATCTTCAAG
30 ACCAGGAGACTAAATATATCTTTTGTCTTGTGGATTGTTTCCCGAAGAC
TACAATATTCCTCCTGAGGAGTTAATGAGGTATGGATGGGGCTTAAATTT
ATTTAAAAAAGTGTATACTATAAGAGAAGCAAGAGCCAGACTCAACACCT
GCATTGAGCGGCTTATCCATACCAATTTGTTGATGGAAGGAGATGTTGTT
GGGTGTGTAAAGATGCATGATCTAGCACTTGCTTTTGTATGGATATGTT
35 TTCTAAAGTGCAGGATGCTTCAATTGTCAACCATGGTAGCATGTCAGGGT
GGCCTGAAAATGATGTGAGTGGCTCTTGCCAAAGAATTCATTAAACATGC
AAGGGTATGTCTGGGTTTCCTATAGACCTCAACTTCCAAACCTCACAAT
TTTAAACTTATGCATGGAGATAAGTTTCTCAAGTTTCTCCAGACTTTT
ATGAACAAATGGAAAAGCTTCAAGTTGTATCGTTTCATGAAATGAAATAT
40 CCGTTTCTTCCCTCGTCTCCTCAATATTGCTCCACCAACCTTCGAGTTCT
TCATCTCCATCAATGCTCATTGATGTTTGTATTGCTCTTGTATTGGAATC
TGTTTAATCTGGAAGTGTTGAGCTTTGCTAATTCTGGCATTGAATGGTTA

CCTTCCAGAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACAGA
TTGTTTTGGTCTTCGTATAGATAAGGGTGTCTTAAAAAATTTGGTCAAAC
TTGAAGAGGTTTATATGAGAGTTGCTGTTCGAAGCAAAAAGCCGGAAT
AGAAAAGCCATTAGCTTCACAGATGATAACTGCAATGAGATGGCAGAGCG
5 TTC

RG2P deduced polypeptide sequence (SEQ ID NO:121)

PIAIQEAVADYL?IELKEKTKSARADMLRKMLVAKSDGGKNKFLVILDDVWQFVDL
EDIGLSPLPNQGVNFKVLLTSRDVDVCTMMGVEANSILNMKILLDEEAQSLFMEFV
10 QISSDVDPKLHKIGEDIVRKCCGLPIAKTMALTLRNKSKDAWSDALSRLHHDLHN
FVNEVFGISYDYLQDQETKYIFLLCGLFPEDYNIPPEELMRYGWGLNLFKKVYTIRE
ARARLNTCIERLIHTNLLMEGDVVGCVKMHDLLALAFVMDMFSKVQDASIVNHGS
MSGWPENDVSGSCQRISLTCKGMSGFPIDLNFPNLTKLMHGDKFLKFPDFYEQ
MEKLQVVSFHEMKYPFLPSSPQYCSTNLRVLHLHQCSLMFDCSCIGNLFNLEVLSF
15 ANSGIEWLPSRIGNLKKLRLLDLTDCFGLRIDKGV LKNLVKLEEVYMRVAVRSKKA
GNRKAISFTDDNCNEMAERS

RG2Q polynucleotide sequence (SEQ ID NO:122)

TGGGGAAGACACAGTGATAGAAAAAAGAAATGTTGTGGAAAAGAGGA
20 AAATGTTTGATTATGCTGTTGTGGCGGTTATAGGGGAAAAGACGGACCCT
ATTGCTCTTCAGAAAAGTGTGCGGATTACTTGCATATTGAGCTAAATGA
AAGCACTAACTAGCAAGAGCAGATAAACTTTGCAAATGGTTCAAGGACA
ACTCGGATGGAGGTAAGAAAAAGTTCCTCGTAATACTCGACGATGTTTGG
CAATCTGTTGATTTGGAAGATATTGGTTTAAGTACTCCTTTTCCAAATCA
25 AGGTGTCAACTTCAAGGTTTTGTTGACATCACGAAAGAGAGAAATTTGCA
CAATGATGGGAGTTGAAGCTGATTTAATTCTCAATGTCAAAGTCTTAGAA
GAAGAAGAAGCACAAAAGTTGTTCTCCTCCAGTTTGTAGAAATTGGTGACCA
ATACCACGAGCTTCATCAGATAGGGGTACATATAGTAAAGAAGTGTTATG
GTTTACCCATTGCCATTAAAACCATGGCTCTTACTTTAAGAAATAAAAGA
30 AAGGATTCATGGAAGGACGCACTCTCTCGTTTAGAGGACCATGACACTGA
AAATGTTGCAAATGCAGTTTTTCGAGATGAACTACCGCAATCTACAAGATG
AGGAGACCAAAGCCATTTTTTTGCTTTGCGGTTTGTTCCTCCGAAGACTTT
GAT.ATTCCTACTGAGGAGTTGGTGAGGTATGGATGGGGCTTAAATCTATT
TAAAAAAGTGTATACCATAAGAAAGGCAAGAACGAGATCGCATAACATGTA
35 TTGAGCGACTCTTGGATTCAAATTTGTTGATTGAAAGTAACGATATTCGG
TGCGTCAAGATACACGATCTGGTGCGCGCTTTTGTGTTTGGATATGTATTG
TAAAGTTGAGCATGCTTCAATTGTCAACCATGGTAATATGCGGACCGAAT
ATAATATGGCTGACTCTTGCAAAACAATTTCAATTAACATACAAGAGTATG
TCTGGGTTTGAGTTTCCAGGAGACCTCAAGTTTCCAAACCTAACAGTTTT
40 GAAACTTATGCANGGAGATAAGTCTCTAAGGTTTCTCAAGACTTTTATC
AATCAATGGAAAAACTTCGGGTTATATCATATGATAAAATGAAGTATCCA
TTGCTTCCCTCATCACCTCAATGCTCCACTAACATCCGAGTGCTTCGTCT

CCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTGTATTGGAAAGCTAT
TGAATTTGGAAGTCCTCAGCTTTTTTAATTCTAACATTGAATGGTTACCT
TCCACAATCAGAAATTTAAAAAAGCTAAGGCTACTAGATTTGAGATATTG
TGATCGTCTTCGTATAGAACAAGGTGTCTTGAAAAATTTGGTCAAACCTG
5 AAGAACTTTATACTGGATATACATCAGCGTTTACAGA

RG2Q deduced polypeptide sequence (SEQ ID NO:123)

GEDTVIEKKKNVVEKRKMFDYAVVAVIGEKTDPIALQKTVADYLHIELNESTKLAR
ADKLCCKWFKDNSDGGKKKFLVILDDVWQSVLEDIGLSTPPNQGVNFKVLLTSR
10 KREICTMMGVEADLILNVKVL EEEEEAQKLF LQFVEIGDQYHELHQIGVHIVKKCYG
LP IAIKTMALTLRNKRKDSWKDALSRLEDHDTENVANAVFEMNYRNLQDEETKAI
FLLCGLFPEDFDIPEELVRYGWGLNLFKKVYTIRKARTRSHTCIERLLDSNLLIESN
DIRCVKIHDLVRAFVLDMYCKVEHASIVNHGNMRTEYNMADSKTISLTYKSMSG
FEFPGDLKFPNLTVLKLMDGDKSLRFPQDFYQSMEKLRVISYDKMKYPLLPSSPQCS
15 TNIRVLR LHECSLRMFDCSCIGKLLNLEVL SFFNSNIEWLPSTIRNLKKLRLLDLRYC
DRLRIEQGV LKNLVKLEELYTGYSAFTE

RG2S polynucleotide sequence (SEQ ID NO:124)

ATTTGGGGTTTTACATTTAATTTTTTTGTGCATGAATGTGAAAATAGACTG
20 CTTATTGATTCTTTGTGTTTCATTGAGTTGATTTTCATTATTACTACCTT
ACAAATTGCTCAGTGATAGATTTCCATTAATTTGCTAATTCGGTTGCTTC
TAAATATGTAGGAGCTACTAAAAGCAAAAATATCGAGCAATGTCGGACCC
AACGGGGATTGCTGGTGCCATTATTAACCCAATTGCTCAGAGGGCCTTGG
TTCCCGTTACAGACCATGTAGGCTACATGATTTCTGCAGAAAATATGTG
25 AGGGTCATGCAGACGAAAATGACAGAGTTGAATACCTCAAGAATCAGTGT
AGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCAGATTCCATCTC
AAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAGCAAATGTGGAA
AACTTTCCGATTGATGTCATCACTTGTTGTAGTCTCAGGATCAGGCACAA
GCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATTGAAAGTCTAACAA
30 GACAGCTCTCCCTGATCAGTTGGACTGATGATCCAGTTCCTCTAGGAAGA
GTTGGTTCCATGAATGCATCCACCTCTGCATCATCAAGTGATGATTTCCC
ATC.AAGAGAGAAAACTTTTACACAAGCACTAAAAGCACTCGAACCCAACC
AAC.AATTCCACATGGTAGCCTTGTGTGGGATGGGTGGAGTAGGGAAGACT
AGAATGATGCAAAGGCTGAAGAAGGCCGCTGAAGAAAAGAAATTGTTTAA
35 TTATATTGTTAGGGCAGTTATAGGGGAAAAGACGGACCCCTTTGCCATTC
AAGAAGCTATAGCAGATTACCTCGGTATACAACCTCAATGAAAAAACTAAG
CCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAAAAGAATTCAGATGG
AGGTAAGACTAAGTTCCTCATAGTACTTGACGATGTTTGGCAATTAGTTG
ATCTTGAAGATATTGGGTAAAGTCCTTTTCCAAATCAAGGTGTCGACTTC
40 AAGGTCTTGTTGACATCAGGAGACTCACAAGTTTGCACTATGATGGGGGT
TGAAGCTAATTCAATTATTAACGTGGGCCTTCTAACTGAAGCAGAAGCTC
AAAGTCTGTTCCAGCAATTTGTAGAACTTCTGAGCCCCGAGCTCCAGAAG

ATAGGAGAGGATATCGTAAGGAAGTGTTGCGGTCTACCTATTGCCATAAA
AACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCATGGAAGGATG
CACTTTCGCGCATAGAGCACTATGACATTCACAATGTTGCGCCCAAAGTC
TTTGAAACGAGCTACCACAATCTCCAAGAAGAGGAGACTAAATCCACTTT
5 TTTAATGTGTGGTTTGTTCCTCGAAGACTTCGATATTCCTACTGAGGAGT
TGATGAGGTATGGATGGGGCTTGAAGCTATTTGATAGAGTTTATACGATT
AGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTGGTGCAGAC
AAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATGCATGATC
TGGTCCGTGCTTTTGTTCCTGGGTATGTTTCTGAAGTCGAGCATGCTTCT
10 ATTGTC AACCATGGTAATATGCCCCGAGTGGACTGAAAATGATATAACTGA
CTCTTGCAAAAAGAATTCATTAAACATGCAAGAGTATGTCTAAGTTTCCAG
GAGATTTCAAGTTTCCAAACCTAATGATTTTGAAACTTATGCATGGAGAT
AAGTCGCTAAGGTTTCTCAAGACTTTTATGAAGGAATGGAAGGCTCCA
TGTTATATCATACGATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTC
15 GATGCTCCACCAACATTCGGGTGCTTCATCTCACTAAATGTTCAATAAG
ATGTTTGATTGCTCTTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAG
CTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAGAAATTTAA
AGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAA
CAGGGTGTCTTGAAAAGTTTAGTCAAACCTGAAGAATTTTATATTGGA
20 TGCATCTGGGTTTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTG
ACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTG
AAAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGACG
CTCTTTTGATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGT
TGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGG
25 TTATTTTGAACAAAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGA
TCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCAT
TCTGCAATTTAAAAGTTCTTATTATTTCAAAGTGTGTAGAGTTGAGATAC
CTTTTCAAACCTCAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGA
AGTTTGTGAATGCGAGAATATGGAAGAACTCATACATACTGGAATTTGTG
30 GAGAAGAGACAATTACTTTCCCTAAGCTGAAGTTTTATCTTTGAGTCAA
CTACCGAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACC
ACATCTCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTT
ATCCGCAGAACAAGTTGCGAACATCTAGTTTGTGGAAGGAAGAGGTAGAT
ATATGTTCTTTATGTTAATAACAATTTAAATAATATTTTCAACCAAATTT
35 CATAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGG
CTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCTAAGTTGGAGACAC
TTCAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTT
AGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGA
TAAGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATC
40 TTGAAGAGCTTAAAGTCAAGAATTGCGGTTCATTGAATCGTTATTCAAC
ATTGACTTGGATTGTGTGCGGTGCAATTGGAGAAGAAGACAACAAGAGCCT
CTTAAGAAGCATCAACATGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGA
GGATAAAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTT

GAAAGCATAAAGATTGAAAAATGTAAGAGGTTTAGCAATATATTACACC
TATCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAG
GTTGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTCAATTTAA
CTTTCTTAAGTAATTAAGGACTAACCTCCTGTTTTTTGAATAATAAAGAG
5 GTGGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACC
ATGAAACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTT
AAAAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTCA
TTAGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACT
AATTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTT
10 AGTGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCC
TAACAAAAAAAACCTATTTGGTTCAGAAGAACCGTAATTCAAGATAACTAA
AATAAAAATATTTGACATTCACTAAGAGCATTTTTTTTTCTAAATATGAT
TGCAAATGAATAAAACTTAAATTTATACAGAAAAGATTTTTATATATGTT
ATACAAAATTTACAAATTGAAACTGGATATGTTAATTAACGGTTTATAAT
15 TCTGGTATCACAAGGGATATATAATAAATATTATTTTCTGTAGTCATT
TATAATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAG
TTAAACTTTTCATAATAAAAATTTATAATTATTATTTATTTTAAATAAATT
ATTAAATTAAGAGATGTATCAAAAATTTAAAGTTATTATAACTTCAAATTT
AACATATAATTAGAAAATATATGATCATAACTTTCCGCAACTCTTCTTTT
20 GTATTAAAATGCCAGAGAAGCTCTTAGTAYATTTTCTAAATCAAAGTCA
CAAACTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTT
TAAGAGTCACCAAATTCAAAGAGTAATCCAATGCTTTCATTACCACTATG
GAGAAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTA
ATTGTTGCTTACTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAACCA
25 AAAAAAATTACATTCATGTATCATTATTCATGACTAGATATATATGAACA
TGAAGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTC
ATGGAATTCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCA
ACCAAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAA
GGATTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTT
30 GTTCTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAAT
GCAAAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCA
CCAACCTCCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTG
AAGGACCCTATGCGGGTGCCTTGC GCGGGTGGAGCTGAATACGAAAGGTC
TTTGGTCTTTGTGAGGGTGATGCTGTGCGGGTTAGCTTGTGCGCATGCTTC
35 CGCGCGGTTGCGGCACATGTGCACAAGTGATGCATGGTGTGTACGTTCTT
GAGTTTTGAGCCTCCGATGCTTAGTCCATTTGGCCCAATTCGAGTCCAAT
CAGCTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTATCTTCAAGTT
AAGCCCAAATTGCCTTCTCCAAATCATCCATAACTTCACAAAATCGCCCG
TTCATCTTAATCCCGAATGCACAATTATTCTCCTGTCTTCCTTTTAAGCA
40 AGATACCACCTTCTTCATGCTTCATCCATCAATAGTACACTTCATGTATC
ATCTCTACTAGTTATTTAGTCCACAATCCTTATTGTCCTCCAAATTTAAT
TATCTCATTTAGTTCCCGTCCACTAGTTTCTTAAAATTTGCAATTAAG
CTC.ACACAAATATTAAGTACCTGAAATGGTCATAAAAATAACAAAAGGAA

AAT.ATGCATGAAGATTAATACTAAATGATGAACGAAATATGCTAAAATAGAC
TATAAAATGAAGTAAATAAAATGAAATTATCGCACTCCGACCACCCTTAT
AGGCTTGTAGTCCATCCACCCTTCATTCTTGTACCAATATGGGATGGAA
ACATCATTAATTAAGCCAAAAAACTAACATATAAGGGGTGAGTGACAAAG
5 GTA.AGTACTAAAGATGAAAATAATCCATTTTTTYYTGTATATACACAACAC
ACACATAGGGGCAGACGTAGGATTCATAGTACAGATTGTTGGTGGCACA
TAAGTGTGCTGGTGACACTTTTTTTTCTTTTACGTAGTGGCACAACAG
TAG.AAAAAACGARAAATTCGAAATTTTTTACAATGTGTSTAAAAAAAAYA
GTGGTTGTTGGTGCCACTATGGACACCAAAGTTGAACTGCCCCCTGCGCGC
10 RCACACACACACATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
ARAGWAWGRRRGAKAKARMCSMSYTTGGGATGTGATACTTCTTTTAGGAA
AATGGAGTTATATCTTTGATATTGTATTTTTTTAATGTAATTTATATATT
TAATCATTTTTAGTTTATAAGTTTTTATTTATTTTGATATGAAAAAAAAGT
CTTTTATACATTGGATTTAACATAAAAAATCCAACAATATTAATCAAAAAG
15 ACC.AMACATGTGGACAMWTATGTATATAAWTAATTCACAATAGTCTTTAG
GAATAGNATTATATATATAATTAATTCTCAATGGTCTTAGGAATAGTAAG
TTCTTATATTTCAAACCTTNGCCACAATTCTTTGKTTACTTWGACACTTY
CCTCTCTCTAATTATATATATATATATATATATATATATATATATACACA
CAC.ACACACACACACTAGATGTGTGCCCGCGCAAAGCAGTGACGTNNNGG
20 AGA.ANACTTTCTTAAGCATAAATAATTATTATTTTTTTATTGGGTATTA
TATA.AATAAAAAATTACAACCTTTAAATAAAATATTTATGTTTATACTTTA
TATTTATATTGCTTGTATACTATTAATATAATAAATTAATATTTATGTCT
AATTTATGAAATGTAAATTAATTTAAATACATGAATTTAATATTTTTTAAA
ATTTTCAGTTTGCTTCAAATTGAGTTTCTTAATTATTTTTTTTAAATTCAN
25 GTATTCAAACCTTTTGGTAAGTATTAAGAATTATTTATGCACAATTGATT
TAT.ACAAAAAA.CTTTGTAACTTATACATCTTAAAATTCAAGATATAACTA
ACATGTTTTACAATATATATATATATATATATATATATATATATATATAT
ATATATATATATATATAGTAAAGCGCANAGGTCATAGGNANAGANTATTT
TCT.ATTATTCTACGTTTTGCCACAAAAGTTTGAACACTTTGCCACTTTTT
30 GTCCCTCCTTAACCTTTTCAATGTTTTGCGACAAAAGTTCCAAAACCTTG
CCACTTTGATCATTCCTCAACTTTTCACCGCATTAGTTTGTGGAGTTGGC
AGTTTTGGTCCCCCTAACTTCGATATTTTCTCCTGCTAGCCAAAAAGGGT
TCC.AGAGTTTCACANTTTTGGTCCCTGACAATAACCAAATGTGAGATGTC
AAA.TTTTTGCCACATTAGTTTGTGGAGTTGTCCCTTTTGGTCCCCCACA
35 TTCGATATTCTACTATACGACCTTATTTTTCTCAAATAACAACACGTATA
TTT.AATTACCAATGATAGAAATAGATATCAAATAAAGTATTTGTAACACC
GTGTAAGAACGGTGCTACTATAGGTAAAAATAAACATTTCAAAGTACGAT
GTCCTAATTGGAAAAAGAGTTTTTAAAAAATAACAACCTAGGGGCGAGTTT
TTTTTACAAGTTTGTATCAAATCATATCAAAATTTAAGGTGGAACGGTGA
40 CCACATTAACCAGAAATGTAATTTATTCTTTGATTTTGATAATTTTTAAT
ATTTTGTGTGATCTATGTATTTAAAAGTAAACAACAAAGAACATAATCC
AAA.ACCCTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCGTCAC
TTACGATGGCGTTACGTCGCTCTCTCACTTCTTACAACCCTTTGTTGCTA

CTCATTACAATAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGG
AATTGAACAAATCTCGTCAAATTTTGGATTTTGTGATGGATTTGAGTAG
AAGTTTGGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACTTGAT
TCTGAGTTATTACTATATATGTAGCCTCTTTACAACGACCAAGGTTTCTT
5 CCAGGTACCATTTGATCTTTTTAGAACCCAGTTGTCTGAAACACCCTGAT
TTGGATCAAATATCACCAACAACCTCTTAAAAACTTGATTAATCAATTGTT
TTCTTCATCTTGATAACAAGTGGAAATGATTTTCTACTTAGATTAACCTGA
AAAAAAAGGTCCATGTGCGTCTGGTGGATCTGGTAAATGAAGATGGAAGG
GAGAGCTGACTTTAAAGACACAAACACGTCACCATATCTTTTATTTTATT
10 TTAATTTGCTTTTTTTCCTATTTCTTTCTTTCTTGATCTCCAGATGGTAT
GTGGTGTGGATAATTTACACATAGAGATTGGGAACGACTGTGTTTTAGAG
AGGACGTGGCTTGGGGTTGAGGATGGTTTATGGCTGGCCGAGTTTCATTT
ATATAAACAAACAAATATATAAAACAAGGGGTAAAATGGCCATCTTATAT
GTATTTAACCGTCCTTTTTTATTTTTTTTTTATTTTTTAAATTTAAGAAGG
15 GGTATACCAGTGTGAGCCTCTTATCCCAACCAGGCAACCAGTCAAATAG
GGACTTAGGTTGTTTGGAAACAGTTCCGTGAGACCGTGACTTGGATGGTA
GATAAATTTAGTAACTTAACCCTTCAATTAACCTACCTTTTTCTTATTA
ACTCAATTTCAACCTAAATTCTGATTCTTGTTTGAAAATAAGTTGCATCT
TTATGTTTGTATTATCCTGTTGCATAGGATCCTTAGCATCTTTTAATAAT
20 TTATTTGAAGGTGAAAGATCCAACTATTTTTTAGCTGTTGGCATTTTCCA
TCATTTGCAACTGTTTCTTGAAAAAAAATACCTAAAATCAAATAACCA
TTTTCAAATCCAAAATTATAAGAGAGAATTGTAAATGGACGTGGAATCGT
AAATCATTAACACAGTTCAGTACACAAGTTGCTAATTACATTTCTTGCTG
TGCAGATTGAAATTCTATCAGAGAAAGAGACATTACAAGAAGTCACTGAT
25 ACTAATATTTCTAATGATGTTGTATTATTCCCATCCTGTCTCATGCACTC
TTTTCATAACCTCCATAAACTTAAATTGGAGAGAGTTAAAGGAGTGGAGG
TGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGAGAATTGGTAACA
ACTCACCATAACCAACAACATCCTATTATACTTCCCAACCTCCAGGAATT
GGATCTAAGTTTTATGGACAACATGAGTCATGTGTGGAAGTGCAGCAACT
30 GGAATAAATTCTTCACTCTTCCAAAACAACAATCAGAATCCCCATTCCAC
AACCTCACAACCATAACATGTTTCTGCTGCAGAGCATTAAAGTACTTGT
TTCGCTCTCATGGCAGAACTTCTTTCCAACTAAAGGATATCTGGATAA
GTGGGTGTAATGGTATTAAAGAAGTTGTTTCAAAGAGAGATGATGAGGAT
GAAGAAATGACTACATTTACATCTACCCACACAACCACCATCTTGTTCCT
35 TCATCTTGATTCTCTCACTCTAAGACTACTGGAGAATCTGAAGTGATTG
GTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATATCTTTCAATAAT
ACCCTGCAACTACTGCTGTTCTTGATCAATTTGAGGTATGCTTTGTACA
TATTCAATTATTTATTTAATTTCTTTTTCTTTGCAATATTCTATAAAT
AATACATTTTATACCCACTATACTAAGATAATAATTACCTAGAGGGATGG
40 ATGCTATGACACAGCTGCTACACTTCAGAACTCTAGTAAGGGCAGTTAT
GGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGGTAATATAGGCAA
TTTAAAGTTTTATTTCTGTAAAGCAGTATTTAGCAAGTACTGGCCAGTAG
GAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATTGTACCCAAGAAT

TTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAGGTGACAGATAT
TGTAGAATAGAACAATATATAATATTACCCAAAACATTTTTTCTAAGGT
TATTCTGTAAATATGTGCTTTCTTGATTTTCATTGAATTTGCATTCCCTAT
ATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCCGAAATTAATTA
5 AAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGAGCACTGGTATCA
TTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTCTTATATAAAAGC
TGTGTATATAGTTTAATTAGTTTTACATCATTTTTTCCATGTGGTGTGCA
GTTGTCTGAAGCAGGTGGTGTCTTGGAGTTTATGCCAATACGCTAGAG
AGATAGAGATATCTAAGTGTAATGTATTGTCAAGTGTGATTCCATGTTAT
10 GCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGAGTAACGGGTTGTGA
TGGCATGAAGGAGGTATTTGAACTCAATTAGGGACGAGCAGCAACAAAA
ACAGAAAGGGTGGTGGTGATGAAGGAAATGGTGGAAATCCAAGAGTAAAT
AAC.AATGTTATTATGCTTCCCAATCTAAAGACATTGAAAATCTACATGTG
CGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGACAC
15 AGCTCCAAGAGTTAAAGATAGTGGGTGCTACGGAATGAAAGTGATTGTG
AAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACAACAAC
AACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTTCTAAGAAGGTTG
TGGTCTTTCCCCGTCTAAAGTCCATTGAACTATTCAATCTACCAGAGCTG
GTAGGATTCTTCTTGGGGATGAATGAGTTCGGTTGCCTTCATTGGAAGA
20 AGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCGAGCTGGTGGGT
CCACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACT
CTTGATCAAGAATCTGGCCTTAACCTTCATCAGGTATATATATATTCCTT
TAATTGGCATGATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTT
ACTTCAAACACATTCACTCTGGTTTCAGTCTAAGTTTATGTTGTTCTAGG
25 AAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCAGTGGA
AAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTTTA
GTACCTGGAATCGTGTGTGGGAGGAGCGTTATTATTCTGATTTGCTTGT
TCTTTATCATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATC
TTTTGATTTTAAATGACAAAATTTTTCCCTGTTACTCTATTGATTGTTG
30 TTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGAT
TGTTATTTTCATATCATGTTGTCCTTTGAATCAAGCTTTTCCATTTTCAA
CCAGGGCAAAGGTCAAAGTAACCTACTTTATGAGATCAAAAACAGCAA
CCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGA
TTAATAATTATAATATCTTGATTAATTCATTAATAATTGGTACAGCACAT
35 ATATGACATTTTAAAGGTTTGTGTTTGTGTTGACATATATATGCCTCTGGC
GTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTGACA
CCTCGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTG
ATCGAATTAGATATGGAATTAAATTATGATGTTAAAAAGATTATCCATC
CAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTTCATGTGAGTAGTT
40 GTTATTGGGTAGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGGAGA
AATGGAAATAGTGGAAATGGTGTGATGAATCGTCACAACTACTACTAC
TACTACTCTTTCAATCTTCGAAACCTCAGAGAAATGAAGTTGCATTTTC
TACGTGGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTTGAG

TTTCCAAACCTAACAAGAGTTCATATAAGTAGGTGTAGAAGGTTAGAACA
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG
ATATTAGTTGGTGCAACCATATGGAGGAGGTGATTGTTAAGGATGCAGAT
GTTTCTGTTGAAGAAGACAAAGAGAGAGAATCTGATGGCAAGACGAATAA
5 GGAGATACTTGTGTTACCTCGTCTAAAATCCTTGAAATTAAAATGCCTTC
CATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATT
TTGGATACTTTAGAAATCTACAAATGCCCAGCAATAACGACCTTCACCAA
GGGAAATTCTGCTACTCCACAGCTAAAAGAAATAGAAACAAGATTTGGCT
CGTTTTATGCAGGGGAAGACATCAACTCCTCTATTATAAAAAGATCAAAC
10 AACAGGTAAATCAGATCTTTGTTGCTTTAATAATTCTTAACTACATTTG
AAAAGCTTCATGCAAGTTTTTTTTTGTATATTGTCAAAAACCGCAACCTA
CATTTTCAGCTTTATATTTATGTACTTTATGCAGGAGTTCAAACAAAAC
CTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGTTCTT
AGTTGCCTATTAATTAATGGCCTTTTAGTTCRTGATTTTTGGATGTAGTY
15 WTCATGATGATGTGAATCTTCTAATACCCCATTCATTGTTTGGTTGAATG
TTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCATATG
AAGGACATTAAAGAACATGGATGCTATGAAGATGTTGGAARAC

RG2S deduced polypeptide sequence (SEQ ID NO:125)

20 MSDPTGIAGAIINPIAQRALVPVTDHVGYMISCRKYVRVMQTKMTELNTSRISVEEH
ISRNTRNHLQIPSQIKDWLDQVEGIRANVENFPIDVITCCSLRIRHKLQKAFKITEQI
ESLTRQLSLISWTD DDPVPLGRVGS MNASTSASSDDFPSREKTFTQALKALEPNQQF
HMYALCGMGGVGKTRMMQRLKKA AEEKL FNYIVRAVIGEKTDPFAIQEAIADYL
GIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQG
25 VDFKVLTSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGED
IVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQE
EETKSTFLMCGLPEDFDIPTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQT
NLLIESDDVGCVKMHDLVRAFLGMFSEVEHASIVNHGNMPEWTENDITDSCKRIS
LTCKSMSKFPDGFKFPNLMILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKYPLL
30 PLAPRCSTNIRVLHLTKCSLKMFD CSCIGNLSNLEVLSFANSRIEWLPSTVRNLKKLR
LLDLRFCDGLRIEQGVLSLVKLEEFYIGNASGFIDN CNEMAERSDNL SALEFAFF
NNKAEVKNMSFENLERFKISVGRSFDGNINMSSHSYENMLQLVTNKGDVLD SKLN
GLFLKTKVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFKLN
ANTLSRLEHLEVCECENMEELIHTGICGEETITFPKLKFLSLSQLPKLSSLCHNVNIIG
35 LPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEIWPCELS
GGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELKVKNCGSIESL FNIDLCVGA
IGEEDNKSLLRSINMENLGKLREVWRIKGADNSHLINGFQAVESIKIECKRFSNIFT
PITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEVTD TNISNDVVLFPSCLMH
SFHNLHKLKLERVKGEVVFEIESESPTSRELVTTHNQHPILPNLQELDLSFMD
40 NMSHVWKCSNWNKFFTL PKQQSES PFHNLT TIHMFSCRSIKYLF SPLMAELLSNLK
DIWISGCNGIKEVSKRDEDEEMTTFTSTHTTTILFPHLDSLTLRLLENLKCIGGGG
AKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEISKCNVLSSVIPCY

AAGQMQLQVLRVTGCDGMKEVFETQLGTSSNKNRKGGGDEGNGGIPRVNNNVI
MLP.NLKTLYMCGGLEHIFTFSALES.LTQLQELKIVGCGYGMKVIVKKEEDEYGEQ
QTTTTTTTKGASSSSSSSSKKVVVFPRLKSIELFNLPELVGFLLGMNEFRLPSLEEVT
IKYCSKMMVFAAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTSGPA
5 TSEGTTWSFHNLIELDMELNYDVKKIIPSELLQLQKLEKIHVSSCYWVEEVFETAL
EAAGRNGNSGIGFDESSQTTTTTTTLFNLRLNREMKLHFLRGLRYTWKSNQWTAFF
PNLTRVHISRCRRLEHVFTSSMVGSLLQLQELDISWCNHMEEVIVKDADVSVEEDK
ERESDGKTNKEILVLPRLKSLKLCPLKGFSLGKEDFSFPLDLEIYKCPAITFTT
KGN.SATPQLKEIETRFGSFYAGEDINSSIIKRSNNRSSNKT.LNVK.ILK

10

RG2T polynucleotide sequence (SEQ ID NO:126)

GGAAGACGACAATGGTGCAACGGTTGAAGAAGGTTGTGAAAGATAAGAAG
ATGTTCCATTATATTGTCGAGGTGGTTGTAGGGGCAAACACTGACCCCAT
TGCTATCCAGGATACTGTTGCAGATTACCTCAGCATAGAACTGAAAGGAA
15 ATACGAGAGATGCAAGGGCTTATAAGCTTCGTGAATGCTTTAAGGCCCTC
TCTGGTGGAGGTAAGATGAAGTTCCTAGTAATTCTTGACGATGTATGGAG
CCCTGTTGATCTGGATGATATCGGTTTAAGTTCCTTGCCAAATCAAGGTG
TTG.ACTTCAAGGTCTTGCTGACATCACGCAACAGTGATATCTGCATGATG
ATGGGAGCTAGTTTAATTTTCAACCTCAATATGTTAACAGACGAGGAAGC
20 ACATAATTTTTTCCGTCGATACGCAGAAATTTCTTATGATGCTGATCCCCG
AGCTTATTAAGATAGGAGAAGCTATTGTAGAGAAATGTGGTGGTTTACCC
ATTGCCATCAAACTATGGCCGTTACTCTTAGAAATAAACGCAAAGATGC
ATGGAAAGATGCACTTTCTCGTTTAGAGCACCGTGACACTCATAATGTTG
TGGCTGATGTTCTTAAATTGAGCTACAGCAATATCCAAGACGAGGAGACT
25 CGGTCGATTTTTTTTGCTATGTGGTTTGTTCCTGAAGACTTTGATATTCC
TACCGAAGACTTAGTGAGGTATGGATGGGGATTGAAAATATTTACCAGAG
TGT.ATACTATGAGACATGCAAGAAAAAGGTTGGACACGTGCATTGAGCGG
CTT.ATGCATGCCAACATGTTGATAAAAAGTGATAATGTTGGATTTGTCAA
GATGCATGATCTGGTTCGTGCTTTTGTGTTGGGCATGTTATCTGAAGTCG
30 AGCATGCATCAATTGTCAACCATGGGGATATGCCAGGGTGGTTTGAAACT
GCAAATGATAAGAACAGCTTGTGCAAAAGAATTCATTAACATGCAAAGG
TATGTCTGCGATTCTGAAGACCTCACGTTTCCAAACCTCTCGATCCTGA
AATTAATGGATGGAGACGAGTCACTGAGGTTTCCTGAAGGCTTTTATGGA
GAAATGGAAAACCTTCAGGTTATATCATATGATAACATGAAGCAGCCATT
35 TCTTCCACAATCACTTCAATGCTCCAATGTTTCGAGTGCTTCATCTCCATC
ACTGCTCATTAAATGTTTGATTGCTCTTCTATTGGAAATCTTTTGAATCTC
GAGGTGCTCAGCATTGCTAATTCTGCCATTAAATTGTTACCTCCACTAT
TGGAGATCTGAAGAAGCTAAGGCTCCTGGATTTGACAAATTGTGTTGGTC
TCTGTATAGCTAATGGCGTCTTTAGAAATTTGGTCAAACCTGAAGAGCTT
40 TAT.ATGAGAGTTGATGATCGAGATTCTTTTTTGTGAAAGCTGATGACAG
CAAGACCATTACCT

RG2T deduced polypeptide sequence (SEQ ID NO:127)

5 KTTMVQRLKKVVKDKKMFHYIVEVVVGANTDPIAIQDTVADYLSIELKGNTRDAR
AYKLRECFKALSGGGKMKFLVILDDVWSPVDLDDIGLSSLPNQGVDFKVLLTSRNS
DICMMMGLIFNLNMLTDEEAHNFFRRYAEISYDADPELIKIGEAIVEKCGGLPIAI
10 LFPEDFDIPTEDLVRYGWGLKIFTRVYTMRHARKRLDTCIERLMHANMLIKSDNVG
FVKMHDLVRAFLGMLSEVEHASIVNHGDMPGWFETANDKNSLCKRISLTCKGMS
AIPEDLTFPNLSILKMDGDESLRFPEGFYGEMENLQVISYDNMKQPFLPQSLQCSN
VRVLHLHHCSLMFDCSSIGNLLNLEVLSIANSAILLPSTIGDLKKLRLLDLTNCVGL
CIANGVFRNLVKLEELYMRVDDRDSFFVKADDSKITIT

RG2U polynucleotide sequence (SEQ ID NO:128)

GCCTTGTGTGGGATGGGTGGAGTGGGAAAGACCACTGTGATGAAGAAGCT
GAAGGAGGTTGTGGTAGGAAAGAACTGTTTAATCATTATGTTGAGGCGG
15 TTATAGGGGAAAAGACAGACCCCATTTGCTATTCAACAAGCTGTTGCCGAG
TACCTTGGTATAAGTCTAACCGAAACCACTAAACCAGCAAGAAGTGTAA
GCTCCGTACATGGTTTGCAAACAACCTCAAATGGAGGAAAGAAGAAGTTCC
TGGTAATACTAGACGATGTATGGCAACCAGTTGATTTGGAAGATATTGGT
TTAAGTCGTTTTCCAAATCAAGATGTTGACTTCAAGGTCTTGATTACATC
20 ACGGGACCAATCAGTTTGCCTGAGATGGGAGTTAAAGCTGATTTAGTTC
TCAAGGTGAGTGTCTGAGGGAAGCGGAAGCACACAGTTTGTTCCTCCAA
TTTTTAGAACCTTCTGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA
AGAAATTGTAAAGAAGTGTGCACTACCCATTGCTATCAAACCATGG
CCTGAACTCTTAGAAGTAAAGTAAGGATACATGGAAGAATGCCCTTTCT
25 CGTTTACAACACCATGACATTAACACAATTGCGTCTACTGTTTTCCAAAC
TAGCTATGACAATCTCGAAGACGAGGTGACTAAAGCTACTTTTTTGCTTT
GTGGTTTATTTCCGGAGGACTTCAATATTCCTACCGAGGACCTATTGAGG
TATGGATGGGGATTGAAGTTATTCAAGGAAGTAGATACTATACGAGAAGC
AAGATCCAAGTTGAAAGCCTGCATTGAGCGGCTCATGCATACCAATTTGT
30 TGATCGAAGGTGATGATGTTAGGTACGTAAAGATGCATGATCTGGTGCGT
GCTTTTGTGTTTGGATATGTTTCTAAAGCCGAGCATGCATCTATTGTCAA
CCATGGTAGTAGTAAGCCAAGGTGGCCTGAAACTGAAAGTGATGTGAGCT
CCTCTTGCAAAGAATTTCAATTAACATGCAAGGGTNTG

35 RG2U deduced polypeptide sequence (SEQ ID NO:129)

ALCGMGGVGKTTVMKKLKEVVVGKKLFNHYVEAVIGEKTDPPIAIQQA VAEYLGIS
LTETTKPARTDKLRTWFANNSNGGKKKFLVILDDVWQPVLDLEDIGLSRFPNQDVD
FKVLITSRDQSVCTEMGVKADLVLKVSVLEEAHSLFLQFLEPSDDVDPELNKIGE
EIVKKCCRLPIAIKTMA.TLRSKSKDTWKNALSRLQHHDINTIASTVFQTSYDNLEDE
40 VTKATFLLCGLFPEDFNIPTEDLLRYGWGLKLFKEVDITREARSKLKACIERLMHTN

LLIEGDDVRYVKMHDLVRAFVLDMFSKAEHASIVNHGSSKPRWPETESDVSSSKR.
ISLTCKG?

RG2V polynucleotide sequence (SEQ ID NO:130)

5 CTGTGGAAGACACGAATGATSAAGAAGCTGAAGGAGGTCGTGGAACAAAA
GAAAATGTTCAATATTATTGTTCAAGTGGTCATAGGAGAGAAGACAAACC
CTATTGCTATTCAAGCAAGCTGTAGCAGATTACCTCTCTATTGAGCTGAAA
GAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTNAATGGTTCGAGGA
CGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGATGATGTATGGCAGT
10 TTGTGATCTTGAAGATATTGGTTTAAGTCCTCTGCCAAATAAAGGTGTC
AACTTCAAGGTCTTGTGACGTTAAGAGATTCACATGTTTGCACCTCTGAT
GGGAGCTGAAGCCAATTCAATTCTCAATATAAAAGTTTTAAAGATGTTN
AAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGCAGGTGATGATGAC
CTGGATCCTGCTTTCATGGGATAGCAGATAGTATTGCAAGTAGATGTCA
15 AGGTTTGCCCATTTGCCATCAAACCATTGCCTTAAGTCTTAAAGGTAGAA
GCAAGCCTGCGTGGGACCATGCGCTTTCTCGTTTGGAGAACCATAAGATT
GGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTATGACAATCT
CCAAGATGAGGTTACTAAATCTATTTTTWTACTTTGTGCTTTATTTCTTG
AAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGTGGGGCTTG
20 AAATTATTTATAGAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAA
CACCTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGGAAGTGATG
ACATTGGATGCGTCAAGATGCACGATGTGGTGCGTGATTTTGTTTGGTAT
ATATTCTCAGAAGTCCAGCACGCTTCAATTGTCAACCATGGTAATGTGTC
AGAGTGGCTAGAGGAAAATCATAGCATCTACTCTTGTAAGAATTTTCAT
25 TAACATGCAAGGGTATGTCTGAGTTTCCCAAAGACCTCAAATTTCCAAAC
CTTTCATTTTGAACTTATGCATGGAGATAAGTCGNTGAGCTTTCCTGA
AGACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATATGATAAAT
TGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTAACGTTCTGA
GTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGCTCTTCAAT
30 TGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTG
AATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGAT
TTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTT
GGTCAAACCTGAAGAGCTTTATATGGGTGTTAATGTCCGTATGGACCAGG
CCGT

35

RG2V deduced polypeptide sequence (SEQ ID NO:131)

LWKTRM?KKLKEVVEQKKMFNIIVQVVIGEKTNPPIAQQAVADYLSIELKENTKEAR
ADKLR?WFEDDGGKKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTLRDSH
VCTLMGAEANSILNIKVKDV?GQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGL
40 PIAIKTIALSLKGRSKPAWDHALSRLNHNKIGSEEVVREVFKISYDNLQDEVTKSIF?L
CALFPEDFDPIEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIG

CVKMHVDVVRDFVWYIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEF
PKDLKFPNLSILKLMHGDKS?SFPEDFYGKMEKVQVISYDKLMYPLLPSSLECSTNV
RVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKG
LRIDNGVLKNLVKLEELYMGVNVVRMDQAV

5

RG2W polynucleotide sequence (SEQ ID NO:132)

TTGGGAAAGAGACAATGATGAAGAATTGAAAGAGGTTGTGGTTGAAAAGA
AAATGTTTAATCATTATGTGGAGGCGGTTATAGGGGAGAAGACGGACCCC
ATTGCTATTTCAGCAAGCCGTTGCAGAGTACCTTGGTATAATTCTAACAGA
10 AACCATAAGGCAGCAAGAACCGATAAGCTACGTGCATGGCTTTCTGACA
ATTCAGATGGAGGAAGAAAGAAGTTCCTAGTAATACTAGACGATGTATGG
CATCCGGTTGATATGGAAGATATTGGTTTAAGTCGTTTCCCAAATCAAGG
TGTCGACTTCAAGGTCTTGATTACATCACGGGACCAAGCTGTTTGCCTG
AGATGGGAGTTAAAGCTGATTTCAGTTATCAAGGTGAGTGTCTAGAGGAA
15 GCTGAAGCACAAAGCTTATTCTGCCAACTTTGGGAACCTTCTGATGATGT
CGATCCTGAGCTCCATCAGATTGGAGAAGAAATTGTAAGGAAGTGTGTG
GTTTACCCATTGCAATAAAAACCATGGCCTGCACTCTTAGAAGTAAAAGC
AAGGATACATGGAAGAATGCACTTTCTCGTTTACAACACCATGACATTAA
CACAGTCGCGCCTACTGTTTTTCAAACCAGCTATGACAATCTCCAAGATG
20 AGGTGACTGGAGATACTTTTTTGCTATGTGGTTTGTTCGGGAGGACTTC
GATATTCCTACTGAAGACTTATTGAAGTATGGATGGGGCTTAAAATTATT
CAAGGGAGTGGATTCTGTAAGAGAAGCAAGATACCAGTTGAACGCCTGCA
TTGAGCGGCTCGTGCATACCAATTTGTTGATTGAAAGTGATGTTGTTGGG
TGCGTCAAGTTGCACGATCTGGTGCGTGCTTTTATTTTGGATATGTTTTG
25 TAAAGCGGAGCATGCTTCGATTGTCAACCATGGTAGTAGTAAGCCTGGGT
GGCCTGAAACTGAAAATGATGTGATCAGGACCTCCTGCAAAAGAATCTCA
TTAACATGCAAGGGTATGATTGAGTTTTCTAGTGACCTCAAGTTTCCAAA
TGTCTTGATTTTAAAACTTATGCATGGAGATAAGTCGCTAAGGTTT

RG2W deduced polypeptide sequence (SEQ ID NO:133)

WERDNDEELKEVVVEKKMFNHYVEAVIGEKTDPPIAQQAVAEYLGILTETTKAAR
TDKLRAWLSDNSDGGRRKKFLVILDDVWHPVDMEDIGLSRFPNQGVDFKVLITSRD
QAVCTEMGVKADSVIKVSVLEEAEQSLFCQLWEPSSDDVDPELHQIGEEIVRKCCG
LPIAIKTMACTLRSSKDTWKNALSRLQHHDINTVAPTQTSYDNLQDEVTGDTF
35 LLCGLFPEDFDIPTEDLLKYGWGLKLFKGVDSVREARYQLNACIERLVHTNLLIESD
VVGCVKLHDLVRAFILDMFCKAEHASIVNHGSSKPGWPETENDVIRTSCKRISLTCK
GMIEFSSDLKFPNVLILKLMHGDKSLRF

RG5 polynucleotide sequence (SEQ ID NO:134)

40 GGGGGGGTGGGGAAGNCGACTCTAGCCCAGAAGNTCTATAATGACCATAA
AATAAAAGGAAGCTTTAGTAAACAAGCATGGATCTGTGTTTCTCAACAAT

ATTCTGATATTTTCAGTTTTTGAAAGAAGTCCTTCGGAACATCGGTGTTGAT
TATAAGCATGATGAAACTGTTGGAGAACTTAGCAGAAGGCTTGCAATAGC
TGTCGAAAATGCAAGTTTCTTTCTTGTGTTGGATGATATTTGGCAACATG
AGGTGTGGACTAATTTACTCAGAGCCCCATTAAACACTGCAGCTACAGGA
5 ATAATTCTAGTAACAACTCGTAATGATACAGTTGCACGAGCAATTGGGGT
GGAAGATATTCATCGAGTAGAATTGATGTCAGATGAAGTAGGATGGAAAT
TGCTTTTGAAGAGTATGAACATTAGCAAAGAAAGTGAAGTAGAAAACCTA
CGAGTTTTAGGGGTTGACATTGTTTCGTTTGTGTGGTGGCCTCCCCCTAGC
CTT

10

RG5 deduced polypeptide sequence (SEQ ID NO:135)

GGVGKTTLAQK?YNDHKIKGSFSKQAWICVSQQYSDISVLKEVLNIGVDYKHDET
VGELSRRLAIAVENASFLLVLDIWDQHEVWTNLLRAPLNTAATGILVTRNDTVA
RAIGVEDIHRVELMSDEVGWKLLLKSMNISKESEVENLRVLGVLDIVRLCGGLPLAL

15

RG7 polynucleotide sequence (SEQ ID NO:136)

GGTGGGGTTGGGAAGACAACGGGCACAAGGAGGCGACTGCCAATACTTCC
GACTTTTATTCATAGAGATGACGAGTCTTATTTTCCTACTACTATAGGGA
GGATATTTGGTTGCGCGAGACGATTCAATGCGCGAAGGGATTCTATCCTT
20 CTTTTTTTCCGCGAAGACTTCGTTCCGGAGGACGGGCTATATTCCCTTTA
ATATTAGTCTAGCCCAGTCTAGGCCAACCATATGGCGATGCGGTAGACCT
CCCAGAGATAGATACTTGATCTTAGAGGATTCACACGTTCAATGGTGGAA
ACTTAAGGAACCGGCTAAGAGTGACTAAACGGAAAAACCCTATTCATTCC
ATAGCCTCATCCGGTCGAGGCATTAAACAATCCATCCCAATCCTCTTTCC
25 TTTGGTCTACTCTAATGATGTGCCCGTTTCGTTGGTGGAATATCTCTTTAT
ACCGACGATTTATATGGGGATTGCCACTAGCGTTG

30

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.
2. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising an leucine rich region (LRR).
3. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising a nucleotide binding site (NBS).
4. The nucleic acid construct of claim 1, wherein the polynucleotide is a full length gene.
5. The nucleic acid construct of claim 1, wherein the further encodes a fusion protein.
6. The nucleic acid construct of claim 1, wherein the RG1 polypeptide is encoded by an RG1 polynucleotide sequence.
7. The nucleic acid construct of claim 6, wherein the RG1 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
8. The nucleic acid construct of claim 1, wherein the RG2 polypeptide is encoded by an RG2 polynucleotide sequence.
9. The nucleic acid construct of claim 8, wherein the RG2 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 (RG2A);

SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID
NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35
(RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ
ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89
5 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D);
SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID
NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107
(RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L);
SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID
10 NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126
(RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132
(RG2W).

10. The nucleic acid construct of claim 1, wherein the RG3 polypeptide is encoded by
15 an RG3 polynucleotide sequence.

11. The nucleic acid construct of claim 10, wherein the RG3 polypeptide is encoded by
a polynucleotide sequence as set forth in SEQ ID NO:68.

20 12. The nucleic acid construct of claim 1, wherein the RG4 polypeptide is encoded by
an RG4 polynucleotide sequence.

13. The nucleic acid construct of claim 12, wherein the RG4 polypeptide is encoded by
a polynucleotide sequence as set forth in SEQ ID NO:69.

25 14. The nucleic acid construct of claim 1, wherein the RG5 polypeptide is encoded by
an RG5 polynucleotide sequence.

15. The nucleic acid construct of claim 14, wherein the RG5 polypeptide is encoded by
30 a polynucleotide sequence as set forth in SEQ ID NO:134.

16. The nucleic acid construct of claim 1, wherein the RG7 polypeptide is encoded by an RG7 polynucleotide sequence.
17. The nucleic acid construct of claim 16, wherein the RG7 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.
18. The nucleic acid construct of claim 1, further comprising a promoter operably linked to the RG polynucleotide.
19. The nucleic acid construct of claim 18, wherein the promoter is a plant promoter.
20. The nucleic acid construct of claim 19, wherein the plant promoter is a disease resistance promoter.
21. The nucleic acid construct of claim 19, wherein the plant promoter is a lettuce promoter.
22. The nucleic acid construct of claim 18, wherein the promoter is a constitutive promoter.
23. The nucleic acid construct of claim 18, wherein the promoter is an inducible promoter.
24. The nucleic acid construct of claim 18, wherein the promoter is a tissue-specific promoter.
25. A nucleic acid construct comprising a promoter sequence from an RG gene linked to a heterologous polynucleotide.
26. A transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide.

27. The transgenic plant of claim 26, wherein the plant promoter is a plant promoter.
28. The transgenic plant of claim 26, wherein the plant promoter is a viral promoter.
- 5 29. The transgenic plant of claim 26, wherein the plant promoter is a heterologous promoter.
30. The transgenic plant of claim 26, wherein the plant is lettuce.
- 10 31. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
- 15 32. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:21 (RG2A); SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).
- 20 33. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:68 (RG3) and SEQ ID NO:69 (RG4).
- 25 30

34. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:134 (RG5).

5 35. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:136 (RG7).

36. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO: 13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ
10 ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), and SEQ ID NO:20 (RG1J).

37. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41
15 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ
20 ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID
25 NO:133 (RG2W).

38. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG3 polypeptide with a sequence as set forth by SEQ ID NO:138.

30 39. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG4 polypeptide with a sequence as set forth by SEQ ID NO:139.

40. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135.

41. A method of enhancing disease resistance in a plant, the method comprising
5 introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence.

42. The method of claim 41, wherein the plant is a lettuce plant.

10 43. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51
15 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O);
20 SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

44. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide
25 selected from the group consisting of SEQ ID NO:138 (RG3); SEQ ID NO:139 (RG4); and SEQ ID NO:135 (RG5).

45. The method of claim 41, wherein the promoter is a tissue-specific promoter or a plant disease resistance promoter.

46. The method of claim 41, wherein the promoter is a constitutive promoter or an inducible promoter.

47. A method of detecting RG resistance genes in a nucleic acid sample, the method
5 comprising:
 contacting the nucleic acid sample with an RG polynucleotide to form a
hybridization complex; and,
 wherein the formation of the hybridization complex is used to detect the RG
resistance gene in the nucleic acid sample.

10

48. The method of claim 47, wherein the RG polynucleotide is an RG1 polynucleotide.

49. The method of claim 47, wherein the RG polynucleotide is an RG2 polynucleotide.

15 50. The method of claim 47, wherein the RG polynucleotide is an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide.

51. The method of claim 47, wherein the RG resistance gene is amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

20

52. The method of claim 51, where the RG resistance gene is amplified by the polymerase chain reaction.

53. The method of claim 47, wherein the RG polynucleotide is labeled.

25

54. An RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(6) : Please See Extra Sheet.		
US CL : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
U.S. : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
APS, DIALOG		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Development of Reliable PCR-Based Markers Linked to Downy Mildew Resistance Genes in Lettuce. Theor. Appl. Genet. 1993. Vol. 85, No. 8, pages 985-993, see entire article.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	KESSELI et al. Analysis of a Detailed Genetic Linkage Map of Lactuca sativa (Lettuce) Constructed From RFLP and RAPD Markers. Genetics. April 1994. Vol. 136, No. 4, pages 1435-1446, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	MICHELMORE, RW. Isolation of Disease Resistance Genes from Crop Plants. Current Opinion in Biotechnology. 1995. Vol. 6, No. 2, pages 145-152, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family	
Date of the actual completion of the international search		Date of mailing of the international search report
14 MARCH 1998		13 APR 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized official PHUONG BUI
Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Recent Amplification of Triose Phosphate Isomerase Related Sequences in Lettuce. Genome. 1992. Vol. 35, No. 4, pages 627-635, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	PARAN et al. Identification of Restriction Fragment Length Polymorphism and Random Amplified Polymorphic DNA markers linked to Downy Mildew Resistance Genes in Lettuce, Using Near-Isogenic Lines. Genome. 1991. Vol. 34, No. 6, pages 1021-1027, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 7, 9, 11, 13, 15, 17, 31-40, 43-44
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

these claims are drawn to numerous sequences identified by SEQ ID NOs. However, since no computer readable form was submitted, no meaningful search could be carried out.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A01H 1/00; C07H 21/04; C07K 14/00; C12N 5/04, 5/10; C12P 19/34; C12Q 1/68